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Abstract 
Trachoma is an ancient blinding disease which remains a public health and socio-economic 
threat to many communities, mainly in sub-Saharan Africa. Repeated conjunctival infection with 
Chlamydia trachomatis is thought to cause prolonged inflammation which leads to scarring and 
blindness, however, the disease is often found to progress in the absence of detected infection. 
Furthermore, despite apparently similar infection exposure, only some individuals progress to 
scarring. The relationship between infection and scarring progression and the 
immunopathological mechanisms underlying it are not clearly understood. A four-year 
longitudinal study was conducted in northern Tanzania in order to identify associations between 
C. trachomatis infection, conjunctival inflammation and immuno-fibrogenic gene expression 
with disease and scarring progression.  
 
Children aged 6-10 years at baseline were eligible for inclusion and 666 children were enrolled 
in the study. Participants were visited every three months for four years. Clinical signs and 
conjunctival swabs for C. trachomatis detection and immuno-fibrogenic gene expression by 
qPCR were collected at each time-point. Conjunctival photographs from baseline and final 
timepoints were graded and compared side-by-side to determine scarring incidence and 
progression. All community members were offered mass drug administration (MDA) with 
azithromycin for trachoma control annually for three years during the study.   
 
Host immuno-fibrogenic gene expression was profiled at the first five time-points. At baseline, 
host immune responses were analysed in relation to C. trachomatis infection, trachomatous 
inflammation – follicular (TF), papillary inflammation (TP) and scarring. Th1 and NK cell 
associated pathways were strongly associated with infection, suggesting their importance in the 
clearance of infection. Growth and matrix factors (MMPs) were strongly associated with the 
inflammation that persisted after infection was cleared (TF/TP), suggesting they might 
contribute to scarring development. Th17 pathway-associated cytokines were associated with 
infection and inflammation, therefore their contribution to protection versus pathology is 
unclear.  
 
The effect of azithromycin on inflammatory gene expression was investigated due to the 
reported immunomodulatory role of this antibiotic. Azithromycin treatment was found to have 
an anti-inflammatory effect on conjunctival gene expression, detectable three months post-
treatment, suggesting that it may protect against pathological inflammation and therefore 
scarring development. The effect was gone by 6 months post treatment. 
 
Of the 448 children with outcome data, 103 (23.0%) had trachomatous scarring progression over 
the four-year study period. In 48 (10.7%) children this was incident scarring, whereas 55 (12.3%) 
had progression of pre-existing scarring. Scarring progression was strongly associated with 
papillary inflammation. Weaker associations between TF and C. trachomatis infection with 
scarring in univariate models were absent in a multivariable model adjusting for TP. These data 
suggest that the effect of infection and TF is mediated through TP, and that other factors 
contributing to the development of TP are important in driving scarring progression. Female sex 
was also associated with scarring progression.  
 
These findings suggest that the use of TP by trachoma control programs might be a more 
discriminating clinical marker to predict future scarring disease and requirements for trichiasis 
surgery than TF. In addition to clearing C. trachomatis infection, MDA might have an additional 
independent mechanism for reducing conjunctival inflammation, which may reduce subsequent 
risk of scarring progression.  
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Format of the thesis 
 
This thesis is submitted in the form of published work. All papers include a list of authors 
involved in the study. The introduction chapter is largely comprised of a general overview of 
trachoma, which is discussed widely and addresses important areas relevant to the findings 
presented in the thesis. Chapters 2 and 3 introduce in detail the main objectives of the thesis 
and the entire work flow methodology from the beginning. Chapters 4 to 8 cover the main 
findings. These chapters comprise of five papers, two papers systematically review the literature 
and three present the findings of the current study. Three papers are already published, one has 
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1. Literature review of Trachoma 
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1.1. Overview 
 
Trachoma is a leading infectious cause of blindness; it is caused by the bacterium Chlamydia 
trachomatis (C. trachomatis).1 In trachoma endemic populations, the disease starts during early 
childhood with repeated Ct infections of the conjunctiva. This provokes recurrent episodes of 
chronic conjunctival inflammation, eventually leading to conjunctival scarring. Scarring of 
conjunctival tissue distorts the upper eyelids: the eyelids roll in towards the eye (entropion) and 
the eyelashes rub the eye surface (trichiasis). This causes pain and damage to the cornea, leading 
to irreversible blindness or severe visual impairments.2 Eyelid surgery to correct trichiasis can 
reduce the risk of corneal damage and sight loss, but recurrent trichiasis is common, and there 
is no treatment to halt the progression of conjunctival scarring.3-9 The time between onset of 
initial infections during childhood and the development of blinding complications is usually 
several decades, making it difficult to study the pathogenesis of this disease. However, current 
evidence suggests that immune responses mediate this process.  
 
There is no known non-human biological reservoir of the forms of C. trachomatis that cause 
endemic trachoma.10 Transmission of this bacterium is thought to be through physical contact 
between infected and uninfected individuals. Secretions from the eyes or nose of infected 
individuals may be transferred through different routes, such as flies, clothes and hands, to 
uninfected individuals. People who are living in crowded conditions, with limited availability of 
water and poor sanitation are thought to be at an increased risk of infection transmission and 
the resulting disease. 
 
Trachoma affects mostly poor communities in Sub-Saharan Africa and some limited parts of 
Asia.11, 12 In 2016, 42 countries were recognised as being trachoma endemic, of which the 
majority are in the World Health Organization (WHO) sub-Saharan Africa Region (AFRO).12 The 
Global Trachoma Mapping Project (GTMP) was conducted to fill the gaps in epidemiological data 
about potentially endemic regions. Recently updated trachoma burden estimates from the WHO 
Weekly Epidemiology Record showed that about 157.7 million people lived in trachoma endemic 
areas requiring interventions, as they were at risk of blindness from trachoma,13 2.8 million were 
suffering from sight threatening trichiasis and need surgery14 and 1.9 million had either already 
developed blindness or had severe visual impairments, of which about 90% are from WHO AFRO 
countries.15 Encouragingly, in the last year Nepal, Ghana and Iran have been validated by WHO 
as having eliminated trachoma as a public health problem. Elimination as a public health 
problem  is defined as evidence that all endemic districts have reached  prevalence thresholds 
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of <5.0% for TF in children 1–9-years old and <0.2% for TT in people aged ≥15 years or an 
approximate <1 case per 1000 in individuals of all ages.16 
 
Trachoma is a neglected tropical disease. It affects some of the world’s poorest communities. 
The morbidity from trichiasis and sight loss can reduce individual productivity, promoting cycles 
of poverty. There is a lack of awareness and resources available for treatment and research. 
During late stages of trachoma women are usually more frequently affected than men.2, 12 Vision 
loss causes social and economic problems to individuals, families and the community at large. 
Several years ago it was estimated that trachoma costs up to US$8 billion per year in lost 
productivity.17 In addition, the mortality rate among individuals blind from trachoma was higher 
than a normally sighted control group.18  
 
To meet this health, social and economic challenge, the WHO-led Alliance for the Global 
Elimination of Trachoma by 2020 (GET2020) was established. This set the target of eliminating 
blinding trachoma by 2020 through the implementation of the SAFE Strategy: Surgery to correct 
trichiasis, Antibiotics distribution to treat C. trachomatis infection, Facial cleanliness and 
Environmental improvements to suppress infection transmission.19 
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1.2. Clinical Features of Trachoma and Grading Systems  
 
Clinically, trachoma has acute and chronic stages. The acute stage, “Active Trachoma”, is mostly 
seen in children who are the major reservoir of infection in trachoma endemic settings. The 
disease is mainly focused in the conjunctiva of the upper eyelid (Figure 1.1a). It is characterised 
by the presence of conjunctival follicles and redness due to papillae (Figure 1.1b-c). These clinical 
signs are thought to develop in response to C. trachomatis infection.  
 
The chronic stage of scarring complication tends to develop later in life and includes conjunctival 
scarring, in-turning of the eyelid (entropion), in-turning of the eyelashes and scratching on the 
eyeball (trichiasis) and corneal blindness (Figure 1.1d-f).20, 21 Active trachoma signs and C. 
trachomatis infection are at their peak during pre-school age children between 3 and 5 years, 
although the disease and infection may begin at any age.2, 22 Development of scarring can 
become visible during childhood and early adulthood, depending on the endemicity of the 
setting.23 
 
There are several systems for grading trachoma signs that have been developed and used over 
the last century, that are discussed below. These have evolved as our understanding of the 
disease process and natural history have developed. The main system that is used today in the 
context of trachoma control programs is the Simplified WHO Trachoma Grading System (Table 
1.1 and Figure 1.1).20  
 
Table 1.1: The WHO Simplified Trachoma Grading System.20 
 
Grade Description  
Trachomatous inflammation, follicular (TF) The presence of five or more follicles (0.5 mm or 
greater in diameter on the central upper tarsal 
conjunctiva) 
Trachomatous inflammation, intense (TI) Inflammatory thickening of the upper tarsal 
conjunctiva with obstruction of more than half 
the normal tarsal vessels 
Trachomatous conjunctival scarring (TS) The presence of easily visible scarring in the 
upper tarsal conjunctiva 
Trachomatous trichiasis (TT) The presence of at least one eyelash rubbing the 
eyeball, or evidence of eyelash removal 
Corneal opacity (CO) The presence of easily visible central corneal 
opacity sufficiently dense to obscure the 
pupillary margin 
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Figure 1.1: Clinical signs of trachoma:20  
(a) Normal conjunctiva is pink, smooth, thin and transparent. (b) Trachomatous Inflammation - 
Follicular (TF) Follicles are round swellings of the conjunctiva, appearing white, grey or yellow 
and associated with ocular irritation and slightly watery discharge. (c) Trachomatous 
Inflammation - Intense (TI) predominately diffuse inflammatory thickening with redness, more 
than half of the blood conjunctival vessels are obscured. (d) Trachomatous scarring (TS) the scars 
are visible as white lines, bands, or sheets (fibrosis) in the conjunctiva, which may distort or 
obscure tarsal blood vessels. (e) Trachomatous trichiasis (TT) eyelashes rub on the surface of the 
eye or evidence of epilation. It is associated with pain. (f) Corneal opacification (CO) scarring of 
the cornea because of TT. Vision may be significantly impaired at this stage. 
 
(a) Normal Conjunctiva (b) Follicular Conjunctivitis (TF) 
  
 
(c) Papillary Inflammation (TI) 
 
(d) Conjunctival Scarring (TS) 
  
 
(e) Entropion and Trichiasis (TT) 
 
(f) Corneal Opacification (CO) 
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Trachomatous inflammation – follicular (TF); refers to localised areas of lymphoid hyperplasia. 
Follicles are white or grey and characterized by a round swelling of 0.5-2mm diameter encircled 
by tiny blood vessels. They contain lymphocytes (a type of white blood cell) and are clearly 
visible on the inner surface of the upper eyelid (conjunctiva). Follicles are often accompanied by 
a mucopurulent discharge, itching and irritation. 
 
Trachomatous inflammation – intense (TI); refers to redness caused by papillae and thickening 
of the conjunctiva in severe cases. Papillae are visible by magnification as small red dots and 
contain a central vascular core. Visibility of deep blood tarsal vessels varies depending on the 
severity of inflammation, ranging from slightly hazy to completely obscured. It is also 
accompanied by a mucopurulent discharge, light sensitivity, itching and irritation.   
 
Trachomatous scarring (TS); As a result of prolonged inflammation, scars appear as spots or 
white lines on the conjunctiva. In severe cases the scars grow and cover most of the conjunctiva. 
Due to tissue fibrosis, glandular tissues in the lids including the lacrimal glands (tear-producing 
glands) can be affected resulting in dryness of the eye. 
 
Entropion/Trichiasis (TT); Accumulating scar tissue causes contraction of the conjunctiva, 
resulting in in-turning of eyelids (entropion) and eyelashes (trichiasis). The eyelashes then rub 
and scratch the cornea, leading to corneal epithelial abrasions and more extensive damage. This 
causes severe pain and the eye may become even drier than before. At this stage lubricating 
glands are severely distorted. Mechanical damage to the cornea increases risk of secondary 
infections.  
 
Corneal opacity (CO); As a result of the mechanical damage caused by in-turned eyelashes, the 
cornea develops scars and becomes cloudy. If in-turned eyelashes/eyelids are left uncorrected 
individuals may develop visual impairment and eventually irreversible blindness. The epithelial 
layer/barrier breakdown can allow other pathogens into the cornea, leading to rapid loss of sight 
from microbial keratitis.  
 
A detailed analysis of the published literature on the rates and risk factors for the natural history 
of disease progression is presented in Chapter 5. 
 
The earliest formal grading system was developed by A. F. MacCallan in 1905. This includes four 
categories of disease (Table 1.2).24, 25 This consisted of upper tarsal immature follicles (presumed 
infection stage), presence of large follicles and papillary hypertrophy, presence of conjunctival 
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scarring with follicles and papillary hypertrophy, and scarring without any other clinical signs. In 
this grading system trichiasis and corneal scarring were not included.  
 
Table 1.2: MacCallan’s system for grading of trachoma.25 
 
Stages Description 
Stage I or Trachoma I (Tr. I) Early stage of "pin head" follicles. 
 
Stage II or Tr. II Subdivided into:  
     Tr. IIa Follicles are large and gelatinous 
     Tr. IIb' Papillary enlargement as well as follicles 
     Tr. IIb" Follicles with the added complication of spring catarrh 
     Tr. IIc 
 
Trachoma complicated by gonococcal conjunctivitis 
Stage III or Tr. III 
 
Where cicatrization has commenced; often non-contagious 
Stage IV or Tr. IV Where cicatrization of the conjunctiva is complete. This 
stage is non-contagious 
 
The Fourth WHO Scientific Meeting on trachoma, held in 1966, recognised 22 clinical signs of 
disease. In this grading system detailed information about each clinical sign was included. This 
was considered to be too complex. Therefore, the WHO subsequently reduced the 1966 detailed 
grading system to five clinical signs called the 1981 “FPC detailed grading system”.26 Each sign 
category has a four point scale, starting with normal and increasing in severity. This grading 
system is presented in Table 1.3 below and the grading area is as illustrated in Figure 1.2. 
 
Figure 1.2: The everted 
upper eyelid. Showing the 
tarsal conjunctiva with 
zones from trachoma 
assessment and grading. 
The numbered zones 
refer to those in the FPC 
Grading System.26 The 
shaded area indicates the 
zone to be examined 
when using the WHO 
simplified system.20   
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Table 1.3: WHO 1981 “FPC detailed grading system”.26 
 
a. Trichiasis and/or entropion (T/E): 
Grade Description  
T/E 0 No trichiasis or entropion. 
T/E 1 Lashes deviated towards the eye, but not touching the globe. 
T/E 2 Lashes touching the globe but not rubbing the cornea. 
T/E 3 Lashes constantly rubbing the cornea. 
 
b. Corneal scarring (CC): 
Grade Description  
C 0 Absent 
C 1 Minimal scarring or opacity but not involving the visual axis, and with clear 
central cornea. 
C 2 Moderate scarring or opacity involving the visual axis, with the papillary margin 
visible through the opacity. 
C 3 Severe central scarring or opacity with the papillary margin not visible through 
the opacity. 
 
c. Upper Tarsal Follicles (TF): 
Grade Description  
F 0 No follicles. 
F 1 Follicles present, but no more than 5 in zones 2 and 3 together.   (1-4) 
F 2 More than 5 follicles in zones 2 and 3 together, but less than 5 in zone 3.   (5-9) 
F 3 Five or more follicles in each of the three zones.   (10+) 
 
d. Upper tarsal papillary hypertrophy and diffuse inflammation (TP): 
Grade Description  
P 0 Absent: normal appearance 
P 1 Minimal: individual vascular tufts (papillae) prominent, but deep 
subconjunctival vessels on the tarsus not obscured.  
P 2 Moderate: more prominent papillae, and normal vessels appear hazy, even 
when seen by the naked eye. 
P 3 Pronounced: conjunctiva thickened and opaque, normal vessels on the tarsus 
are hidden over more than half of the surface. 
 
e. Conjunctival scarring (TS): 
Grade Description  
C 0 No scarring on the conjunctiva 
C 1 Mild: fine scattered scars on the upper tarsal conjunctiva, or scars on other parts 
of the conjunctiva. 
C 2 Moderate: more severe scarring but without shortening or distortion of the 
upper tarsus. 
C 3 Severe: scarring with distortion of the upper tarsus. 
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However, this revised detailed grading system (1981) was not easily adopted by non-specialist 
health workers. Therefore, the WHO developed the simplified trachoma grading system, 
described above, as a tool particularly for use by non-specialist health workers to identify the 
key features of the disease for programmatic purposes, shown in Table 1.1 above.20 The grading 
area is as illustrated in the diagram above (Figure 1.2). The detailed WHO FPC system is mostly 
used for research studies, as it allows classification of different clinical signs based on their 
severity. This is the system we generally use in our field studies in Tanzania. The relationship 
between the detailed FPC grading system and simplified grading system are outlined in table 1.4 
below. This links the grading results using two systems for decision purposes such as 
implementing mass drug administration in a community.   
 
Table 1.4. Correlation between simplified and detailed FPC grading system 
 
Simplified grading system Detailed FPC grading system 
TF F2/F3 
TI P3 
TS C1/C2/C3 
 
Many studies have reported mismatches between the presence of clinical signs and infection. 
This is explored in a detailed meta-analysis presented in Chapter 4. These studies tend to find 
that clinical inflammation persists longer than infection. A study conducted in The Gambia which 
followed participants every two weeks for 6 months found that younger age was strongly 
associated with persistence of disease.27 At the age of 0-4 years the median estimated duration 
of disease was 13.2 weeks, whereas in 4-14 years olds it was 5.3 weeks, while at the age of 15 
years and above the median duration was 1.7 weeks. A similar trend was seen for infection 
duration, where in children aged 0-4 years, 5-14 years and 15 years and above infection 
persisted for 3.8 weeks, 2.1 weeks and 1.4 weeks, respectively. Faal et al, also investigated the 
duration of infection and clinical signs;  median duration of disease was 54 days and median 
duration of infection was 23 days.28  In a mathematical model, the estimated duration of clinical 
signs (TF and/or TI) in children aged between 0 and 4 years was 32 weeks, which reduced to 18.8 
weeks in children aged 5 to 14 years, and to 7 weeks in older children and adults.29 In the same 
mathematical model, the estimated duration of C. trachomatis infection in children aged 
between 0 and 4 years old was 15.4 weeks, reducing to 8.2 weeks in children aged 5 to 14 years 
old and to 7.6 weeks in older children and adults.29 In general, the estimated duration of disease 
was longer than infection duration across all ages, due to the persistence of disease after 
infection has been cleared. Similar trend of reduced active trachoma following increase in age 
was also reported by Dawson in 1970’s however, infection data were missing.22 
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1.3. Chlamydia trachomatis infection 
 
Chlamydia trachomatis is a non-motile, obligate, aerobic intracellular Gram-negative bacterium 
that infects epithelial cells.30, 31 C. trachomatis was first described in 1942,32 however, it was not 
possible to culture until 1957, when it was first cultured in chicken embryo yolk sacs.33  
 
C. trachomatis has a biphasic developmental cycle, the metabolically active and non-infectious 
stage is referred to as a Reticulate Body (RB) and the metabolically inactive infectious phase is 
known as an Elementary Body (EB) (Figure 1.3).31 However, recent evidence has challenged this 
dogma by showing some metabolic activity in the EB.34 EBs enter host epithelial cells and trigger 
the formation of a peri-nuclear inclusion body where they transform into RBs and replicate.35 
There is a subsequent transformation back into the EB form, prior to release from the host cell. 
About 60% of the surface protein is Major Outer Membrane Protein (MOMP), which has 
epitopes which distinguish the different serovars. 
 
Figure 1.3: Chlamydia developmental cycle.  
 
 
 
The EB is a resistant structure covered by a rigid cell wall, which is used for survival under 
unfavourable conditions. It has the ability to induce its own endocytosis (uptake by the cell) 
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when it comes into contact with a permissive host cell. This is the main method of entry to host 
epithelial cells.36 EBs recognize receptors sites on host epithelial cells, and are taken up by  
clathrin-mediated endocytosis and the Rho-family GTPase Rac1.36, 37 EBs enter host epithelial 
cells and trigger the formation of a peri-nuclear inclusion body where they differentiate into 
RBs. The RB is an intra-cytoplasmic form with a diameter of 1.0 to 1.2 μm.38, 39 Inside the inclusion 
body the RB grows and multiplies, dividing by binary fission. After synthesis of cell walls, the 
progeny differentiates back into infectious EBs. EB progeny mature for about 2 days and are 
then released by the host plasma membrane in a process known as exocytosis, extrusion or by 
cell lysis.40, 41 The ruptured cell can produce an estimated 100 to 1000 EBs, which have diameters 
ranging from 0.25 to 0.30 μm.38, 39 Differentiation between the two phases is controlled by 
histone-like protein. Histone (Hcta) expression is suppressed during RB late stage development 
to trigger differentiation into EBs.42 
 
C. trachomatis causes conjunctival infection, urogenital infection and lymphogranuloma 
venereum in men and women, transmitted through contact with infectious secretions. Genital 
infections cause urethritis, cervicitis, proctitis, epididymitis and pelvic inflammatory disease, 
which can lead to infertility in women.43 Lymphogranuloma venereum can cause disseminated 
infection that affects the lymphatic system.44    
 
MOMP of C. trachomatis is the largest component of the cell wall surface protein, comprising 
up to 60%. It’s encoded by a single copy gene on the chlamydial chromosome known as Omp1. 
Other surface proteins are PorB (a porin-like molecule), C. trachomatis outer membrane 
complex protein A (OmcA), OmcB and polymorphic membrane proteins (pmp). MOMP 
maintains rigidity of the wall structure, which facilitates the formation of pores for 
solute/nutrient diffusion from the extracellular environment. Chlamydia have outer membrane 
proteins containing lipopolysaccharide but lacking rigid peptidoglycan.45 The absence of rigid 
peptidoglycan is important for intracellular adaption and enables bacteria to evade host 
immune recognition by TLR2. Peptidoglycan, a polymer which constitute sugar (alternating 
residues of β-(1,4) linked N-acetylglucosamine and N-acetylmuramic acid) and amino acids (L-
alanine, D-glutamate, meso-diaminopimelic acid, and a dipeptide of D-alanine-D-alanine) is only 
exposed during dividing of RBs but not in EBs.46 Chlamydia have the necessary genes and 
synthesis machinery required to make peptidoglycan, which forms the cell wall of many 
bacteria, however, it is only a minor constituent of the cell wall in chlamydia. MOMP is 
responsible for adhesion to host cells and therefore facilitates EB entry to host cells. The MOMP 
type is used to determine different strains of C. trachomatis known as serovars. There are 19 
serovars of this bacterium.47 The ocular serovars A, B, Ba and C are responsible for endemic 
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trachoma.48 Serovars D-K are responsible for genital infection. They can also infect the 
conjunctiva; however, they do not cause endemic trachoma. Genital strains are able to infect 
both ocular and genital sites because they can synthesise tryptophan while ocular serovars 
cannot.49 Serovars L1, L2 and L3 cause lymphogranuloma venereum.  
 
C. trachomatis produces heat shock proteins that protect from conditions of stress by stabilizing 
cellular proteins.50 Chlamydial GroE operons (GroEL and GroES) are the major heat shock 
proteins that have been studied.50, 51 These proteins are implicated in disease pathogenesis and 
are recognised by Toll-like receptors (TLRs) as part of the innate immune system.52-55 These 
proteins are highly conserved among the chlamydial species.    
 
The ability to change between EB and RB facilitates the pathogenesis of C. trachomatis. Several 
factors are reported to be associated with the pathogenesis of this pathogen. Adhesion of EBs 
to host cells is mediated through sialic acid receptors on non-phagocytic epithelial cells (mucosal 
epithelial cells and vascular endothelial cells).56, 57 The chlamydial cell wall prevents fusion of the 
intra-epithelial phagosome with lysosomes; this prevents exposure to phagolysosomes, 
protecting C. trachomatis and allowing it to replicate. The ability of chlamydia to alter its surface 
protein (MOMP) prevents host immune cell recognition.58 The release of enzymes by chlamydia 
such as chlamydial proteasome/protease-like activity factor (CPAF), helps the bacteria to evade 
the host immune response.59-62 These enzymes degrade host transcription factors (RFX5) and 
upstream stimulation factor 1 (USF-1) which inhibit production of major histocompatibility 
complex. Similarly chlamydia use ChlaDub1, a protease that inhibits the NF-NB activation and Ik-
Bα degradation in its evasion from host immune response. The presence of small needle-like 
projections, called a type III secretion apparatus, helps chlamydia to enter the host cells and 
enables it to inject proteins directly into the cytoplasm of the host cell. The chlamydial plasmid 
is also thought  to be involved in pathogenesis through triggering of inflammation.63-67  
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1.4. Differential diagnosis of trachoma 
 
There is some overlap between the clinical signs of trachoma and those of other ocular diseases. 
Some are infectious while others are auto-immune. Chronic follicular conjunctivitis can be 
caused by viruses such as Adenovirus, herpes simplex virus and Molluscum contagiosum; and 
bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Moraxella spp., 
Haemophilus influenzae and urogenital strains of C. trachomatis.68, 69 Furthermore, topical 
medication such as for pediculosis palpebrarum (lice infestation) and conjunctivitis or eye 
cosmetics may also cause chronic follicular conjunctivitis.  
 
Conjunctival scarring and entropion may be related to Stevens-Johnson syndrome, chemical 
injury, mucus membrane pemphigoid and sarcoidosis.70 Often the patient’s history can help 
distinguish these conditions. Unaccompanied papillary inflammation without follicles may be 
caused by other bacteria, viruses, allergy or other physical activities such as prolonged exposure 
to smoke, pollen and dust. Corneal scarring may also be caused by infection with other bacteria, 
viruses, fungi and/or traumatic injury.      
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1.5. Epidemiology  
 
1.5.1. Burden of the disease   
The WHO alliance for the global elimination of trachoma aims to eliminate trachoma by the year 
2020, however, the burden of trachoma in hyperendemic areas of some of the world’s poorest 
countries is still very substantial.13 A key step forward in the worldwide drive to eliminate 
trachoma has been to define the global burden. This was achieved through the Global Trachoma 
Mapping Project (GTMP), which has mapped the prevalence of TF and TT in previously 
unmapped districts where trachoma was suspected to be endemic. It was a collaboration 
between ministries of health of endemic countries and NGO partners. The program was 
completed in 2016 and was the largest ever infectious disease survey. It estimated that around 
190 million people live in areas that require active intervention for trachoma control. The 
highest burden of disease was found in rural areas of sub-Saharan African countries, some parts 
of Asia, Australia, Central and South America and the Middle East. The African continent carries 
about 89% (37 countries out of 41) of trachoma burden reported in 2016.15 Ethiopia, the country 
with the greatest burden, had 69.8 million individuals living in areas needing SAFE and Nigeria 
had 19.9 million.13  In Tanzania 3.2 million individuals are living in areas that warrant SAFE, with 
2.7 million currently receiving MDA treatment.  
 
In 2016, 247,000 people were reported as having received trichiasis surgery and about 83 million 
received antibiotics for trachoma in the African region.16 The overall worldwide coverage of 
antibiotic was 44.8% (85million/190million) in 2016 (compared to 29.6% in 2015), of individuals 
living in areas that warrant SAFE intervention for elimination of trachoma as a public health 
problem.16 The highest burden of disease is found in women and children in poor communities, 
characterised by limited educational opportunities, crowded conditions and limited access to 
hygiene and sanitation. Recent statistics show that the number of women requiring surgery to 
correct trichiasis is about four times more than men.12  
 
1.5.2. Distribution  
In the past few years trachoma has been significantly declining as a result of ongoing efforts to 
eliminate the disease by the year 2020. For example, the estimated number of people living in 
endemic districts, at risk of trachoma blindness, has declined from 317 million in 2010 to 157.7 
million in 2018. This is over 50% decrease within the last 7 years and rate of decline is increasing 
with implementation of new control programmes, following GTMP. Several countries have been 
declared to have achieved the trachoma elimination goals such as Cambodia, Ghana, Islamic 
Republic of Iran, Lao People’s Democratic Republic, Mexico, Morocco and Oman.13 In addition, 
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China, The Gambia, Myanmar and Iraq have also claimed to have achieved elimination however, 
it has not yet been verified by WHO.13 In Africa, known trachoma endemicity is mostly in the 
Sahel region and East Africa. The endemic areas are shaped like a seven over the continent, 
crossing from the west to the horn of Africa in the east and then turning south through East 
Africa (Figure 1.4). Data from the Global Trachoma Mapping Project is being used to guide 
trachoma control measures by Ministries of Health. However, data is currently lacking from 
some countries, largely due to inaccessibility from ongoing conflict.  
 
Figure 1.4. A map showing at district level the prevalence of active trachoma in Africa 
countries. Source:  The Trachoma Atlas. Available at: www.trachomaatlas.org. Accessed 23rd 
September 2018. 
 
 
 
Trachoma was widespread in Tanzania. From previous reports the prevalence of active 
trachoma was highest in Central, West and Northern parts, these areas are dry for most of the 
year.71-73 However, a recent report showed that there has been a significant reduction in the 
prevalence of the disease in most parts of the country and the highest burden of disease is now 
localised in the north of Tanzania, where this study was conducted (Figure 1.5).13 Areas in 
Northern Tanzania with a high prevalence of trachoma are mostly occupied by pastoralists. They 
usually live in compounds with animal enclosures at the centre surrounded by huts with a high 
density of flies. Access to water is very limited. As a result, unclean faces with many flies 
surrounding their eyes are commonly seen. This probably facilitates high rates of transmission.  
The work described in this thesis was conducted on the western side of Mount Kilimanjaro 
(Figure 1.6).    
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Figure 1.5: Map showing at district level the prevalence of active trachoma in Tanzania. 
Source:  The Trachoma Atlas. Available: www.trachomaatlas.org. Accessed 23rd September 
2018. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Satellite image of part of Kilimanjaro and Arusha regions of Northern Tanzania. The 
study area has three villages, one in Arusha region and two in Kilimanjaro region. The study 
villages are located within the black square of the image. Source: 
https://www.google.com/maps/place/Tanzania/@-
2.9616596,37.0059386,67373m/data=!3m1!1e3!4m5!3m4!1s0x184b51314869a111:0x885a17
314bc1c430!8m2!3d-6.369028!4d34.888822  Accessed 28th October 2018. 
 
 
Study site 
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1.5.3. Transmission  
The transmission of ocular C. trachomatis between people in trachoma endemic settings has not 
been directly studied in detail. The generally accepted perspective is that transmission occurs 
through contact with discharge from the eyes, nose or throat secretions of an infected person. 
C. trachomatis may be transmitted on skin, fomites (e.g. clothing and towels) and flies that feed 
on facial secretions (Figure 1.7). All these routes of transmission in trachoma endemic settings 
are very common, particularly in children who are the principle reservoir of infection. Because 
of close contact with children, women are also thought to be at greater risk of being exposed to 
infection. Trachoma is predominantly a disease of poverty. There are several risk factors, which 
have been consistently associated with the disease, discussed below in section 1.4.4.  
 
Figure 1.7: Illustration of C. trachomatis infection transmission from infected to uninfected 
persons. This diagram was kindly provided by Professor Matthew Burton, LSHTM 
 
 
 
1.5.4. Risk factors of trachoma disease 
There are several risk factors for both active trachoma and Ct infection, which have been 
associated fairly consistently in different trachoma endemic populations in different countries. 
These include: 
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Age 
The prevalence of the disease and infection is highest in younger children. It is likely that this is 
due to a combination of more frequent exposure to the infection and longer duration. Studies 
from three different trachoma endemic sites in The Gambia and Tanzania found a strong 
association between children less than 10 years old and load of infection.74 A mathematical 
model using data from a Gambian community examined every two weeks for 6 months found 
both more frequent and longer duration of infection and active trachoma in children aged less 
than 5 years when compared to older children and adults.29 This may reflect a greater exposure 
of children to chlamydial infection and a less effective immune response to it. Transmission is 
likely to be more frequent for behavioural reasons: infrequent face washing, playing together 
and close sleeping conditions with other affected children. Active trachoma is very rare in adults 
however, it can also be diagnosed in trachoma endemic communities.75 The trend of   disease 
from infection and active trachoma to scarring complication such as trichiasis to corneal 
opacification are strongly associated with age.2  
 
Sex 
Trachoma occurs more frequently in females,12 with clinical signs more frequent in all stages in 
the natural history of trachoma, however, this difference between the sexes is only statistically 
significant at an older age/late stages of disease.2 In earlier studies from Tanzania active 
trachoma was diagnosed more frequently in females than males.2  According to a recent WHO 
report, females were four times more likely to have trichiasis than males.12 This is suggested to 
be due to a greater lifetime exposure to C. trachomatis infection from closer contact with 
children.76 
 
Limited water supply 
Communities with poor water supply tend to have more trachoma, possibly reflecting general 
disadvantages in hygiene and sanitation, leading to more transmission.2, 77, 78 Dirty faces are 
frequently associated with eye and nose discharge, which may transmit C. trachomatis through 
person to person contact or via flies.2, 79, 80 Studies done by Bailey and colleagues in The Gambia, 
and West and colleagues in Central Tanzania found there was a significant relationship between 
poor accessibility of water, less face washing and active trachoma.81, 82 Similar findings of 
association between active trachoma and limited access to water were reported in children from 
Guinea Bissau.83 Face washing is thought to reduce transmission to others, by physically 
removing the infected secretions. However, this relationship has not always been consistently 
observed, for example, in Niger, Abdou and colleagues found no association between water 
supply and active trachoma or infection.84 This study has several shortcomings which the 
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authors recognised; there was no method to assess whether increased water access was directly 
associated with face washing as they were only relying on the distance between the houses and 
water sources. Furthermore, children from both intervention and control villages were given 
tetracycline eye ointment which could directly interfere with findings and C. trachomatis 
infection prevalence was higher in intervention villages than control (26% vs 15%, respectively) 
which might cause some bias due to different infection transmission rates. 
 
Flies and Sanitation 
Eye-seeking flies, such as Musca sorbens, are hypothesised to carry C. trachomatis from infected 
to uninfected eyes. Multiple studies have found associations between the presence of flies 
around eyes and active trachoma and C. trachomatis infection.85-88 A study in children aged 
between 1-5 years found strong association between flies and clinical signs of trachoma but not 
C. trachomatis infection.78 Facial flies together with less educated household heads in pre-
treated communities was associated with C. trachomatis infection prevalence at the community 
level.89 Societies with little or no access to latrines may have more faecal contamination in the 
environment. This provides places for flies to breed, resulting in increased fly density in the 
environment and increased risk of transmitting infection.90 However, intervention studies have 
not found consistent results, with some recording an impact on active trachoma and others 
not.91, 92 
 
Crowding 
Trachoma tends to cluster within communities, perhaps reflecting the transmission dynamics.72, 
93-95 Humans are the only known biological reservoir of C. trachomatis in trachoma endemic 
settings. Most families affected by trachoma are economically poor with no education. They 
tend to sleep in the same house/room and probably share clothes, towels, handkerchiefs, beds 
and many other facilities, which may be contaminated with C. trachomatis from secretions of 
infected individuals. Several studies have found clustering of infection to occur at the bedroom 
level.85 
 
Host Genetics  
Individuals living in trachoma endemic communities are thought to have relatively equal 
exposure to C. trachomatis infection, yet they experience different outcomes; while some suffer 
severely from the disease (progressing to scarring and trichiasis), others suffer less and some 
not at all.96 Heritable factors are thought to predispose some people to more severe/scarring 
disease than others.73, 97-101 Variation in HLA class I and 2 genes, cell surface receptors, cytokines, 
transcription factors and extracellular matrix (ECM) enzymes have each been studied for 
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association with trachoma, using a variety of methods including single nucleotide polymorphism 
(SNP) typing, variation across loci and family studies (reviewed by Derrick et al).102 A single 
genome wide association study  did not confirm the genes identified in these previous candidate 
gene approaches associated with scarring disease but rather confirmed that variation at the 
pathway level consistent with trachoma transcriptome results was associated with risk of 
scarring.101 
 
Education 
Lack of public health education for individuals in trachoma endemic areas may be a risk factor 
for disease. Communities should be educated about the major risk factors that cause disease 
and available control measures. Kuper and colleagues reported weak evidence of an association 
between disease and health education.103  
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1.6. Trachoma Control (SAFE strategy)  
 
Blindness caused by trachoma is a great threat to an individual’s quality of life and transforms 
individuals from being productive into being dependent on others.104 Due to the public health, 
social and economic challenges of Trachoma, in 1993 the WHO developed the SAFE strategy for 
trachoma control, designed using prior information from different approaches conducted in 
different trachoma endemic areas. In 1996 the WHO and other allies including non-
governmental organizations and eye health stakeholders initiated a resolution to eliminate the 
disease as a public health problem. Elimination was defined as reducing the prevalence of 
trichiasis to less than 0.2% in people aged 15 years and above (or approximately less than 1 case 
per 1000 people of all ages) and reducing TF prevalence to less than 5% in children aged 1 to 9 
years, in formerly endemic districts.15 The strategy agreed was focused on individuals with 
trichiasis and infection.105 There are ongoing efforts in trachoma endemic areas worldwide to 
eliminate trachoma as a public health problem by 2020 using the SAFE strategy. Four 
components are included in the strategy as follows:  
 
Surgery to correct trachomatous trichiasis. Prior to the introduction of the SAFE strategy, 
trichiasis was largely managed through epilation of eyelashes that are touching the eyeball. A 
similar approach is still in place for some individuals today who have minor trichiasis or decline 
surgery and in areas where surgery is unavailable or inaccessible. Surgery is the preferred 
method to manage trichiasis.106 
 
In surgery to correct trichiasis, the marginal part of the eyelid is rotated outwards away from 
the globe, so that the lashes cannot continue to touch the eye.107 Individuals offered surgery 
should  have one or more eyelashes which turn in and touch the eye.106 This procedure is 
performed by trained ophthalmologists, ophthalmic nurses or medical assistants. 
 
Recurrent trichiasis is a major challenge to this control measure; recurrence rates of 60% three 
years after surgery have been reported.5 The WHO has recommended two procedures of eyelid 
surgery; bilamellar tarsal rotation (BLTR) and posterior lamellar tarsal rotation (PLTR). Recently 
it was reported that more cases of recurrent trichiasis were found in individuals who went for 
BLTR procedure relative to the PLTR procedure.9 In the last decade a series of trials have 
explored alternative approaches to try to improve results, including measures to reduce 
inflammation after surgery.3, 7, 108-112 There can be considerable inter-surgeon variation, which 
has led to developments such as HeadStart, that are used to train surgeons on model eyelids.113 
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In addition to antimicrobial activity, doxycycline was also reported to have both anti-matrix 
metalloproteinase and anti-inflammatory effects on Trichiasis-Derived Conjunctival Fibroblasts 
and other body tissues abnormalities.114-117 As discussed in section 1.7.4 and 1.7.5, TT develops 
following distortion of normal collagen textures/tarsal plate following prolonged inflammation 
and abnormal expression of matrix-metalloproteinase in the conjunctiva. Recently, Habtamu 
and colleagues reported a trial of the effect of oral doxycycline in prevention of recurrence on 
trichiasis post-operated cases.108 This was a randomized control trial conducted in individuals 
aged over 18 years with upper eye lid TT associated with conjunctival scarring who received 
community-based screening and surgery in an Ethiopian hyperendemic community. They 
excluded all individuals who had previously received TT surgery. Patients were randomized to 
doxycycline or placebo in a 1:1 ratio, and given this for 28 days. All participants were examined 
at 10 days, 1, 6, and 12 months after surgery.  At the 12th month, 58 (12%) of individuals who 
received doxycycline and 62 (12%) of those who received placebo had developed postoperative 
TT (adjusted OR 0·91, p=0·63). The authors concluded that doxycycline has not associated with 
reduction of post TT recurrence. 
 
Antibiotics to reduce the reservoir of C. trachomatis infection within a community. The most 
commonly used antibiotic is azithromycin; single oral dose (20 mg/kg up to a maximum dose of 
1g). This is not used in children below 6 months of age, who are given tetracycline eye ointment; 
twice a day for 6 weeks. The WHO has recommended at least three rounds each annually of 
Mass drug administration (MDA) to all community members if the prevalence of TF is more than 
10% in children aged 1-9 years old (TF1-9) in the district and coverage should be at least 80% of 
the total population. When the prevalence of TF1-9 is 5% and above but less than 10%, 
assessment should be conducted at the community level and treatment should be offered 
where the TF1-9 prevalence is >10%. If the TF1-9 prevalence is less than 5% mass treatment is not 
recommended. One of the key challenges with MDA is that TF is used as a decision factor instead 
of infection. Due to the delay between the control of infection and the clearance of clinical signs 
at both individual and population levels, this might lead to treating communities where infection 
was already brought under control. Currently tests for infection are not being used by trachoma 
control programmes to guide their use of MDA, with the exception of the Amhara regional 
control programme where PCR based tests are used within the context of surveillance surveys.  
 
Prior to azithromycin, topical tetracycline eye ointment was recommended to treat trachoma 
and the dosage was to be applied for at least 6 weeks twice a day, or 5 days consecutively every 
month for 6 months.26 There are several challenges of using tetracycline; including the need for 
supervision during application and the need to apply it multiple times. It is not feasible for 
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technical personnel to assist in many settings hence the drug has to be left with the caregivers 
for daily application, introducing doubt about treatment reliability at a community level. 
Tetracycline may cause discomfort/blurring of vision to the patients. Furthermore, it was not 
clear if treatment was effective in cases where extraocular sites such as the nasopharynx or 
nasal secretions were involved. Hence a single oral dose of directly observed azithromycin 
treatment would be much preferred for effectiveness in control programmes.  
 
A single oral dose of azithromycin was previously reported to be effective in genital C. 
trachomatis infection.118, 119 Since then several clinical trials were done using azithromycin as an 
alternative to tetracycline. Bailey and colleagues conducted a clinical trial in The Gambia in the 
early 1990’s comparing azithromycin and tetracycline.120 Follow up conducted 6 months post 
treatment found that trachoma had resolved in 76 (78%) of the 97 subjects who received 
azithromycin, compared with 70 (72%) of 97 who were treated with tetracycline (95% Cl for 
difference - 6% to 18%). However, tetracycline treatment was delivered by the research team.  
 
Schachter and colleagues led another clinical trial in Egypt, The Gambia, and Tanzania; three 
doses of oral azithromycin were given in interval of one week to the trachoma endemic villages 
selected community-wide or treated with 1% topical tetracycline once daily for six weeks.121 
Clinical examination and sample collection were done at baseline and after one year and C. 
trachomatis was detected by ligase chain reaction (LCR).  After one year, C. trachomatis infection 
was more reduced in azithromycin treated than tetracycline ((93% versus 77% in Egypt, 78% 
versus 66% in The Gambia, 64% versus 55% in Tanzania).  
 
Another study conducted in The Gambia included a randomized controlled trial of azithromycin 
compared to tetracycline without supervision of administration of the ointment.122 The study 
included 314 children aged 6 months to 10 years with clinical signs of trachoma who randomly 
received ether of the two treatments. Six months after treatment children were assessed for 
clinical signs without testing for C. trachomatis infection. A single dose of azithromycin was 
significantly associated with resolution of intense inflammation (P = 0.023, Fisher’s exact test). 
Another study in Tanzania evaluated the effectiveness of a single dose of azithromycin and C. 
trachomatis was detected using PCR.123 One round of azithromycin in addition to tetracycline 
was enough to bring down infection from 9.5% at the baseline to 0.1% two years later.  
 
Azithromycin (also known as Zithromax) is one of the three commonly used macrolide 
antibiotics; the others are erythromyin and clarithromycin. Azithromycin is stable in acid and 
has a broad range of antibacterial activities. Apart from trachoma, azithromycin is used to treat 
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a variety of conditions such as sexually transmitted diseases, bronchitis, pneumonia, ear 
infections and upper respiratory tract infection. It was reported to be effective in treating 
Toxoplasma gondii infection in pregnant women.124 In patients with cystic fibrosis long term oral 
azithromycin treatment was associated with a reduced rate of decline in lung function leading 
to a reduced morbidity and mortality rate.125 Azithromycin was also reported to be beneficial 
for individuals with malaria,126-130 and is used in the elimination program for yaws, which is also 
planned for eradication by 2020.131 In combination with sulphadoxine pyrimethamine, 
azithromycin was reported to prevent low birthweight in Papua New Guinea.132 In Central 
Tanzania azithromycin was associated with reduction of diarrhoea in children.133 A larger 3 
country study (in Malawi, Tanzania and Niger) following zithromax MDA specifically conducted 
to investigate this effect confirmed modest but significant reduction in mortality rate among 
children aged between 1-59 months.134 
 
  Azithromycin was further reported to reduce the child mortality rate in Ethiopia.135 In a mouse 
model inoculated with Acinetobacter baumannii, azithromycin was associated with reduction of 
lung inflammation.136 In combination with ampicillin, azithromycin reduced streptococcal sepsis 
in a murine model.137 Although widely regarded as safe, azithromycin was reported to be the 
possible cause of acute and chronic kidney damage in both cystic fibrosis patients and healthy 
individuals and authors advised that it should not to be used by patients with kidney disease,138, 
139 however, these finding were either case reports or followed prolonged intake of drug. Some 
studies have reported an association between azithromycin and increased risk of death due to 
cardiovascular disease,140 however, other studies did not confirm this association.141 Known side 
effects of azithromycin include diarrhoea, nausea, abdominal pain, vomiting, rash, 
hepatotoxicity, hypersensitivity reactions (for example angioedema, acute generalized 
exanthematous pustulosis, Stevens-Johnson syndrome, toxic epidermal necrolysis), and C. 
difficile associated diarrhoea. 
 
The promotion of Facial cleanliness in children and Environmental improvements (the F and E 
components of SAFE) aim to reduce the transmission of trachoma, given the risk factors 
described above in section 1.4.4. Some epidemiological studies have found an association 
between dirty faces and active trachoma in children (refer section 1.4.4). Poor sanitation was 
reported to be associated with breeding sites for eye-seeking flies which can carry eye or nose 
secretions from infected to uninfected individuals while other finding reported the opposite 
(refer section 1.4.4). Despite controversial findings about the significance of suppressing 
transmission of the bacterium, face washing and improving hygiene in the surrounding 
environment could be generally beneficial beyond trachoma control.    
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1.7. Immunopathophysiology of trachoma 
 
1.7.1. Physiological barriers 
Physiological barriers prevent infection and colonization by many infectious agents at the ocular 
surface. The eyelids form the primary physical barrier that protects the eye. The ocular surface 
is coated in the tear film.  In the absence of tears the cornea becomes dry and may be subjected 
to injury and infection.68, 142 The tear film has three layers: external oily layer, middle aqueous 
layer and inner mucin layer. Tears are rich in antibodies and antimicrobial peptides and consist 
of a salty fluid which spreads evenly across the front of the eye to keep it moist and to create an 
unfavourable environment for pathogens. Evaporation of tears is reduced by an oily outer layer, 
produced by the Meibomian glands, which lie within the tarsal plate of the eyelid and release 
secretions from the edge of the lower and upper eyelids (Figure 1.8). Lachrymal glands produce 
the aqueous layer, which contains many components that contribute to protection.  
 
Figure 1.8: Sagittal view of the eyelids and globe. This figure can be accessed from 
http://ophthalmologylife.blogspot.com/2012/03/anatomy-of-conjunctiva.html) 
 
 
Proteins called mucins make up the mucous layer that protects the conjunctiva. Mucins which 
are produced by corneal surface and conjunctival epithelial cells are an important barrier to 
pathogens and also act as lubricating agents and clearing molecules.143 There are several ocular 
mucins.  MUC7 is derived from the lacrimal gland; MUC5AC a gel-forming mucin is among the 
major mucins expressed by the ocular surface and is reported to be produced by goblet cells; 
MUC16 is produced and present in the lacrimal gland and epithelial cells of the nasolacrimal 
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ducts; MUC4 and MUC1 are produced from corneal and conjunctiva epithelia.144-148 MUC16 is 
produced by lacrimal gland ductal epithelium, accessory lacrimal glands and nasolacrimal duct 
epithelium. The role of MUC7, MUC5AC, MUC4 and MUC1 are discussed in more detail in 
chapter 4. 
 
1.7.2. Innate immune response 
Innate immune cells consist of leukocytes (neutrophils, basophils, eosinophils), Natural killer 
(NK) cells, mast cells, macrophages, and dendritic cells (DCs). Innate immune responses react 
immediately but do not confer long lasting or protective immunity to the host, however, there 
is some recent evidence of memory in innate immune cells (trained immunity or innate immune 
memory), for example, in macrophages and NK cells.149, 150 Trained immunity was reported to be 
mediated through epigenetic reprogramming and signals effecting transcription factors. 
 
The innate immune response is initiated by the binding of pathogen-associated molecular 
patterns (PAMPs) on microorganisms to host cell receptors known as pattern recognition 
receptors (PRRs). Epithelial cells and circulating cells of the innate immune system 
(macrophages, dendritic cells (DCs), neutrophils, NK cells) possess PRRs, the most important of 
which are the TLRs and the nucleotide-binding oligomerization domain (NOD) proteins. These 
receptors recognise and bind to the PAMPs, enabling cells to recognize microbial structural 
elements. Upon ligand binding, PRRs induce an intracellular signalling cascade which leads to 
the activation of transcription factors (e.g. nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-NB)) that bind to nuclear DNA, promoting the production of pro-
inflammatory cytokines. For C. trachomatis TLR2 and TLR4 are important for recognition. TLR2 
is the PRR for the C. trachomatis cell wall component peptidoglycan. TLR4 is the PRR for C. 
trachomatis cell membrane component lipopolysaccharide (LPS) and heat shock protein. 
 
In vitro studies have shown that initial innate immune responses to C. trachomatis infection 
occur at the epithelial cell surface, causing epithelial cells to produce pro-inflammatory 
cytokines and chemokines 20–24 hours after infection has been established and lasted for 2–4 
days throughout the chlamydial developmental cycle.151, 152 These include Chemokine ligand 5 
(CCL5) Chemokine ligand 16 (CXCL16), CXCL10, CXCL1, Interleukin 1α (IL-1α), IL-8, IL-12, IL-6, 
GM-CSF (granulocyte-macrophage colony stimulating factor), TNF (tumour necrosis factor), and 
GRO (growth-related oncogene). Release of these proinflammatory mediators triggers the rapid 
recruitment of neutrophils, macrophages, dendritic cells (DCs) and natural killer (NK) cells to the 
site of infection. T and B lymphocytes are also recruited after activation of the adaptive immune 
response (discussed further below). Innate immune cells limit the infection through 
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phagocytosis and destroying infected cells (NK cells). In addition, antimicrobial peptides 
produced by epithelial cells limit infection through mediating inflammation on epithelial and 
inflammatory cells, influence diverse processes as proliferation, immune induction, cytokine 
release, chemotaxis, protease-antiprotease balance.153-157 
 
Infected epithelial cells and macrophages are activated during infection which continue to 
promote the influx of additional inflammatory cells. Epithelial cells, neutrophils, macrophages, 
DCs and NK cells release different substances such as matrix metalloprotease (MMP) 7, 9, 10, 
and 12, tissue inhibitor of matrix metalloproteinase 1, and secreted protein acidic cysteine-rich-
like 1, which are thought to cause damage to the extracellular matrix. Studies in murine models 
of genital chlamydial infection have suggested that innate immune responses mediated through 
TLR2 receptors contribute to the development of fallopian tube scarring.151, 158 TLRs, dendritic 
cells and macrophages/monocytes have been linked to wound healing and fibrosis through 
triggering inflammation during tissue repair in chronic diseases.159-162  
 
Findings from human studies support the role of the conjunctival epithelium in the innate 
immune response to C. trachomatis infection. Both immunohistochemistry and gene expression 
studies of the conjunctival epithelium showed upregulation of proinflammatory and 
antimicrobial mediators such as IL-1α, IL-1β, TNF-α, PDGF, CXCL5, and S100A7.163-166 Biopsy and 
gene expression studies found Major Histocompatibility Complex (MHC) class I which was 
expressed throughout the epithelial cells and MHC class II on the superficial layers increased in 
individuals with active trachoma.167, 168 Presence of markers for Natural Killer (NK) cells and 
neutrophils indicated that these cells were recruited to the site of infection and activated in both 
human and animal models of infection and disease.165, 169, 170 NK cells control chlamydial infection 
through the production of interferon gamma (IFN-J) and by killing stressed or infected host 
cells.171 In animal models NK cells are found at site of infection within 12 hours. Inflammation 
can contribute to the development of chronic tissue damage, however, secretory leukocyte 
protease inhibitors produced by epithelial cells and elafin can contrast the action of matrix 
metalloproteases, helping to reduce the damage.172 MHC is a cell surface molecule encoded by 
a large gene family responsible for recognition of foreign antigens. It is referred to as the human 
leukocyte antigen (HLA) complex in humans. Each molecule has one binding site that can bind 
different peptides. Genes in this complex are categorized into three groups: class I, class II, and 
class III. MHC class I and II proteins bind peptides that belong to a group of molecules known as 
the Immunoglobulin Supergene Family, which includes immunoglobulins, T cell receptors 
(TCRs), CD4, CD8, and others. CD4 binding to MHC class II and CD8 binding to MHC class I. 
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Many studies have reported a strong association between trachomatous scarring and innate 
immune responses. Scarring was associated with increased inflammatory cell infiltrates on 
hematoxylin and eosin staining and CD45+, CD8 + and CD56+ cells (but not CD3+ cells) were 
enriched, leading the authors to suggest that these were NK cell infiltrates.173 Several genes of 
the innate immune response have been frequently found to be highly expressed in people with 
trachomatous scarring. These include psoriasin (S100A7), defensin-β4A, INDO, TNFA, IL-1B, 
DEFB4A, CXCL5, SAA1, ARG, NOS2, serum amyloid A1.174 In addition, scarred conjunctivae were 
found to have greater infiltrates of NK cells when compared with controls.173 As C. trachomatis 
infection is very rarely detected in adults with scarring, the factors driving innate immune 
responses in the conjunctival epithelium are not clear. 
 
1.7.3. Adaptive immune response 
The adaptive immune response is mediated by T and B lymphocytes. These cells are antigen-
specific and once exposed to their antigen and activated by dendritic cells they generate effector 
and memory cells. Memory cells enable a faster and amplified response on second exposure to 
that same antigen. B cells generate antibodies, whilst T cells can be split into two major 
phenotypic groups, MHC class II restricted CD4+ T helper cells and MHC class I restricted CD8+ 
cytotoxic T cells. Cytotoxic T cells kill infected cells by recognition of antigen expressed on the 
cell’s MHC class I. Helper T cells help other immune cell types by producing cytokines and are 
essential for activating intracellular killing in macrophages and high-affinity B cell antibody 
responses. Subtypes of helper T cells are induced by different cytokine milieus and have 
different roles and functions. T helper 1 (Th1) cells, induced by Interleukin-12 (IL-12) and IL-18 
are primarily associated with intracellular infections and promote the activation of intracellular 
killing mechanisms in macrophages by release of IFN-γ, IL-6, IL-12 and TNFα.175, 176 Th2 cells, 
induced by IL-4 are more associated with extracellular infections and generation of antibody 
responses.175-177 T regulator cells (Treg) are a subset of CD4+ T cells that supress inflammation. 
They are involved in the prevention of autoimmune diseases by maintaining self-tolerance; 
suppression of allergy, oral tolerance, asthma and feto-maternal tolerance; however, they may 
limit beneficial responses by suppressing inflammation required for clearing infection and 
limiting anti-tumour responses.178, 179 Markers of Tregs (but not exclusive of other T cells) are 
CD25, CTLA-4, GITR, LAG-3, CD127 and FOXP3. Treg cells secrete the anti-inflammatory 
cytokines IL10 and TGFβ. Th17 cells are another pro-inflammatory subset of CD4+ T cells. Their 
development requires the presence of specific factors, TGFβ with IL-6 or IL-21, their growth and 
stabilization is dependent on IL-21, transcriptional control involves STAT3, RORγt and RORα and 
survival and maintenance requires IL-23.180-182 Th1 (CD4+ IFN-γ+), Th2 (CD4+ IL-4+) and Treg (IL-
10, TGFβ) cells inhibit the development of Th17 cells.183 Th17 cells and their associated cytokines 
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(IL-17) appear to have a major coordinating role in inflammation in many situations, regulating 
the production of different pro-inflammatory cytokines/chemokines and recruiting 
neutrophils.184-193 
 
C. trachomatis infection triggers adaptive responses and protection from infection that is 
thought to rely mainly on T cell responses (cell-mediated immunity (CMI)) and B lymphocyte 
responses. Studies from urogenital infection animal models showed that mice cannot clear 
infection in the absence of T cells.194-196 Athymic Mice (without lymphocytes) infected with C. 
trachomatis were not able to clear infection within 20 days, in contrast to the control group, and 
infection was still detectable after 265 days.196 However, athymic mice were able to clear 
infection after adoptive transfer of T cells from wild type mice. IFN-γ is largely responsible for 
infection clearance. IFN-y is produced by NK cells, CD4+ T and CD8+ T cells. IFN-γ induces the 
activation of enzymes such as indoleamine-2,3-dioxygenase (IDO), which inhibits chlamydial 
growth through depletion of the essential amino acid tryptophan, and nitric oxide synthase 
(iNOS), which kills bacteria inside phagolysosomes and depletes intracellular iron (also limiting 
the growth of chlamydia).197-199 Immunohistochemical staining of conjunctival biopsies from 
cynomolgus monkeys found infiltrates of CD4+ T-helper cells, CD8+ T cells and B lymphocytes 
were predominant in the conjunctival inflammatory response to C. trachomatis infection in 
active trachoma relative to a control group.200 Immunohistochemistry studies from biopsy 
samples obtained from human subjects with active trachoma found more inflammatory cell 
infiltrates  of CD4+ T-helper cells, CD8+ T cells and B lymphocytes in trachoma specimens than 
the control group.163 Gene expression studies following human responses from trachoma 
endemic areas found expression of IFN-γ was higher in individuals with C. trachomatis infection 
but was reduced in individuals with active trachoma without C. trachomatis infection.164 Studies 
in children whose active clinical signs persisted for over 6 months showed that they had weaker 
lymphoproliferative responses to C. trachomatis antigens compared to children whose clinical 
signs resolved over that time.201 
 
T cells and particularly IFN-γ are thought to be essential for the clearance of chlamydial 
infections. Whilst adaptive immune responses are crucial for clearance of infection, their role in 
the papillary inflammation that drives scarring progression (particularly in adults without C. 
trachomatis infection) is unknown.  
 
1.7.4. Protection from reinfection 
In trachoma endemic communities ocular C. trachomatis infection frequency and duration 
decrease with age and infection is rarely detected in adults.27, 29 This has led to the conclusion 
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that protective immune responses develop (albeit slowly) following multiple previous infections, 
enabling adults to quickly clear reinfection. Non-human primates inoculated with serotype E of 
C. trachomatis developed severe but self-limiting conjunctivitis and when re-challenged with the 
same strain, there were only mild clinical signs that rapidly resolved.202 Studies from human 
volunteers in the 1960’s found that individuals were protected after reinfection with the same 
strain but were still susceptible to infection from other strains.203, 204 This was consistent with a 
trachoma clinical trial in the 1960’s where serovar-specific immunity from a live vaccine was 
induced in the short-term.205, 206 Some degree of protective immunity through T-cell mediated 
memory responses are likely to contribute to the rapid resolution of reinfection. Studies in 
animal models found a live-attenuated vaccine was safe and effective in preventing C. 
trachomatis infection.207 In the study, Cynomolgus macaques were infected with a trachoma 
strain deficient for the 7.5-kb conserved plasmid and were then challenged with plasmid-free 
strains, this resulted in a short lasting infection without any ocular complications. When the 
animals were challenged with multiple infections of the same attenuated (plasmid free) strain, 
no inflammation was induced and infection was associated with induction of anti-inflammatory 
immune responses. However, when challenged with organisms possessing the plasmid, partial 
protection was detected and animals had lower infection loads than controls.  
 
Several recent studies from animal models and humans have demonstrated the role of different 
T lymphocyte subtypes in protection from chlamydial infection. MHC genotyping of Cynomolgus 
macaques infected with plasmid-free C. trachomatis suggested that MHC class II alleles were 
associated with protection from infection.207 A study in women aged ≥16 years evaluated T cell 
phenotypes in PBMCs based on the women’s urogenital C. trachomatis status.208 C. trachomatis 
infected women had higher expression of T cell activation markers (CD38+HLA-DR+), Th1- and 
Th2-associated effector phenotypes (CXCR3+CCR5+ and CCR4+, respectively), and T cell homing 
marker (CCR7) for both CD4+ and CD8+ T cells relative to uninfected women. During follow up 
after treatment, expression of these markers associated with CD4+ and CD8+ T cells was 
reduced. Women who were not re-infected during follow-up had relatively higher expression of 
CD8+ T cells co-expressing CXCR3 with CCR5 or CCR4 than the re-infected group. A longitudinal 
study in women at high risk of urogenital C. trachomatis infection measured the production of 
IFN-γ from CD4+ and CD8+ peripheral blood cells. The authors found that women who became 
infected had a lower frequency of IFN-γ positive CD4+ cells relative to women that remained 
uninfected, whereas the frequency of CD8+ T cell responses was similar in both groups.209 These 
findings show that both CD4+ and CD8+ T cells are involved in protection from C. trachomatis 
infection.  
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1.7.5. Pathogenesis of scarring 
Tissue fibrosis (scarring) is a product of activated mesenchymal and fibrotic cells.210 
Myofibroblasts, the main effectors in tissue fibrosis, produce excessive ECM and cause tissue 
contraction and distortion, ultimately leading to loss of tissue function.211-213 Fibrosis has been 
shown to be driven by chronic infection and inflammation in a number of diseases such as 
microvascular disease, toxic epithelial injury, diabetes mellitus, myocardial infarction, chronic 
obstructive pulmonary disease, atherosclerosis, chronic colitis, stroke, and skin diseases such as 
scleroderma.159, 210 
  
Our research group has previously conducted a number of case-control studies of individuals 
with scarring trachoma (compared to normal matched controls). A study from Ethiopia found 
several pro-inflammatory cytokines such as IL-1β, CXCL5, and S100A7, and tissue-remodelling 
proteins MMP-7, MMP-9 and MMP-12 and HAS3 were up-regulated.166 These individuals also 
had increased IL-10, which may have a regulatory anti-inflammatory effect in this context. These 
findings were replicated in a study of a similar design conducted in Tanzania.174 MMPs are a 
family of proteolytic enzymes, which have been linked to the development of scar tissue in many 
diseases.214-218 MMPs degrade the ECM and promote contraction of scar tissue.  
 
Cytokines and chemokines appear to play a central role on both the initiation and progression 
of fibrosis through the recruitment of inflammatory cells to the site of tissue injury.219, 220 During 
pathological responses, fibrosis is associated with production of proteolytic enzymes, angiogenic 
factors, fibrogenic cytokines, growth factors and fibrillar extracellular matrix.221 TGFβ, PDGF, 
CTGF and FGF are the most prominent growth factors associated with fibrosis.222-227 Many of 
these promote the recruitment of leukocytes, local proliferation of fibroblasts and the 
accumulation of ECM proteins.210 Several factors that were most strongly associated with 
scarring trachoma in the studies from Ethiopia and Tanzania (IL-1β, CXCL5, and S100A7) 
generally arise as part of innate immune responses. In particular they have been shown in both 
tissue culture experiments and in disease models to be produced by epithelial cells. This 
suggests that the epithelium may have a central role in producing the chronic inflammatory 
response that is believed to drive trachomatous scarring. However, data from longitudinal 
studies are required. In vitro studies are consistent with these inflammatory responses, with the 
release of cytokines and chemokines, provoked by C. trachomatis infection of non-immune cells 
(epithelia and endothelia).151, 228  
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1.7.6. Evidence from histology studies 
Despite much effort in recent decades the immunopathogenesis of scarring trachoma remains 
poorly understood. Several studies were conducted in the past using conjunctival biopsies 
collected from trachoma patients. In children with active trachoma conjunctival biopsy tissues 
contained inflammatory cell infiltrates in which macrophages, polymorphonuclear leucocytes, 
dendritic cells and T lymphocytes (both CD4+ and CD8+) were found.163, 167 C. trachomatis 
intracellular inclusion bodies were seen in epithelial cells and were strongly associated with 
inflammatory cell infiltrates. The presence of these infiltrates in the stroma was linked to the 
presence of follicles, mainly containing B-lymphocytes and surrounded by a T lymphocytic layer. 
Infiltrates of T and B lymphocytes, macrophages, plasma cells and neutrophils were surrounding 
the follicles. In the stroma of healthy conjunctival tissue collagen types I, III and IV were found 
whereas in active trachoma cases there was more collagen type V in the stroma with 
infiltrates.229 In individuals with trachomatous conjunctival scarring biopsy tissues had a thin 
conjunctival epithelium associated with loss of goblet cells and with compact scars replacing the 
normally loose vascular stroma underneath the epithelium.230 The thick scar tissue was largely 
composed of collagen type V. There was an increase in the deposition of collagen type IV in the 
conjunctival basement membrane of cases, replacing the normal collagen types I and III.231 The 
presence of new and different collagens changed the orientation of collagen fibrils from 
horizontal to vertical arrangement, resulting in distortion of the tarsal plate which eventually 
causes in-turning of eyelids and eyelashes.230 The tarsal plate maintained its thickness in 
trachoma cases however, glands such as the meibomian glands were severely weakened, which 
was associated with chronic inflammatory infiltrates. Inflammatory infiltrates dominated by T 
cells were also found in studies on biopsies of scarred individuals with trichiasis.232 However, the 
protective and pathological correlates of disease are not well defined, partly because this 
requires detailed long-term studies. It remains unclear which immunological responses lead to 
the tissue damage and scarring that causes blindness.  
 
1.7.7. Microbiology and Microbiome 
The papillary inflammation associated with scarring and disease progression is often found in 
the absence of C. trachomatis, particularly in adults.233 The factors driving this inflammation are 
unknown but might include normally benign things such as dust or components of the normal 
ocular microflora (which might exacerbate inflammation in an epithelium that has already been 
compromised by chlamydial infection), or it is possible that other pathogenic infections may be 
responsible. Changes in mucin expression at the ocular surface might alter the interaction of the 
epithelium with flora which may lead to more inflammation. 
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Ocular surface colonization by resident bacteria may serve as a defensive mechanism by 
inhibiting the growth of pathogenic bacteria.234 Two recent studies in mice have examined the 
role of ocular commensal organisms in protection from pathogenic infection. In one study, 
colonisation of the conjunctiva with Corynebacterium mastitidis led to the production of IL-17 
by JGT cells, which protected against pathogenic infection with Candida albicans and 
Pseudomonas aeroginosa.235  In the second study, colonisation of germ-free mice with coagulase 
negative Staphylococcus (CNS) induced resistance against P. aeruginosa keratitis.236 Changes to 
the ocular surface can also allow some ocular commensal organisms to behave as pathogens 
and cause disease or allow other pathogens to gain access and colonise the ocular surface.237 In 
animal models (monkeys) which were frequently inoculated with C. trachomatis or developed 
clinical signs of trachoma were inoculated with three common human pathogens (Haemophilus 
influenzae, Haemophilus aegyptius and Streptococcus pneumoniae); they found no difference in 
susceptibility to infection between animals with trachoma and other animals without trachoma. 
The authors suggested that C. trachomatis is essential in the development of blindness, while 
other bacteria may only be important in determining the severity of disease through increasing 
the amount of discharge, hence preventing clearance of infection or increasing chances of C. 
trachomatis reinfection.238   
 
In humans there is some evidence that ocular non-chlamydial bacteria are more commonly 
found in trachoma-diseased individuals than controls. Several studies have examined the 
relationship between the presence of active trachoma, C. trachomatis and other bacterial 
pathogens. However, these studies tended not to be population based and pre-dated sensitive 
molecular tests for C. trachomatis. Studies conducted in Tunisia, Morocco and Egypt frequently 
cultured Haemophilus spp, pneumococci, Moraxella sp, diplobacilli, Neisseria spp, 
Staphylococcus aureus, Streptococcus viridians, Corynebacterium xerosis, Staphylococcus 
pyogenes, Escherichia coli and diphtheroids from the conjunctiva.22, 239-243 Haemophilus spp was 
the most dominant in all studies done in North Africa. The Tunisian study found an association 
between ocular bacterial pathogens and seasonal epidemics of purulent conjunctivitis but not 
normal flora.22 Both pathogens and commensal flora were significantly reduced after antibiotic 
treatments,240-242 however, with the exception of Haemophilus, other species were highly 
affected by environmental changes in the absence of antibiotics.241 Conjunctivitis was frequently 
seen in young children and was associated with the prevalence of both pathogens and normal 
flora.241, 242 A study in India found no association of bacterial isolates in individuals with different 
stages of trachoma.243 The prevalence of pathogenic bacteria in children with trachoma was 
significantly reduced after a single dose of azithromycin in a longitudinal study done in a 
trachoma endemic area of Nepal,244 however, the distribution of specific bacterial species 
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remained the same. These studies were either cross sectional,22, 242, 243, 245, 246 case-control 240 or 
longitudinal with a short follow up duration,239, 241, 244 and relied on either bacterial culture or 
staining methods. No convincing link has been identified between intense/follicular 
inflammation and scarring. 
 
Recent population based studies have also identified the presence of other bacteria in 
individuals with active trachoma, trachomatous scarring, trichiasis and corneal opacification.3, 
69, 245-247 Species were either strongly associated with disease episodes or were more frequently 
detected in diseased individuals. In Tanzania, in a cross sectional study of children from an area 
with a low prevalence of active trachoma, TF was independently associated with the presence 
of Streptococcus pneumoniae and Haemophilus influenzae (type B and non–type B).246 In the 
same study no association was found between active follicular trachoma and C. trachomatis 
infection. In a cross-sectional study conducted in Northern Tanzania in adults with TS and control 
subjects, bacteria were cultured from 54% cases and 34% controls.245 Amongst TS cases the 
proportion that was culture positive was directly proportional to the severity of scarring. To date 
there is one published study of the  association between scarring progression and non-ocular 
bacterial infection in which Hu and colleagues conducted a two year longitudinal study in 
Northern Tanzania investigating progression of scarring and non-chlamydial ocular bacteria.248 
They recruited 800 participants with scarring but without trichiasis and were assessed at 
baseline, 6, 12, 18, and 24 months.  Samples were collected for laboratory bacterial culture and 
C. trachomatis detection. At 24 months data of 452 participants were available for comparison 
and photographs were assessed directly side-by-side between baseline and 24 months for 
scarring progression. There was significant association between progression of scarring and non-
chlamydial ocular bacteria, particularly those considered pathogens (OR = 2.39; 95% CI: 1.10 to 
5.16). However, contrary to this study, a cross sectional study from central Tanzania done in 
women aged between 18 and 47 years found no association between the presence of scarring 
and non-chlamydial bacterial infection.249  
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1.8. Current status of Trachoma/C. trachomatis Vaccine Development 
 
The C. trachomatis vaccine strategies that are generally being considered are based on 
induction of neutralising antibodies, prevention of Ct  entry to the host epithelial cells and 
prevention of bacterial cells replication.250 For several decades there have been attempts to 
develop vaccines against trachoma/chlamydia, however these have only induced short-term 
or partial protection.251, 252 A study of children in The Gambia who were visited regularly for 
more than 6-months showed that children who quickly cleared infection or disease had more 
focused antibody responses,,253 suggesting that protection is associated with focused 
antibody responses to a few specific antigens that can be targeted for vaccine design. 
Currently there are ongoing trials both in animal models and humans in which Chlamydial 
Major Outer Membrane Protein (MOMP) has emerged as the most suitable target, which 
can be delivered as a combined systemic and mucosal vaccine. MOMP is the main 
component of the only C. trachomatis vaccine in current human phase I clinical trials and it 
is the focus of several candidate vaccines. This clinical trial is sponsored by Statens Serum 
Institut in collaboration with Imperial College London: “Safety and Immunogenicity of a 
Chlamydia Vaccine CTH522 (CHLM-02)“ with ClinicalTrials.gov Identifier number 
NCT03926728. Two main designs of CTH522, are CAF01 liposome designed to aid cellular 
immunity and AL (aluminium hydroxide) to aid antibody production. Another ongoing clinical 
trial (number NCT02787109) recently published preliminary findings that found that 
recombinant protein subunit was safe.254 All vaccinated groups were able to induce anti- 
CTH522 IgG seroconversion while none of the placebo group experienced seroconversion. 
Of all evaluated CTH522, CAF01 immunogenicity profile was better which promises further 
vaccine development.
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1.9. Summary 
Trachoma remains a significant public health problem which affects the world’s most 
marginalised communities. C. trachomatis pathogenesis is challenging to understand 
because of the complex immunological interaction between host and pathogen and the 
length of the disease’s natural history. There is a gap of understanding of which components 
play a major role in protection from chlamydial infection and development of scarring. 
Evidence suggests that innate immune responses, driven by the conjunctival epithelium, play 
an important role in tissue damage and development of fibrotic complications. Detailed 
longitudinal studies are required to examine the contribution of C. trachomatis infection and 
components of the host immune response to progressive scarring trachoma. 
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2. Research Aims and Objectives 
 
 
Athumani M. Ramadhani – PhD Thesis 54 
2.1 Rationale   
Repeated conjunctival infection with C. trachomatis during childhood is thought to drive 
trachomatous inflammation and scarring. However, data supporting the role of repeated 
infection in driving scarring incidence and progression is limited. This warrants further 
investigation in order to improve our understanding of trachoma pathogenesis and control. 
The immunopathological mechanisms underlying how C. trachomatis infection and 
trachomatous inflammation drive scarring progression are also unclear. Understanding these 
mechanisms could enable development of therapeutic or prophylactic interventions 
designed to prevent or halt conjunctival scarring. Furthermore, it is not known whether these 
immune responses are impacted by treatment with the immunomodulatory antibiotic 
Azithromycin for trachoma control.  
 
The purpose of this study was to investigate C. trachomatis infection, clinical signs of 
inflammation and gene expression in a longitudinal cohort of children, in order to identify 
the key risk factors and immunological pathways associated with disease and progression. 
To achieve this, a four-year longitudinal study was conducted in a cohort of 666 children 
aged 6 to 10 years at baseline from a trachoma endemic community in northern Tanzania. 
Children were visited every three months for four years and clinical signs and conjunctival 
swabs were collected for detection of C. trachomatis and host gene expression. 
   
2.2 Hypotheses:  
1. The relationship between C. trachomatis infection and active trachoma is weaker 
after the initiation of MDA 
2. Distinct risk factors are associated with different clinical stages of trachoma 
3. Distinct immune responses are associated with C. trachomatis infection, conjunctival 
inflammation which persists after the clearance of infection, and scarring trachoma 
4. Azithromycin has an immunomodulatory effect on conjunctival gene expression 
responses 
5. Repeated ocular infection with C. trachomatis and clinical signs of inflammation are 
associated with increased risk of incident and progressive scarring trachoma 
 
 
 
Athumani M. Ramadhani – PhD Thesis 55 
2.3. Specific objectives: 
1. To perform a literature review and meta-analysis to examine the relationship 
between C. trachomatis infection and active trachoma at a population level before 
and after MDA for trachoma control 
2. To perform a literature review of longitudinal studies to describe the rates and risk 
factors for trachomatous scarring progression in all clinical stages of the disease  
3. To describe clinical signs and infection prevalence at the baseline time-point of the 
four-year longitudinal study and to investigate associations with conjunctival gene 
expression responses  
4. To analyse the stability of conjunctival gene expression responses prior to MDA and 
to determine the changes that occur following MDA treatment 
5. To describe the rates of scarring incidence and progression in the four-year 
longitudinal cohort study and to examine risk factors (C. trachomatis infection, TF, 
TP, age and sex) associated with scarring progression.   
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3. Research Methodology 
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3.1 Overview  
 
3.1.1 Study country  
This study was conducted in the United Republic of Tanzania (Tanzania), one of the five East 
Africa Countries (Figure 3.1). It has the largest population in East Africa and the lowest 
population density with a current population estimate of about 54 million.255 Two third of 
the population is living in rural areas and youths (<25 years) account for 2/3 of the total 
population. The domestic growth product (GDP) per capita was estimated to be 1304 USD in 
2017, ranked 159 out 187 worldwide. The country's Human Development Index (HDI) value in 
2017 was 0.538, one of the lowest HDI in the world ranking 154 out of 189 
countries/territories.256 Tanzania is one of 42 trachoma endemic countries identified by the 
GTMP from 2012 to 2016.12 2018 data from the WHO estimated that about 3,216,046 potentially 
require intervention with mass antibiotic drug treatments (MDA), facial cleanliness, and 
environmental hygiene for trachoma control.13 A total of 2,651,671 (8.2%) had received 
antibiotic treatment and 2120 were operated on to correct trachomatous trichiasis in 2017. In 
a recently published report from Tanzania which surveyed 104,959 participants for clinical signs 
of trachoma in 23,171 households; 44,511 children aged 1 to 9 years old  examined for follicular 
trachoma (TF) and 65,255 aged  15 and above examined for trichiasis.257 Approximately 1.9% of 
children were found with TF and 0.3% of adults found with trichiasis. Out of 31 districts 
surveyed, 3 qualified for mass MDA with azithromycin. To control the disease requires multi-
sectoral involvement including health services and water supply. Unfortunately, areas with most 
trachoma cases are falling under poor health services and long-lasting shortage of clean water.  
 
Figure 3.1. Map of Tanzania. Source: http://ontheworldmap.com/tanzania/tanzania-regions-
map.html Accessed 28th October 2018. 
 
 
 
 
 
 
 
 
 
 
 
Study site 
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3.1.2 Study Site  
This study was conducted in between Mount Kilimanjaro (Kilimanjaro region) on the eastern 
side and Mount Meru (Arusha region) on the western side. The field site is about 100km away 
from Kilimanjaro Christian Medical centre (KCMC) where this study was coordinated, which is 
about 2 hours’ drive by Landrover. Despite the rocky terrain the roads are passable throughout 
the year, however, during the rainy season mud can be a challenge in some areas (Figure 3.2).  
Health services are not easily accessible to this community due to either government facility 
shortage or nature of the community members being pastoralists hence some temporarily move 
away from their homes searching for pastures and water. The area is dry for most of the year 
and has lots of dust, with the exception between February and May when there is rainfall.  
 
Ethical clearance to perform this study was received from the National Institute for Medical 
Research (NMR) (Reference. NIMR/HQ/R.8a/Vol. IX/1213) and the London School of Hygiene & 
Tropical Medicine Ethics Committee (Application number 5988). The study was then introduced 
to Regional Medical Officers, District Medical Officers and the village leaders. From a pilot study 
carried out in 2012 and previous studies by our group in the neighbouring villages, the 
prevalence of active trachoma (and C. trachomatis infection) in 1-9 year olds was found to be 
above 10%, this qualified for MDA as per WHO recommendations.  
 
The pilot study was conducted by collecting conjunctival swab samples selected randomly from 
children aged between 6 and 10 years from the study site which were analysed in the KCMC-
KCRI biotechnology laboratory (KCRI-BL) for C. trachomatis detection. C. trachomatis DNA was 
isolated from RNAlater stored swabs using the QIAamp DNA minikit (Qiagen, Crawley, United 
Kingdom) and was detected using the Amplicor CT/NG kit (Roche Molecular Systems, 
Branchburg, NJ) as previously described.85 Out of 41 samples tested 16 (39.0%) were positive. 
From this study was planned to collect samples from this previously untreated community 
before the first MDA treatment, which was scheduled to be done 6 months (determined by the 
availability of Azithromycin) after commencing the study and after three time-points of 
examination.  
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Figure 3.2. Infrastructure, geographical features and habitat of the study area. Clockwise from 
top left; challenges of transport during rainy season, children with high density of flies which 
may be associated with transmission, drought, livestock grazing  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 Study designs and sample size 
This longitudinal cohort study aimed to investigate factors associated with progression of 
scarring and host immune responses in individuals with C. trachomatis infection, active 
trachoma (TF/TP) and scarring sequalae in children aged between 6-10 years at the beginning 
of the study. A total of 666 children were found eligible during registration, however, during 
recruitment only 616 were available whereas the other 50 either refused to participate or 
moved away during enrolment. They were visited every three months for four years. There were 
three potential outcomes to consider: the progression of scarring, the persistence of 
inflammatory disease between visits, and the number of episodes of C. trachomatis infection 
available for study.  
 
Clinical Scarring: Previous study in the same area but different village found prevalences of TF 
and C. trachomatis were 13.7% and 5.3% respectively in children under 10 years.246 Furthermore 
other unreported findings from the same area suggests that some 30% of 10-year olds in 
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trachoma endemic communities have microscopic scarring detectable by In vivo Confocal 
Microscopy (IVCM), which is not clinically apparent. Using the data from earlier studies from a 
neighbouring community with the same patterns of life, we estimated that over a 4-year period 
it is plausible that 20% (5.4% per annum) would have shown evidence of incident or progressive 
scarring in a cohort of 6-10-year olds in a community with 30% active trachoma (TF) prevalence 
in 1-9 year olds. Assuming that we wish to detect a risk factor (exposure) present in one-third of 
subjects, which increases the relative risk of emergent scarring by 2, we made the following 
calculations in Table 3.1.  
 
Table 3.1. Sample size calculation.  
Power Confidence (equivalent number of comparisons) 
Estimated 
sample size 10% dropout Total 
0.8 95% 291 29 320 
0.9 95% 384 38 422 
0.8 99% (5) 417 42 459 
0.8 99.5% (10) 468 47 515 
0.8 99.9% (50) 591 59 650 
 
To detect fine scarring, side-by-side digital photographs were compared between the baseline 
(or second time-point for those who were not present during enrolment in the baseline) and 
final time-point (or 16th time point for those missed in the final time-point) by an experienced 
ophthalmologist (Matthew Burton) to 448 children (whose were data available). 
 
Inflammatory Trachoma: In a study of 650 6-10 year olds subjects in a stable endemic 
community with 30% disease prevalence in 1-9 year olds we expect that at each time point, 
some 20% (130) of subjects aged 6-10 would have disease from previous information. In earlier 
longitudinal studies from The Gambia, 60% of clinically diseased 6-10 year olds resolved their 
clinical signs of inflammatory disease at 3 months of follow up.27, 29 Allowing for annual 
treatment of the affected communities, loss of independence arising from the fact that the same 
subjects may become diseased again at another follow up, and dropout, it is reasonable to 
expect that a cohort of 650 subjects followed for 4 years would yield more than 243 disease 
(active trachoma) episodes. For gene expression data measured in the cohort, values were 
normalized relative to the expression of HPRT1 in the same sample, to adjust for variable 
concentrations and then interpreted by comparing fold change of control versus cases (C. 
trachomatis infection, TF, TP and scarring) adjusted for age and sex.  
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C. trachomatis Infection: We anticipated that 10% (65) of subjects would show evidence of C. 
trachomatis infection at baseline. A cohort study of 650 6-10-year olds was therefore expected 
to yield adequate numbers of infected participants for the studies outlined. 
 
SAFE strategy; All community members who were found with trichiasis were offered surgery 
free of charge at the nearest available health centre. The majority of individuals with TT 
accepted the offer and most of those surgeries were done at KCMC referral Hospital. All 
community members were offered free of charge mass drug administration (MDA) once 
annually for the first three years. This was done together with district eye coordinators who 
were responsible for dispensing drugs to people while our field team were registering their 
personal details. The drugs consisted a single-dose of azithromycin i.e. 1g for adults and 20mg/kg 
for children and tetracycline eye ointment applied twice a day in both eyes for six weeks which 
was offered to pregnant women and infants aged below six months. Under guidance of village 
leaders, drugs were given mostly at their homes, where we asked all household members who 
were around to come back to their homes for treatment. In some cases, children were given 
drugs at their schools if the time for treatment was due when children were at schools. This was 
done through guidance of teachers and village leaders. All community members who received 
drugs were registered in our database. Some people refused the treatment for different 
reasons, mostly based on previous MDA history, some believed themselves to have healthy eyes 
and others were away from their homes mostly for livestock activities because the majority of 
these community members are pastoralists. We had opportunity to promote health education 
messages in the communities about face washing and general hygiene environments. It was 
positively taken by most community members, however, some interpreted it in a negative way; 
telling them about face washing was perceived as insulting them as it was interpreted that we 
see them as dirty. This could have been rectified through using their leaders and some of 
educated individuals among themselves.  
 
3.3 Procedures for sample collection and processing 
3.3.1 Selecting eligible families for study and Informed Consent 
The main factors considered when recruiting participants were age and being a resident of one 
of three study villages. All children aged between 6 and 10 years were eligible for being included 
in the study. Individuals who had clinical disease other than trachoma at the beginning of study 
which could have been confused with trachoma diagnosis were excluded from the study. In 
collaboration with the regional eye care teams of Kilimanjaro and Arusha Regions, we identified 
a number of communities with an ongoing problem with active trachoma in children of at least 
30%. These communities were contacted, and the nature of the study explained. A census of the 
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children was conducted, and children aged 6-10 years (both male and female) were enrolled 
into the study if their parents or guardian gave consent. The children enrolled into the cohort 
may or may not have had active trachoma at baseline, although overall >30% had clinical signs 
of active disease. We included all children aged 6-10 years (male and female) and excluded 
children under 6 years or older than 10 years and/or that had other chronic conjunctival disease, 
such as vernal conjunctivitis. 
 
The study was conducted in three trachoma endemic villages. Prior to commencing the 
fieldwork activities in January 2012, the team met with the leaders of each of the three 
communities to explain the purpose and nature of the study. Following agreement between 
village leaders and our team, several community meetings were held to sensitise the entire 
community about the proposed research project and related activities. During the enumeration 
phase the team visited all households in the study area. At each household they met with 
parents / legal guardians of the children who would be potentially eligible for enrolment. The 
parents / guardians of the child were informed about nature of the study and asked if they would 
be willing for their child to participate. The nature of the study was explained in detail in either 
Kiswahili or Maasai by the field worker. There was an opportunity to discuss and ask questions. 
Finally, if the parent or guardian agreed to allow the child to be enrolled into the study this was 
documented on a consent form in Kiswahili including their signature or thumb print and 
witnessed by a third party. Following the agreements between two parties, children were visited 
at either their home or at school where they were examined, samples were collected and 
treatment was offered if the MDA schedule was due. Collecting samples from schools took less 
time and cost because the majority of children were available all at once, and setting up facilities 
for examination were done only once instead of multiple times at different households. In 
schools the study was introduced at the beginning and teachers were informed about presence 
of participants at their school. Therefore, during follow up time, the list was presented to 
teachers and they kindly assisted us to find the children from their classes. However, teachers 
had no mandate on enrolment of children to the study. After enrolment children were invited 
for examination as detailed below.  
 
3.3.2 Field team training, travel and working facilities 
Field team and field facilities were previously established by Prof. Matthew Burton. Some 
members of the field team had previously been working in trachoma fieldwork for years; 
however, before commencing the study a short training was conducted at KCMC to refresh 
previous procedures and to introduce new ones. Ophthalmic nurses (Patrick Massae and Aiweda 
Malisa) each had experience of over 10 years in trachoma fieldwork. Fieldworkers (Alex 
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Pallangyo and Phillipo Mollel) who were assigned the task of informed consent were from the 
study area and were very familiar with the majority of the society’s language; they also recorded 
participant’s personal details and grading scores. Conjunctival photographs were taken by 
qualified and experienced persons (Henry Marielle and Kelvin Mbuya). An experienced driver 
(Antipas Massae) was employed who managed driving conditions despite the poor transport 
infrastructure challenges (Figure 3.3).  
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Figure 3.3. Sample collecting process. Clockwise from left: travelling to the field for children 
examination, preparation of tent behind the car for examination process, examining eyes and 
collecting swab samples from the eye.  
 
 
 
The following were brought for field work; consent forms (only at beginning of the study), the 
list of study participants file, a laptop for clinical data collection, clinical data collection paper 
forms (as backup), boxes containing empty and RNAlater pre-filled tubes for swab storage, a 
cool box containing icepacks, examination gloves, preservative-free proxymetacaine 
hydrochloride placed inside the cool box throughout the field work, 2.5X binocular magnifying 
loupes with bright torch for clinical examination, a digital camera (Nikon D90 with 105mm Macro 
lens) for ocular conjunctival photography (including spare batteries) and waste disposal bags, 
which were returned to KCMC for proper disposal. 
 
Samples were collected by the nurse wearing hand gloves which were changed after each 
individual examination. Left eyes of the children were anaesthetised with a drop of preservative-
free proxymetacaine hydrochloride 0.5%w/v so that participants did not experience any 
discomfort. The upper conjunctiva of the left eye was examined by the nurse using x2.5 loupes 
and a bright torch and graded for clinical signs using the 1981 WHO “FPC” detailed grading 
system.26 The conjunctiva was photographed using a digital camera and then two swab samples 
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were taken. The first swab was horizontally rubbed against the conjunctiva four times, with a 
quarter turn each time, and then stored in labelled RNAlater tubes for gene expression analysis 
and C. trachomatis detection. The same procedure was followed for the second swab collection 
however, that was stored in dry tubes for future study of non-chlamydial infections. After every 
50 clinical swab samples were collected, an air control swab was collected. This was done by 
waving the swab in the air near to participants everted eye for a few seconds and then the same 
storage and downstream procedures were followed as for clinical swab samples. Air control 
swab samples were labelled like clinical swab samples to avoid laboratory bias. There was no 
loss of specimen. Swab samples stored in RNAlater were labelled CR001, CR002, CR003, etc and 
those stored dry were labelled CD001, CD002, CD003, etc. All swab samples were kept in a cool 
box packed with icepacks in the field and were transferred to KCMC later on the same day for 
further storage (Figure 3.4). The dry swab samples were stored in -800C freezers on the same 
day, while the RNAlater stored samples were stored at 2-80C in the fridge overnight to maximize 
absorption before prolonged storage in -800C freezer in the following day.   
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Figure 3.4. Sample storage and processing facilities. Clockwise from left: KCRI-BL where 
samples were stored and processed, Biorepository were samples were stored, Sample 
processing facilities and ViiA7 PCR machine used for both gene expression and C. trachomatis 
detection analyses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An Access database was created for data collection in the field, with only a very limited number 
of individuals who accessed it. All data collection forms and consent forms were archived in a 
secure office locked in a cabinet. Data was entered onto a password-protected computer. 
 
3.3.3 Laboratory team training and working facilities 
Most of the laboratory work was done at  KCRI-BL, Moshi, Tanzania using the laboratory facility 
the project had already established. Only C. trachomatis detection of baseline and second time-
point samples was done in the UK at LSHTM laboratories because the samples were tested using 
diagnostic droplet digital PCR assay that had been evaluated against Roche CT/NG Amplicor (a 
ddPCR machine is not available at KCRI-BL). At all remaining time-points including the second 
time-point, C. trachomatis detection and conjunctival gene expression profiling were done at 
KCRI-BL. C. trachomatis detection for the second time point was done both in London and Moshi 
using different detection methodologies for comparison purposes. The relative diagnostic 
performance of the C. trachomatis qPCR assay used for the majority of this study was also 
formally evaluated in a separate study.258 In the laboratory, experiments were performed by 
myself and two junior laboratory technologists (Karim Mtengai and Elias Mafuru), each at 
different times, who were recruited to work alongside me under close supervision. A post-
doctoral research fellow (Dr Tamsyn Derrick) from LSHTM later joined the team and helped to 
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oversee the laboratory work. All team members were trained about the ethics of the study as 
per KCRI regulations which requires all laboratory users to attend Good Clinical Laboratory 
Practise (GCLP) training and various challenges were solved as required.   
 
3.3.4 Preparation of dry and RNAlater tubes for field work 
Sample tubes for swab collection during field work (discussed above) were prepared in the pre-
PCR preparation room using gloves. Sterile 2-millilitre screw cap tubes were packed in sample 
storage boxes (each stores 100 tubes) for dry swab sample collection. The same number of clean 
2-millilitre screw cap tubes were filled with 200Pl of RNAlater using an automatic dispenser and 
then packed in the storage boxes. The boxes were then handed to the field team.      
 
3.3.5 Gene expression procedures 
Genes of interest were selected following previous findings from Tanzania and The Gambia by 
Prof. Matthew Burton, Prof. Martin Holland and myself. These genes were selected because 
they were thought to have a significant role in trachoma. Previous work from The Gambia, 
Ethiopia and Tanzania reported their differential expression in active trachoma, scarring and 
trichiasis.101, 165, 166, 259-261  Primers and probes for each target were pre-printed onto TaqMan Low 
Density Array cards (Thermo Fisher Scientific), providing a high-throughput platform for gene 
expression profiling of a large number of samples. Several cards were initially tested and were 
found to work before commencing the work. At baseline 91 genes were tested on two separate 
array cards. From analysis of baseline results, 46 genes were chosen as they were found to be 
most related to infection and/or clinical signs. The selected 46 genes were used for the rest of 
follow up time-points.  At the baseline, expression of three different reference genes: HPRT1, 
GAPDH, and RPLP0 were measured. However, only HPRT1 was used throughout for 
normalization as it was expressed at a relatively similar level to the majority of other transcripts 
of interest, whilst GAPDH and RPLP0 expression was very high. Data were analysed using relative 
quantification by comparing control versus cases by using the Delta delta CT method.262 
Extraction of RNA and gene expression protocols are presented in appendices 3, 5 and 6.  
 
3.3.6 C. trachomatis infection detection procedures 
The procedure for C. trachomatis detection by qPCR is presented in appendices 3 and 4. Three 
genes were targeted; Homo sapiens RNase P/MRP 30-kDa subunit gene (RPP30) (human 
endogenous control gene for insuring that sample was successfully extracted), C. trachomatis 
outer membrane complex protein B (OMCB) (single copy gene from C. trachomatis 
chromosome), and Plasmid open reading frame 2 (pORF2) gene and primers and probes 
sequences are displayed in table 3.2. Detection of infection using droplet digital PCR (ddPCR) at 
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baseline was described by Roberts and colleagues,263 this was done in London. Following this, a 
qPCR assay for detection of C. trachomatis by qPCR on the ViiA7 thermal cycler at KCRI-BL was 
optimised for use for all subsequent time-points.  
 
Table 3.2. Oligonucleotides used in C. trachomatis detection. 
Targets/ Product sizes primers and probe sequences 
RPP30/65 bp forward: 5’ AGATTTGGACCTGCGAGCG 3’, 
 reverse: 5’ GAGCGGCTGTCTCCACAAGT 3’,  
 probe: 5’ [HEX] TTCTGACCTGAAGGCTCTGCGCG [BHQ1] 3’ 
OMCB/106 bp forward: 5’ GACACCAAAGCGAAAGACAACAC 3’,  
 reverse: 5’ ACTCATGAACCGGAGCAACCT 3’,  
 probe: 5’ [FAM] CCACAGCAAAGAGACTCCCGTAGACCG [BHQ1] 3’ 
Plasmid/109 bp forward: 5’ CAG CTT GTA GTC CTG CTT GAG AGA  
 reverse: 5’ CAA GAG TAC ATC GGT CAA CGA AGA  
 Probe [NED] 5’ CCC CAC CAT TTT TCC GGA GCG A [BHQ1] 3’ 
 
3.3.7 Optimization of C. trachomatis detection using quantitative PCR (qPCR) in KCRI-
BL 
One of the most critical parts of this work was optimization of C. trachomatis detection at KCRI-
BL. The primers and probes used in this work were previously reported,263 and were developed 
into a triplex assay for C. trachomatis detection by the trachoma research group at LSHTM. 
ddPCR was used for absolute quantification of nucleic acid with the reaction mixture of 20µl and 
a concentration of 0.3µM each primer and probe (PLASMID/RPP30), and 4.95µl of unknown 
quantity sample DNA. PCR thermal cycling conditions were 95°C for 10 minutes followed by 40 
cycles of 95°C for 15 seconds and 60°C for 30 seconds.   
 
Twenty-four clinical samples were tested using the ViiA7 PCR machine in which all were 
amplified. However, OMCB produced abnormal curves whereas both Plasmid and RPP30 
produced logarithmic curves (Figure 3.5). The status of all 24 samples were known before (by 
ddPCR) and not all were positive, therefore this was false positivity of the plasmid target. The 
similar amplification between the plasmid and RPP30 channels suggested that there was 
fluorescence leakage across the two fluorophores, while the unusual curves of OMCB were 
thought to be due to the long storage of master mix (retesting using new master mix generated 
normal OMCB curves) (Figure 3.5).  
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Figure 3.5. Amplification plots of 24 clinical samples using three targets showing amplification 
curves 
 
 
 
New standards, primers and probes from LSHTM were used and the ATTO fluorophore used on 
the original plasmid probe was replaced by NED. Four known C. trachomatis positive clinical 
samples, 115 unknown clinical samples, standards and a positive control sample (C. trachomatis 
strain L2 cultured in HeLa cells in London, scraped into RNAlater, sent to KCRI-BL were extracted 
on site using a DNA/RNA Purification Kit (Norgen Biotek Corp, Canada) were tested. The 
standards and C. trachomatis L2 DNA worked on all 3 channels, although amplification of L2 DNA 
appeared less efficient than amplification of standards, perhaps indicating some sample 
inhibition as results of uncleaned nucleic acids from protein and other cells debris or reagents 
used in the procedure (Figure 3.6). In clinical samples RPP30 was detected (with an expected CT 
value ~27) but OMCB and Plasmid were not detected. This might have been a result of inhibition 
in clinical samples (perhaps a result of carry-over of inhibitors during the extraction process, 
either from the extraction kit, the swab or the sample itself) and a low concentration of 
chlamydial DNA compared to RPP30.  
  
Plasmid RPP30 OMCB 
    Old MM 
MM 
New MM 
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Figure 3.6. Amplification plots of three targets of C. trachomatis detection, showing 
amplification curves of standards, positive control (L2) and clinical samples  
 
 
 
To check that all three targets were present in clinical samples, conventional PCR was run with 
all three primer pairs separately (RPP30, plasmid and OMCB) data not shown. OMCB and 
plasmid bands were detected by gel electrophoresis for the standards, L2, C. trachomatis 
positive clinical samples (n= 3), and no OMCB or plasmid bands were detected for C. trachomatis 
negative clinical samples (n=3). The RPP30 band was particularly weak. Chlamydial DNA was 
therefore present and amplified by the primers, using the same master mix as used in qPCR. This 
suggested that the problem was due to the probes failed to separate the reporter dyes from 
quencher dyes resulted into no signal, perhaps in combination with sample inhibition.  
 
The standards, L2 and known C. trachomatis positive clinical samples were next tested using 
SYBR green dye (which is incorporated into double stranded DNA) on a Rotorgene thermal 
cycler, using the same primers pairs. The standards and L2 amplified RPP30, OMCB and plasmid 
targets with the expected sigmoidal amplification curves and cycle threshold values <30 cycles 
in single plex assays using SYBR green Table 3.3. Some of the RPP30/OMCB/plasmid wells did 
not amplify for the clinical samples, however, this was inconsistent within samples and 
correlated with a low sample volume. Of the C. trachomatis targets that did amplify in clinical 
samples, CT values were <30, suggesting that target was present. However, the curves were not 
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sigmoidal but more linear at 45 degrees, suggesting the reaction was less efficient and again 
indicating the presence of inhibitors or sub-optimal reaction chemistry in clinical samples.  
 
Table 3.3. Cycle threshold values of all three targets (run in separate wells) in standards and 
C. trachomatis positive clinical samples tested using SYBR green on a Rotorgene qPCR machine  
 
SYBR Cycle threshold values 
 
RPP30 OMCB PLASMID 
Standard 8 13.62 10.6 11.71 
Standard 7 17.16 15.46 15.67 
Standard 6 20.76 18 19.46 
L2 25.15 18.85 18.44 
CR1-041 39.09 26.37 28.55 
CR1-250 23.26 
  
CR1-218 
 
26.41 29.15 
CR1-262 23.05 27.94 28.85 
 
In summary, plasmid and OMCB targets failed to reproducibly amplify in C. trachomatis positive 
clinical samples using TaqMan master mix on the qPCR ViiA7 machine. End-point PCR and qPCR 
using SYBR green showed that the primers amplified the product and the target was present in 
the clinical samples. The assay worked well with standards and a positive control sample but 
failed with clinical samples for plasmid and OMCB, whereas RPP30 worked well for both 
standards and clinical samples. This is possibly due to the high concentration of RPP30 in all 
clinical samples relative to chlamydial targets. These data suggested that some degree of sample 
inhibition in clinical samples (but not in the relatively cleaner standards/positive control 
sample), in combination with inefficient reaction chemistry, led to a lack of amplification of the 
least abundant targets.  
 
New TaqMan Multiplex Master Mix was ordered and performance was found to be much better 
than TaqMan Universal Master Mix. TaqMan Multiplex Master Mix is designed for multiplex 
reactions (whereas Universal is not) and therefore contains a higher concentration of reaction 
components.  In order to evaluate the assays performance in clinical samples, samples from the 
second cohort time-point were tested by ddPCR at LSHTM (for plasmid and RPP30 targets only, 
due to sample volume contraints) and by qPCR in KCRI-BL and results were compared. Relative 
to ddPCR, qPCR had a sensitivity of 100%, specificity of 97.2%, positive predictive value of 83% 
and negative predictive value of 100% (Table 3.3). There was a good correlation between 
estimated target concentration by qPCR and ddPCR, and also between OMCB and plasmid 
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targets by qPCR (figure 3.7). This qPCR assay performance was deemed sufficient and was used 
to test all subsequent time-points for C. trachomatis. The protocol for this assay was attached 
in the appendix 4B. 
 
Table 3.4. C. trachomatis qPCR results in cohort time-point 2 samples relative to ddPCR.  
 
 qPCR negative qPCR positive 
ddPCR negative 445 13 
ddPCR positive 0 65 
  
Figure 3.7. Correlation between target concentration estimated by A) qPCR and ddPCR and B) 
between OMCB and plasmid chlamydial targets, in clinical samples from time-point 2.  
A      B  
  
 
3.4 Analyses of data 
Clinical data collected in Access were transferred to STATA for analysis. Data were merged with 
gene expression results and C. trachomatis detection results exported from the ViiA7 PCR 
machine.   
TaqMan is a molecular technique that amplifies nucleic acid concurrently with generation of 
detectable specific signals.264 It utilises a pair of primers and non-extendable probes. Probes are 
short specific sequence oligonucleotides which bind within the region delimited by primers. 
Probes differ from primers because they cannot be extended by Taq polymerase due to lack of 
free OH group and presence of both reporter (florescent molecule/dye) at 5’ end and quencher 
(quenching fluorescent signal from the reporter) at 3 end’. Primer extension product starts from 
the 5’ end toward 3’ end using Taq polymerase. Probe binds to downstream (5’ → 3’) of primers 
during PCR reactions, labelled with reporter and quencher is degraded by 5’-3’ endonuclease 
activities of Taq polymerase following hybridisation to specific target for fluorophore base 
detection.265, 266 Degradation of the probe releases the fluorophore from it following break of 
the proximity to the quencher, consequently releasing the quenching effect and allowing 
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fluorescence of the fluorophore.267 Energy transfer from reporter to quencher (Fluorescence 
Resonance Energy Transfer) inhibit fluorescence due to proximity to each other, however 
following separation of quencher from reporter by the enzyme, reporter emits fluorescence 
with a dye-specific wavelength. Emitted fluorescence is equivalence to the amount of PCR 
product accumulated and that the process repeats to every cycle without interference of 
accumulated PCR product. Fluorescence signals permit quantitative measurements of the 
accumulated product during exponential stages of the PCR. The technology referred to 
hydrolysis probes are designed to increase the specificity of quantitative PCR. TaqMan has 
advantages over SybrGreen following presence of Probes; TaqMan detects only specific PCR 
product hence used in multiplex reactions and contribute to susceptibility of mutations in the 
template. However, TaqMan is relatively more expensive. 
 
Interaction terms were tested in some of analyses in this thesis. Interaction occurs when there 
are three or more variables which are related. Statistically, an interaction term refers to a 
situation in which the effect of one independent (causal) variable to outcomes depends on or is 
affected by a second independent (causal) variable specifically when these causes cannot be 
pooled together. Referring to chapter 4 of this thesis in methodology section in the 4th paragraph 
the relationship between clinical signs and infection was analysed separately before and after 
treatment data and then tested for interaction effect of these two variables (pre- and post-
treatment) to assess whether the association between clinical signs and infection was similar. 
Also in the 7th chapter, methodology section (subheading ‘Statistical analysis’, 3rd paragraph) the 
change in gene expression was assessed following different time-points and then tested for 
interaction before and after MDA. Therefore interaction helps to expand understanding of the 
relationship between different variables and have significant implication on interpreting the 
results. 
 
3.5 Summary 
Samples were successfully collected every 3 months for 4 years, with three annual MDA-
azithromycin treatments. The total number of samples collected at each time-point of 
examination is summarised below (Table 3.5). Sample collection at every time-point took about 
three weeks in total. No adverse events, social harms or protocol violations were reported in 
the study.  Overall, the majority of human housekeeping gene (HPRT1) expression CT values 
were below 30 and were normally distributed, which allowed parametric statistical tests to be 
used (Figure 3.8).  
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Table 3.5. Statistics of examination time-points 
Time-points  Date Completed No. children seen 
1 25 March 2012 506 
2 22 May 2012 536 
3 28 September 2012 473 
4 23 November 2012 468 
5 18 February 2013 478 
6 17 May 2013 472 
7 30 September 2013 472 
8 15 November 2013 459 
9 7 February 2014 451 
10 12 May 2014 409 
11 2 September 2014 433 
12 24 November 2014 432 
 
Figure 3.8. Normal distribution of the human housekeeping gene, HPRT1, with the majority of 
CT values below 30 in all time-points. 
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4. The relationship between Active Trachoma and ocular 
Chlamydia trachomatis infection before and after mass antibiotic 
treatment 
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The Relationship between Active Trachoma
and Ocular Chlamydia trachomatis Infection
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Abstract
Background
Trachoma is a blinding disease, initiated in early childhood by repeated conjunctival infec-
tion with the obligate intracellular bacterium Chlamydia trachomatis. The population preva-
lence of the clinical signs of active trachoma; ‘‘follicular conjunctivitis” (TF) and/or ‘‘intense
papillary inflammation” (TI), guide programmatic decisions regarding the initiation and ces-
sation of mass drug administration (MDA). However, the persistence of TF following resolu-
tion of infection at both the individual and population level raises concerns over the
suitability of this clinical sign as a marker for C. trachomatis infection.
Methodology/Principle Findings
We systematically reviewed the literature for population-based studies and those including
randomly selected individuals, which reported the prevalence of the clinical signs of active
trachoma and ocular C. trachomatis infection by nucleic acid amplification test. We per-
formed a meta-analysis to assess the relationship between active trachoma and C. tracho-
matis infection before and after MDA. TF and C. trachomatis infection were strongly
correlated prior to MDA (r = 0.92, 95%CI 0.83 to 0.96, p0.0001); the relationship was simi-
lar when the analysis was limited to children. A moderate correlation was found between TI
and prevalence of infection. Following MDA, the relationship between TF and infection
prevalence was weaker (r = 0.60, 95%CI 0.25 to 0.81, p = 0.003) and there was no correla-
tion between TI and C. trachomatis infection.
Conclusions/Significance
Prior to MDA, TF is a good indicator of the community prevalence of C. trachomatis infec-
tion. Following MDA, the prevalence of TF tends to overestimate the underlying infection
prevalence. In order to prevent unnecessary additional rounds of MDA and to accurately
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ascertain when elimination goals have been reached, a cost-effective test for C. trachoma-
tis that can be administered in low-resource settings remains desirable.
Author Summary
Trachoma is the leading infectious cause of blindness worldwide, caused by the bacterium
Chlamydia trachomatis. Repeated infection of the conjunctiva during childhood can initi-
ate chronic conjunctival inflammation. This can lead to conjunctival scarring, in turning
of the eyelashes, abrasion of the eyelashes on the cornea and eventually blindness later in
adulthood. TheWorld Health Organization recommendsmass drug administration
(MDA) for infection control when the prevalence of the clinical sign of Active Trachoma
(TF) is 10% in 1–9 year olds. This systematic review of the literature examined the rela-
tionship between TF and C. trachomatis infection before and after MDA in order to evalu-
ate the usefulness of TF for guiding trachoma control programmes. The population
prevalence of TF and C. trachomatis infectionwere strongly correlated prior to MDA,
however the relationship was weaker after MDA with a greater tendency for TF to overes-
timate the underlying infection prevalence. A cost effective test for C. trachomatis suitable
for use in low resource settings could prevent unnecessary additional rounds of MDA in
the population and could identify when trachoma elimination goals have been reached at
an earlier time point.
Introduction
Sight loss from trachoma is the end result of a scarring disease process that is initiated in early
childhoodby the obligate intracellular bacteriumChlamydia trachomatis [1]. Repeated infec-
tion of the conjunctiva by C. trachomatis causes a recurrent chronic follicular conjunctivitis
(TF) of the upper eyelid mucosal surface (Fig 1) [2]. This can sometimes be particularly severe
with intense papillary inflammation (TI). Together, TF and / or TI are collectively referred to
Fig 1. The natural history of an episode of ocular C. trachomatis infection and the associated conjunctival inflammatory response.
Trachomatous Inflammation–Follicular (TF): the presence of five or more follicles in the upper tarsal conjunctiva. Trachomatous Inflammation–Intense
(TI): pronounced inflammatory thickening of the upper tarsal conjunctiva that obscures more than half of the normal deep tarsal vessels [2].
doi:10.1371/journal.pntd.0005080.g001
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as “Active Trachoma”. Conjunctival scarring gradually develops, usually becoming visible from
early adulthood. Eventually the scarring causes the eyelashes to turn in and scratch the surface
of the eye. If left uncorrected, trichiasis traumatises the cornea surface, resulting in opacifica-
tion and sight loss.
There is a variable relationship between the clinical signs of Active Trachoma and the pres-
ence of C. trachomatis infection. The natural history of an infection episode in children is prob-
ably characterised by a brief “pre-clinical” phase, in which there is detectable infection but the
clinical signs of the inflammatory response are yet to develop (Fig 1). Human volunteer experi-
ments in which the conjunctiva was inoculatedwith C. trachomatis indicated that the signs of
disease typically take about 10 days to develop in previously uninfected individuals [3]. This is
followed by a variable period of time in which both infection and disease can be detected at the
same time; this may last for several days to many weeks. The immune response brings the
infection under control, completely clearing it or reducing it to undetectable levels. However,
inflammatory clinical signs persist, typically lasting several weeks after the resolution of the
infection. In children aged 4–15 years, data from longitudinal cohort studies estimate the
median duration of infection range between 23 days and 8 weeks, and the median duration of
disease between 54 days and 18 weeks [4–6]. The duration of disease and infection declines
with increasing age. Therefore, at an individual level there is frequently a large mismatch
betweenwhen infection can be detected and the clinical signs of disease are found [7].
The most recent estimates from theWorld Health Organization (WHO) Alliance for the
Global Elimination of Trachoma by 2020 (GET2020) estimates indicate that about 200 million
people live in trachoma endemic areas in 42 countries, 2.2 million have visual impairment or
blindness, and about 3.2 million have trichiasis [8]. To meet this large public health challenge,
the GET2020 Alliance recommends the implementation of the SAFE Strategy which tackles
the disease at different stages: Surgery to correct trichiasis,Antibiotics to treat chlamydial
infection and Facial cleanliness and Environmental improvements to suppress transmission of
the infection [1].
The antibiotic azithromycin is being used in community-widemass drug administration
(MDA); it is given as a single oral dose on an annual basis in endemic districts. Decisions
around when to initiate and stop MDA are guided by the prevalence of TF in children in
endemic communities. According to the current guidelines, azithromycin MDA is indicated
for entire districts where the prevalence of TF in 1–9 year olds is 10%. Moreover, the determi-
nation of whether a program has controlled the active stage of trachoma as a public health
problem also rests on the district level prevalence of TF [9].
Therefore, in view of the significance attached to TF for making programmatic decisions, it
is important to understand the relationship between active disease and chlamydial infection in
endemic communities. It is probable that this relationship changes after the introduction of
MDA and will vary with different levels of endemicity. Several studies have specifically investi-
gated what clinical signs can tell us about infection [7, 10–19]. However, in addition there are
many other population-based studies, which report on both disease and infection, that can
contribute information. Here we systematically review the published literature for reports that
can inform our understanding of the relationship between clinical signs of active disease and C.
trachomatis infection, both before and after the introduction of MDA.
Methods
In this reviewwe included population-based studies and studies involving a random selection
of participants that report the relationship between signs of Active Trachoma (TF, TI, TF/TI)
and the detection of ocularC. trachomatis by nucleic acid amplification tests (NAAT),
Active Trachoma and Ocular Chlamydia trachomatis Infection
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including polymerase chain reaction (PCR), polymerase chain reaction/enzyme immunoassay
(PCR-EIA), ligase chain reaction (LCR) and transcription-mediated amplification (TMA).We
excluded studies which did not test individuals without Active Trachoma for infection. Refer-
ences were identified through searching PubMed for articles using the terms (i) “trachoma”
AND “Chlamydia trachomatis”, (ii) “Trachoma” AND “PCR”, (iii) “Trachoma” AND “LCR”,
(iv) “Trachoma” AND “azithromycin”. The search was limited to 1991 onwards, the year of
the first report of the use of PCR to test for ocularC. trachomatis infection in a trachoma
endemic population [20]. The search was last updated on 5th May 2016.
The titles and abstracts of all articles resulting from these searches were screened by two
authors (AMR,MJB) for potentially eligible publications. These two authors then indepen-
dently assessed the potentially eligible articles for inclusion and extracted the data. The bibliog-
raphies of publications meeting the inclusion criteria were also reviewed for any additional
publications not already identified. Studies were excluded where the participant sample was
not population-based. Several studies were identifiedwith multiple related published reports
arising from the same data. These are considered as a single study, but for completeness we
include all the relevant references.
Core information was extracted using a standardised form. The core information included
country, year of publication, study design, study population size, age group, TF prevalence, TI
prevalence, TF/TI prevalence (if TF alone was not reported),C. trachomatis infection preva-
lence, diagnostic test used, grading system, use of antibiotic for infection control. The clinical
grading system was recorded: the 1981 DetailedWHO FPC System or the 1987 Simplified
WHO Trachoma Grading System [2, 21]. For the purpose of this review the prevalence levels
of TF in the populations studied were categorised as follows: Hypoendemic<10%, Mesoen-
demic 10–20% and Hyperendemic>20% [12].
Due to the heterogeneity in the study designs and the reporting of data, only a limited meta-
analysis was performed. Studies report the results for different age groups. Where available we
separately present both the “All Age” results and those for children (15 years). In the meta-
analysis we use the results from children only where these are available; where these are not
available, the all age results are used. Summary graphs are presented of the relationship
between: (i) the community prevalence of disease signs and C. trachomatis infection, (ii) the
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of TF
for infection, by the community prevalence of disease signs. The degree of correlation between
these was tested using Pearson’s correlation coefficient,weighted by study size. The relation-
ship between signs and infectionwas analysed separately for pre-treatment and post-treatment
data, then a test for interaction was performed on the two datasets combined to test whether
the association between signs and infectionwas similar in the pre and post-treatment data. For-
est plots were generated to illustrate the strength and heterogeneity of the relationship between
disease signs and detection of infection; study heterogeneity was estimated using the I2 statistic.
Hierarchical summary receiver operating characteristics (HSROC) curveswere plotted to illus-
trate the relationship between the sensitivity and specificity of signs of TF for the presence of C.
trachomatis infection and a pooled estimate of sensitivity and specificity was made in both the
pre and the post MDA studies. All analyses were performed using Stata 13. A Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and flow diagram
are included in the supporting information (S1 Checklist and S1 Fig).
Results
The search returned a list of 718 publications. The findings from pre and post-MDA studies
are presented separately. Thirty-six separate population-based studies reported findings prior
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to the introduction of MDA. Several had multiple related publications; yielding a total of 48
publications (Table 1). Twenty-one studies reported findings following the introduction of
MDA met inclusion criteria, in a total of 35 publications (Table 2).
Pre-Treatment
Of the 36 pre-treatment study populations, 24 were hyperendemic, 8 mesoendemic and 4
hypoendemic (Table 1). The studies were conducted in populations from Tanzania (12), The
Gambia (7), Ethiopia (6), Nepal (4), Niger (3), Cameroon (1), Guinea Bissau (1), Egypt (1) and
Australia (1). The SimplifiedWHO Trachoma Grading System was used in 28 studies and 8
used the DetailedWHO FPC System. The majority of studies (25) used the commercially pro-
ducedAmplicor CT/NG (Roche) PCR assay, five used ligase chain reaction (LCR, Abbott Labo-
ratories), and six used in-house PCR assays. Four of the 36 studies listed in Table 1 did not
report the community prevalence of C. trachomatis infection, however they report infection on
a selected subset of individuals [11, 22–24]. These four studies were therefore retained in
Table 1 as they contribute useful information, however they were excluded from the meta-anal-
ysis. Of the remaining 32 studies included in the meta-analysis, 29 studies reported data for
childhood age groups (variable age ranges), seven of which also reported all age data, and three
studies reported only all age data.
Prior to the introduction of MDA there was evidence of a strong positive correlation
between the community-level prevalence of Active Trachoma and the community-level preva-
lence of detectedC. trachomatis, using data from all 32 studies (r = 0.92, 95%CI 0.83 to 0.96,
p<0.0001), Fig 2A. The correlation was similar when the analysis was limited to children only
data (29 studies; r = 0.91, 95%CI 0.82 to 0.96, p<0.0001). The correlation was much weaker for
all age data (10 studies; r = 0.51, 95%CI -0.18 to 0.86 p = 0.13). Overall, the community preva-
lence of TF is typically greater than the underlying community prevalence of detectedC. tra-
chomatis, with TF having a higher prevalence than C. trachomatis in 25 out of the 32 studies.
The mean difference in prevalence was 10.4% (95% CI 5.9%-15.0%, p = 0.001).
There were 19 studies that reported the prevalence of TI separately from TF. There was evi-
dence of a moderate positive correlation between the community-level prevalence of TI and
the community-level prevalence of detectedC. trachomatis (r = 0.75, 95%CI 0.45 to 0.90
p = 0.0002), Fig 2B. Although there are only a limited number of studies, in all communities
where the TI prevalence was>20% the prevalence of C. trachomatis was at least 30%. In con-
trast, where the TI prevalence was below 20% there was a considerable degree of variation in
the underlying community prevalence of infection.
There was sufficient data at the individual level presented to estimate the sensitivity, speci-
ficity, PPV and NPV for 21 studies. The sensitivity of TF for identifying the presence of C. tra-
chomatis infection varied substantially with the prevalence of TF in the community, Fig 3A.
There was evidence of a strong positive correlation (r = 0.82, 95%CI 0.59 to 0.92, p<0.0001). In
contrast, there was a strong negative correlation between the specificity of TF for infection and
the community prevalence of TF (r = -0.92, 95%CI -0.97 to -0.80, p<0.0001), Fig 3B. The For-
est plot of the pre-treatment relationship between disease and detection of infection at the indi-
vidual level showed an overall strong association (OR 6.05, 95% CI 5.49 to 6.67, p<0.0001),
although there was marked heterogeneity (I2 = 87.1%, p<0.001), Fig 4A. A plot of sensitivity
against specificity of the pre-treatment studies using TF as a test for C. trachomatis infection at
the individual level showed that the overall estimated sensitivity was moderate (57.1% (45.4–
68.1%) and the overall specificitywas good (81.1% (73.4–87.0%), Fig 5A.
The relationship between the community-level prevalence of Active Trachoma and the pro-
portion of people with TF who were infected with C. trachomatis (Positive Predictive Value,
Active Trachoma and Ocular Chlamydia trachomatis Infection
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005080 October 26, 2016 5 / 26
Table 1. Active Trachoma and Chlamydia trachomatis (Ct) infection prior to mass antibiotic treatment.
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
1991, [20]
Baseline cross-sectional
population-based data for a
treatment trial. One child aged
1–7 years was randomly
selected from 234 households
in a village.
1–7 years:
234
1–7 years:
Ⴠ TF/TI 58.5%
(137/234
Ⴠ TI 15.8%
(37/234)
1–7 years:
47.9% (112/
234)
1–7 years:
65.0% (89/
137)
1–7 years:
23.7% (23/
97)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: in-house
PCR-EIA for OMP1.
Gambia,
1994, [29]
Cross-section survey of the
entire population of two
villages
Ⴠ All ages:
1332
Ⴠ 0–15
years: 714
All ages:
Ⴠ TF/TI 15.0%
(200/1332)0–
15 years:
Ⴠ TF/TI 29.8%
(183/714)
Ⴠ All ages:
17.2% (229/
1332)
Ⴠ 0–15 years:
29.8% (183/
714)
Ⴠ All ages:
72.0%
(144/200)
Ⴠ 0–15
years:
73.2%%
(134/183)
Ⴠ All ages:
7.5% (85/
1132)
Ⴠ 0–15
years:
9.2% (49/
531)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: in-house
PCR for plasmid, detected
by agarose gel
electrophoresis.
Gambia,
1994, [22]
Cross-section survey of the
entire population of one
village. Only 133 individuals
were tested for Ct infection by
PCR. All active cases were
tested. A sample of 37 normal
individuals from two
households were tested.
All ages: 844 All ages:
Ⴠ TF/TI 11.4%
(96/844)
Data not
available
All ages:
51.0% (49/
96)
All ages:
5.4% (2/
37)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: in-house
PCR for plasmid, detected
by agarose gel
electrophoresis.
Ⴠ The clinically normal group
are not necessarily
representative of the whole
community as they are
drawn from two households
only.
Nepal, 1998,
[30]
All children under 11 years in
primary school and all children
from four randomly selected
households.
0–10 years:
70
0–10 years:
Ⴠ TF/TI 38.6%
(27/70)
Ⴠ TI 7.1% (5/
70)
0–10 years:
57.1% (40/70)
0–10
years:
66.7% (18/
27)
0–10
years:
51.2% (22/
43)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: in-house
PCR for OMP1.
Ⴠ The sample was not
necessarily representative of
the child population of this
community.
Egypt, 1999,
[10, 31]
Baseline cross-sectional,
population-based survey; pre-
treatment data from a RCT of
azithromycin vs tetracycline.
Ⴠ All ages:
2069
Ⴠ 1–10
years: 731
All ages:
Ⴠ TF/TI 19.7%
(408/2069)
Ⴠ TI 5.8%
(120/2069)
Ⴠ 1–10 years:
TF/TI 48.3%
(353/731)
Ⴠ TI 13.0%
(95/731)
Ⴠ All ages:
35.7% (739/
2069)
Ⴠ 1–10 years:
48.6% (355/
731)
Ⴠ All ages:
66.9%
(273/408)
Ⴠ 1–10
years:
69.4%
(245/353)
Ⴠ All ages:
31.6%
(466/1661)
Ⴠ 1–10
years:
29.1%
(110/378)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: LCR,
Abbott Laboratories.
Gambia,
1999, [31]
Baseline cross-sectional,
population-based survey; pre-
treatment data from a RCT of
azithromycin vs tetracycline.
Ⴠ All ages:
1747
Ⴠ 0–10
years: 730
All ages:
Ⴠ TF/TI 15.8%
(277/1747)
Ⴠ TI 7.0%
(122/1747)0–
10 years:
Ⴠ TF/TI 33.8%
(247/730)
Ⴠ TI 13.7%
(100*/730)
Ⴠ All ages:
35.9% (628/
1747)
Ⴠ 0–10 years:
39.3% (287/
730)
All ages:
59.9%
(166/277)
All ages:
31.4%
(462/1470)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: LCR,
Abbott Laboratories.
Ⴠ Main results presented for
all ages, possible to derive
some of the indicators for the
0–10 year group.
(Continued )
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Table 1. (Continued)
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
1999, [31]
Baseline cross-sectional,
population-based pre-
treatment survey; data from a
RCT of azithromycin vs
tetracycline.
Ⴠ All ages:
2653
Ⴠ 0–10
years: 940
All ages:
Ⴠ TF/TI 31.8%
(844/2653)
Ⴠ TI 16.4%
(436/2653)
0–10 years:
Ⴠ TF/TI 60.1%
(565/940)
Ⴠ TI 24.7%
(233*/940)
Ⴠ All ages:
18.5% (491/
2653)
Ⴠ 0–10 years:
34.6% (325/
940)
All ages:
48.3%
(408/844)
All ages:
4.6% (83/
1809)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: LCR,
Abbott Laboratories.
Ⴠ Main results presented for
all ages, possible to derive
some of the indicators for the
0–10 year group.
Ⴠ In this study there was
some concern about sample
degradation, leading to an
underestimate of infection
Nepal, 1999,
[11]
Cross-sectional survey of all
children in six villages. Swabs
and LCR test done on all
active cases and 1/8 without
active disease.
0–10 years:
726
years:
Ⴠ TF/TI 6.3%
(46/726)
0–10 years:
0%(0/90)
0–10
years: 0%
(0/46)
0–10
years: 0%
(0/44)
Ⴠ Hypoendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: LCR,
Abbott Laboratories.
Nepal, 2001,
[23]
Baseline cross-sectional
population-based data from a
RCT of mass vs targeted
antibiotic treatment. Children
recruited from 17 wards. Only
the children with active
disease and a similar sized
random sample of the others
were tested by LCR.
1–7 years:
619
1–7 years:
Ⴠ TF/TI 19.0%
(118/619)
Data not
available
1–7 years:
24.8% (29/
117)
1–7 years:
4.2% (5/
118)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: LCR,
Abbott Laboratories.
Gambia,
2003, [7, 27,
32, 33]
Baseline population-based
survey of a longitudinal study
of MDA. All residents of 14
villages.
Ⴠ All ages:
1319
Ⴠ 1–9 years:
492
All ages:
Ⴠ TF/TI 7.8%
(103/1319)
Ⴠ TI 1.4% 19/
13191–9
years:
Ⴠ TF 16.3%
(80/492)
Ⴠ TI 2.6% (13/
492)
Ⴠ All ages:
7.2% (95/1319)
Ⴠ 1–9 years:
9.3% (46/492)
Ⴠ All ages:
22.3% (23/
103)
Ⴠ 1–9
years:
23.8% (19/
80)
Ⴠ All ages:
5.9% (72/
1216)
Ⴠ 1–9
years:
6.6% (27/
412)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: Amplicor
PCR, Roche.
Tanzania,
2003, [27, 34,
35]
Baseline population-based
survey for a longitudinal study
of MDA. All residents of a
single sub-village.
All ages: 956 All ages:
Ⴠ TF/TI 18.2%
(174/956)
Ⴠ TI 11.6%
(111/956)
All ages: 9.5%
(91/956)
All ages:
33.3% (58/
174)
All ages:
4.2% (33/
782)
Ⴠ Hyperendemic Setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2003, [27,
36–39]
Baseline population-based
survey for a longitudinal study
of MDA. All residents of a
single village.
Ⴠ All ages:
871
Ⴠ 0–10
Years: 325
All ages:
Ⴠ TF/TI 35.8%
(312/871)
Ⴠ TI 10.9%
(95/871)
Ⴠ 0–10 Years:
F/TI 72.6%
(236*/325)
Ⴠ All ages:
56.9% (496/
871)
Ⴠ 0–10 Years:
64.9% (211*/
325)
All ages:
77.2%
(241/312)
All ages:
45.6%
(255/559)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2004, [17]
Random selection of 100
children aged 1–6 years from
four villages.
1–6 years:
100
1–6 years:
Ⴠ TF 79% (79/
100)
Ⴠ TI 55% (55/
100)
1–6 years:
63.0% (63/100)
1–6 years:
72.2% (57/
79)
1–6 years:
28.6% (6/
21)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
(Continued )
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Table 1. (Continued)
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Gambia,
2006, [40]
Cross-sectional population-
based study of school children
aged 4–15 years from nine
villages.
4–15 years:
331
4–15 years:
Ⴠ TF 18.2%
(60/331)
Ⴠ TI 1.5% (5/
331)
4–15 years:
21.8% (72/331)
4–15
years:
41.7% (25/
60)
4–15
years:
15.3% (38/
249)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: in-house
RT-PCR assay for
chlamydial 16S rRNA
Tanzania,
2006a, [41]
Cross-sectional population-
based study of children aged
1–9 years from two
hyperendemic villages.
1–9 years:
464
1–9 years:
Ⴠ TF 44.0%
(204/464)
1–9 years:
24.8% (115/
464)
1–9 years:
36.3% (74/
204)
1–9 years:
13.6% (41/
301)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2006b, [41]
Cross-sectional population-
based study of children aged
1–9 years from one
hypoendemic village.
1–9 years:
200
1–9 years:
Ⴠ TF 12.5%
(25/200)
1–9 years:
6.5% (13/200)
1–9 years:
32.0% (8/
25)
1–9 years:
2.9% (5/
175)
Ⴠ Hypoendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Niger, 2007,
[42]
Cross-sectional study of
randomly selected children
from 12 villages.
1–5 years:
651
1–5years:
Ⴠ TF/TI 43.0%
(280*/651)
Ⴠ TI 16%
(104*/651)
1–5years:
21.0% (137*/
651)
1–5years:
37.3%
(103*/267)
1–5years:
9.0% (33*/
365)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2007, [43]
Cross-sectional population-
based study of children aged
0–10 years from two
hyperendemic villages.
0–10 years:
56
0–10 years:
Ⴠ TF/TI 78.6%
(44/56)
Ⴠ TI 46.4%
(26/56)
0–10 years:
39.3% (22/56)
0–10
years:
43.1% (19/
44)
0–10
years:
25.0% (3/
12)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Nepal, 2008,
[44]
Cross-sectional study of 9
randomly selected households
from one village
All ages: 127 All ages:
Ⴠ TF 26.8%
(34/127)
Ⴠ TI 38.6%
(49/127)
All ages:
38.6% (49/127)
All ages:
44.1% (15/
34)
All ages:
36.6% (34/
93)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Gambia,
2009, [45, 46]
Cross-sectional survey using
a two-stage cluster random
sampling strategy with
probability of selection
proportional to size, in 19
enumeration areas in Lower
River Region, The Gambia.
1–9 years:
876
1–9 years:
Ⴠ TF 12.3%
(108/876)
Ⴠ TI 0.1% (1/
876)
1–9 years:
0.3% (3/876)
1–9 years:
0.9% (1/
108)
1–9 years:
0.3% (2/
768)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2009, [47]
Cross-sectional population-
based sample of 8 randomly
selected children (1–5 years)
per village from eight villages.
1–5 years:
120
1–5 years:
Ⴠ TF/TI 60.8%
(73/120)
Ⴠ TI 44.2%
(53/120)
1–5 years:
40.8% (49/120)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2010, [18, 48]
Cross-sectional population-
based sample of children (1–5
years) living in 24 villages.
1–5 years:
1200
1–5 years:
Ⴠ TF/TI 86.0%
(mean village
prevalence)
1–5 years:
52.9% (mean
village
prevalence)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ⴠ NB: The data are reported
a mean of the prevalence
across all 24 villages.
Gambia,
2010, [25, 49]
Cross-sectional population-
based survey of ~100
randomly selected children
aged 0–5 years from 48
enumeration areas.
0–5 years:
5033
0–5 years:
Ⴠ TF 6.3%
(316/5033)
Ⴠ TI 0.6% (28/
5033)
0–5 years:
0.8% (39/5033)
0–5 years:
0.9% (3/
316)
0–5 years:
0.7% (36/
4717)
Ⴠ Hypoendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche.
(Continued)
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Table 1. (Continued)
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
2010, [49–
51]
Cross-sectional population-
based survey of ~100
randomly selected children
aged 0–5 years from 32
enumeration areas. The
villages were purposely
selected based on having a
preliminary survey prevalence
of !20%.
0–5 years:
3122
0–5 years:
Ⴠ TF 30.8%
(963/3122)
Ⴠ cTI 7.8%
(244/3122)
0–5 years:
21.9% (684/
3122)
0–5 years:
48.9%
(471/963)
0–5 years:
9.8% (213/
2159)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche.
Niger, 2010,
[52]
Cross-sectional study of
randomly selected children
from 12 villages
1–5 years:
557
1–5 years:
Ⴠ TF/TI 41.6%
(232/557)
1–5 years:
20.1% (112/
557)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Australia,
2011, [14]
Population-based cross-
sectional study in five
Aboriginal communities.
All ages:
1282
All ages:
Ⴠ TF 8.4%
(108/1282)
All ages: 3.6%
(46/1282)
All ages:
17.6% (19/
108)
All ages:
2.3% (27/
1174)
Ⴠ Hypoendemic setting
Ⴠ Clinical grading: variation
of the detailed WHO-FPC
system [14]
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2011, [26, 53]
Cross-sectional population-
based survey in three villages
0–9 years:
473
0–9 years:
Ⴠ TF 13.7%
(65/473)
Ⴠ TI 1.3% (6/
473)
0–9 years:
5.3% (25/473)
0–9 years:
6.1% (4/
65)
0–9 years:
5.1% (21/
408)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: Amplicor
PCR, Roche.
Tanzania,
2011, [54, 55]
Cross-sectional baseline
population-based survey in 4
villages.
0–8 years:
1991
0–8 years:
Ⴠ TF 27.8%
(553/1991)
0–8 years:
23.7% (463/
1956)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2011, [56]
Cross-sectional baseline,
population-based survey of
four communities
0–9 years:
2118
0–9 years:
Ⴠ TF/TI 27.7%:
(586/2118)
0–9 years:
23.6% (499/
2118)
0–9 years:
33.1%
(194*/586)
0–9 years:
13.6%
(209/1532)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2011, [57]
Cross-sectional population-
based survey in 23
communities. Both arms of a
cluster RCT at baseline.
0–9 years:
1168
0–9 years:
Ⴠ TF/TI 66.5%
(770/1158)
0–9 years:
44.7% (516/
1168)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2012, [19, 58,
59]
Cross-sectional baseline,
population-based survey of
0–9 year olds in 12
communities
0–9 years:
583
0–9 years:
Ⴠ TF/TI 68.3%
(393/575)
0–9 years:
42.4% (248/
584)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Cameroon,
2012, [24]
Cross-sectional study, with a
random selection of children
from 30 villages, with
probability proportional to size.
Only children with signs of
Active Trachoma were tested
for infection by PCR.
1–9 years:
2397
0–9 years:
Ⴠ TF/TI 26.2%
(628/2397)
Ⴠ TI 5.2%
(124/2397)
Data not
available
0–9 years:
35.0%
(220*/628)
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: in-house
PCR assay for chlamydial
rRNA gene.
Niger, 2012,
[60, 61]
Cross-sectional study for
randomly selected children
from 48 communities.
0–5 years:
4484
0-5years:
Ⴠ TF 26.0%
(1166*/4484)
0-5years:
20.7% (928*/
4484)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
(Continued )
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PPV) showed a positive correlation (r = 0.80, 95%CI0.56 to 0.91, p<0.0001), Fig 3C. The pat-
tern of this distribution suggests that when the community-level prevalence of TF is below 20%
the PPV of TF for the presence of C. trachomatis infection drops substantially. Above a com-
munity-level prevalence of TF of 20% the PPV is typically 40–70%, across a wide range of TF
prevalence.
The relationship between the community-level prevalence of Active Trachoma and the pro-
portion of people without TF who were not infected with C. trachomatis (Negative Predictive
Value, NPV) showed a strong negative correlation (r = -0.81, 95%CI-0.92 to -0.57, p<0.0001),
Fig 3D.When the community-level TF prevalence was greater than 20%, the NPV was more
variable.
Post-Treatment
Of the 21 studies from populations following the introduction of MDA, prior to the first treat-
ment, 15 were hyperendemic, 3 mesoendemic and 3 hypoendemic (Table 2). The studies were
conducted in populations from Tanzania (10), Ethiopia (5), The Gambia (3), Nepal (2), and
Egypt (1). The SimplifiedWHO Trachoma Grading System was used in 17 studies and four
used the DetailedWHO FPC System. The majority of studies (15) used the Amplicor CT/NG
(Roche) PCR assay, four used LCR (Abbott), one used an in-house PCR and one used the
Aptima Combo2 (Hologic) TMA assay. There was one study included in Table 2 that did not
report the community prevalence of C. trachomatis infection, and was therefore not included
in the meta-analysis [23]. One of the Gambian studies involved surveys in four separate dis-
tricts; we have included these as four separate sets of data in the analysis [25]. This resulted in
23 discrete studies included in the meta-analysis: for 20 studies data was available on children
only (variable age ranges), two of which also reported all age data, and three other studies
reported only all age data.
Table 1. (Continued)
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Guinea
Bissau, 2013,
[62, 63]
Cross-sectional population-
based survey across multiple
communities
Ⴠ All ages:
1508
Ⴠ 1–9 years:
618
All ages:
Ⴠ TF/TI 11.1%
(167/1508)
Ⴠ TI 2.0% (29/
1508)1–9
years:
Ⴠ TF/TI 22.0%
(136/618)
Ⴠ TI 3.2% (21/
618)
Ⴠ All ages:
17.9% (269/
1507)
Ⴠ 1–9 years:
25.4% (157/
618)
Ⴠ All ages:
63.3%
(100/158)
Ⴠ 1–9
years: 86/
129
(66.7%)
Ⴠ All ages:
12.1%
(164/1351)
Ⴠ 1–9
years: 83/
537
(15.5%)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2013, [64]
Cross-sectional population-
based survey of children from
one village.
0–9 years: 27 0–9 years:
Ⴠ TF 44.9%
(57/127)
Ⴠ TI 16.5%
(21/127)
0–9 years:
27.6% (35/127)
0–9 years:
29/57
(50.9%)
0–9 years:
6/70
(8.6%)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche.
Tanzania,
2014, [65]
Cross-sectional population-
based survey of all 1–6 year
olds in a single village
1–6 years:
208
1–6 years:
Ⴠ TF/TI 47.0%
(98/208)
1–6 years:
25.0% (52/208)
Data not
available
Data not
available
Ⴠ .Hyperendemic setting
Ⴠ Clinical grading: simplified
WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche.
* Estimated value inferred from available data in publication.
doi:10.1371/journal.pntd.0005080.t001
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Table 2. Active Trachoma and Chlamydia trachomatis (Ct) infection after the introduction of mass antibiotic treatment.
Country,
Year
Study design Time
Point
post 1st
MDA
Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
1993, [20,
66]
Cross-section survey of
randomly selected
children one month after
the completion of a one
month tetracycline
treatment course, given
as MDA to the entire
community.
1 month 1–7 years:
227
1–7 years:
Ⴠ TF/TI
41.9% (95/
227)
Ⴠ TI 2.6% (6/
227)
1–7 years:
23.8% (54/
227)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: in-house
PCR-EIA for OMP1.
Egypt, 2003,
[10, 31]
Cross-section
population-based survey
14 months after
azithromycin MDA.
14
months
1–10 years:
354
1–10 years:
Ⴠ TF/TI
26.0% (92/
354)
1–10 years:
5.1% (18/354)
1–10
years:
9.8% (9/
92)
1–10
years:
3.4% (9/
262)
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: LCR,
Abbott Laboratories.
Ⴠ Only the azithromycin
arm is included.
Gambia,
1999, [31]
Cross-section
population-based survey
12 months after
azithromycin MDA.
12
months
All ages:
Ⴠ 675 (exam)
Ⴠ 540
(tested)
All ages:
Ⴠ TF/TI 8.6%
(58*/675)
Ⴠ TI 2.2%
(15*/675)
All ages: 8.3%
(45/540)
Data not
available
Data not
available
Ⴠ Hyperendemic setting,
pre treatment
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: LCR,
Abbott Laboratories.
Ⴠ Only the azithromycin
arm is included.
Tanzania,
1999, [31]
Cross-section
population-based survey
12 months after
azithromycin MDA.
12
months
All ages:
Ⴠ 1308
(exam)
Ⴠ 1162
(tested)
All ages:
Ⴠ TF/TI
24.6% (322*/
1308)
Ⴠ TI 6.3%
(83*/1308)
All ages: 7.0%
(82/1162)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: LCR,
Abbott Laboratories.
Ⴠ Only the azithromycin
arm is included.
Nepal, 2001,
[23]
Cross-section survey of
randomly selected
normal children and a
purposive sample of
children with Active
Trachoma, 6 months
after azithromycin MDA.
6 months 1–7 years:
Ⴠ 5262
(exam)
Ⴠ 394
(tested)
1–7 years:
Ⴠ TF/TI 16%
(841*/5262)
Data not
available
1–7
years:
11.8%
(31/263)
1–7
years:
5.1% (6/
118)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: LCR,
Abbott Laboratories.
Tanzania,
2004, [34,
35]
Cross-sectional survey of
all residents of a sub-
village, 24 months after
MDA
24
months
All ages: 842 All ages:
Ⴠ TF/TI 5.8%
(49/842)
All ages: 0.1%
(1/842)
All ages:
2.0% (1/
49)
All ages:
0.0% (0/
793)
Ⴠ Hyperendemic setting,
pre-treatment
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Gambia,
2005, [7, 27,
32, 33]
Cross-sectional survey of
all residents of 14 small
villages, 12 months after
MDA
12
months
Ⴠ All ages:
1210
Ⴠ 1–9 years:
440
All ages:
Ⴠ TF/TI 3.9%
(47/1210)1–9
years:
Ⴠ TF 6.8% 30/
440)
Ⴠ TI 0.9% (4/
440)
Ⴠ All ages:
2.3% (28/
1210)
Ⴠ 1–9 years:
5.4% (24/440)
Ⴠ All ages:
29.8%
(14/47)
Ⴠ 1–9
years:
36.7%
(11/30)
Ⴠ All ages:
1.2% (14/
1163)
Ⴠ 1–9
years:
3.2% (13/
410)
Ⴠ Mesoendemic setting,
pre-treatment
Ⴠ Clinical grading: detailed
WHO-FPC system
Ⴠ Chlamydia test: Amplicor
PCR, Roche.
Tanzania,
2005, [27,
36–39]
Cross-sectional survey of
residents of a village, 12
months after MDA
12
months
0–7 years:
287
0–7 years:
Ⴠ TF/TI
46.8% (134*/
287)
0–7 years:
12.8% (37*/
287)
Data not
available
Data not
available
Ⴠ Hyperendemic
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
(Continued )
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Table 2. (Continued)
Country,
Year
Study design Time
Point
post 1st
MDA
Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
2007, [39]
Cross-sectional of
population-based survey
5 years after baseline
MDA and 3.5 years after
a second MDA.
5 years 0–10 years:
464
0–10 years:
Ⴠ TF 30.2%
(140/464)
Ⴠ TI 10.6%
(49/464)
0–10 years:
25.9% (120/
464)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2008, [67]
Cross-sectional
population based sample
of children from 32
communities. These had
received between 1 and 3
rounds of MDA, with the
most recent does less
than 6 months in about
half the communities.
Variable 3–9 years:
1459
3–9 years:
Ⴠ TF 23.6%
(345/1459)
3–9 years:
3.0% (44/
1459)
3–9
years:
6.1% (21/
345)
3–9
years:
6.1% (23/
1114)
Ⴠ Hyperendemic setting
Ⴠ Heterogeneous
treatment history
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2009, [47]
Cross-sectional
population-based sample
of 8 randomly selected
children (1–5 years) per
village from eight
villages. The villages had
received MDA biannually
for 2 years, with the last
dose 18 months prior to
the survey.
42
months
0–5 years:
120
0–5 years:
Ⴠ TF/TI
47.5%: (57/
120)
Ⴠ TI 30.0%
(36/120)
0–5 years:
15% (18/120)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2010, [18,
48]
Cross-sectional
population-based sample
of children (1–5 years)
living in 24 villages.
Communities had
received 4 biannual
MDA, the most recent 6
months before survey
24
months
1–5 years:
1234
1–5 years:
Ⴠ TF/TI
39.2% (mean
village
prevalence)
1–5 years:
2.0% (mean
village
prevalence)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ⴠ NB: The data are
reported a mean of the
prevalence across all 24
villages.
Tanzania,
2011, [15]
Cross-sectional
population-based sample
of children from 71
communities. All
communities had
received 3 to 7 rounds of
MDA.
Variable 0–5 years:
7817
0–5 years:
Ⴠ TF 10.0%
(784/7817)
Ⴠ TI 3.2%
(252/7817)
0–5 years:
5.5%% (429/
7817)
0–5
years:
23.5%
(184/784)
0–5
years:
3.5%
(245/
7033)
Ⴠ Mesoendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Heterogeneous MDA
history. Wide range of
community level
prevalence of infection and
disease. Summary data
here pools these
communities
Ethiopia,
2011, [57]
Cross-sectional
population-based survey
in 24 communities. Both
arms of a cluster RCT of
latrine provision received
a single round of MDA at
baseline.
24
months
0–9 years:
1211
0–9 years:
Ⴠ TF/TI
47.0% (567/
1207)
0–9 years:
14.6% (177/
1211)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Ⴠ Data from both arms
combined.
Ethiopia,
2012, [19,
58, 59, 68,
69]
Cross-sectional survey of
50 children per village
under 10 years in 12
villages. Three annual
rounds of MDA were
given. The final survey
was months after the last
MDA.
36
months
0–9 years:
577
0–9 years:
Ⴠ TF 43.5%
(251/577)
0–9 years:
4.3% (25/577)
Data not
available
Data not
available
Ⴠ Hyperendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
(Continued )
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Table 2. (Continued)
Country,
Year
Study design Time
Point
post 1st
MDA
Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Gambia,
2013, [25,
70]
Cross-sectional
population-based sample
of children from 48
communities enrolled in
an cluster RCT from four
districts. 24 communities
had 3 annual MDA and
24 communities had a
single round of MDA at
baseline. Survey was 3
years after the first round
of MDA.
36
months
0–5 years:
Ⴠ District 1:
1128
Ⴠ District 2:
1199
Ⴠ District 3:
1243
Ⴠ District 4:
1246
0–5 years:
Ⴠ TF 0.2% (2/
1128)
Ⴠ TF 0.3% (3/
1199)
Ⴠ TF 3.8%
(47/1243)
Ⴠ TF 6.4%
(80/1246)
0–5 years:
Ⴠ 0.5% (6/
1128)
Ⴠ 0.1% (1/
1198)
Ⴠ 1.1% (13/
1241)
Ⴠ 0.3% (4/
1235)
0–5
years:
Ⴠ 0.0% (0/
2)
Ⴠ 0.0% (0/
3)
Ⴠ 6.4% (3/
47)
Ⴠ 0.0% (0/
80)
0–5
years:
Ⴠ 0.5% (6/
1126)
Ⴠ 0.1% (1/
1196)
Ⴠ 0.8%
(10/1196)
Ⴠ 0.3% (4/
1166)
Ⴠ Hypoendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche.
Ⴠ Data from both trial arms
were combined, and
presented separately for
each district.
Tanzania,
2014, [51,
71]
Cross-sectional survey of
all children under 10
years in four villages.
Four annual rounds of
MDA were given. The
final survey was 6
months after the last
MDA.
42
months
0–9 years:
2234
0–9 years:
Ⴠ TF/TI 7.9%
(176/2234)
0–9 years:
5.1% (114/
2234)
Data not
available
Data not
available
Ⴠ Hyperendemic setting,
pre-treatment
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2014, [71,
72]
Cross-sectional
population-based sample
of children aged 0–5
years in 32 villages, 100
children per village.
Survey was done 12
months after the third
MDA.
36
months
0–5 years:
3136
0–5 years:
Ⴠ TF 7.6%
(237/3136)
0–5 years:
4.5% (142*/
3136)
0–5
years:
29.5%
(70/237)
0–5
years:
2.5%
(72*/
2899)
Ⴠ Hyperendemic setting,
pre-treatment
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Tanzania,:
2015,[73]
Cross-sectional
population-based of
residents of a village,
which had received 2
rounds of MDA 12 and 10
years previously.
12 years Ⴠ All ages:
571
Ⴠ 1–9 years:
200
All ages:
Ⴠ TF 2.5%
(14/571)1–9
years:
Ⴠ TF 6.5%
(13/200)
Ⴠ TI 1.5% (3/
200)
All ages: 0%
(0/571)1–9
years: 0% (0/
200)
Data not
available
Data not
available
Ⴠ Hyperendemic setting,
pre-treatment
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Nepal, 2016,
[74]
Cross-section survey of
1–9 year olds in 24
randomly selected
communities. Four
rounds of MDA. The
survey was conducted 5
years after the first round.
5 years 1–9 years:
1124
1–9 years:
Ⴠ TF/TI 0.3%
(3/1124)
1–9 years: 0%
(0/1124)
Data not
available
Data not
available
Ⴠ Hypoendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2016, [75]
Random sample of
children aged 1–9 years,
from 30 hamlets. 50
children were sampled
per hamlet. Communities
had received variable
rounds of MDA, between
4 and seven years
previously.
7 years 1–9 years:
1474
1–9 years:
Ⴠ TF 0.4%
(6*/1474)
1–9 years:
1.1% (16/
1474)
Data not
available
Data not
available
Ⴠ Hypoendemic setting
Ⴠ Clinical grading:
simplified WHO system
Ⴠ Chlamydia test: Aptima
Combo2, Hologic
* Estimated value inferred from available data in publication.
a Additional data sub-divided by district were provided by the authors of this study.
doi:10.1371/journal.pntd.0005080.t002
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Fig 2. The relationship between the prevalence of disease signs and infection before and after the
introduction of MDA. (a) Community prevalence of TF (or TF/TI) vs. the community prevalence of C. trachomatis
infection before the introduction of MDA. (b) Community prevalence of TI vs. the community prevalence of C.
trachomatis infection before the introduction of MDA. (c) Community prevalence of TF (or TF/TI) vs. the community
prevalence of C. trachomatis infection after the introduction of MDA. (d) Community prevalence of TI vs. the
community prevalence of C. trachomatis infection after the introduction of MDA. (e) Community prevalence of TF (or
TF/TI) vs. the community prevalence of C. trachomatis infection after the introduction of MDA, showing only the
communities with less than 15% TF. Data from population-based studies, summarised in Tables 1 and 2. The size of
the circles reflects the sample size. Line fitted by linear regression, weighted by the size of the studies.
doi:10.1371/journal.pntd.0005080.g002
Fig 3. The relationship between the individual level presence of Active Trachoma (TF or TF/TI) and the
detection of C. trachomatis infection by community TF prevalence before the introduction of MDA. (a)
Sensitivity of TF for infection. (b) Specificity of TF for infection. (c) Positive Predictive Value (PPV) of TF for C.
trachomatis infection. (d) Negative Predictive Value (NPV) of TF for C. trachomatis infection. Data from population-
based studies, summarised in Table 1. The size of the circles reflects the sample size. Line fitted by linear
regression, weighted by the size of the studies, except for the PPV which was fitted by polynomial.
doi:10.1371/journal.pntd.0005080.g003
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Following the introduction of MDA there was evidence of a moderate positive correlation
between the community-level prevalence of Active Trachoma and the community-level preva-
lence of detectedC. trachomatis, using data from all 23 studies (r = 0.60, 95%CI0.25 to 0.81,
p = 0.003), Fig 2C. The relationship was similar when the analysis was limited to the 20 studies
of children only (r = 0.60, 95%CI0.21 to 0.82, p = 0.005). However, for the five studies report-
ing results for all ages there was no significant correlation (r = 0.72, 95%CI-0.18 to 0.86
p = 0.18). The overall impression is that the relationship between disease and infection is more
uncertain post-MDA, such that the community-level prevalence of TF can substantially overes-
timate the underlying community-level prevalence of C. trachomatis; the community preva-
lence of TF can remain high (>20%) even when the prevalence of infection has declined
(<10%), Fig 2C and 2E.
Fig 4. A Forest plot showing the relationship between Active Trachoma (TF or TF/TI) and the detection of C.
trachomatis infection at the individual level (a) before and (b) after the introduction of MDA, grouped by
community TF prevalence level. Studies are ordered by increasing prevalence of TF, the size of the grey boxes
represent the how much weight each study contributes to the overall estimate, the blue diamonds represent the
subtotal and overall pooled odds ratio estimates. The odds ratios are for ocular C. trachomatis infection as the
outcome and TF as the explanatory variable.
doi:10.1371/journal.pntd.0005080.g004
Fig 5. Sensitivity versus specificity of each study, using TF to diagnose C. trachomatis infection at the individual
level (a) before and (b) after the introduction of MDA. Each circle represents the estimate for a single study, with
the size of the circle representing the size of the study. The red square is the estimated pooled sensitivity and
specificity for all studies (Pre- or Post-MDA). The orange dashed line represents the 95% CI (or confidence region
in 2 dimensions) for the sensitivity and specificity. The grey curve (hierarchical summary receiver operating
characteristic (HSROC) curve) represents the estimated relationship between sensitivity and specificity in these
studies, with the grey dashed line indicating the region in which we would expect 95% of studies to fall.
doi:10.1371/journal.pntd.0005080.g005
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We found evidence that the relationship between the prevalence of TF and the prevalence of
C. trachomatis infection differs between pre and post-MDA. Assuming a linear relationship
betweenC. trachomatis and TF, the prevalence of C. trachomatis was associated with an
expected 6.5% increase for every 10% increase in TF in pre-MDA studies, compared with an
increase of 2.8% in post-MDA (test for interaction p = 0.004).This demonstrates that as the
prevalence of TF increases, the expected increase in C. trachomatis is higher in pre-MDA com-
munities than in post-MDA communities.
There were only eight studies that reported the prevalence of TI separately from TF after the
introduction of MDA. There was no evidence of a correlation between the community-level
prevalence of TI and the community-level prevalence of detectedC. trachomatis (r = 0.50, 95%
CI -0.31 to 0.89 p = 0.20), Fig 2D. However, it is noteworthy that the prevalence of TI was low
(<10%) in all but two communities.
There was sufficient data presented to estimate the sensitivity, specificity, PPV and NPV
for only 10 studies at the individual level after introduction of MDA. Therefore, only limited
inference can be drawn. The sensitivity of TF for identifying the presence of C. trachomatis
infection after the introduction of MDA varied widely, across a range of community-level TF
prevalence levels, Fig 6A. In contrast, there was evidence of a strong negative correlation
between the specificity of TF for infection and the community prevalence of TF (r = -0.99, 95%
CI -0.99 to -0.96, p<0.0001), Fig 6B. The Forest plot of the post-treatment relationship between
disease and detection of infection at the individual level showed an overall strong association
(OR 8.38, 95% CI 7.09 to 9.90, p<0.0001), although there was marked heterogeneity (I2 = 75%,
p<0.001), Fig 4B. Although this overall OR is slightly higher post-MDA compared to pre-
MDA, it should be noted that this result is calculated from individual-level data, whereas the
correlations betweenTF and C. trachomatis infection prevalence (Fig 2) are calculated from
population-level data. Compared to the pre-MDA situation (Fig 5A), after the introduction of
MDA the individual level sensitivity was weaker (39.2% (30.9%, 48.2%) while specificity was
stronger (96.1% (89.6%, 98.6%), Fig 5B.
The community-level prevalence of Active Trachoma and the proportion of people with TF
who were infected with C. trachomatis (PPV) did not appear to be correlated (r = 0.16, 95%CI
-0.52 to 0.72, p = 0.65), Fig 6C. Finally, the proportion of people without TF who were not
infected with C. trachomatis (NPV) was high (>90%), across the limited range of community-
level prevalence of Active Trachoma in these studies, Fig 6D.
Discussion
It has long been observed that the relationship between the signs of Active Trachoma and the
detection of C. trachomatis infection at the individual level is not highly concordant [12]. Sur-
veys, including those in this review, consistently find that within endemic populations there
are many individuals with signs of disease who do not have detectable infection and conversely
there are people who do not meet the diagnostic criteria for Active Trachoma (TF or TI) who
do have detectable infection. Therefore, at the individual level, signs of infection cannot be
depended upon to determine which members of an endemic community have ocularC. tracho-
matis infection.
In a trachoma endemic population, the main reason for this mismatch between active dis-
ease and infection is probably the different time courses of the typical infection and disease epi-
sodes, outlined in the introduction and illustrated in Fig 1. In addition, it is also possible that
other factors contribute to this mismatch. Some individuals who have detectable infection but
do not meet the diagnostic criteria for TF may have a mild trachomatous follicular conjunctivi-
tis. Others may have previously acquired immunity and are able clear the infectionwithout
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developing any detectable inflammatory signs. Alternatively, a positive NAAT test for C. tra-
chomatis in a clinically normal individual could arise through cross-contamination during
sample collection or processing. Clinical signs similar to those of Active Trachoma can also
arise for other reasons, such as viral or bacterial infections, vernal conjunctivitis and hypersen-
sitivity reactions [26].
It is clear that clinical signs are not a reliable indicator for C. trachomatis at the individual
level. There is no point-of-care diagnostic test available for programmes to use to determine
which individual members of a community are infected, and who would therefore benefit from
targeted antibiotic treatment. Moreover, a strategy of testing everybody is not considered a
Fig 6. The relationship between the individual level presence of Active Trachoma (TF or TF/TI) and the
detection of C. trachomatis infection by community TF prevalence after the introduction of MDA. (a)
Sensitivity of TF for infection. (b) Specificity of TF for infection. (c) Positive Predictive Value (PPV) of TF for C.
trachomatis infection. (d) Negative Predictive Value (NPV) of TF for C. trachomatis infection. Data from 6
population-based studies, summarised in Table 2. The size of the circles reflects the sample size.
doi:10.1371/journal.pntd.0005080.g006
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practical option. Therefore, theWHO guidance and the standard practice is to conduct com-
munity-wide antibiotic distribution of the entire population of endemic districts.
Decisions around the initiation and cessation of trachoma control measures are based on
the prevalence of TF in children aged 1–9 years, determined through district level surveys, such
as those conducted by the Global Trachoma Mapping Project. District-wide antibiotic treat-
ment programmes and F&Emeasures to suppress transmission are initiated where the initial
prevalence of TF is 10%. Below 10% TF the advice is to conduct sub-district level surveys. If a
sub-district has 10% TFMDA and F&E are implemented. For sub-districts between 5% and
9.9% TF the guidance is to consider targetedMDA and F&Emeasures. For sub-districts<5%
noMDA is needed and implementation of F&E can be considered.
The dependence on the clinical signs of disease to guide programmatic decisions raises the
important question of how accurate these clinical signs are as a proxy measure for C. trachoma-
tis infection at the population level. This question is particularly relevant after the introduction
of MDA, when the association between clinical signs and infection prevalence at the population
level is weaker, and as we try to determine when elimination targets have been reached.
In this systematic review, we found that prior to the introduction of antibiotic treatment the
relationship between the community-level prevalence of TF in children correlated well with that
of infection. The prevalence of TF was usually slightly greater than that of infection. Therefore,
over a wide prevalence range, the community-level prevalence of TF in children is a reliable indi-
cator that broadly reflects the underlying population burden of infection. The association
between disease and infection for all ages was much weaker than that for children only; this sup-
ports the rationale for measuring TF in 1–9 year olds as the key indicator group for determining
the need of antibiotic. The prevalence of TI was less well correlated than TF with infection before
MDA, with the disease prevalence generally underestimating the level of infection.
At the individual level the utility of TF as a marker for infection is highly sensitive to the
underlying prevalence of TF. Both the sensitivity and PPV rise substantially with increasing TF
prevalence, and the specificity and NPV both drop. This sensitivity increase is therefore offset
by a corresponding decrease in the specificity of this test in high TF prevalence communities.
The usefulness of TF as an indicator of an individual’s infection status is dependent on both
the sensitivity and the specificity of the test; too low a sensitivity leads to C. trachomatis
infected individuals not receiving treatment, whereas too low a specificity leads to wasted
resources treating uninfected individuals. The PPV possibly gives the clearest indication of
where TF is useful as an indicator of an individual’s infection status; when the prevalence of TF
is low (~5–10%), TF will only indicate an estimated 10% probability that the individual has C.
trachomatis infection. This probability increases steadily with prevalence and once the commu-
nity prevalence reaches 30%, the estimated PPV is in the order of 50–70%. Thus, where the
population TF prevalence is above 30%, a positive TF diagnosis gives a 50–70% probability that
an individual will be C. trachomatis infected.
After the introduction of MDA the relationship between the community prevalence of TF
and chlamydial infection is less certain. Although the relationship betweenActive Trachoma
and C. trachomatis infection appears to remain strong at the individual level, the population-
level data suggests that post-MDA, Active Trachoma has a greater tendency to overestimate
the underlying population prevalence of C. trachomatis infection. Below the 10% TF level the
prevalence of infectionwas consistently low, and therefore below this level, TF prevalence
appears to be a goodmarker for infection having being brought under control. However, in the
studies where the prevalence of TF was above 10% after the introduction of MDA, the underly-
ing prevalence of C. trachomatis infectionwas much less predictable. In some settings TF prev-
alence persists at high levels despite relatively little infection being detected. There might be
several reasons for this observation. For example, if the loads of infection are substantially
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lower following the introduction of MDA these may not be so readily detected by diagnostic
tests. Other bacterial speciesmight also provoke a follicular conjunctivitis more readily in indi-
viduals previously infected with C. trachomatis [26]. However, whatever the explanation, it is
likely that in some settings, the prevalence of TF will underestimate the impact MDA has had
on the prevalence of C. trachomatis. This might lead to the on-going use of MDA after the
infection has been adequately controlled.
There is much less published data on the relationship betweenTI and infection following
the introduction of MDA. In general, the prevalence of TI appears to reduce more readily than
TF. A number of studies have investigated the relationship between the load of infection and
disease signs. These suggest that TI is particularly associated with high loads of infection [27].
Therefore, the decline in TI may reflect a shift to less intense infections. However, there were a
few studies in which the prevalence of TI was low, but the prevalence of infection remained
substantial.
We identified a reasonable number of studies reporting the community-level relationship
between disease and infection prior to treatment, over a wide TF prevalence range. There were,
however, fewer studies documenting the situation following the introduction of MDA, poten-
tially limiting the conclusions that can be drawn after MDA. However, there was generally less
detail in these reports about the individual-level relationship between clinical signs and infec-
tion. The studies came mostly from several East andWest African countries, providing reason-
able geographical coverage of the regions with the greatest trachoma burden. Standard WHO
definitions of disease were generally used and the large majority of studies used the same com-
mercially produced PCR assay, providing consistency across studies. However, there was some
methodological heterogeneity. The age groups reported varied; where possible we use the data
for children only in the meta-analysis to try to provide greater consistency between studies.
The sample sizes varied considerably (from 56 to 7817); we weighted our analyses to adjust for
size. The sampling methodology also varied considerably. The studies included were generally
population-based samples or surveys of the entire resident population of a defined area.
Overall, the use of TF prevalence to guide the decision to initiate MDA in previously
untreated districts appears to be reliable. In contrast, the situation following treatment is more
uncertain, calling into question the reliability of clinical signs for monitoring progress towards
the achievement of the elimination targets [28]. There are reports from hyperendemic regions
that have receivedmany rounds of high-coverageMDA that suggest that the prevalence of TF
can be recalcitrant, even when C. trachomatis infection appears to have been brought under
control. Therefore, contextually appropriate, cost-effective tests for C. trachomatis infection
that can be administered in low-resource settings, and used to estimate the infection prevalence
in a population-based sample, would be very helpful in guiding decisions around the cessation
of MDA. Such tests are anticipated to reduce the number of annual rounds of MDA required
and lead to the confirmation of trachoma control at an earlier stage.
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Blinding Trachoma: Systematic Review of
Rates and Risk Factors for Progressive
Disease
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Abstract
Background
Sight loss from trachoma is the end result of a scarring disease process starting in early
childhood and characterised by repeated episodes of conjunctival inflammation (active tra-
choma). Subsequently, the conjunctiva becomes scarred, causing the eyelashes to turn
inwards and scratch the cornea (trichiasis), damaging the corneal surface and leading to
corneal opacification and visual impairment. It is thought that this process is initiated and
driven by repeated infection with Chlamydia trachomatis. We review published longitudinal
studies to re-examine the disease process, its progression rates and risk factors.
Methodology/Principal Findings
We searched PubMed for studies presenting incidence and progression data for the differ-
ent stages of trachoma natural history. We only included studies reporting longitudinal data
and identified 11 publications meeting this criterion. The studies were very heterogeneous
in design, disease stage, duration, size and location, precluding meta-analysis. Severe con-
junctival inflammation was consistently associated with incident and progressive scarring in
five studies in which this was examined. One study reported an association between C. tra-
chomatis infection and incident scarring. No studies have yet demonstrated an association
between C. trachomatis infection and progressive scarring. Several studies conducted in
regions with low prevalence active disease and C. trachomatis infection found evidence of
on-going scarring progression.
Conclusions/Significance
Overall, there are few longitudinal studies that provide estimates of progression rates and
risk factors, reflecting the challenges of conducting such studies. Our understanding of this
disease process and the long-term impact of control measures is partial. Intense conjuncti-
val inflammation was consistently associated with scarring, however, direct evidence dem-
onstrating an association between C. trachomatis and progression is limited. This suggests
that on-going chlamydial reinfection may not be mandatory for progression of established
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scarring, indicating that sight threatening trichiasis may continue to evolve in older people in
formerly endemic populations, that will require service provision for years after active dis-
ease is controlled.
Introduction
Sight loss from trachoma is the end result of a scarring disease process. The widely accepted
view is that it follows the natural history illustrated in Fig 1 [1]. Trachoma is caused by the obli-
gate intracellular bacterium Chlamydia trachomatis. In a typical endemic setting, repeated
chlamydial infection of the conjunctiva starts early in life. This can initiate recurrent episodes
of chronic conjunctival inflammation, characterised by the formation of lymphoid follicles
most easily seen in the upper tarsal conjunctival surface. In the Simplified WHO grading sys-
tem this is referred to as Trachoma Inflammation—Follicular (TF), which is equivalent to F2
and F3 of the detailed WHO-FPC grading system [2, 3]. In some cases the inflammation can
be more marked, with severe papillary hypertrophy, referred to as Trachoma Inflammation—
Intense (TI) in the simplified system and P3 in the detailed system [2, 3]. These signs of “Active
Trachoma”, TF and TI, are most frequently found in younger children, becoming less prevalent
with increasing age. They are characterised by a cell-mediated adaptive immune response to C.
Fig 1. Natural history of trachoma: Normal healthy tarsal conjunctiva without inflammation, follicular
trachoma (TF), intense inflammatory trachoma (TI), scarring trachoma (TS), trichiasis (TT) and
corneal opacification (CO).Ct: Chlamydia trachomatis.
doi:10.1371/journal.pntd.0004859.g001
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trachomatis [4]. With time trachomatous conjunctival scarring (TS) gradually develops as a
result of inflammation-induced tissue damage [2, 4]. The Simplified WHO grading of TS is
taken to be equivalent to the grades C1-C3 of the Detailed WHO grading system [2, 3]. In
highly endemic regions TS can develop in childhood, whereas in less endemic regions it usually
becomes visible from early adulthood.
Chronic conjunctival inflammation is also frequently found in adults with established con-
junctival scarring, Fig 1. This later stage conjunctival inflammation is usually not follicular in
nature, C. trachomatis infection is rarely detected and it is characterised by a prominent innate
epithelial immune response [4–6]. It is possible that non-chlamydial infections, dryness and
irritation of the scarred conjunctiva also contribute to driving inflammation and progression in
the context of established scarring, Fig 1 [4].
Eventually the conjunctival scarring causes the eyelashes to turn in, such that they now
scratch the surface of the eye, which is referred to as trachomatous trichiasis (TT) [2]. If the tri-
chiasis is left uncorrected it traumatises the surface of the cornea resulting in sight loss from
corneal opacification (CO). Again other pathogens (bacteria and fungi) may contribute to the
development of corneal scarring through secondary infections, Fig 1.
The most recent World Health Organization (WHO) estimates suggest that about 232 mil-
lion people live in trachoma endemic areas in 51 countries [7]. Approximately 1.2 million peo-
ple are irreversibly blind from trachoma. A further 40 million are thought to be affected by
active trachoma, and are at risk of developing scarring and blindness [8]. To meet this large
public health challenge, the WHO-led Global Alliance for the Elimination of Trachoma by
2020 recommends the implementation of the SAFE strategy which tackles the disease at differ-
ent stages: Surgery to correct trichiasis, Antibiotics to treat chlamydial infection and Facial
cleanliness and Environmental improvements to suppress transmission of infection [1].
Despite many years of research, there are relatively few detailed longitudinal studies that
investigate the rates and determinants of disease progression through these stages. An under-
standing of this process is relevant to disease control measures and planning. In this review we
draw together and re-examine the literature on the natural history of trachoma, to identify the
rates and risk factors for progression through the stages of this disease process.
Methods
References were identified through searches of PubMed for articles published at any date, by
use of the terms (i) “trachoma” AND (ii) “scarring”, “trichiasis”, “cornea opacity”, “Chlamydia
trachomatis”, “visual impairment” OR “blindness”. Articles resulting from these searches and
relevant publications cited in these articles were reviewed. We included longitudinal studies
which: (1) reported the incidence and/or progression of conjunctival scarring; (2) the incidence
and/or progression of trachomatous trichiasis; (3) the incidence and/or progression of corneal
opacification; (4) the incidence and/or progression of visual impairment and blindness from
trachoma. For the purposes of this review, we define incident disease (conjunctival scarring, tri-
chiasis or corneal opacification) to be the development of these signs in individuals who did
not previously have evidence of them. We reviewed the bibliographies of publications meeting
these inclusion criteria for any additional publications that might also meet them. This search
yielded 1595 articles and one author screened the titles and abstracts of these for potentially eli-
gible publications. Two authors (AR and MB) jointly reviewed potential articles for eligibility
and extracted the data.
For each disease progression stage we extracted and recorded core information using a stan-
dardised form and present this in the Tables. The core information included country, year of
publication, population active disease level, study design, study population, duration of follow-
Rates and Risk Factors for Blinding Trachoma
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up, numbers of participants, number and proportion progressing, grading system, use of anti-
biotic for infection control. Additional information on specific associations with disease pro-
gression and clinical inflammation, C. trachomatis infection, gender and age were collected if
reported. For the purpose of this review the prevalence levels of TF in the populations or
regions studied were categorised as follows: Hypoendemic<10%, Mesoendemic 10–20% and
Hyperendemic>20% [9]. For some reports data on active disease prevalence was not pre-
sented, therefore, we have categorised the active disease prevalence level for such studies based
on other contemporary sources of information about disease prevalence for the same regions.
Clinical signs are reported using the specific trachoma grading systems used in the study
(details provided in Tables 1–5), these were usually either the Simplified or the Detailed WHO
Trachoma Grading Systems [2, 3]. Due to the heterogeneity of the study designs and reports a
meta-analysis was not performed.
Results/Discussion
Progression from Active to Scarring Trachoma
We identified four prospective cohort studies that reported the relationship between active tra-
choma and the subsequent development of incident scarring (new conjunctival scarring in
those with no prior visible conjunctival scarring), Table 1 [10–13]. Three of these were from
Tanzania and one from Tunisia. In addition, we identified a report of a mathematical model of
the five year incidence of TS, based on cross-sectional age-stratified data from Tanzania [14].
The study designs were heterogeneous in terms of sample size, clinical grading system used,
MDA treatment background and study duration. All four were conducted in hyperendemic
communities, which had not previously received mass drug administration (MDA) for tra-
choma control. After enrolment all the communities received some form of antibiotic treat-
ment, although this was variable in nature and frequency (Table 1). The duration of the follow-
up varied from 5 to 14 years. The assessment of clinical signs used either the simplified or
detailed WHO Trachoma Grading Systems [2, 3]. In two studies the development of incident
scarring was identified by a change in the clinical field grading [10, 11]. In the other two studies
the development of incident scarring was identified through the grading of photographs, using
a more detailed scar grading system [12, 13].
The earliest study, from Tunisia, found that 17% of individuals (n = 82, children and young
adults) without conjunctival scarring at baseline developed severe scarring with distortion of
the tarsal plate (C3) over a 14 year period (Table 1) [10]. This study also reported on scarring
progression and incident TT, which are discussed below. It did not report the proportion of
individuals who developed milder degrees of scarring during the same period, nor did it report
chlamydial infection data. A strong association was found between the presence of TI at base-
line and the subsequent development of severe scarring (RR = 18), and a weaker association for
the presence of TF (RR = 2.8). Unfortunately, the reported details are fairly limited, and the
scarring incidence rates are not disaggregated by gender.
The first Tanzanian study was a 7-year cohort of children (baseline age 1–7 years) with and
without “constant severe trachoma” (defined by the presence of TI on at least 3 out of 4 exami-
nations during the baseline year) [11]. At 7 years, 29.2% of children with “constant severe tra-
choma” (n = 96) developed incident TS, compared to only 9.6% of the comparison group
(n = 94). Incident scarring was independently associated with “constant severe trachoma”,
increasing age and female gender. Incident scarring was associated with the presence of TI at
the 7-year time-point. The cohort was tested for C. trachomatis infection at the 7-year time-
point only; those that had incident scarring were more likely to be infected at that point (OR
2.48, p = 0.02).
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Table 1. Progression from active to scarring trachoma.
Country /
Year
Study design Participants Progression to TS Comments
Tunisia,
1990 [10]
Prospective 14-year study of the resident
population of a trachoma-endemic
Tunisian village. Conducted to identify
clinical signs and environmental factors
associated with development of scarring.
A random sample of people seen at
baseline were re-examined at 14-years.
Baseline, 1969–72: 2000 people, of
all ages. Follow-up, 1986–87: 213
people who were aged 1 month to 32
years at baseline. Loss to follow-up:
Information not provided. Baseline
Scarring:
• C0 82 (38.7%)
• C1 51 (24.0%)
• C2 58 (27.4%)
• C3 21 (9.9%)
• Baseline: 82 had no
scarring (C0).
• At 14 years 14/82
(17.1%) had developed
severe scarring (C3)
• Incident TS rate: 1.2%/
year
• Hyperendemic setting (Regional
survey data)
• No previous MDA, however during the
1980’s systematic antibiotic treatment
was carried out which dramatically
reduced active trachoma.[35]
• Clinical grading: detailed WHO-FPC
system.[3]
• The data presentation and analysis in
this report are relatively limited.
However, it represents the first long term
study of the relationship between
inflammation and subsequent scarring.
The report only includes the rate of
transition from no scarring (C0) to C3
(the most severe grade with distortion),
it is likely that many other individuals
without scarring at baseline would have
gone on to develop some lesser degree
of scarring (C1 or C2). Data not
disaggregated by gender.
• Predictors of severe scarring (C3) at
14 years (whole group of 213):
! Baseline TF (F2/F3): RR 2.8
! Baseline TI (P3): RR 18
! Household density (closeness of
houses): RR 1.3
Tanzania,
1997 [14]
Mathematical model of the 5-year
incidence of TS in women. Using age-
stratified cross-sectional data on the
different clinical stages.
• 4898 women in survey.
• Loss to follow-up: N/A
• Incident TS (model) by
age group: 15–19 years:
3.1% / 5 yrs; 55–59 age:
14.3% / 5 yrs
• Incident TS rate: 15–19
years: 0.6%/year; 55–59
years: 4.9%/year
• Hyperendemic setting
• No previous MDA.
• Clinical grading: simplified WHO
system.[2]
Tanzania,
2001 [11]
Prospective cohort study of “constant
severe trachoma” in the development of
incident trachoma scarring in children.
Cases of “constant severe trachoma”
were defined by the presence of severe
inflammatory trachoma (TI) on at least 3
out of 4 examinations during the baseline
year. The comparison group was defined
as children “without constant severe
trachoma” (up to 2 episodes of TI out of
4). The two groups were matched by
age, gender and neighbourhood. Swabs
were collected for C. trachomatis
infection by PCR at 7 years only.
• Baseline, 1989: Age 1–7 years;
Cases 118; Comparison 118.
• Follow-up, 1996: Age 8–14 years;
Cases 96; Comparison 94
• Loss to follow-up: 42
• 7 year Incident TS:
Cases: 28/96 (29.2%);
Comparison 9/94 (9.6%).
• Incident TS rate: Cases:
4.2%/year; Comparison:
1.4%/year
• Hyperendemic setting. (Regional
survey data)
• No previous MDA. After baseline MDA
with topical tetracycline eye ointment
was administered for 30 days.[36]
• Clinical grading: simplified WHO
system.[2]
• Predictors of incident scarring at 7
years:
! Age (per year): OR 1.32, 95% CI 1.07–
1.62
! Female: OR 2.49, 95% CI 1.02–6.08
! Constant severe trachoma: OR 4.85,
95% CI 2.05–11.4
• Incident scarring was highest in those
who had TI and lowest in those that had
TF at the 7-year follow-up (1996):
! Cases: TF 1/30 (3.3%), TI 22/40
(55.0%), None 5/26 (19.2%)
! Comparison: TF 1/30 (3.3%), TI 5/13
(38.5%), None 3/51 (5.9%)
• C. trachomatis infection at the 7-year
time point was more frequently detected
in individuals that developed scarring:
TS 12/26 (42.9%) vs no TS 20/67
(29.9%), OR 2.48, p = 0.02. The clinical /
infection status of individuals from the
two groups was unknown during the 7
year interval.
(Continued)
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In a separate cohort of Tanzanian children (n = 183) who were aged<10 years at baseline,
the 5-year cumulative incidence of TS was 17.4%. In a logistic regression model, the develop-
ment of TS was strongly associated with increasing age, female gender, “constant severe tra-
choma” (10+ follicles or TI or both, on at least 3 of 5 visits during the initial 18 months) and/or
“constant C. trachomatis infection” (infection on at least 3 of 5 visits during the initial 18
months), compared to those without constant severe trachoma or constant infection, Table 1
[12]. The infection and disease states were not analysed as separate variables.
In the fourth prospective study to investigate incident conjunctival scarring in previously
unaffected individuals, a cohort of Tanzanians of all ages (n = 367) was recruited and followed
for 5 years (Table 1) [13]. The overall cumulative incidence of TS was 20.4% in 5 years. The
Table 1. (Continued)
Country /
Year
Study design Participants Progression to TS Comments
Tanzania,
2009 [12]
Prospective cohort study of the impact of
C. trachomatis infection and severe
trachoma on development of scarring.
Participants were all children under 10
years (at baseline) living in a single
village; examined at baseline, 2, 6, 12,
18 months and 5 years. Definitions:
• “Constant infection”: infection on at
least 3 of 5 visits during the initial 18
months.
• “Constant severe trachoma”: severe
trachoma (10+ follicles or TI or both) on
at least 3 of 5 visits during the initial 18
months.
• “Constant infection and constant
severe trachoma”: combination of the
above.
• Cohort of 189 children, aged 0–9
years at baseline (2000).
• Loss to follow-up: 6
• Baseline TS prevalence:
6/189 (3.0%)
• Incident TS by 5 years:
32/183 (17.4%)
• Incident TS rate: 3.5%/
year
• Hyperendemic setting (70% TF at
baseline)
• Clinical grading: simplified WHO
system with additional more detailed
grading of scarring on photographs.[2,
13]
• MDA was administered at baseline and
at 18 months.
• Chlamydia test: Amplicor PCR, Roche
• Baseline:
! Scarring: male; 2/90 (2.1%), female; 4/
99 (4.0%)
! C. trachomatis infection: male; 35/90
(38.8%), female 43/99 (43.4%)
• Incident TS at 5 years by disease/
infection group:
! No infection/disease: 4/59 (6.8%)
! Sporadic infection/disease: 12/79
(15.2%)
! Constant severe trachoma only: 7/20
(35.0%)
! Constant infection only: 4/9 (44.4%)
! Constant severe trachoma and
constant infection: 5/16 (31.2%)
• Significant predictors of incident
scarring at 5 years (multivariable logistic
regression model):
! Age (per year) OR 1.26, 95% CI 1.08–
1.47
! Gender (female) OR 2.55, 95% CI
1.13–5.75
! Sporadic infection/disease (relative to
no infection/disease): OR 1.76, 95% CI
0.48–6.50
! Constant infection and/or severe
disease (relative to no infection/
disease): OR 5.74, 95% CI 2.39–13.77
Tanzania,
2009 [13]
Prospective cohort study of incident and
progressive scarring. Participants were
individuals of all ages, examined at
baseline and 5-years.
• Baseline (2000): 990 people of all
ages.
• Follow-up (2005): 487 people of
which 453 had gradable images from
all time points.
• Loss to follow-up: 437
• Baseline TS prevalence:
86/453 (18.9%)
• Incident TS by 5 years:
75/367 (20.4%)
• Incident TS rate: 4.1%/
year
•Hyperendemic setting (70% TF at
baseline)
• Clinical grading: simplified WHO
system with additional more detailed
grading of scarring on photographs.[2,
13]
• MDA was administered at baseline and
at 18 months.
• There was a trend of increasing
incidence with age, p = 0.038
doi:10.1371/journal.pntd.0004859.t001
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Table 2. Progression of scarring trachoma.
Country /
Year
Study design Participants Progression of TS to TS+ Comments
Tunisia,
1990 [10]
Prospective 14-year study of the
resident population of a trachoma-
endemic Tunisian village. Conducted
to identify clinical signs and
environmental factors associated
with development of scarring. A
random sample of people seen at
baseline were re-examined at
14-years.
Baseline, 1969–72: 2000 people of
all ages. Follow-up, 1986–87: 213
people who were aged 1 month to
32 years at baseline. Loss to follow-
up: Information not provided.
Baseline Scarring:• C0 82 (38.7%)
• C1 51 (24.0%)
• C2 58 (27.4%)
• C3 21 (9.9%)
Progressive Scarring, by 14
years: “worse scarring”
reported in 146/213
(68.5%):• C0 to C3: 14/82
(17.1%)
• C1 to C3: 10/51 (19.2%)
• C2 to C3: 40/58 (69.0%)
Progressive TS rate:
• C0 to C3: 1.2%/year
• C1 to C3: 1.4%/year
• C2 to C3: 4.9%/year
• Hyperendemic setting (Regional
survey data)
• No previous MDA, however during
the 1980’s systematic antibiotic
treatment was carried out which
dramatically reduced active
trachoma.[35]
• Clinical grading: detailed WHO-FPC
system.[3]
• The data presentation and analysis
in this report are relatively limited.
The “worse scarring” analysis
appears to include incident scarring
cases as well as deterioration of
established scarring. Not possible to
sub-divide the presented data. Data
not disaggregated by gender.
• Predictors of severe scarring (C3) at
14 years (whole group of 213):
! Baseline TF (F2/F3): RR 2.8
! Baseline TI (P3): RR 18
! Household density (closeness of
houses): RR 1.3
Tanzania,
2009 [13]
Prospective cohort study of incident
and progressive scarring.
Participants were people of all ages,
examined at baseline and 5-years.
• Baseline, 2000: 990 people of all
ages.
• Follow-up, 2005: 487 people of
which 453 had gradable images
from all time points.
• Loss to follow-up: 437
• Baseline TS prevalence:
86/453 (18.9%).
• Progressive TS by 5
years: 40/85 (47.1%)
• Progressive TS rate:
9.4%/year
• Hyperendemic setting (70% TF at
baseline)
• Clinical grading: simplified WHO
system with additional more detailed
grading of scarring on photographs.
[2]
• MDA was administered at baseline
and at 18 months.
• There was no evidence for a
difference in the proportion showing
progression with age
Ethiopia,
2015 [17]
Prospective cohort study of
progressive scarring in adults with
established scarring and minor
trichiasis (<6 lashes touching the
eye). Examined and swabs collected
every 6 months for two years. Swabs
were analysed for C. trachomatis
infection and expression of several
genes potentially involved with
inflammation and scarring.
Progressive scarring was determined
by direct comparison of baseline and
two year photographs.
• Baseline, 2008: 650 participants.
• 585 people had paired
photographs from baseline and 24
months.
• Loss to follow-up: 65
• Progressive scarring by 2
years:
• 135/585 (23.1%)
• Progressive TS rate:
11.6%/year.
• Hyperendemic setting (Regional
survey data)
• Clinical grading: detailed WHO-FPC
system, with more detailed grading of
scarring on photographs.[3]
• MDA had been delivered in this
region of Ethiopia several times
before the start of the study and
during the two year period.
• Progressive scarring was strongly
associated with and increasing
number of inflammatory (P2/P3)
episodes: OR 5.93, 95%CI 3.3–10.6,
p<0.0001.
• There was no association between
scarring progression and age,
gender or body mass index. No
episode of C. trachomatis infection
were detected.
• Gene expression analysis (106
progressors vs 106 non-
progressors): clinical inflammation
(not scarring progression) was
associated with increased
expression of S100A7, IL1B, IL17A,
CXCL5, CTGF, CEACAM5,MMP7,
CD83 and reduced SPARCL1.
(Continued)
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cumulative incidence of scarring generally increased with age, although it was noted it was par-
ticularly rapid in younger children, for reasons that could not be determined. In this study the
relationship between incident TS and the signs of active trachoma or the presence of infection
were not reported. The study found that at baseline and at five years, across all age groups, the
cross-sectional prevalence of TS was higher in females than males. However, data disaggregated
by gender were not presented on the 5-year incidence of new scarring in this cohort.
The data from a mathematical model supports these longitudinal studies. The 5-year cumu-
lative incidence of new scarring in females, based on cross-sectional data, indicated increasing
incidence with increasing age: 3.1% in 15–19 year olds and 14.3% in 55–59 year olds [14].
Overall, there are surprisingly few prospective studies and relatively limited data investigat-
ing the link between active trachoma and/or chlamydial infection and the development of inci-
dent TS. Three studies present consistent evidence that severe conjunctival inflammation (TI)
is associated with substantially increased risk of new scarring several years later [10–12]. The
evidence from these studies for an association between TF, in the absence of TI, and the devel-
opment of scarring is less clear. In the Tunisian study there was an increase in risk associated
with TF (RR = 2.8), however, no test statistics (95%CI) were provided to assess the strength of
this evidence [10]. In the Tanzanian populations TF was common and affected most of the
children at some point in the observation periods [11, 12]. However, those that were found to
have only sporadic disease or infection were not at a significantly higher risk of incident TS
than those with no episodes of disease or infection [12].
The evidence from these prospective studies demonstrating a link between repeated or per-
sistent C. trachomatis infection and subsequent incident TS is limited to only one study from
Table 2. (Continued)
Country /
Year
Study design Participants Progression of TS to TS+ Comments
Tanzania,
2015 [17]
Prospective cohort study of
progressive scarring in adults with
established scarring. Examined and
swabs collected every 6 months for
two years. Swabs were analysed for
C. trachomatis infection and
expression of several genes
potentially involved with inflammation
and scarring. Progressive scarring
was determined by direct
comparison of baseline and two year
photographs.
• Baseline, 2009: 804 participants
• 577 people had paired
photographs from baseline and 24
months
• Progressive scarring by 2
years:
• 173/577 (30.0%)
• Progressive TS rate:
15.0%/year.
• Hypoendemic setting (Regional
survey data)
• Clinical grading: detailed WHO-FPC
system, with more detailed grading of
scarring on photographs.[3]
• No MDA has been delivered to this
region.
• Progressive scarring was strongly
associated with and increasing
number of inflammatory (P2/P3)
episodes: OR 5.76, 95% CI 2.6–12.7,
p<0.0001.
• No association between scarring
progression and gender or body
mass index.
• Progressors were a bit older: 50.9
years vs 43.8 years, p<0.0001. C.
trachomatis infection was very rare
and not associated with progression.
• Gene expression analysis (97
progressors vs 97 non-progressors):
clinical inflammation (not progressive
scarring) was associated with
increased expression of S100A7,
IL17A, CXCL5,MMP7 and
CEACAM5. Only IL1B (Fold Change
1.54, p = 0.0067) and S100A7 (Fold
Change 1.43, p = 0.027) had
associations with progressive
scarring of marginal significance.
doi:10.1371/journal.pntd.0004859.t002
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Table 3. Progression to trachomatous trichiasis.
Country /
Year
Study design Participants Progression of TS to TT Comments
Tunisia,
1990 [10]
Prospective 14-year study of the
resident population of a trachoma-
endemic Tunisian village.
Conducted to identify clinical signs
and environmental factors
associated with development of
scarring. A random sample of
people seen at baseline were re-
examined at 14-years.
Baseline, 1969–72: 2000 people
of all ages. Follow-up, 1986–87:
213 people who were aged 1
month to 32 years at baseline.
Loss to follow-up: Information not
provided. Baseline Scarring:
• C0 82 (38.7%)
• C1 51 (24.0%)
• C2 58 (27.4%)
• C3 21 (9.9%)
Progression to TT occurred in
17/213 (8.0%). The risk of
progression to TT was related
to the baseline scarring
severity:
• C0 1/82 (1.2%)
• C1 0/51 (0%)
• C2 8/58 (13.8%)
• C3 8/21 (38.1%)
Progression from TS to TT:
0.6%/year
• C0: 0.1%/year
• C1: 0.0%/year
• C2: 1.1%/year
• C3: 2.7%/year
• Hyperendemic setting (Regional
survey data)
• No previous MDA, however
1980s systematic antibiotic
treatment was carried out which
dramatically reduced active
trachoma[35]
• Clinical grading: detailed
WHO-FPC system.[3]
• The data presentation and
analysis in this report are relatively
limited. The risk of developing TT
was greater with increasing
baseline scarring and
inflammation.
Tanzania,
1997 [14]
Mathematical model of the 5 year
incidence of TT in women. Using
age-stratified cross-sectional data
on the different clinical stages.
• 4898 women in survey.
• Loss to follow-up: N/A
• Incidence of TT by age in all
women: 15–19 age 0.3% / 5
years 55–59 age 6.4% / 5
years
• Incidence of TT by age in
women with TS at baseline:
15–19 age 3.2% / 5 years;
55–59 age 15.1% / 5 years
• Incident TT rate in all
women: 15–19 years: 0.06%/
year; 55–59 years: 1.3%/
year.
• Incident TT rate in women
with TS: 15–19 years: 0.6%/
year; 55–59 years: 3.0%/year
• Hyperendemic setting
• No previous MDA.
• Clinical grading: simplifiedWHO
system.[2]
Tanzania,
1999 [19]
Prospective 7 year cohort study to
measure the incidence of TT in
women with and without baseline
conjunctival scarring. The cohort
was recruited from six villages. All
women were examined for TS and
TT at baseline (1989). Seven years
later all available women who had
TS (without TT) at baseline and a
similar sized random sample of
those without any TS were re-
examined.
• Cohort participants who
completed the follow-up at 7
years: 523 with TS at baseline.
503 without TS at baseline.
• Loss to follow-up: 468
• Incidence of trichiasis at
7-years by baseline TS
status: TS: 9.2% / 7 years No
TS: 0.6% / 7 years.
• Incident TT rate: 1.3%/year
in women with pre-existing
scarring. 0.1%/year with no
TS
• Hyperendemic setting (Regional
survey data)
• No previous MDA
• Clinical grading: simplifiedWHO
system.[2]
• Predictors of trichiasis:
! Age (increase per year): OR
1.03, 95%CI: 1.01–1.06
! Infection at follow up: OR 2.51,
95%CI: 1.1–5.69
Gambia,
2001 [20]
The 1986 Gambian National
Blindness and Eye Disease Survey
was a 1% sample of the total
population. In this 8174 people
were examined. 12 years later
individuals who were found to have
TS in 1986 were retraced and
assessed for the development of TT
and CO.
• Baseline, 1986: 639/8174 people
"18 years were found to have TS
• Follow-up, 1998: 326/639 (51%)
were re-examined
• Loss to follow-up: 313
• Progressed from scarring to
trichiasis: 19/297, 6.4% / 12
years.
• Incident TT rate in people
with TS: 0.5%/year
• Hypoendemic setting (Regional
survey data)
• No previous MDA
• Clinical grading: simplifiedWHO
system.[2]
• Risk factor for trichiasis:
!Old age: OR 1.07, 95% CI 1.01–
1.12
Gambia,
2010 [21]
Five year prospective study of the
population of 14 adjacent Gambian
villages.
• Baseline, 2001: 592 people >15
years
• 5-years, 2006: 456 people >15
years
• Loss to follow-up: 136
• Baseline TT: 9/592 (1.5%).
• 5-year TT: 6/456 (1.3%)
• Incident TT Cases: 2/456,
0.4% / 5 years
• Incident TT rate in all adults:
0.1%/year
•Mesoendemic setting (15% TF at
baseline)
• No previous MDA
• Clinical grading: detailed
WHO-FPC system.[3]
• At 5-years, 3/6 case had TT at
baseline and 1/6 was a new
resident
doi:10.1371/journal.pntd.0004859.t003
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Tanzania [12]. In this study, data on disease and infection were combined for the analysis, so it
is not possible to determine the independence of the effect of infection from disease. Notably,
although a small proportion of individuals with only sporadic disease and/or infection did
develop TS, they were not at significantly greater risk of scarring than individuals who had no
disease or infection episodes documented. This might suggest that in a programmatic context,
reducing the pressure of infection and associated TI through MDAmight reduce disease in the
majority of individuals below a threshold required for the development of scarring.
As would be expected from the known cross-sectional age-specific prevalence of TS from
population based surveys, the three prospective Tanzanian studies and the mathematical
model found clear and consistent evidence of increasing risk of incident TS with increasing age
[11–14]. However, it is noteworthy that some incident scarring was developing during child-
hood in these populations. Similarly, the prospective Tanzanian studies found that females
were at consistently higher risk of incident TS than males, probably because of a greater life-
time exposure to chlamydial infection [11–13].
West and colleagues suggested that there might be two distinct routes to the development of
TS [11]. Firstly, in the “classical”model, which may account for the majority of TS cases, are
individuals who are repeatedly exposed to C. trachomatis. In this group the risk of TS is pri-
marily determined by the cumulative number of infection episodes experienced. This is
Table 4. Progression of trachomatous trichiasis.
Country /
Year
Study design Participants Progression of TT to TT+ Comments
Gambia,
2002 [22]
One year longitudinal study of
individuals with TT in at least one
eye.
• Baseline, 1996: 190 people.
•Major trichiasis 135; Minor
trichiasis 55.
• Follow-up, 1997: 169 people
were re-examined at 12
months.
• Loss to follow-up: 21
• Progression of Minor to Major
trichiasis: 18/55 (33%) / 1 year
• Progression of unilateral to
bilateral TT: 21/46 (46%) / 1
year
• Hypoendemic setting (Regional
survey data)
• No previous MDA.
• Clinical grading: simplifiedWHO
system.[2]
Gambia,
2006 [23]
Four year longitudinal study of
individuals with TT in at least one
eye, who had declined surgery.
Examined at baseline and 4 years.
• Baseline, 1996: 220 people
• Follow-up, 2000: 153 people
were re-examined
• Loss to follow-up: 67
• Progression of Minor to Major
trichiasis: 28/75 (37.3%) eyes.
• Progression Rate: 9.3%/year
• Progression of unilateral to
bilateral trichiasis: 12/42 (29%)
eyes
• Progression rate: 7.3%/yr
• Hypoendemic setting (Regional
survey data)
• No previous MDA
• Clinical grading: detailed WHO-FPC
system.[3]
• Univariate association between TT
progression and conjunctival
inflammation (P2 or P3) at 4-years:
OR 3.07, 95%CI 1.23–7.70, p =
0.017. This was not significant in a
logistic regression model.
• C. trachomatis was detected in 2/
146 (1.4%) tested at 4-years and was
not associated with TT progression.
Ethiopia
2011 [24,
25]
Two year prospective randomised
controlled trial of epilation vs
surgery for Minor trichiasis (<6
lashes). 650 individuals were
randomised to the epilation arm at
baseline and followed every six
months for two years. Outcome
measure was presence of 5
+ lashes. At two years all were
offered TT surgery, 383 chose to
continue epilating and were
followed up for an additional two
years.
• Baseline, 2008: 650 people
• Primary outcome data
available for 637 people at 2
years (2010).
• Follow-up, 2012: 383 people
who continued epilating were
re-examined. Loss to follow-
up: at 2 years: 13; at 4 years:
267
• At 2 years: progression of
Minor to Major trichiasis: 84/637
(13.2%) eyes.
• Progression rate: 6.6% / year.
• At 4 years, comparing
baseline to four years, 82 /383
(21.4%) had more eyelashes
touching and 200/383 (52.2%)
had fewer.
• Hyperendemic setting (Regional
survey data)
• Clinical grading: detailed WHO-FPC
system, with more detailed grading of
scarring on photographs.[3]
•MDA had been delivered in this
region of Ethiopia several times
before the start of the study and
during the two year period.
doi:10.1371/journal.pntd.0004859.t004
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Table 5. Progression to corneal opacification, visual impairment and blindness.
Country /
Year
Study design Participants Progression of TT to CO Comments
Tanzania,
1997 [14]
Mathematical model of the 10 year
incidence of CO in women. Using age-
stratified cross-sectional data on the
different clinical stages.
• 4898 women in survey.
• Loss to follow-up: N/A
Incidence of CO,
attributable to trachoma:
All women:
• 15–24 yrs 0.16% / 10
years
• 45–54 yrs 2.80% / 10
years
Progression rate:
• 15–24 yrs 0.02%/year
• 45–54 yrs 0.3%/year
Women with TT:
• 15–24 yrs 27.2% / 10
years
• 45–54 yrs 53.5% / 10
years
Progression rate:
• 15–24 yrs 2.72%/year
• 45–54 yrs 5.35%/year
• Hyperendemic setting
• No previous MDA
• Clinical grading: simplified WHO system.[2]
• In this model around half of all corneal
opacity was due to causes other than
trachoma. In women under 35 years these
other causes dominated. In older ages
trachoma was the main cause.
Gambia,
2001 [20]
The 1986 Gambian National Blindness and
Eye Disease Survey was a 1% sample of
the total population. In this 8174 people
were examined. 12 years later the people
who were found to have TS in 1986 were
retraced to assess them for the
development of TT and CO.
• Baseline, 1986: 639/8174
people !18 years were found
to have TS
• Follow-up, 1998: 326/639
(51%) were re-examined
• Loss to follow-up: 313
• Progressed from TS to
CO: 18/302 (5.9%) / 12
years.
• Progression rate: 0.5%/
year
• Progressed from TT to
CO: 4/20 (20%) / 12 years.
• Progression rate: 1.7%/
year
• Hypoendemic setting (Regional survey
data)
• No previous MDA
• Clinical grading: simplified WHO system.[2]
• Risk factor for corneal opacity:
" Trichiasis at baseline: OR 8.4, 95% CI 1.8–
39.2
• Old age: OR 1.07, 95% CI 1.01–1.12
• Progressed from TS to incident visual
impairment / blindness:
" 53/321 (16.5%), all causes
" 8/321 (2.5%), attributed to cornea scarring
• Progressed from TT to incident visual
impairment / blindness:
" 4/26 (15.4%), all causes
" 2/26 (7.7%), attributed to cornea scarring
Gambia,
2002 [22]
One year longitudinal study of individuals
with TT in at least one eye. Progression was
considered significant if the baseline cornea
grading had been CC0 / CC1 and the 1-year
grade was CC2 / CC3.
• Baseline, 1996: 190 people.
Major TT 135. Minor TT 55.
• Follow-up, 1997: 169 people
were re-examined at 12
months
• Loss to follow-up: 21
• Incident CO in
individuals with TT: 10/104
(10%) / 1 year
• Progressive CO in
individuals with un-
operated Major TT: 33/96
(34%) / 1 year
• Hypoendemic setting (Regional survey
data)
• No previous MDA
• Clinical grading: detailed WHO-FPC system
used for cornea grading.[3]
• Change in vision over one year:
" 8/88 (9%) had incident visual impairment or
blindness.
• There was a non-significant trend to more
visual deterioration with major TT (9%)
compared to minor TT (4%) at baseline.
Gambia,
2006 [23]
Four year longitudinal study of individuals
with TT in at least one eye, who had
declined surgery. Examined at baseline and
4 years.
• Baseline, 1996: 220 people
• Follow-up, 2000: 153 people
were re-examined, with 241
eyes that had not been
surgically treated.
• Loss to follow-up: 67
• Incident CO in eyes with
TT at baseline: 16/211
(7.6%) / 4 years.
• Progression rate: 1.9%/
year
• Hypoendemic setting (Regional survey
data)
• No previous MDA
• Clinical grading: detailed WHO-FPC
system.[3]
• At baseline 30/241 eyes had CO.
• CO was only found in eyes with TT. New
CO was associated with the presence of
Major TT at 4-years (14/16 had major TT).
Incident CO by 4 years was more frequent in
eyes that had Major TT at baseline:
"Minor or no TT at baseline: 6/117 (5.1%)
"Major TT at baseline: 10/99 (10.1%).
• There was an overall deterioration in visual
acuity over the 4 years, of 0.22 LogMAR unit.
This change was more marked (non-
significant) for eyes with TT (0.30) than for
those without TT (0.15). 29/221 eyes had
newly deteriorated to <3/60. However, only 6/
29 were due to CO, the large majority were
due to cataract.
(Continued)
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consistent with the observation that TS incidence is higher in females and with increasing age.
This model has since been incorporated into the design of mathematical models of the scarring
sequelae of trachoma [15, 16]. The second route, which may account for a minority of people
who develop TS, is characterised by the development of a severe and persistent inflammatory
phenotype, “constant severe trachoma”. Data from several of these prospective studies is con-
sistent with this hypothesis [10–12]. Whether these individuals are responding unfavourably to
C. trachomatis, to other bacteria, or are genetically prone to develop a severe persistent inflam-
matory phenotype is unclear [4].
Progression of Scarring Trachoma
We identified four prospective cohort studies which reported the rates and risk factors for the
progression of established trachomatous conjunctival scarring (Table 2) [10, 13, 17]. One was
from Tunisia, one from Ethiopia and two from Tanzania. There was some heterogeneity in the
study designs, although the two parallel studies we conducted in Ethiopia and Tanzania used
similar designs and were reported together [17]. Three studies were conducted in hyperen-
demic communities [10, 13, 17] and one in a hypoendemic community [17]. The Tunisian and
both Tanzanian studies were in areas which had not previously received MDA [10, 13, 17].
After enrolment, three of the study populations received some form of antibiotic treatment for
trachoma control, although this was variable in nature and frequency (Table 2). The Ethiopian
study was conducted in an area that had previously received MDA on several occasions and
continued to do so during the study period [17]. The second Tanzanian study was conducted
in an area where the current prevalence of active trachoma is below treatment thresholds [17].
The duration of follow-up varied from 2 to 14 years. The assessment of clinical signs used
either the simplified or detailed WHO Trachoma Grading Systems [2, 3].
The identification of progressive scarring used different methodologies. In the Tunisian
study the development of scarring was based on a change in the clinical field grading score
[10]. In the other three studies the progression of scarring was identified through the grading
of photographs. For one study this was done by the comparison of an independent grading of
the baseline and five-year photographs [11]. In the other two studies the baseline and two-year
photographs were graded using a detailed grading system for scarring [18]. The photographs
were directly compared side-by-side for assessment of progression, possibly allowing for more
subtle changes in TS to be detected [17].
The Tunisian study (described above) reported scarring progression in 68.5% of individuals
(n = 120) over 14 years (Table 2) [10]. However, this report is limited in the level of detail
Table 5. (Continued)
Country /
Year
Study design Participants Progression of TT to CO Comments
Ethiopia,
2011 [17]
Two year prospective randomised controlled
trial of epilation vs surgery for Minor
trichiasis (<6 lashes). 650 individuals were
randomised to the epilation arm at baseline
and followed every six months for two years.
The change in CO was assessed by direct
comparison on digital photographs.
• Baseline, 2008: 650 people
• Primary outcome data
available for 637 people.
• Loss to follow-up: 13
• Change in CO, in people
with Minor trichiasis who
were epilating at 2 years:
• Increased CO: 33/603
(5.5%) / 2 years; 2.75%/
year
• Reduced CO: 7/603
(1.2%) / 2 years; 0.6%/
year
• Hyperendemic setting (Regional survey
data)
• Clinical grading: detailed WHO-FPC
system, with more detailed grading of corneal
scarring on photographs.[3]
• MDA had been delivered in this region of
Ethiopia several times before the start of the
study and during the two year period.
• One eye per person analysed.
• 87/603 (14.5%) had a deterioration in visual
acuity of >0.3 LogMAR units by 2 years. Most
of this was not associated with a deterioration
in CO, suggesting that other causes such as
cataract were responsible.
doi:10.1371/journal.pntd.0004859.t005
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provided and it appears that the total progression estimate may include some individuals who
were incident scarring cases. There is some partial information on progression from mild or
moderate scarring (C1 / C2) to the most severe grade (C3), Table 2. The specific risk factors for
progression to C3 are not presented. However, as noted above, the development of new C3 in
those who had no scarring at baseline was associated with TI at baseline.
In the first Tanzanian study progression of conjunctival scarring occurred in 47.1% of indi-
viduals (n = 85, all ages) who had some established TS at baseline, over a five year period
(Table 2) [13]. There was no difference by age in the proportion with evidence of progression.
No data on the relationship between scarring progression and gender, clinical inflammation or
C. trachomatis infection were reported.
In our study in Ethiopia, progression of conjunctival scarring developed in 23.1% of partici-
pants (n = 585) over a 2 year period (Table 2) [17]. This was a prospective cohort of adults who
had minor trichiasis at baseline that was managed by epilation. They were examined and pho-
tographed every six months, with swab samples collected for C. trachomatis PCR and conjunc-
tival gene expression analysis. There was a strong relationship between progressive scarring
and increasing number of observed episodes of clinical inflammation, defined as P2 or P3 in
the detailed WHO grading system (OR 5.93, 95%CI 3.3–10.6, p<0.0001). There was no evi-
dence of an association between scarring progression and gender, age or body mass index
(BMI). The samples from individuals with progressive scarring and a frequency matched sam-
ple of individuals who did not show progressive scarring were tested for C. trachomatis by PCR
on 4 occasions; all samples were negative for C. trachomatis. Conjunctival inflammation, but
not scarring progression, was associated with increased gene expression of a mixture of pro-
inflammatory cytokines (IL1B, IL17A, CXCL5), anti-microbial effectors (S100A7) and factors
associated with tissue remodelling (CTGF,MMP7, reduced SPARCL1).
In the parallel cohort study we conducted in Tanzania we used the same protocol, including
sample collection, as the Ethiopian study; all individuals had conjunctival scarring at baseline,
were aged 18 years or more and no individuals had baseline trichiasis [17]. Progression of con-
junctival scarring was observed in 30.0% of participants (n = 577) over a 2-year period
(Table 2). Again, there was a strong relationship between progressive scarring and an increas-
ing number of episodes of clinical inflammation (P2/P3), of a similar magnitude to that found
in the Ethiopian study (OR 5.76, 95% CI 2.6–12.7, p<0.0001). There was no evidence of an
association between scarring progression and gender, age or BMI. In this Tanzanian cohort
there were 804 people with TS recruited and tested for C. trachomatis by PCR at baseline, of
which only 4 samples were positive. At 6, 12 and 18 months after baseline, the samples from
the individuals with progressive scarring and a frequency matched sample of individuals in the
cohort who did not show progressive scarring were also tested for C. trachomatis and only one
sample was positive. In this study progressive scarring was associated with a modest increase in
expression of IL1B and S100A7. In addition, increased S100A7, IL17A, CXCL5,MMP7 and
CEACAM5 expression were associated with clinical inflammation (P2/P3).
A consistent finding across these studies was that trachomatous conjunctival scarring con-
tinues to progress over time. The studies are probably too heterogeneous to provide an overall
estimate range for disease progression. However, it is noticeable that in the two studies using
the same protocol the rates of scarring progression were similar [17]. Moreover, it might have
been anticipated that the Ethiopian cohort, which was conducted in a hyperendemic region,
would have experienced a greater proportion of progression than that observed in a region of
Tanzania that had a low level of active trachoma, and was therefore not included in the
national antibiotic distribution programme.
There was a strong association between conjunctival inflammation and progressive scarring,
with individuals experiencing more inflammatory episodes being at greater risk of progression
Rates and Risk Factors for Blinding Trachoma
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[10, 17]. In two studies the immunofibrogenic correlates of clinically apparent inflammation
were investigated using gene expression analysis, and this demonstrated that its presence was
associated with increased expression of a range of pro-inflammatory factors [17]. These obser-
vations are consistent with the findings for incident scarring outlined above; children who
experienced more episodes of active trachomatous inflammation were more likely to develop
incident scarring (Table 1) [11, 12].
There are three noteworthy findings from these four cohort studies of progressive scarring.
Firstly, we found no published evidence that the progression of established scarring was associ-
ated with the detection of C. trachomatis infection [17]. Indeed, infection was detected in only
very few individuals with TS. This contrasts with the observation, albeit from limited prospec-
tive data, of an association between the development of incident scarring and episodes of chla-
mydial infection [12]. Secondly, we found no published evidence of a difference between males
and females in the proportions showing signs of scarring progression. Again, this contrasts
with the findings for incident scarring outlined above, which developed more frequently in
females (Table 1). Thirdly, amongst people with established scarring the proportion showing
scarring progression did not vary with age. This also contrasts with the findings for incident
scarring, which developed more frequently with increasing age.
Therefore, once TS is established the risk of scarring progression does not appear to be asso-
ciated with exactly the same set of risk factors that were associated with the development of
incident scarring. This could be interpreted as suggesting that progression of established scar-
ring is less dependent than incident scarring on recurrent C. trachomatis infection, episodes of
which are more frequent in females and accrue with increasing age. It may also indicate that
other factors such as non-chlamydial bacterial infection, a dry ocular surface or altered tissue
inflammatory or scarring responses may also contribute to a pro-inflammatory / pro-fibrotic
state. This might be anticipated as scarred ocular surface tissue probably has altered physiology
and compromised defence mechanisms. However, prospective data on these factors has not
been reported.
Progression to Trachomatous Trichiasis
We identified four prospective cohort studies which report rates and risk factors for the devel-
opment of trachomatous trichiasis (Table 3) [10, 19–21]. One was from Tunisia, one from Tan-
zania and two from The Gambia. In addition, we identified a mathematical model based on
cross-sectional data from Tanzania [14]. Two studies were conducted in hyperendemic areas
and two in hypoendemic areas. None of the study populations had previously received system-
atic MDA for trachoma control. After enrolment, two of the study populations received some
form of antibiotic treatment for trachoma control, although this was variable in nature and fre-
quency (Table 3) [10, 21]. The duration of follow-up varied from 5 to 14 years.
The Tunisian study (described above) reported incident TT in 8.0% over a 14 year period
[10]. The risk of developing TT was related to the baseline conjunctival scarring severity, being
1.2% in people with no scarring and rising to 38.1% in those with severe baseline scarring (C3),
Table 3. The Tanzanian study was a 7 year cohort of females with and without TS at baseline
[19]. In those with TS at baseline 9.2% developed TT, and of those without TS at baseline 0.6%
developed TT by 7-years. The development of TT was associated with increasing age and the
detection of C. trachomatis infection at the 7-year time-point. The number of individuals with
C. trachomatis infection at follow up was 60/513 (11.7%) in the group with TS at baseline and
36/501 (7.5%) in the group with no TS at baseline. The first of the Gambian studies reported
the 12-year incidence of TT in people with TS at baseline to be 6.4% [20]. The development of
TT was associated with increasing age. The second Gambian study was a five year study of all
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the residents of 14 villages, most (94%) of whom did not have scarring at baseline. The five
year cumulative incidence of TT in those>15 years was 0.4% [21].
The mathematical model estimated the 5 year cumulative incidence of TT in women from a
hyperendemic region of Tanzania using age-stratified cross sectional data from different clini-
cal stages [14]. The cumulative incidence of TT was highest in older women (6.4% versus 0.3%
in young women) and in women with TS at baseline (15.1% in 55–59 year olds, 3.2% in 15–19
year olds).
Progression of Trachomatous Trichiasis
We identified three prospective cohort studies that reported the rates and risk factors for the
progression of trachomatous trichiasis from unilateral to bilateral disease, or from minor tri-
chiasis (<6 lashes touching the eye) to major trichiasis (6+ lashes touching the eye), Table 4
[22–25]. Two of these were from The Gambia and one from Ethiopia. The Gambian studies
were both conducted in hypoendemic areas. The Ethiopian study was in a hyperendemic set-
ting with on-going MDA. The duration of follow-up varied from 1 to 4 years.
In the first Gambian study, 46% of people with unilateral trichiasis (n = 46) had developed
bilateral disease in one year [22]. Of those with minor trichiasis (n = 55), 33% progressed to
major trichiasis. In the second Gambian study 29% of people with unilateral trichiasis (n = 42)
progressed to bilateral disease in four years and 37% of minor trichiasis (n = 75) progressed to
major trichiasis [23]. In this second study several factors were analysed in relation to the pro-
gression of trichiasis over four years: age, gender, conjunctival inflammation (at four years),
chlamydial infection and pathological bacterial infection (at four years). In univariate analysis
only conjunctival inflammation at 4-years was associated with TT progression. However, no
factor was significant in a multivariable model. It is noteworthy that at 4-years both conjuncti-
val inflammation and bacterial infection were independently associated with the presence of
major trichiasis. Only 2/146 samples tested were positive for C. trachomatis at the 4-year time-
point.
The Ethiopian study was of a group of people with minor trichiasis (n = 650) who were in
the epilation arm of a randomised controlled trial of epilation vs. surgery, with regular follow
up over a two year period [24]. Individuals were equipped with high quality forceps and a rela-
tive was trained in how to perform epilation. During the first two years 13% of study eyes pro-
gressed from minor to major trichiasis. After two years all participants were offered surgery for
their trichiasis. About a third accepted surgery at two years, while the majority (n = 383) chose
to continue with epilation and were followed up for an additional two years [25]. Comparing
the amount of trichiasis by counting the absolute number of lashes touching the eye at baseline
with that at four years, 21.4% of these 383 individuals were found to have had some degree of
increase in the number of lashes touching the eye, however this was difficult to assess in the
context of regular epilation. In addition, 36.6% had only a modest increase in the degree of
entropion, although it should be noted that this is a variable and difficult clinical sign to grade.
In a multivariable model, over the four years, progression to major trichiasis was associated
with older age and having!3 lashes touching the eye at baseline.
Progression to Corneal Opacification, Visual Impairment and Blindness
We identified four prospective cohort studies that reported the rates and risk factors for the
development of corneal opacification (CO) and visual impairment (Table 5) [20, 22–25]. Three
were from The Gambia, conducted in hypoendemic areas. One study was from a hyperendemic
area of Ethiopia, with on-going MDA. The duration of follow-up varied from 1 to 12 years. In
addition, the mathematical model based on Tanzanian cross-sectional data provided 10 year
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estimates for the development of CO [14]. We have not included prospective data on CO
change from clinical trials where TT was treated with surgery.
The first Gambian study found the 12-year cumulative progression from TS to CO to be
5.9% and for TT to CO to be 20% [20]. Risk factors for incident CO were increasing age and
TT at baseline. Visual impairment developed in 16.5%, but only 2.5% of this was attributed to
CO; most was due to cataract (Table 5). The second Gambian study found that in one year inci-
dent CO developed in 10% of people with TT and that CO progressed in 34% with major tri-
chiasis [22]. New visual impairment or blindness developed in 9%. The third study from The
Gambia found incident CO developed in 7.6% of eyes with TT at baseline over the course of
four years, with the risk being greater for those with major TT (Table 5) [23]. Again, the risk of
visual impairment was increased with TT, however, the large majority of incident cases of
visual impairment were due to cataract.
The four year Ethiopian study of people with minor trichiasis has been outlined above [24,
25]. Incident or progressive CO was determined by the comparison of photographs in this
study. At 2 years, 5.5% of the 650 individuals with minor trichiasis had some increase in CO.
When modelled at 4-years, incident/progressive CO was associated with being!50 years of
age and having moderate CO at baseline. Visual acuity deteriorated in 14.5% by>0.3LogMAR
by 2 years, however, most of this was not attributable to changes in CO.
The mathematical modelling study, described above, found that the overall incidence of CO
was higher in older women: 2.8% in 45–54 years versus 0.16% in 15–24 years [14]. The cumula-
tive incidence rates were estimated to be very much higher in those with TT at baseline: 53.5%
in 45–54 year olds and 27.2% in 15–24 year olds. This model estimated around half of all CO
was due to causes other than trachoma. In women<35 years these other causes dominated,
whereas in older women trachoma was the main cause.
Conclusions
Conducting long-term prospective studies of the rates and risk factors of progressive trachoma
from active disease through to blindness is complex and expensive. Here we have reviewed the
longitudinal studies that contribute to our understanding of this disease process. In addition to
these longitudinal studies, there are many cross-sectional studies that provide indirect evidence
about risk factors for progression. The prospective studies are relatively few in number, of vari-
able design and frequently small in size. The determination of the presence of progression in
conjunctival scarring can be challenging, particularly where there is also extensive inflamma-
tion masking scar tissue. Despite these limitations, collectively they provide evidence that sup-
ports much of the widely accepted description of the natural history of trachoma, illustrated in
Fig 1.
The studies of incident and progressive conjunctival scarring were consistent in showing a
strong association with repeated or persistent conjunctival inflammation. In contrast, the evi-
dence linking the development of incident conjunctival scarring with C. trachomatis infection
is limited to only one study. Moreover, in two large cohorts with scarring progression rates of
23.1% and 30% over 2 years only very few episodes of chlamydial infection were detected.
The model proposed by West and colleagues, and outlined above, suggests that the majority
of individuals who develop TS do so after repeated rounds of infection by C. trachomatis. In
addition, there appears to be a subgroup of individuals who experience repeated or protracted
intense inflammation, who are at increased risk of developing scarring. It is anticipated that the
introduction of control programmes involving MDA and F and E interventions to limit trans-
mission, will reduce the number of episodes of infection experienced and therefore the risk of
developing incident scarring. However, the potential impact of control measures on halting
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progression of previously established scarring is less certain. A treatment intervention that
could reduce chronic conjunctival inflammation in adults in trachoma-endemic areas might be
desirable to prevent scarring progression.
The lack of a clear association between chlamydial infection and scarring progression in
adults could have a number of explanations [17]. It is possible that the number and frequency
of clinical observations and tests for chlamydial infection in these studies were too few to cap-
ture infection events. It is also possible that the detection of infection in adults is more difficult
than in children, because of lower infection loads or shorter infection duration, due to the
acquisition of some protective immunity [26–28]. This potential explanation might imply that
only brief bursts of infection with C. trachomatis is needed to trigger chronic inflammation
and an associated scarring response.
Alternatively, it is possible that conjunctival inflammation observed in adults with estab-
lished conjunctival scarring may have additional causes besides C. trachomatis. A number of
studies have found cross-sectional associations between non-chlamydial bacteria cultured from
the conjunctival surface and the presence of inflammation at all stages of the natural history of
trachoma [23, 29–33]. Currently however there are no longitudinal data to determine whether
this inflammation associated with other infections represents a pro-fibrotic state that contrib-
utes additional scarring, or whether it is a by-product of the altered physiological environment
of a scarred conjunctiva. Longitudinal studies that include tests for C. trachomatis and non-
chlamydial bacteria are needed to determine their relative contributions to scarring
progression.
These observations raise important issues of programmatic significance for trachoma con-
trol, particularly over whether conjunctival scarring can continue to develop and progress in
individuals with intermittent or chronic inflammation, but in the absence of on-going regular
chlamydial infection. Several long-term population based studies of the impact of MDA have
demonstrated that even after C. trachomatis has been cleared or brought down to very low
prevalence levels, the prevalence of signs of active conjunctival inflammation persist for some
years [21, 34]. While it is possible that the cross-sectional nature of these studies may have
missed recent infection episodes, it is striking that the inflammatory phenotype was still pres-
ent after the prevalence of C. trachomatis infection had been reduced to a low level, and this
may have significance for disease progression. A question worth consideration is whether the
clinical sign TI should be included in the monitoring of trachoma control in addition to TF,
because of the consistently strong association between TI and incident and progressive scar-
ring. Finally, these data support the recommendation that trachoma control programmes
maintain mechanisms to detect and treat trichiasis for many years to come.
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Trachoma, caused by Chlamydia trachomatis, is the world’s leading infectious cause
of blindness and remains a significant public health problem. Much of trachomatous
disease pathology is thought to be caused indirectly by host cellular and immune
responses, however the immune response during active trachoma and how this initiates
progressive scarring is not clearly understood. Defining protective vs. pathogenic
immune response to C. trachomatis is important for vaccine design and evaluation.
This study reports the baseline results of a longitudinal cohort of Tanzanian children,
who were monitored for 4 years in order to determine the immunofibrogenic and
infectious correlates of progressive scarring trachoma. In this cohort baseline, 506
children aged 6–10 years were assessed for clinical signs, infection status and the
expression of 91 genes of interest prior to mass azithromycin administration for trachoma
control. C. trachomatis was detected using droplet digital PCR and gene expression
was measured using quantitative real-time PCR. The prevalence of follicles, papillary
inflammation and scarring were 33.6, 31.6, and 28.5%, respectively. C. trachomatis was
detected in 78/506 (15.4%) individuals, 62/78 of whom also had follicles. C. trachomatis
infection was associated with a strong upregulation of IFNG and IL22, the enrichment
of Th1 and NK cell pathways and Th17 cell-associated cytokines. In individuals with
inflammation in the absence of infection the IFNG/IL22 and NK cell response was
reduced, however, pro-inflammatory, growth and matrix factors remained upregulated
and mucins were downregulated. Our data suggest that, strong IFNG/IL22 responses,
probably related to Th1 and NK cell involvement, is important for clearance of
C. trachomatis and that the residual pro-inflammatory and pro-fibrotic phenotype
that persists after infection might contribute to pathological scarring. Interestingly,
females appear more susceptible to developing papillary inflammation and scarring
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thanmales, even at this young age, despite comparable levels ofC. trachomatis infection.
Females also had increased expression of a number of IFNγ pathway related genes
relative to males, suggesting that overexpression of this pathway in response to infection
might contribute to more severe scarring. Longitudinal investigation of these factors
will reveal their relative contributions to protection from C. trachomatis infection and
development of scarring complications.
Keywords: trachoma, Chlamydia trachomatis, gene expression, mass azithromycin administration, longitudinal
study, active trachoma, conjunctival scarring
INTRODUCTION
Trachoma, a Neglected Tropical Disease caused by the bacterium
Chlamydia trachomatis, remains the leading infectious cause of
blindness worldwide. It is characterized by repeated conjunctival
infection initiated early in childhood, triggering inflammation
(trachomatous inflammation—intense and trachomatous
inflammation—follicular) that drives scarring and trichiasis (in-
turned eyelashes) and eventually blinding corneal opacification
(Hu et al., 2013a; Taylor et al., 2014; Ramadhani et al., 2016a).
The burden of this disease is high; current estimates indicate 200
million people live in trachoma endemic areas in 42 countries
(World Health Organization, 2016). Approximately 1.9 million
people are visually impaired or irreversibly blind from trachoma
(Bourne et al., 2013). To meet this public health challenge, the
WHO-led Global Alliance for the Elimination of Trachoma
recommends the implementation of the SAFE strategy which
tackles the disease at different stages: Surgery to correct trichiasis,
Antibiotics to treat chlamydial infection and Facial cleanliness
and Environmental improvements to suppress transmission of
infection (Taylor et al., 2014).
Our understanding of this disease process is only partial (Hu
et al., 2013a). There are few detailed long-term longitudinal
studies that investigate the risk factors for and pathophysiology
of scarring trachoma (Dawson et al., 1990; West et al., 2001;
Wolle et al., 2009a,b; Burton et al., 2015). These studies
have consistently found incident and progressive scarring to
be strongly associated with clinically apparent conjunctival
inflammation (Ramadhani et al., 2016a). However, only one
study has prospectively examined the relationship between
C. trachomatis infection and the development of incident
scarring in younger people; this found that the detection of
infection and/or severe inflammation on multiple occasions
was associated with increased risk of new scarring (Wolle
et al., 2009b). The relationship between chlamydial infection
and progression of previously established scarring in adults
has been prospectively examined in two longitudinal cohorts;
neither found an association (Burton et al., 2015). This raises
the possibility that progressive scarring may not be entirely
dependent on continual re-exposure to C. trachomatis. It is
possible that repeated chlamydial infection results in long-term
physiological changes in conjunctival tissue responsiveness, such
that other pro-inflammatory factors may stimulate on-going
fibrotic responses (Kechagia et al., 2016). For trachoma control
programmes, this raises the possibility that scarringmay continue
to progress after ocular chlamydial infection has been eliminated
from the population. The implication of this is that services for
managing incident trichiasis may be needed for many years.
Previously, we and others have explored the immunological
correlates of the different stages of trachoma mostly through
cross-sectional studies using a range of methodologies, including
gene expression and protein analysis, immunohistochemistry
and genome wide association studies (Bobo et al., 1996; Burton
et al., 2004, 2011b, 2015; Skwor et al., 2008; Holland et al.,
2010; Natividad et al., 2010; Derrick et al., 2013, 2016a,b; Hu
et al., 2013a, 2016; Roberts et al., 2015). These studies have
shown an increase in pro-inflammatory and matrix factors
(IL1B (interleukin 1 beta), TNF (tumor necrosis factor), S100A7
(psoriasin), IL17A, IFNG (interferon gamma), perforin, IL12,
IL10, CXCL5, CTGF (connective tissue growth factor) andMMP9
(matrix metalloproteinase 9) in individuals with active trachoma
and/or chlamydial infection, indicating the involvement of a
type 1 T helper (Th1) cell response, NK cell cytotoxicity and
potentially Th17 cells. In individuals with trachomatous scarring
and/or trichiasis, factors involved in innate pro-inflammatory
responses and matrix remodeling (IL1B, CXCL5, S100A7, CTGF,
MMP7, andMMP9) were upregulated.
To understand the immunofibrogenic correlates of
progressive conjunctival scarring we conducted a long-term
cohort study. Here we present the baseline findings for a large
panel of factors, to define those to be examined in the prospective
study.
METHODS
Ethics Statement
This study was reviewed and approved by the Tanzanian
National Institute for Medical Research Ethics Committee, the
Kilimanjaro Christian Medical Centre Ethics Committee, and
the London School of Hygiene and Tropical Medicine Ethics
Committee. It adhered to the tenets of the Declaration of
Helsinki.
Study Population
The study was conducted in three adjacent trachoma endemic
villages in Kilimanjaro and Arusha regions, Northern Tanzania.
The villages are relatively remote, geographically neighbors
and have similar patterns of life and traditions. This area is
predominantly inhabited by people of the Maasai tribe. Pastoral
activities are the main occupation. The area is dry for much of the
year, except for the rainy season (February to May). Water supply
is therefore limited, and largely depends on a long-distance
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water pipe scheme from Mount Kilimanjaro. Family units are
organized in Bomas, with living huts arranged in a circle around
a central animal enclosure, which is often characterized by a high
density of flies.
In January 2012, we recruited a cohort of children aged
6–10 years from these villages. The cohort has subsequently
been followed-up every 3 months for 4 years to investigate the
pathogenesis of conjunctival scarring. All children, aged 6–10
years, who were normally resident in one of the three villages,
were eligible for inclusion. We chose this restricted age group as
we considered that they were more likely to show evidence of
incident or progressive conjunctival scarring during the 4 years
of the study. At the outset community meetings were held to
introduce the study. Each household was then visited to meet the
parents or legal guardians of children eligible for enrolment. A
field worker explained the nature of the study in detail in either
Swahili or Maasai language. There was an opportunity to discuss
and ask questions. Finally, if the parent or guardian agreed to
allow the child to be enrolled into the study this was documented
on a consent form in Kiswahili, and witnessed by a third
person.
Clinical Assessments and Sample
Collection
The left eye of each child was examined by an ophthalmic
nurse experienced in grading trachoma. The examinations were
all performed under standardized conditions, using x2.5 loupes
and a bright touch. The conjunctiva was anesthetized with a
drop of preservative-free proxymetacaine hydrochloride 0.5%w/v
(Minims R⃝, Chauvin Pharmaceuticals Ltd, Surrey, UK). The
eyelid was everted, examined and photographed (Nikon D90
with 105 mm Macro lens). Two conjunctival swab samples
(Dacron polyester, Puritan Medical Products Company, Maine,
USA) were collected for C. trachomatis detection and gene
expression analysis. The swabs were passed across the upper
tarsal conjunctiva four times, with a quarter turn between each
pass. The first swab was placed directly into a tube containing
RNAlater (Thermo Fisher Scientific, Massachusetts, USA) and
the second into a dry tube. The samples were placed into a cool
box. Later the same day the dry swab samples were stored directly
at−80◦C and the RNAlater samples kept at 4–8◦C overnight and
then stored at−80◦C. Air control swabs were collected after every
50 samples by passing a swab 10 cm from a participant’s everted
eye, these were labeled and processed identically to participant
samples.
Clinical signs were graded using the 1981 WHO Detailed
Trachoma Grading System (FPC) (Dawson et al., 1981). This
sub-divides the features into several four-point severity scales:
follicles (F), papillary inflammation (P), and conjunctival
scarring (C). This system corresponds to the WHO Simplified
Trachoma Grading System in the following way: Trachomatous
inflammation-Follicular (TF) is equivalent to F2/F3 and
Trachomatous inflammation-Intense (TI) is equivalent to P3
(Thylefors et al., 1987). For the purpose of this study, we consider
that both P2 and P3 represent clinically significant papillary
inflammation, and refer to this as “TP” (Burton et al., 2015).
We followed the widely used definition of “Clinically Active
Trachoma”: TF and/or TI. The digital photographs were graded
by an ophthalmologist experienced in trachoma assessment,
using the FPC system, supplemented by a previously described
system for fine grading of conjunctival scarring, that quantifies
the extent of the conjunctiva involved (Hu et al., 2011). The
ophthalmologist was masked to the infection status.
Extensive public health education about trachoma was
provided to the community through village level meetings and
during the house-to-house visits, including the importance of
face washing for children and environmental improvements.
Trichiasis surgery was provided free of charge within the
community. Subsequently, all residents of the three villages have
been offered three rounds of annual mass antibiotic treatment
with oral azithromycin (and topical tetracycline ointment for
infants under 6 months and pregnant women), during the course
of the longitudinal study.
C. trachomatis Detection
To detect C. trachomatis, we extracted DNA from swab samples
stored in dry tubes using the PowerSoil DNA Isolation Kit
(Mo Bio Laboratories, California, USA), according to the
manufacturer’s instructions. The cells attached to the swabs were
initially disrupted by bead beating to release their contents.
C. trachomatis DNA was detected using a previously described
droplet digital PCR assay (Roberts et al., 2013). All samples
were tested for the C. trachomatis plasmid and the human gene
RPP30. Samples in which C. trachomatis plasmid was detected
were retested for C. trachomatis omcB (a single-copy gene on
the chlamydial chromosome). Five microliters of template DNA
was added per reaction. PCR reaction conditions were as follows:
95◦C for 10 min, then 40 cycles of 95◦C for 10 s and 60◦C for
30 s and finally 98◦C for 12 min. Droplets were then examined
for fluorescence on a QX100 Droplet Reader (Bio-Rad, UK),
providing a quantitative result.
Human Gene Expression Analysis
Total RNA was extracted from the swab stored in RNALater
using a DNA/RNA Purification Kit (Norgen Biotek Corp,
Canada), following the manufacturer’s instructions. RNA was
reverse transcribed using the SuperScript R⃝ VILO R⃝ cDNA
Synthesis Kit (Life Technologies). Quantitative real-time PCR
was performed to measure the relative abundance of a panel of
human transcripts, using the TaqMan R⃝ Microfluidic 384-well
Low-Density Array (TLDA) (Life Technologies) on a ViiA7 real-
time PCR instrument (Thermo Fisher Scientific, Massachusetts,
USA). These cards have separate channels for eight samples,
each containing 48 wells, pre-printed with the assay primers and
probes. We used two different TLDA designs and measured the
expression of 91 different genes of interest for each sample. The
selected genes are listed in Table 5. We measured expression of
three different reference genes: HPRT1, GAPDH, and RPLP0.
HPRT1 was selected as the most suitable for normalization as it
was expressed at a relatively similar level to the majority of other
transcripts of interest, whereas GAPDH and RPLP0 were very
highly expressed. The choice of transcripts tested was informed
by previous gene expression studies including transcriptome
analysis experiments on samples from The Gambia, Ethiopia
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and Tanzania and by a genome-wide association study from The
Gambia (Holland et al., 2010; Natividad et al., 2010; Burton et al.,
2011b,c, 2015; Roberts et al., 2015).
Statistical Analysis
Data were managed in Access and transferred to STATA
v14 for analysis. The ophthalmologist’s grading of the digital
photographs was used for analysis. The ddPCR results were
initially exported to R for analysis; the critical cut-off value for
designating a positive result for each target was 0.2 plasmid
copies/µl of eluted DNA, 0.2 omcB copies/µl and >0.3 RPP30
copies/µl. Samples were designated C. trachomatis positive if
plasmid and human RPP30 were detected.
The associations between each of the clinical signs (follicular
inflammation, papillary inflammation and scarring) and
C. trachomatis infection were assessed using univariable
logistic regression with infection as the outcome variable. The
associations between scarring and each of the other clinical
signs, infection, sex and age were investigated with logistic
regression, using presence of scarring as the outcome variable.
Initially, univariable logistic regression was performed using
each exposure in turn, and then a multivariable analysis was
performed in order to provide an unbiased estimate of the
association between exposure and outcome adjusting for all
clinical features.
The gene expression data were normalized relative to the
expression of HPRT1 in the same sample, to adjust for variable
concentrations of cDNA. This was done by the !CT method.
Distributions of !CT values were plotted to assess them for
normality. Fold change differences in gene expression between
different phenotypic groups (Infection, follicular inflammation,
papillary inflammation and scarring), vs. individuals without
those clinical signs or infection, were calculated using the
!!CT method. Linear regression was used to compare the two
groups in each comparison, with !CT values as the dependent
variable and each phenotype group in turn as the independent
variable, adjusting for age and sex. To take account of multiple
comparisons we used a false discovery rate (FDR) of 5%
(Benjamini and Hochberg, 1995). The linear regression analyses
were repeated, but rather than taking the four phenotypic
groups individually, they were all included as exposures in a
multivariable model with age and sex, providing estimates of the
fold-changes associated with each phenotype.
A heatmap of !CT values for each gene of each participant
was produced, to indicate visually whether the expression of
individual genes was consistently of higher or lower expression
in groups of individuals with clinically active Trachoma (TF
and/or TI) and/or infection. A principal component analysis
(PCA) was performed on the gene expression data and clinical
disease and infection status were overlaid on plots in order
to visually indicate any associations between the first two
components and infection, active trachoma and scarring. These
associations were tested formally using a logistic regression
analysis, with the principal components as the exposure
variables. For the heatmap and PCA, only individuals with
complete expression data could be included. Therefore, so
as not to lose too many individuals, any target with >5%
of observations missing was excluded from these analyses,
as well as the lasso regression and co-expression analyses
described below. Any individuals with missing observations
on the remaining targets were excluded from these analyses
also.
For each of infection, active trachoma and scarring, a
multivariable logistic regression was performed using this subset
of gene expression levels as exposure variables, with the aim of
retaining those expressions most strongly associated with the
outcome of interest, adjusting for all other expression levels.
Due to the large number of exposure variables, a penalized
logistic regression was performed using the lasso technique
(Tibshirani, 1997). The list of genes most strongly associated with
each outcome was entered into ConsensusPathDB (http://cpdb.
molgen.mpg.de/) gene set over-representation analysis, with all
genes tested entered as background. Enriched pathway-based sets
with a minimum overlap between pathway and input gene list of
two and a p< 0.05 were identified.
A network graph based on the specimen-to-specimen Pearson
correlation was generated using miru (https://kajeka.com/miru).
The overall expression correlation matrix and graph were
constructed from the raw cycle threshold expression values.
The filtered dataset including only individuals and genes
with complete expression data was used. Pearson correlation
coefficients (r) ≥0.85 were retained and used as cut-offs in
network construction. Nodes in the graph are individual mRNA
transcripts linked by an edge if r was ≥0.85. The graph was
then clustered using a Markov Clustering algorithm with an
inflation value of 2.2. The partitioned clusters of expression
contain sets of transcripts that exhibit a very high degree
of co-expression across the sample set. The co-expression
clusters or modules were then investigated for enrichment
at the pathway level using ConsensusPathDB as described
above, using all genes tested as background. A single value
for each cluster of each individual was defined using the first
principal component and this value was used to investigate
differential expression associated with disease and infection
phenotypes.
RESULTS
Study Participants
A total of 506 children between the ages of 6 and 10 years
were recruited and examined. Their demographic and clinical
characteristics are described in Table 1. There were almost equal
numbers of male and female children, with a mean age of 7.5
years. Most (97.4%) of the children were of the Maasai ethnic
group.
Active Trachoma
Trachomatous inflammation-Follicular (TF, F2/F3) was present in
170 (33.6%) children (Table 1). However, a further 135 (26.7%)
had evidence of mild follicular conjunctivitis (F1). Significant
conjunctival papillary inflammation (TP, P2/P3) was observed in
160 (31.7%) children, of which 64 (12.7%) had intense papillary
inflammation (TI, P3).
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TABLE 1 | Demographic characteristics, clinical signs and C. trachomatis
infection status.
Category n/506 (%)
Sex (Male) 251 (49.6%)
ETHNIC GROUP
Maasai 493 (97.4%)
Chaga 7 (1.4%)
Sonjo 4 (0.8%)
Pare 2 (0.4%)
Age in years (mean and range) 7.5 (6–10)
SIMPLIFIED WHO GRADING
TF 170 (33.6%)
TI 64 (12.7%)
TS 144 (28.5%)
DETAILED “FPC” WHO GRADING
Follicles
F0 201 (39.7%)
F1 135 (26.7%)
F2 81 (16.0%)
F3 89 (17.6%)
Papillae
P0 180 (35.6%)
P1 166 (32.8%)
P2 96 (19.0%)
P3 64 (12.7%)
Scarring
C0 362 (71.5%)
C1 120 (23.7%)
C2 21 (4.2%)
C3 3 (0.6%)
DETAILED TARSAL CONJUNCTIVA SCARRING GRADING SYSTEM
S0 362 (71.5%)
S1a 71 (14.0%)
S1b 28 (5.5%)
S1c 26 (5.1%)
S2 19 (3.8%)
S3 0 –
C. trachomatis PLASMID DETECTED
No 428 (84.6%)
Yes 78 (15.4%)
The clinical signs were determined by grading of photographs.
C. trachomatis Infection and Active
Trachoma
C. trachomatis plasmid was detected by ddPCR in 78 (15.4%)
individuals. There was a strong association between the presence
of TF and the detection of C. trachomatis plasmid; 62/78 (79.5%)
of C. trachomatis positive individuals had TF (Table 2). Of the 16
infected children who did not have TF, 11 (68.8%) had signs of
mild follicular conjunctivitis (F1). However, only 62/170 (36.5%)
individuals with TF had detectable infection. There was a similar
strong association between the presence of TP and chlamydial
infection (Table 2).
Infection load and the concentration of RPP30 endogenous
control DNA were quantified. The concentration of plasmid
DNA ranged from 0.22 to 3023 copies/µl, omcB ranged from 0.2
to 742 copies/µl and RPP30 ranged from 0.32 to 1,081 copies/µl
of eluted DNA. All samples had detectable RPP30. There was
a marked positive trend in both the proportion infected and
the load of infection with increasing F-Score and increasing P-
Score (Table 2). There was a consistent ratio of plasmid to omcB
copies/µl: geometric mean ratio of 4.57 to 1 (95% CI 3.91–5.34)
and a median of 4.79 to 1 (95%CI 4.01–5.21). The correlation
between plasmid and omcB copies/µl is illustrated in Figure 1.
The ratio did not vary with either the follicular or papillary
clinical severity scores (data not shown).
Conjunctival Scarring
Conjunctival scarring was relatively frequent, being found in
144 (28.5%) individuals; this was mostly mild scarring (Table 1).
There was a significant association between the detection of
C. trachomatis and scarring [p = 0.002, OR = 2.23 (95%CI
1.4–3.7)]. The load of infection also increased with scarring
severity (Table 2). There were univariate associations between
conjunctival scarring and TF, TP (P2/P3), C. trachomatis
detection and female sex (Table 3). However, in a multivariable
model only TP, female sex and age were independently associated
with scarring.
There was strong evidence (p = 0.0047) that even at this
young age females are proportionately more likely to have signs
of established scarring than males (Table 4). Similarly, there was
some evidence (p = 0.048) that females had slightly increased
odds of TP. No evidence was found of an association between sex
and the odds of TF or chlamydial infection (p = 0.12 and 0.25,
respectively) (Table 4).
Conjunctival Gene Expression
The expression of 91 target genes was measured relative to
that of HPRT1. Out of the 506 participants, samples from
12 individuals failed the qPCR for all target genes, leaving
494 individuals for gene expression analysis. The number of
participant samples with detectable expression for each target
is shown in Supplementary Table 1 (N). Multivariable linear
regression analysis was performed using data for all 91 genes
from 494 individuals.
Four sets of comparisons were performed: (1) infected v non-
infected, (2) TF v no TF, (3) TP v no TP, and (4) TS v no TS.
The relative Fold Change (FC) between these paired groups,
calculated by the!!CT method, are presented in Supplementary
Table 1 along with the p-values for the linear regression (adjusted
for age and sex) for each comparison.
As clinical signs and infection may be highly correlated
in their association with the expression of specific targets we
tested for independent associations with each target’s expression
usingmultivariable linear regressionmodels,Table 5. More genes
were significantly differentially expressed in individuals with
C. trachomatis infection (55/91) relative to individuals with
TP (33/91), TF (11/91), and TS (17/91) in these multivariable
models (P < 0.05). C. trachomatis Infection was associated
with increased expression of multiple cytokines and chemokines
(CCL2, CXCL13, CCL18, CSF2, FOXP3, IFNG, IDO1, IL1B,
IL6, IL8, IL10, IL12B, IL17A, IL19, IL21, IL22, IL23A), cell
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TABLE 2 | C. trachomatis plasmid detection and clinical signs; both the simplified and detailed WHO “FPC” grading system.
C. trachomatis plasmid OR (95%CI) p-value Geometric mean
No (%) Yes (%) Plasmid omcB
FOLLICULAR INFLAMMATION
No TF 320 (95.2%) 16 (4.8%) 1 – – 2.99 0.86
TF 108 (63.5) 62 (36.5%) 11.48 (6.4–20.7) 5.95E-16 16.27 4.26
FPC FOLLICLE SCORE
F0 196 (97.5%) 5 (2.5%) 1 – – 3.41 1.04
F1 124 (91.9%) 11 (8.2%) 3.48 (1.2–10.2) 0.024 2.82 0.81
F2 65 (80.3%) 16 (19.8%) 9.65 (3.4–27.4) 2.03E-05 20.05 4.17
F3 43 (48.3%) 46 (51.7%) 41.93 (15.7–111) 7.97E-14 15.13 4.29
PAPILLARY INFLAMMATION
No TP 323 (93.4%) 23 (6.7%) 1 – – 4.11 1.23
TP (P2/P3) 105 (65.6%) 55 (34.4%) 7.36 (4.3–12.5) 2.45E-13 17.67 4.64
FPC PAPILLARY SCORE
P0 173 (96.1%) 7 (3.9%) 1 – – 2.53 0.72
P1 150 (90.4%) 16 (9.6%) 2.63 (1.1–6.6) 0.038 5.09 1.41
P2 73 (76%) 23 (23.9%) 7.79 (3.2–18.9) 6.07E-06 13.47 2.65
P3 32 (50%) 32 (50.0%) 24.71 (10.0–60.8) 2.95E-12 21.47 6.99
SCARRING
No 318 (87.9%) 44 (12.2%) 1 – – 9.67 2.59
Yes 110 (76.4) 34 (23.6%) 2.23 (1.4–3.7) 0.002 14.38 4.35
FPC SCARRING SCORE
C0 318 (87.9%) 44 (12.2%) 1 – – 9.67 2.59
C1 89 (74.2%) 31 (25.8%) 2.52 (1.5–4.2) 0.0005 12.33 4.08
C2 18 (85.7%) 3 (14.3%) 1.20 (0.3–4.3) 0.77 70.24 7.85
C3 3 (100%) 0 – – –
DETAILED SCARRING SCORE
S0 318 (87.9%) 44 (12.2%) 1 – – 9.67 2.59
S1a 56 (78.9%) 15 (21.1%) 1.94 (1.0–3.7) 0.047 7.98 3.44
S1b 21 (75.0%) 7 (25.0%) 2.41 (1.0–6.0) 0.059 15.24 4.26
S1c 17 (65.4%) 9 (34.6%) 3.83 (1.6–9.1) 0.0024 21.61 5.32
S2 16 (84.2%) 3 (15.8%) 1.36 (0.4–4.8) 0.64 70.24 7.85
S3 0 – 0 – – –
P-values were calculated by Pearson χ2. TP is equivalent to P2 or P3 of the FPC papillary score.
cycle components (CDC25C, TTK, TYMS), matrix modifiers
(MMP7, MMP9, MMP12, TGFB1), NK cell markers (CD247,
NCR1, NCAM1) and intracellular signaling molecules/regulators
(CD274, IKZF1, RHOH, SAMSN1, SERPINB3, SERPINB4,
STAT1, STAT4, SOCS1, TBX21), Table 5. Infection was associated
with particularly marked increases in expression of IFNG (FC:
7.12, p-value: 1.32E-42) and IL22 (FC: 6.49, p-value: 1.6E-23).
There was reduced expression of several factors includingmucins
(MUC1, MUC4, MUC5AC, MUC7) and SPARCL1.
Clinical signs of active trachoma were associated with
increased expression of multiple cytokines, chemokines,
antimicrobial peptides, matrix modifiers, following a similar
pattern to infection (Table 5). TP was associated with more
substantial increases in a wider range of factors than TF (Table 5):
antimicrobial peptides (DEFB4A, S100A7), cytokine/chemokines
(CXCL5, CXCL13, CCL18, CCL2, IL1B, IL8, IL10, IL17A, IL19,
IL23A, PTGS2), matrix modifiers (MMP7, MMP9, MMP12)
and intracellular signaling molecules/regulators (CD274,
SAMSN1, SERPINB3, SERPINB4, SOCS3). Several cytokines
and chemokines (CCL18, CXCL13, IL19, and S100A7) had a FC
>2 in children with TP. Conjunctival scarring was associated
with modestly increased expression (>1.2 FC) and borderline
significance of several chemokines and cytokines (CCL2,
CCL20, CXCL5, CSF3, IL1B, IL8, IL10, IL21, IL33, FGF2) in the
multivariable linear regression models (Table 5). SPARCL1 was
significantly downregulated in TF and TP but not TS.
Only 108 individuals had detectable gene expression for all 91
targets, so in order to retain a reasonable number of individuals in
the PCA and lasso analyses, which require complete records for
all individuals, targets which were missing >5% of observations
were excluded. This resulted in the exclusion of eight transcripts
(USP6, IL13, CTNND2, FGF2, SERPINB4, IL22, PREX2v1,
PREX2v2) for which there was no detectable expression in >5%
individuals. In individuals with detectable expression of these
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FIGURE 1 | The relationship between paired measures of copies of Chlamydia
trachomatis plasmid/µl vs. omcB/µl in the same sample. Correlation
R-squared = 0.989.
TABLE 3 | Univariable and multivariable associations between conjunctival
scarring and other clinical features, C. trachomatis infection, sex and age.
Variable OR 95% CI p-value
UNIVARIABLE ANALYSIS
TF 2.28 (1.53–3.40) 5.20E-05
TP (P2/P3) 2.98 (1.99–4.47) 1.22E-07
Plasmid 2.23 (1.36–3.67) 0.002
Sex (Female) 1.76 (1.19–2.61) 0.005
Age 1.06 (0.97–1.17) 0.217
MULTIVARIABLE LOGISTIC REGRESSION
TF 1.39 (0.79–2.44) 0.251
TP (P2/P3) 2.60 (1.52–4.44) 4.83E-04
Plasmid 1.33 (0.75–2.37) 0.326
Sex (Female) 1.63 (1.08–2.45) 0.019
Age 1.16 (1.05–1.29) 0.005
eight targets, raw CT values were generally very high (CT >
33). These eight targets were excluded from the heatmap, PCA,
lasso regression and co-expression network analyses, retaining
a complete expression dataset for 83 genes. Among the 494
individuals, 36 were excluded as they hadmissing data among the
83 included targets, resulting in a final dataset of 458 individuals
and 83 genes. Excluding further genes offered minimal gains in
sample size. A heatmap of !CT values separated by clinical and
infection phenotype is presented in Figure 2. Infected individuals
with or without active trachoma had a visibly distinct pattern
of gene expression, whereas the !CT values of normal healthy
controls and individuals with active trachoma in the absence of
infection appeared more similar overall.
PCA analysis was performed for 458 individuals that had
complete gene expression data for 83 targets and active
trachoma/infection and scarring status were overlaid on plots,
Supplementary Figures 1A,B. Principal component 1 (PC1) was
strongly associated with infection and active trachoma; for a
one unit increase in PC1 there was an estimated 35% decrease
in the odds of infection (95% CI 27–41%, p < 0.001) and an
estimated 23% decrease in the odds of active trachoma (95% CI
9–28%, p < 0.001). PC1 loadings showed that as genes in the
chemokines/cytokines and regulator/signaling pathways groups
were up-regulated, PC1 became smaller, suggesting that the
odds of infection/active trachoma was greater among individuals
where these genes are up-regulated. The expression of mucins,
CDH1, SPARCL1, and S100A4 showed the reverse relationship,
as when these genes were down-regulated the PC1 was smaller.
Principal component 2 (PC2) was associated with increased odds
of active trachoma alone, with a unit increase in PC2 being
associated with an estimated 15% increase in the odds (95% CI 7–
24%, p< 0.001), however there was no evidence of an association
between PC2 and infection. There was evidence of a weaker
association between PC1 and scarring, with an estimated 10%
decrease in the odds of scarring (95% CI 6–14%, p < 0.001) per
unit increase in PC1, Supplementary Figure 1B. There was no
evidence of an association between scarring and PC2.
Three lasso logistic regressions were performed, first using
infection (with or without active disease) as the outcome and the
83 targets, age and sex of 458 individuals as exposures. Then,
excluding all infected individuals, active trachoma (uninfected
only) was used as the outcome against uninfected individuals
without active trachoma and the same 83 targets, age and
sex as the exposures of interest. Finally, the regression was
performed using scarring as the outcome and the same set of
exposures in all 458 individuals. The transcripts most strongly
associated with each of the three outcomes, and biological
pathways with members that were over-represented in each
relative to the background (83 targets) are listed in Table 6.
Genes most strongly associated with infection were associated
with Th1 cell development and NK cell pathways, whilst
genes most associated with active trachoma in the absence of
C. trachomatis infection were enriched for members of leukocyte
transendothelial migration, TNF receptor, MMP activation,
collagen formation and collagen fibrils assembly pathways. Genes
most strongly associated with the TS phenotype were enriched for
members of immunoregulatory interactions between lymphoid
and non-lymphoid cells.
Networks of co-expression, independent of differential
expression, were explored in the complete expression data of
83 transcripts and 458 individuals using Miru. The undirected
graph contained 51 nodes connected by 121 edges. Markov
clustering partitioned the network into 5 separate clusters of
co-expressed genes that accounted for 38/51 (74.5%) of the
transcripts in the original network. Cluster 1 contained 11 co-
expressed transcripts, cluster 2 contained 10 transcripts, there
were 6 transcripts in each of cluster 3 and 4, and 5 transcripts
in cluster 5 (Supplementary Table 2A), the remaining nodes
were not connected in the graph. The most connected gene
transcript or hub in each module was MyD88/REL (cluster 1),
IKZF1/VIM (cluster 2), STAT1 (cluster 3), SRGN (cluster 4), and
IL10/IL17A/IL21 (cluster 5).
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TABLE 4 | The relationship between sex and (i) clinical signs, (ii) Chlamydia trachomatis infection and (iii) infection load.
Male (%) Female (%) OR (95% CI) p-value
FOLLICULAR INFLAMMATION
No TF 175 (69.7%) 161 (63.1%) 1 – –
TF 76 (30.3%) 94 (36.9%) 1.34 (0.9–1.9) 0.12
PAPILLARY INFLAMMATION
No TP 182 (72.5%) 164 (64.3%) 1 – –
TP (P2/P3) 69 (27.5%) 91 (35.7%) 1.46 (1.0–2.1) 0.0479
SCARRING
No TS 194 (77.3%) 168 (65.9%) 1 – –
TS 57 (22.7%) 87 (34.1%) 1.76 (1.2–2.6) 0.0047
INFECTION
No 217 (86.5%) 211 (82.6%) 1 – –
Plasmid 34 (13.6%) 44 (17.2%) 1.33 (0.8–2.2) 0.25
GEOMETRIC MEAN AMONG THOSE WITH INFECTION
Plasmid 9.45 (4.6–19.3) 13.37 (7.5–23.7) 0.44α
omcB 2.93 (1.5–5.8) 3.50 (2.1–5.9) 0.67α
αDifferences between chlamydial load geometric means in males and females were calculated using a t-test.
Pathway enrichment analysis was performed for each cluster
relative to the background of 83 transcripts (Supplementary Table
2B)."CT values for the transcripts in each cluster were collapsed
into a single value for each of the 458 individuals, represented
by the first principal component. Multivariable linear regression
was then performed for each cluster, using the first principal
component as the outcome variable and TF, TP, TS, infection,
age, and sex as independent variables (Supplementary Table 2C).
Cluster 1 was enriched for cell cycle and apoptosis pathways,
however the combined expression value was not differentially
expressed in any condition. Cluster 2 was significantly associated
with infection and TF and was marginally enriched for the
retinoblastoma pathway. Cluster 3 was highly enriched for Th1/2
cell differentiation, IFNγ, IL-12, CD8, and NK cell signaling
pathways and was strongly associated with infection and age and
marginally associated with sex, but interestingly not with TP or
TF. Conversely, cluster 4 was enriched for TNF, inflammasome,
TLR and NFkB signaling pathways and was associated with TP,
TS, and age but not infection. Cluster 5 was enriched for the
allograft rejection pathway and was associated with infection, TP,
TS and age.
DISCUSSION
Clinical Disease and C. trachomatis
Infection
In this study, conducted in communities prior to azithromycin
MDA, there was a relatively high TF (34%) and moderate
C. trachomatis (15.4%) prevalence in 6–10 year olds. There was
a strong relationship between infection and clinical signs. The
largemajority (79.5%) of individuals withC. trachomatis detected
by ddPCR had TF (F2/F3). Moreover, most individuals (68.8%)
with detectable chlamydial infection but without TF had a mild
follicular conjunctivitis (F1). There were few cases of infection in
the absence of clinical signs. This is consistent with earlier studies
which found a stronger correlation as the underlying prevalence
of infection increased (Ramadhani et al., 2016b). However, in
common with many other studies reporting the relationship
between disease and infection, a minority (36%) of individuals
with TF had detectable infection, probably due to the shorter
duration of infection episodes relative to disease (Grassly et al.,
2008; Burton et al., 2011a,c; Lee et al., 2014). With increasing
severity of both TF and TP scores, there was an increasing
proportion with infection and increasing loads of infection.
Consistent with earlier studies, increasing load appeared to be
more closely related to increasing TP rather than TF (Burton
et al., 2003; Solomon et al., 2003; Michel et al., 2011; Derrick et al.,
2016a).
In the present cross-sectional study conjunctival scarring
was associated with TP, female sex and increasing age but not
C. trachomatis infection, which is consistent with several earlier
cohort studies (Dawson et al., 1990; West et al., 2001; Wolle et al.,
2009b; Burton et al., 2015; Hu et al., 2016). However, longitudinal
data supporting an association between TF or C. trachomatis
infection and progressive scarring are limited (Ramadhani et al.,
2016a). We found females had more TP and TS than males,
whereas C. trachomatis infection and TF prevalence were not
significantly different between the sexes (Table 4). This might
suggest that there are additional determinants of TP and TS
development beyond the initial C. trachomatis infection. It
is generally believed that the difference in the proportion of
males and females developing scarring sequelae of trachoma
is attributable to a greater life-time exposure to repeated
C. trachomatis infection among females (Taylor et al., 2014).
While that may well be the case, the data from this study
also suggest that even at a relatively young age, females appear
more susceptible to developing TP and TS than males, despite
comparable levels of C. trachomatis infection. This finding
is consistent with the observation that in general, females
generate stronger immune responses than males, making them
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TABLE 5 | Multivariable linear regression models for conjunctival gene expression in the presence of clinical signs, C. trachomatis plasmid, female sex and age.
Target TF TP TS Plasmid Sex (female)α Ageβ
FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value
ANTIMICROBIAL PEPTIDES
Defensin, beta 4B,defensin, beta 4A
(DEFB4A)
0.77 0.0919 2.08 2.37E-06 1.12 0.3844 1.28 0.1459 1.37 0.0044 0.92 0.0022
Psoriasin-1 (S100A7) 1.40 0.1605 2.86 8.94E-06 1.25 0.2520 1.77 0.0279 1.36 0.0672 0.88 0.0039
CELL CYCLE
CD53 molecule (CD53) 0.98 0.7932 1.19 0.0033 1.08 0.1263 1.15 0.0340 1.03 0.4334 0.98 0.1419
M-phase inducer phosphatase 3
(CDC25C)
1.17 0.0490 1.08 0.3434 1.04 0.5710 1.36 0.0005 1.02 0.7103 0.99 0.4182
Cyclin-dependent kinase 13 (CDK13) 1.00 0.9318 0.88 0.0037 1.02 0.6393 0.92 0.0908 1.00 0.8874 1.01 0.1454
Catenin (cadherin-associated
protein), delta 2 (CTNND2)
1.08 0.7376 0.81 0.3716 1.02 0.9196 0.79 0.3411 0.90 0.5413 1.06 0.1744
Sun Domain Family, Member 6
(NSUN6)
0.94 0.0874 0.98 0.5339 1.04 0.2220 1.01 0.8099 0.95 0.0359 1.01 0.1160
Phytanoyl-coa 2-hydroxylase (PHYH) 0.92 0.0678 0.95 0.2639 1.01 0.8297 0.85 0.0010 0.97 0.4291 1.02 0.0196
Tumor protein p53 (TP53) 1.01 0.7419 0.85 0.0001 1.03 0.3965 1.01 0.8485 0.97 0.3148 1.01 0.0460
TTK protein kinase (TTK) 1.16 0.0209 1.11 0.0933 1.10 0.0719 1.31 0.0002 0.98 0.7333 0.99 0.4067
Thymidylate synthetase (TYMS) 1.11 0.0590 1.16 0.0050 1.00 0.9654 1.62 6.38E-15 1.05 0.2448 0.99 0.1936
CYTOKINES/CHEMOKINES
Chemokine ligand 18 (CCL18) 1.00 0.9903 3.03 6.14E-10 0.94 0.6534 1.99 0.0004 0.97 0.8422 0.89 0.0006
Chemokine ligand 2 (CCL2) 0.95 0.7092 1.63 0.0008 1.39 0.0060 3.36 1.45E-13 1.13 0.2284 0.87 1.06E-07
Chemokine ligand 20 (CCL20) 1.45 0.0005 1.04 0.7406 1.33 0.0011 1.23 0.0735 0.97 0.7140 0.95 0.0035
Chemokine receptor 6 (CCR6) 1.53 0.0011 0.83 0.1466 1.11 0.3398 1.10 0.4912 1.12 0.2129 0.96 0.1173
Colony stimulating factor 2 (CSF2) 1.19 0.0798 1.05 0.6564 1.13 0.1416 2.45 2.83E-15 1.14 0.0690 0.99 0.5702
Colony stimulating factor 3 (CSF3) 0.97 0.8494 1.40 0.0206 1.52 0.0005 0.85 0.3008 0.99 0.8901 0.91 0.0008
Chemokine ligand 13 (CXCL13) 1.41 0.0321 2.01 1.22E-05 1.14 0.3140 2.11 2.29E-05 1.23 0.0733 0.87 3.46E-06
Chemokine ligand 5 (CXCL5) 1.11 0.4860 1.82 0.0001 1.60 0.0001 0.82 0.2278 0.88 0.2371 0.88 6.49E-06
Forkhead box P3 (FOXP3) 1.02 0.7750 1.02 0.7818 0.91 0.0840 1.25 0.0014 0.95 0.2135 1.00 0.9477
Indoleamine 2,3-dioxygenase 1
(IDO1)
1.17 0.1491 1.28 0.0187 1.24 0.0139 1.73 3.53E-06 1.34 0.0001 0.89 1.05E-08
Interferon gamma(IFNG) 1.36 0.0109 1.09 0.4791 1.12 0.2396 7.12 1.32E-42 1.29 0.0025 0.91 2.97E-05
Interleukin 10 (IL10) 1.13 0.2184 1.49 3.48E-05 1.22 0.0141 1.78 7.86E-08 1.09 0.2106 0.94 0.0004
Interleukin 12 beta (IL12B) 1.15 0.2315 1.19 0.1340 1.07 0.4853 3.42 3.90E-21 1.23 0.0106 0.97 0.2047
Interleukin 13 (IL13) 1.63 0.1091 0.66 0.1804 0.80 0.2701 1.38 0.2585 1.03 0.8545 1.07 0.1290
Interleukin 17A (IL17A) 1.16 0.2561 1.65 0.0001 1.19 0.0928 2.34 1.85E-09 1.18 0.0688 0.90 3.56E-06
Interleukin 19 (IL19) 0.96 0.7566 2.63 5.69E-11 1.16 0.2150 2.11 3.75E-06 1.43 0.0006 0.88 6.69E-07
Interleukin 1 beta(IL1B) 0.97 0.8261 1.72 5.46E-06 1.36 0.0021 1.55 0.0009 1.04 0.6251 0.92 0.0002
Interleukin 21 (IL21) 1.68 0.0003 1.36 0.0290 1.34 0.0132 3.10 1.69E-12 1.16 0.1432 0.90 0.0001
Interleukin 22 (IL22) 1.14 0.4452 1.26 0.1548 1.31 0.0511 6.49 1.60E-23 1.22 0.0973 0.93 0.0302
Interleukin 23A (IL23A) 0.98 0.8604 1.70 3.81E-08 1.10 0.2287 1.87 3.62E-09 0.99 0.8875 0.93 3.13E-05
Interleukin 33 (IL33) 0.96 0.6351 0.92 0.3465 1.28 0.0009 1.27 0.0164 0.96 0.5468 1.03 0.0472
Interleukin 6 (IL6) 0.92 0.5490 1.27 0.0721 1.27 0.0303 1.80 0.0001 0.92 0.3965 0.94 0.0057
Interleukin 8 (IL8) 0.87 0.1443 1.43 0.0001 1.24 0.0041 1.32 0.0063 1.00 0.9975 0.97 0.0751
Prostaglandin-endoperoxide synthase
2 (PTGS2)
0.90 0.3527 1.45 0.0009 1.26 0.0116 1.18 0.1781 0.98 0.7886 0.97 0.0978
Tumor necrosis factor (TNF ) 1.39 0.0040 0.93 0.4934 1.16 0.1187 1.30 0.0383 1.15 0.0965 1.00 0.8808
EMT MARKERS
Alpha smooth muscle actin (ACTA2) 1.10 0.1559 0.83 0.0039 1.14 0.0144 1.29 0.0004 1.04 0.3549 0.99 0.4144
Epithelial cadherin (CDH1) 0.94 0.2482 0.93 0.1746 1.05 0.2799 0.78 4.22E-05 0.99 0.7167 1.00 0.9175
Cadherin 1, type 1, E-cadherin
(epithelial) (CDH1)
0.95 0.3727 0.92 0.1964 1.04 0.4101 0.73 3.06E-06 0.99 0.8120 1.01 0.5096
(Continued)
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TABLE 5 | Continued
Target TF TP TS Plasmid Sex (female)α Ageβ
FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value
Neuronal cadherin (CDH2) 0.98 0.8576 0.71 0.0066 1.18 0.1088 1.11 0.4339 1.00 0.9960 1.04 0.0558
S100 calcium binding protein A4
(S100A4)
0.88 0.0691 0.71 1.83E-06 1.15 0.0213 0.47 1.99E-20 0.90 0.0393 1.03 0.0093
Vimentin (VIM) 1.02 0.6112 1.04 0.4486 1.04 0.2589 1.51 8.85E-15 1.01 0.7266 1.01 0.3843
MATRIX MODIFIERS
Connective tissue growth factor
(CTGF-1)
0.98 0.8349 0.81 0.0191 0.98 0.7534 1.20 0.0721 0.79 0.0003 1.02 0.2769
Connective tissue growth factor
(CTGF-2)
0.89 0.2310 0.85 0.0721 0.91 0.2245 1.21 0.0675 0.82 0.0036 1.03 0.0828
Fibroblast growth factor 2 (basic)
(FGF2)
0.86 0.3151 1.11 0.4830 1.43 0.0032 1.48 0.0124 0.87 0.1988 1.01 0.7147
Matrix metallopeptidase 12 (MMP12) 1.31 0.0246 1.48 0.0010 1.26 0.0188 2.00 1.84E-07 1.11 0.2136 0.92 0.0002
Matrix metallopeptidase 7 (MMP7) 0.94 0.5657 1.41 0.0024 1.04 0.7042 0.38 1.63E-14 0.93 0.3375 0.96 0.0488
Matrix metallopeptidase 9 (MMP9) 1.37 0.0048 1.43 0.0012 1.20 0.0519 1.77 3.45E-06 0.98 0.8380 0.96 0.0371
Platelet-derived growth factor beta
polypeptide (PDGFB)
1.00 0.9393 1.08 0.1904 1.16 0.0043 1.43 1.55E-07 1.06 0.1638 0.96 0.0002
SPARC-like 1 (hevin) (SPARCL1) 0.53 0.0048 0.39 3.20E-05 0.85 0.3842 0.46 0.0020 0.75 0.0794 1.20 1.29E-05
Transforming growth factor, beta 1
(TGFβ1)
1.02 0.6999 0.99 0.7693 1.08 0.0491 1.23 0.0001 0.99 0.6965 0.98 0.0305
Transforming growth factor, beta 2
(TGFβ2)
0.97 0.7251 0.96 0.6469 1.08 0.3172 0.91 0.3438 0.92 0.2258 1.01 0.6926
RESPONSE TO MICROBIOTA
Arachidonate 5-lipoxygenase (ALOX5) 0.88 0.0111 0.97 0.4844 1.05 0.2353 0.67 1.78E-13 0.97 0.4387 1.01 0.2310
B-cell CLL/lymphoma 2 (BCL2) 1.00 0.9769 0.94 0.1509 1.09 0.0239 1.13 0.0212 0.97 0.4448 1.00 0.8130
CD40 molecule, TNF receptor
superfamily member 5 (CD40)
0.98 0.6989 0.98 0.7901 1.06 0.2693 1.25 0.0009 1.06 0.1592 1.00 0.8334
Dual oxidase 2 (DUOX2) 0.92 0.3364 1.38 0.0004 1.09 0.2734 1.19 0.0852 1.20 0.0047 0.94 0.0001
V-rel avian reticuloendotheliosis viral
oncogene homolog (REL)
0.96 0.3595 1.08 0.0911 1.05 0.1697 1.03 0.5774 1.05 0.1108 1.00 0.6653
Tumor necrosis factor receptor
superfamily, member 1A (TNFRSF1A)
0.87 0.1556 0.99 0.9463 1.07 0.3766 0.81 0.0448 0.96 0.5130 1.02 0.3991
Tumor necrosis factor receptor
superfamily, member 1B (TNFRSF1B)
0.89 0.1026 1.18 0.0164 1.10 0.0956 1.02 0.8439 0.96 0.4386 1.00 0.7988
MUCINS
Mucin 1, cell surface associated
(MUC1)
0.92 0.1555 1.04 0.4586 1.03 0.4947 0.82 0.0013 1.00 0.9901 1.00 0.8866
Mucin 4, cell surface associated
(MUC4)
0.93 0.3097 1.15 0.0472 1.06 0.3140 0.70 1.02E-05 0.96 0.4576 0.98 0.0865
Mucin 5AC, oligomeric
mucus/gel-forming (MUC5AC)
0.77 0.0561 0.61 0.0002 1.25 0.0464 0.56 0.0001 0.97 0.7651 1.04 0.0811
Mucin 7, secreted (MUC7) 0.86 0.3401 0.69 0.0217 0.94 0.6225 0.42 1.48E-06 0.63 0.0001 1.10 0.0012
NK CELL MARKERS
CD247 molecule (CD247) 1.12 0.0847 1.02 0.7505 1.00 0.9863 1.80 1.78E-15 1.06 0.2277 0.98 0.0376
Neural cell adhesion molecule 1
(NCAM1)
0.85 0.0590 0.76 0.0007 1.14 0.0524 1.79 3.62E-10 0.92 0.1385 1.00 0.9652
Natural cytotoxicity triggering
receptor 1 (NCR1)
1.11 0.1621 1.00 0.9473 1.13 0.0531 2.31 1.68E-22 1.07 0.2349 0.95 0.0002
PATTERN RECOGNITION RECEPTORS
Nucleotide-binding oligomerization
domain containing 2 (NOD2)
0.88 0.1748 1.21 0.0348 1.13 0.1221 1.08 0.4293 0.90 0.0932 0.99 0.4252
Toll-like receptor 2 (TLR2) 1.01 0.8677 1.01 0.9108 1.26 0.0013 0.84 0.0615 1.02 0.7880 0.98 0.1690
Toll-like receptor 4 (TLR4) 0.99 0.9140 1.20 0.0184 1.20 0.0039 1.02 0.8485 0.94 0.2395 0.97 0.0550
(Continued)
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TABLE 5 | Continued
Target TF TP TS Plasmid Sex (female)α Ageβ
FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value
REGULATORS/SIGNALING PATHWAYS
CD274 molecule (CD274) 1.01 0.8828 1.44 0.0001 1.16 0.0507 2.47 1.18E-18 1.20 0.0046 0.95 0.0030
Chromodomain helicase DNA binding
protein 8 (CHD8)
0.93 0.0593 1.01 0.7501 1.04 0.2423 1.00 0.9029 0.98 0.4950 1.01 0.2923
COMM domain containing 6
(COMMD6)
0.99 0.9205 0.96 0.6492 1.00 0.9510 0.89 0.2836 0.99 0.8589 0.99 0.6788
Hematopoietically expressed
homeobox (HHEX )
1.34 8.54E-06 0.92 0.2204 1.07 0.1923 1.11 0.1411 1.04 0.3702 1.00 0.7584
IKAROS family zinc finger 1 (Ikaros)
(IKZF1)
1.11 0.0319 0.99 0.9105 1.04 0.3969 1.37 1.44E-08 1.00 0.9898 1.01 0.2868
Myeloid differentiation primary
response 88 (MYD88)
0.93 0.0303 1.05 0.1445 1.07 0.0151 1.00 0.9773 1.01 0.6856 1.00 0.6936
Marginal zone B and B1 cell-specific
protein (MZB1)
1.16 0.2162 1.24 0.0712 0.95 0.6338 2.07 8.27E-08 1.21 0.0279 0.98 0.3593
Nuclear factor of kappa light
polypeptide gene enhancer in B-cells
1 (NFKB1)
0.95 0.1251 1.06 0.1139 1.04 0.1457 1.13 0.0022 0.99 0.7545 1.00 0.5891
Phosphatidylinositol-3,4,5-
trisphosphate-dependent Rac
exchange factor 2 (PREX2v1)
1.06 0.5998 0.81 0.0744 0.90 0.2736 1.38 0.0115 0.95 0.5644 1.02 0.4858
Phosphatidylinositol-3,4,5-
trisphosphate-dependent Rac
exchange factor 2 (PREX2v2)
1.07 0.5708 1.08 0.5194 0.84 0.0985 1.05 0.6832 0.86 0.0769 1.03 0.1608
Ras homolog family member H
(RHOH)
1.20 0.0034 1.01 0.8137 1.03 0.6026 1.47 4.37E-08 1.11 0.0183 0.97 0.0227
SAM domain, SH3 domain and
nuclear localization signals 1
(SAMSN1)
1.03 0.6236 1.32 4.02E-05 1.04 0.5155 1.36 0.0001 1.05 0.2859 0.97 0.0229
Serpin peptidase inhibitor B3
(SERPINB3)
0.87 0.3173 1.90 6.73E-06 1.32 0.0175 2.65 8.33E-10 0.86 0.1311 0.94 0.0185
Serpin peptidase inhibitor clade B
member 4, (SERPINB4)
0.75 0.2648 2.85 0.0001 1.25 0.3075 4.38 1.95E-07 0.97 0.8763 1.02 0.7506
Suppressor of cytokine signaling 1
(SOCS1)
1.15 0.0606 1.10 0.2035 1.09 0.1646 2.06 1.08E-17 1.05 0.3178 0.94 6.95E-06
Suppressor of cytokine signaling 3
(SOCS3)
1.01 0.9205 1.50 4.53E-05 1.34 0.0004 1.21 0.0777 1.02 0.7518 0.93 0.0001
Serglycin (SRGN) 0.91 0.2568 1.28 0.0018 1.12 0.0767 0.97 0.7165 0.98 0.7288 0.99 0.6097
Signal transducer and activator of
transcription 1 (STAT1)
1.02 0.8024 1.12 0.0565 1.11 0.0391 1.97 1.34E-22 1.09 0.0392 0.95 9.97E-07
Signal transducer and activator of
transcription 3 (STAT3)
0.93 0.1345 1.06 0.1683 1.14 0.0007 1.00 0.9584 0.96 0.2153 0.98 0.0423
Signal transducer and activator of
transcription 4 (STAT4)
1.02 0.8085 1.00 0.9741 1.04 0.4556 1.85 5.37E-18 1.04 0.3692 0.98 0.0535
T-box 21 (TBX21) 1.21 0.0044 1.00 0.9917 1.07 0.2307 2.18 6.56E-25 1.11 0.0197 0.97 0.0060
Ubiquitin specific peptidase 6 (Tre-2
oncogene) (USP6)
0.70 0.1911 0.87 0.6216 0.72 0.1582 0.97 0.9124 0.65 0.0322 0.99 0.7936
αFC>1 indicates expression was greater in females than males.
βFC calculated with an age unit increase of 1 year.
FC = fold change. Using the Benjamini and Hochberg approach for adjusting for multiple comparisons, in order to control the false discovery rate <5% only tests with a p-value below
0.0142 (highlighted in bold) are considered statistically significant.
more susceptible to diseases resulting from immune-mediated
pathology (Klein and Flanagan, 2016).
Among infected individuals, the C. trachomatis plasmid:omcB
ratio (4.57:1) was very similar to the ratio reported from a range
of ocular and genital C. trachomatis isolates (mean 4.0:1) and
from a population-based trachoma study in Guinea Bissau (5.3:1)
(Pickett et al., 2005; Last et al., 2014). In common with the
study from Guinea Bissau, we did not find evidence of variation
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FIGURE 2 | Heatmap of the expression of each of the 83 retained genes in 458 individuals. Each row represents an individual, with individuals grouped as per their
disease and infection status and the relevant group indicated on the right: Group (A) Infected, Active Trachoma; (B) Infected, no Active Trachoma; (C) Uninfected,
Active Trachoma; (D) Uninfected, no Active Trachoma. !CT values of genes are represented in the columns, with genes that tend to be expressed together located
next to one another. Red means that an individual has a higher expression of that gene, blue, a lower expression, relative to that individual’s expression of the
endogenous control gene HPRT1.
in the plasmid copy number with increasing disease severity
scores.
Host Gene Expression
IFNGwas strongly upregulated in association withC. trachomatis
infection, consistent with previous findings in trachoma endemic
populations (Burton et al., 2004; Holland et al., 2006; Natividad
et al., 2010). Several NK cell markers were also upregulated
in association with C. trachomatis infection: NCR1, CD56
(NCAM1), and CD247. IFNγ, NCAM1, and NCR1 were among
the genes most strongly associated with increased odds of
C. trachomatis infection, and Th1 and NK cell pathways were
enriched in this gene set (Table 6). A strong IFNG response
and transcriptional signatures associated with NK cell activation
and cytotoxicity were closely associated with C. trachomatis
infection and active trachoma in a West African population
(Natividad et al., 2010), and infiltrates suggestive of NK cells were
identified in scarred conjunctival biopsy tissue from individuals
with trachomatous trichiasis from Tanzania (Hu et al., 2016). In
peripheral blood from adults with trichiasis and controls that
were stimulated ex-vivo with C. trachomatis antigens, NK cells
and to a lesser extent CD8+ T cells were the major sources of
IFNγ with <50% of the IFNγ produced by CD4+ T cells (Gall
et al., 2011). In a non-human primate live-attenuated ocular
chlamydial vaccine study, depletion of CD8+ cells abrogated
protective immunity, however the contribution of CD4+ and
NK cells was not investigated (Olivares-Zavaleta et al., 2014).
IFNγ is a crucial component of the Th1 response to restrict
C. trachomatis survival via tryptophan depletion, macrophage
activation and promoting leukocyte adhesion, migration and
activation (Beatty et al., 1994; Mosser and Edwards, 2008;
Redgrove and McLaughlin, 2014). Interestingly, whilst IFNG
was strongly upregulated in individuals with C. trachomatis
infection, there was much less upregulation in individuals with
disease but not infection, suggesting that the IFNG response is
quickly down-regulated once C. trachomatis has been cleared.
Supporting this observation, cluster 3, which was enriched for
Th1, NK, IL-12, and IFNγ pathways, was strongly associated
with infection but not with TF or TP. Cluster 3 expression was
also marginally associated with female sex, and IFNG, IDO1,
IL12B, and IL19 were each upregulated in females relative to
males (Table 5). Both the number of activated CD4+ cells and
their relative expression of pro-inflammatory genes including
IFNG have previously been shown to be higher in females than
males (Hewagama et al., 2009; Sankaran-Walters et al., 2013).
Our data suggest that increased expression of IFNG and related
pathways in females may contribute to the observed differences
in tissue responsiveness (TP and TS) between the sexes in the
context of equal infection exposure. In support of this hypothesis,
a longitudinal study conducted in The Gambia that visited
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TABLE 6 | Lasso logistic regression of gene expression by infection, active
disease (in only uninfected individuals) and scarring status.
C. trachomatis
infection
Active trachoma
(uninfected only)
Scarring
IFNG HHEX IL33
IL17A CDH1v2 CXCL5
NCAM1 MMP9 IDO1
MZB1 MMP7 CCL2
CTGF IDO1 MUC5AC
NCR1 IL21 IL21
TYMS IFNG MMP9
SERPINB3 CXCL5 TLR2
IKZF1 RHOH PDGFB
MUC7 TNFRSF1B CD40
CD53 S100A4 CDH2
IL21 SPARCL1 IL10
IL12B VIM SERPINB3
SOCS1 MYD88 NCR1
TBX21 TNFRSF1A TTK
S100A7 NCAM1 BCL2
IL10 FOXP3 SOCS3
S100A4 FOXP3
MMP7 CCL18
CSF3 CTGF2
ALOX5 COMMD6
PDGFB SAMSN1
ACTA2 CD247
CDC25C
CDH2
FOXP3
STAT4
IL6
OVER-REPRESENTED PATHWAYS
IL-12 and STAT4
dependent signaling
pathway in Th1
development [15:3/3]*
Inflammatory Response
Pathway [32:3/4]
Immunoregulatory
interactions between a
Lymphoid and a
non-Lymphoid cell [211:3/4]
NO2-dependent IL-12
pathway in NK cells
[9:3/3]
Activation of Matrix
Metalloproteinases [31:2/2]
Signaling events mediated
by PTP1B [53:3/4]
Assembly of collagen fibrils
and other multimeric
structures [49:2/2]
Leukocyte transendothelial
migration [116:2/2]
Collagen formation [94:2/2]
TNFs bind their
physiological receptors
[30:2/2]
*[x:y/z] x = total number of genes in pathway, y = number of pathway genes present in
input list, z = number of pathway genes present in background.
For each outcome, the genes whose expression was most strongly associated are listed.
Biological pathways with members that are over-represented (P ≤ 0.05) in each gene list
relative to the background (all genes tested) are shown for each phenotype, in descending
order.
participants every 2 weeks found that the likelihood of developing
infection or active disease and the duration of infection were
independent of sex, however males had a reduced duration of
active disease relative to females (Grassly et al., 2008). Whilst
Th1 responses and IFNG are essential for controlling chlamydial
infection, excessive responses are thought to cause collateral
tissue damage and contribute to chlamydial pathology (Van
Voorhis et al., 1997; Rank et al., 2000). It is therefore possible that
a female predisposition to overproduce Th1 responses and IFNG
may tip the balance from protection toward pathological tissue
damage. However, further research is required to clarify this
hypothesis and a direct causal relationship cannot be determined
from this cross-sectional analysis.
The cytokine genes IL1β , IL6, IL17, IL21, IL22, IL23,
and TGFβ1 were strongly expressed in individuals with
C. trachomatis infection. Th17 cells are generated in the presence
of TGFβ1, IL-1β, IL-6, IL-21, and IL-23 and classically produce
IL-17, IL-22, and IL-21 (Manel et al., 2008; Zielinski et al., 2012).
IL21 expression was also upregulated in individuals with TF
and TS. Individuals with TP significantly upregulated IL17 and
IL23 expression and IL21 at marginal significance. The combined
expression of cluster 5, containing IL10, IL17A, IL21, CXCL13,
and MMP12, was significantly associated with C. trachomatis
infection, TF, TP, and TS. Th17 cells have important roles in
mucosal immunity against bacteria and fungi, however they
are also associated with the inflammatory pathology of diseases
such as Crohn’s disease, psoriasis and rheumatoid arthritis
(Tesmer et al., 2008). Epithelial cells stimulated by IL-17 and
IL-22 upregulate chemokines, cytokines, antimicrobial peptides
and growth factors such as IL-6, IL-8, S100A7, and GM-
CSF (CSF2) (Wolk et al., 2006; Eyerich et al., 2010); these
transcripts were upregulated in individuals with C. trachomatis
infection (S100A7 at marginal significance). IL8 and S100A7
were also upregulated in individuals with TP. IL-8 and S100A7,
amongst other factors induced by Th17 cells, are chemotactic for
neutrophils, an influx of which is associated with C. trachomatis
infection and contributes to pathology in animal models of
urogenital and ocular infection (Frazer et al., 2011; Lacy et al.,
2011). IL-22, which was highly upregulated with infection, is
also important in the maintenance of epithelial health and
barrier function (Radaeva et al., 2004; Rutz et al., 2013). The
relative contributions of IL-17 and associated responses to
protection from C. trachomatis infection and maintenance of
barrier function vs. pathological tissue damage remain unclear.
In murine models of genital C. trachomatis infection higher levels
of IL-17/Th17 cells have been associated with greater pathology
(Lu et al., 2012; Vicetti Miguel et al., 2016), whereas in IL-23
knock-out mice which had greatly reduced levels of IL-17 and
IL-22 there was no difference in infection burden or oviduct
pathology compared to wild type mice (Frazer et al., 2013).
Longitudinal investigation of these factors is expected to further
our understanding of the role of Th17 cell associated cytokines in
human chlamydial pathogenesis.
STAT1 and STAT4, which promote Th1 cell development
(Nishikomori et al., 2002; Mikhak et al., 2006; Zhu et al.,
2010), were upregulated in response to C. trachomatis infection.
STAT1 and STAT4 have previously been shown to be associated
with active trachoma and ocular C. trachomatis infection, and
STAT1 was upregulated in cervical epithelial cells infected with
C. trachomatis in vitro which was found to inhibit chlamydial
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growth (Lad et al., 2005; Natividad et al., 2010). STAT3, which
is required for Th17 development (Zhu et al., 2010; Yang
et al., 2011), was not differentially regulated, contrasting the
upregulation of Th17 cytokines. SOCS1, IL10, and FOXP3 were
upregulated in individuals with C. trachomatis infection and
SOCS3 and IL10 were upregulated in individuals with TS and
TP, indicative of inflammatory regulation. Upregulation of IL10
expression has previously been reported in individuals with
active trachoma and a genetic polymorphism in IL10 was
associated with trachomatous scarring (Mozzato-Chamay et al.,
2000; Burton et al., 2004; Natividad et al., 2005; Faal et al.,
2006; Skwor et al., 2008). However, the role of Tregs and IL-10
in trachoma remains unclear; dampening inflammation might
result in less tissue damage, but conversely it might also prolong
survival of C. trachomatis (Zhang et al., 2009).
MMP9, MMP12, TGFβ1, and PDGF were significantly
upregulated in individuals with C. trachomatis infection.MMP7,
MMP9, and MMP12 were upregulated in individuals with TP,
MMP9 was upregulated in TF and FGF2 and PDGF were
upregulated in individuals with TS. MMP7 was downregulated
in infected individuals. MMP7 has consistently been found to
be upregulated in scarring trachoma and trichiasis alongside
MMP9 and MMP12 but there is less evidence for a role of
MMP7 in active trachoma (Holland et al., 2010; Burton et al.,
2011b, 2015; Hu et al., 2012). Degradation of the extracellular
matrix and basement membrane by MMP9 and MMP12, in
part derived from macrophage and neutrophil degranulation
(Shapiro et al., 1993; Kjeldsen et al., 1994), facilitates connective
tissue remodeling and leukocyte migration into the epithelium
(Ozdemir et al., 1999; Zeng et al., 1999; Misko et al., 2002).
Whilst MMPs are an essential part of the wound healing process
(Nwomeh et al., 1998; Wolf et al., 2017), MMP9 overexpression
has been linked to aggressive contractile scarring in proliferative
vitroretinopathy and failure of rat corneal cells to re-epithelialize
following corneal injury (Fini et al., 1996; Kon et al., 1998).
SPARCL1 was down-regulated in individuals with
C. trachomatis infection, TF and TP, consistent with previous
studies (Hu et al., 2012; Burton et al., 2015). SPARCL1 codes for a
secreted glycoprotein which regulates extracellular matrix (ECM)
and cell-matrix adhesion (Girard and Springer, 1996) SPARCL1
inhibits cell proliferation and migration and reduced SPARCL1
expression has been linked to cancer metastases (Nelson et al.,
1998; Sullivan and Sage, 2004). In a murine corneal injury
model, knock-out of SPARCL1 led to excessive accumulation
of collagen type IV from myofibroblasts and irregular fibrotic
ECM formation (Chaurasia et al., 2013). Addition of exogenous
SPARCL1 rescued the wild type phenotype with a cessation
of collagen IV production, replacement with collagen I from
keratinocytes and restoration of normal ECM architecture.
Consistent with this, immunohistochemistry and histology
studies using tissue from individuals with scarring trachoma
have demonstrated a reduction in collagens I and III, an
increase in collagens IV and V and progressive disorganization
of collagen fibers in scarring trachoma relative to healthy
conjunctival tissue (Abu El-Asrar et al., 1998; Hu et al., 2013b;
Derrick et al., 2016b). Genes that were most strongly associated
with active trachoma in the absence of C. trachomatis infection
were enriched for pathways of leukocyte transendothelial
migration, TNF receptors, MMP activation, collagen formation
and assembly (Table 6). Active trachoma signs often persist after
the clearance of C. trachomatis infection (Grassly et al., 2008;
Burton et al., 2011a,c; Lee et al., 2014) and inflammation is linked
to progressive scarring (Ramadhani et al., 2016a). We found that
TP but not infection was associated with TS in the multivariable
model (Table 3). These results suggest that the inflammatory
phenotype following the clearance of C. trachomatis infection
is characterized by collagen formation and assembly, MMP-
mediated matrix remodeling and leukocyte influx, and that these
pathways might be causative factors in the scarring process.
We found significantly reduced expression of MUC1, MUC4,
MUC5AC, and MUC7 in individuals with C. trachomatis
infection, and MUC5AC expression was reduced in those with
TP. MUC1 and MUC4 are primarily expressed by apical cells
of the stratified epithelia, MUC7 by lacrimal gland epithelia
and MUC5AC by goblet cells (Gipson and Argueso, 2003).
MUC7 expression was also significantly reduced in females
relative to males. MUC5AC and MUC7 down-regulation has
previously been reported in individuals with trachomatous
trichiasis, however expression ofMUC1 andMUC4was increased
in this later stage of disease (Burton et al., 2011b). IL-22
stimulates the upregulation of MUC4 and MUC1, therefore, one
might expect a corresponding increase in mucin expression in
infected individuals (Turner et al., 2013). This inconsistency
and the broad reduction in mucin expression during infection
may reflect a loss of epithelial homeostasis and a potential
reduction in barrier function. This in turn could result in
increased access of bacteria to the epithelial cell surface,
promoting inflammation. In patients with ulcerative colitis,
reduction of goblet cells, mucin production and microbial
diversity were identified as causative factors in disease etiology
(Alipour et al., 2016). Microbial dysbiosis can itself be caused by
inflammation, creating a positive feedback loop (Winter et al.,
2013). Decreased diversity has previously been found in the
conjunctival microbiome of individuals with scarring trachoma
relative to healthy controls (Zhou et al., 2014). Furthermore,
penetration of the mucin barrier and contact between epithelial
cells and bacteria was demonstrated in ulcerative colitis patients
with acute inflammation, whereas the mucin barrier of healthy
controls was impenetrable (Johansson et al., 2014). It is tempting
to speculate that reduced barrier function resulting from
inflammation and loss of mucins causes microbial dysbiosis
and contact between bacteria and epithelial cells, leading to
persistent conjunctival inflammation, which in turn contributes
to trachomatous scarring.
Consistent with our previous studies in various clinical stages
of trachoma (Burton et al., 2011b,c, 2012, 2015; Hu et al., 2012),
the antimicrobial peptide S100A7 was upregulated in individuals
with TP and was marginally associated with C. trachomatis
infection. S100A7 is secreted by epithelial cells in response to
microbial challenge and expression can also be stimulated by
IL-22 (Wolk et al., 2006). It is chemotactic for neutrophils and
interferes with pathogen membrane permeability and enzyme
function (Ganz, 2003; Guilhelmelli et al., 2013). The upregulation
of S100A7 in various clinical stages of trachoma could support the
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loss of epithelial barrier function hypothesis described above and
could contribute to chronic inflammation.
There was differential expression of several cell cycle genes
(CD53, CDK13, CDC25C, PHYH, TYMS, TTK, TP53) in
individuals with C. trachomatis infection and/or TP (Table 5).
These expression changes could reflect regulation of the cell
cycle in response to infection or inflammation, such as the
proliferation or contraction of infiltrating inflammatory cells
and cells effecting the wound healing response. Studies have
reported that progression of the cell cycle is slow in cells infected
with C. trachomatis (Kun et al., 2013; Elwell et al., 2016) and
C. trachomatis is known to interfere with host cell apoptosis as
a survival mechanism (Fischer et al., 2004; Ying et al., 2007;
Siegl et al., 2014). Cluster 1 was enriched for genes in apoptosis
pathways, however the combined expression of this cluster was
not associated with clinical phenotypes or infection.
CONCLUSIONS
Our results, illustrated in a graphical summary (Figure 3),
suggest that IFNG and IL22 were acutely upregulated in
response to C. trachomatis infection and expression appeared
to be reduced following the clearance of infection, despite the
persistence of inflammation. This might suggest that the sources
of these cytokines are important in the clearance of infection
and that the inflammatory phenotype differs once infection has
been cleared, shifting away from a Th1/NK cell dominated
response. The upregulation of Th17 cell-associated cytokines
in infection and TP phenotypes implies the involvement of
Th17 cells, although it remains unclear whether they contribute
more to protection or pathology. Epithelial cells appear to
be highly active, with possible loss of epithelial homeostasis
and barrier function resulting in loss of mucins and a pro-
inflammatory anti-microbial phenotype, perhaps exacerbating
inflammation. The upregulation of growth factors and MMPs,
derived in part from infiltrating macrophages and neutrophils,
and the down-regulation of SPARCL1 are likely to contribute
to matrix remodeling, collagen deposition and conjunctival
scarring in the post-infection inflammatory phase. Females were
more susceptible to TP and TS and although this was not
associated with a significant difference in infection prevalence,
there was some evidence of increased IFNG related pathway
activity in females. A caveat of this study is that gene expression
may not correlate directly to protein expression and this
will require further work. Despite this, we anticipate that
FIGURE 3 | Graphical summary illustrating the host immune pathways hypothesized to be associated with different trachoma phenotypes. Genes most strongly
associated with each phenotype are shown in italics with the direction and strength of expression illustrated by arrows. Pathways that were most enriched for each
phenotype are shown. Ct EBs, C. trachomatis elementary bodies; N, epithelial cell nucleus; NK, Natural killer cells; Th1, Th1 T cells; Th17, Th17 T cells; PMN,
neutrophil; Mφ, macrophage; red cross-hatching, fibrosis. The mucus layer is shown in green, the epithelial cell layer in blue, and the stroma in beige.
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longitudinal investigation of these transcriptional signatures and
relation to infection and ongoing clinical signs will enhance our
understanding of their relative contributions to protection and
pathology.
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Supplementary figure 1: Principal component analysis. (a) Infection and Active Trachoma 
status. (b) Scarring status. 
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Supplementary Table 1: Comparison of conjunctival gene expression in the presence of C. 
trachomatis plasmid, follicular inflammation (TF), papillary inflammation (TP) and 
scarring trachoma, adjusted for age and sex. N – number of individuals with detectable 
expressions. FC – fold change. P-value. Using the Benjamini and Hochberg approach only 
tests with a p-value below 0.0350 have a False Discovery Rate of <5%. 
   
Infected vs not TF vs no TF TP vs no TP TS vs no TS 
Target N FC p-value FC p-value FC p-value FC p-value 
Antimicrobial Peptides 
Defensin, beta 4B,defensin, beta 4A (DEFB4A) 494 1.57 0.0044 1.31 0.0330 1.96 4.70E-08 1.33 0.0258 
Psoriasin-1 (S100A7) 492 3.43 5.81E-07 3.24 1.58E-09 4.30 3.88E-14 1.91 0.0012 
Cell Cycle 
Catenin (cadherin-associated protein), delta 2 (CTNND2) 327 0.75 0.1967 0.89 0.5377 0.79 0.2123 0.95 0.7887 
CD53 molecule (CD53) 494 1.24 0.0003 1.15 0.0022 1.24 2.78E-06 1.14 0.0049 
Cyclin-dependent kinase 13 (CDK13) 494 0.87 0.0029 0.91 0.0080 0.86 4.29E-05 0.97 0.4573 
M-phase inducer phosphatase 3 (CDC25C) 485 1.53 1.88E-07 1.36 2.03E-06 1.29 7.11E-05 1.13 0.0548 
Phytanoyl-coa 2-hydroxylase (PHYH) 494 0.80 7.36E-07 0.85 6.84E-06 0.87 0.0001 0.96 0.2410 
Sun Domain Family, Member 6 (NSUN6) 494 0.98 0.4884 0.94 0.0235 0.96 0.1036 1.02 0.5273 
Thymidylate synthetase (TYMS) 494 1.82 8.78E-25 1.41 2.79E-13 1.41 5.38E-13 1.13 0.0144 
TTK protein kinase (TTK) 493 1.51 6.25E-10 1.37 1.50E-09 1.34 3.26E-08 1.21 0.0005 
Tumor protein p53 (TP53) 494 0.95 0.2391 0.93 0.0281 0.87 9.41E-06 0.99 0.7425 
Cytokines/Chemokines 
Chemokine ligand 2 (CCL2) 490 4.29 3.77E-21 2.00 4.32E-08 2.39 3.53E-12 1.83 2.73E-06 
Chemokine ligand 5 (CXCL5) 493 1.22 0.1911 1.63 6.09E-05 2.08 1.55E-09 1.88 2.64E-07 
Chemokine ligand 13 (CXCL13) 491 3.48 2.10E-13 2.76 5.04E-14 3.11 2.55E-17 1.62 0.0006 
Chemokine ligand 18 (CCL18) 488 3.16 9.96E-10 2.33 1.82E-08 3.59 3.75E-18 1.37 0.0411 
Chemokine ligand 20 (CCL20) 493 1.59 1.86E-05 1.68 1.24E-09 1.46 8.91E-06 1.49 4.27E-06 
Chemokine receptor 6 (CCR6) 493 1.29 0.0493 1.45 0.0003 1.12 0.2586 1.17 0.1329 
Colony stimulating factor  2 (CSF2) 489 2.79 1.15E-22 1.68 1.93E-09 1.53 1.10E-06 1.32 0.0015 
Colony stimulating factor  3 (CSF3) 493 1.05 0.7614 1.22 0.0805 1.47 0.0009 1.62 3.30E-05 
Forkhead box P3 (FOXP3) 491 1.25 0.0004 1.08 0.1071 1.07 0.1985 0.95 0.2866 
Indoleamine 2,3-dioxygenase 1 (IDO1) 494 2.18 2.74E-12 1.69 3.79E-09 1.73 7.00E-10 1.47 1.99E-05 
Interferon gamma(IFNγ) 491 8.81 2.54E-57 2.74 1.64E-17 2.28 6.80E-12 1.56 0.0003 
Interleukin 1 beta(IL1β) 493 2.05 1.11E-08 1.64 6.93E-07 2.07 1.42E-13 1.65 7.84E-07 
Interleukin 6 (IL6) 493 2.00 2.11E-07 1.35 0.0056 1.51 0.0001 1.43 0.0010 
Interleukin 8 (IL8) 493 1.49 1.92E-05 1.23 0.0054 1.51 2.73E-08 1.38 2.27E-05 
Interleukin 10 (IL10) 492 2.33 2.73E-16 1.78 2.63E-12 1.97 1.40E-16 1.50 1.91E-06 
Interleukin 12 beta (IL12β) 480 3.99 2.91E-30 1.92 1.38E-10 1.84 2.20E-09 1.35 0.0045 
Interleukin 13 (IL13) 214 1.38 0.1496 1.37 0.1247 1.02 0.9098 0.83 0.3233 
Interleukin 17A (IL17A) 492 3.23 4.00E-18 2.11 6.23E-12 2.37 1.15E-15 1.57 5.34E-05 
Interleukin 19 (IL19) 493 3.21 1.35E-13 2.20 3.83E-10 3.26 5.97E-22 1.63 0.0001 
Interleukin 21 (IL21) 480 4.89 2.08E-24 3.09 2.34E-19 2.70 3.82E-15 1.87 1.99E-06 
Interleukin 22 (IL22) 427 8.01 4.91E-33 2.66 1.26E-10 2.50 1.81E-09 1.81 0.0002 
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Interleukin 23A (IL23A) 492 2.38 3.16E-17 1.68 4.06E-10 2.04 1.15E-18 1.36 0.0002 
Interleukin 33 (IL33) 494 1.26 0.0121 1.04 0.6076 1.02 0.7717 1.28 0.0007 
Prostaglandin-endoperoxide synthase 2 (PTGS2) 494 1.37 0.0054 1.24 0.0175 1.52 3.22E-06 1.39 0.0003 
Tumor necrosis factor (TNF) 492 1.53 0.0002 1.49 1.02E-05 1.25 0.0139 1.26 0.0123 
EMT Markers 
Alpha smooth muscle actin  (ACTA2) 492 1.28 0.0002 1.10 0.0729 0.97 0.5791 1.14 0.0118 
Epithelial cadherin (CDH1) 493 0.73 4.34E-08 0.84 6.89E-05 0.84 0.0002 0.98 0.7421 
Cadherin 1, type 1, E-cadherin (epithelial) (CDH1) 494 0.69 2.16E-09 0.82 9.65E-05 0.83 0.0002 0.97 0.5543 
Neuronal cadherin (CDH2) 482 0.98 0.8961 0.86 0.1328 0.76 0.0049 1.09 0.4063 
S100 calcium binding protein A4 (S100A4) 493 0.39 1.39E-32 0.58 8.58E-17 0.56 1.66E-19 0.93 0.2657 
Vimentin (VIM) 494 1.57 3.65E-20 1.20 2.99E-06 1.19 1.55E-05 1.11 0.0073 
Matrix Modifiers 
Connective tissue growth factor (CTGF-1) 493 1.08 0.4138 0.91 0.2104 0.83 0.0117 0.94 0.3853 
Connective tissue growth factor (CTGF-2) 494 1.04 0.6659 0.84 0.0218 0.81 0.0052 0.87 0.0603 
Fibroblast growth factor 2 (basic) (FGF2) 399 1.54 0.0021 1.12 0.3424 1.25 0.0569 1.51 0.0005 
Matrix metallopeptidase 7 (MMP7) 493 0.42 1.38E-13 0.84 0.0674 1.05 0.6140 0.99 0.9536 
Matrix metallopeptidase 9 (MMP9) 493 2.51 8.58E-15 2.11 1.91E-15 2.11 2.14E-15 1.51 2.08E-05 
Matrix metallopeptidase 12 (MMP12) 493 2.85 3.14E-16 2.17 3.60E-14 2.23 3.53E-15 1.62 4.33E-06 
Platelet-derived growth factor beta polypeptide (PDGFβ) 492 1.53 1.88E-11 1.22 9.88E-05 1.25 1.59E-05 1.24 3.14E-05 
SPARC-like 1 (hevin) (SPARCL1) 484 0.22 1.74E-10 0.23 1.04E-14 0.21 1.54E-16 0.52 0.0009 
Transforming growth factor, beta 1 (TGFβ1) 493 1.25 3.23E-06 1.10 0.0156 1.08 0.0572 1.11 0.0077 
Transforming growth factor, beta 2 (TGFβ2) 492 0.89 0.2044 0.93 0.3235 0.93 0.3581 1.05 0.5253 
Microbiota Response 
Arachidonate 5-lipoxygenase (ALOX5) 494 0.62 1.44E-20 0.77 1.62E-10 0.81 1.06E-06 0.96 0.3789 
B-cell CLL/lymphoma 2 (BCL2) 494 1.11 0.0217 1.02 0.6071 0.99 0.7735 1.09 0.0241 
CD40 molecule, TNF receptor superfamily member 5 (CD40) 494 1.24 0.0004 1.05 0.2999 1.05 0.3513 1.08 0.1334 
Dual oxidase 2 (DUOX2) 494 1.32 0.0022 1.19 0.0180 1.40 2.70E-06 1.19 0.0202 
Tumor necrosis factor receptor superfamily, member 1A 
(TNFRSF1A) 
494 0.76 0.0046 0.82 0.0105 0.88 0.0995 1.01 0.8651 
Tumor necrosis factor receptor superfamily, member 1B 
(TNFRSF1B) 
494 1.05 0.5043 1.01 0.8897 1.14 0.0190 1.13 0.0337 
V-rel avian reticuloendotheliosis viral oncogene homolog 
(REL) 
494 1.05 0.2782 1.02 0.5318 1.08 0.0413 1.07 0.0657 
Mucin 
Mucin 1, cell surface associated (MUC1) 494 0.80 0.0001 0.89 0.0110 0.95 0.2538 1.00 0.9778 
Mucin 4, cell surface associated  (MUC4) 494 0.73 1.17E-05 0.91 0.1154 1.02 0.7338 1.04 0.4983 
Mucin 5AC, oligomeric mucus/gel-forming (MUC5AC) 494 0.41 2.69E-10 0.50 6.86E-10 0.48 2.05E-11 0.96 0.7406 
Mucin 7, secreted (MUC7) 494 0.33 1.76E-11 0.52 6.24E-07 0.49 8.02E-08 0.74 0.0248 
NK Cell Markers 
CD247 molecule (CD247) 493 1.93 6.19E-22 1.37 1.65E-08 1.28 1.14E-05 1.11 0.0776 
Natural cytotoxicity triggering receptor 1 (NCR1) 492 2.50 1.13E-30 1.50 1.27E-09 1.38 1.14E-06 1.28 0.0003 
Neural cell adhesion molecule 1 (NCAM1) 493 1.50 2.08E-06 0.90 0.1171 0.83 0.0080 1.10 0.1742 
Pattern Recognition Receptors 
Nucleotide-binding oligomerization domain containing 2 
(NOD2) 
491 1.13 0.1847 1.04 0.6135 1.19 0.0174 1.17 0.0377 
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Toll-like receptor 2 (TLR2) 493 0.89 0.1577 1.01 0.8602 1.03 0.6513 1.24 0.0018 
Toll-like receptor  4 (TLR4) 493 1.13 0.1092 1.15 0.0218 1.26 0.0002 1.26 0.0002 
Regulators/Signalling Pathways 
CD274 molecule (CD274) 493 2.99 5.54E-29 1.73 1.58E-11 1.92 3.44E-16 1.43 1.41E-05 
Chromodomain helicase DNA binding protein 8 (CHD8) 494 0.97 0.4299 0.95 0.0481 0.98 0.4673 1.02 0.4319 
COMM domain containing 6 (COMMD6) 493 0.87 0.1506 0.93 0.3440 0.92 0.2886 0.97 0.6802 
Hematopoietically expressed homeobox (HHEX) 493 1.26 0.0004 1.35 1.19E-08 1.15 0.0083 1.14 0.0177 
IKAROS family zinc finger 1 (Ikaros) (IKZF1) 494 1.45 2.24E-13 1.24 2.04E-07 1.16 0.0002 1.10 0.0232 
Marginal zone B and B1 cell-specific protein (MZB1) 493 2.44 1.08E-12 1.65 5.78E-07 1.64 1.03E-06 1.15 0.1880 
Myeloid differentiation primary response 88 (MYD88) 494 1.00 0.8889 0.97 0.2443 1.02 0.3767 1.07 0.0156 
Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 1 (NFKB1) 
494 1.13 0.0005 1.03 0.3739 1.07 0.0168 1.06 0.0341 
Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac 
exchange factor 2 (PREX2v1) 
462 1.28 0.0335 1.02 0.7928 0.89 0.2381 0.90 0.2483 
Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac 
exchange factor 2 (PREX2v2) 
445 1.09 0.4465 1.10 0.3299 1.09 0.3703 0.88 0.2025 
Ras homolog family member H (RHOH) 494 1.63 4.48E-14 1.38 4.78E-10 1.26 8.00E-06 1.13 0.0271 
SAM domain, SH3 domain and nuclear localization signals 1 
(SAMSN1) 
494 1.57 2.47E-10 1.35 8.85E-08 1.48 2.48E-12 1.17 0.0067 
Serglycin (SRGN) 494 1.05 0.5256 1.07 0.2821 1.24 0.0006 1.17 0.0122 
Serpin peptidase inhibitor B3 (SERPINB3) 493 3.43 2.87E-16 1.83 7.66E-07 2.45 8.52E-14 1.72 1.21E-05 
Serpin peptidase inhibitor clade B member 4, (SERPINB4) 406 5.93 1.95E-11 2.32 0.0002 3.80 8.81E-10 1.80 0.0089 
Signal transducer and activator of transcription 1 (STAT1) 493 2.13 1.90E-31 1.38 2.63E-09 1.40 5.78E-10 1.25 6.72E-05 
Signal transducer and activator of transcription 3 (STAT3) 493 1.02 0.6831 1.00 0.9047 1.06 0.1165 1.14 0.0003 
Signal transducer and activator of transcription 4 (STAT4) 493 1.88 2.22E-22 1.25 3.32E-05 1.21 0.0005 1.12 0.0312 
Suppressor of cytokine signalling 1  (SOCS1) 493 2.34 4.52E-27 1.56 6.81E-12 1.48 1.55E-09 1.26 0.0006 
Suppressor of cytokine signalling 3 (SOCS3) 493 1.53 3.68E-05 1.44 6.37E-06 1.71 2.48E-11 1.53 2.02E-07 
T-box 21 (TBX21) 493 2.42 7.94E-36 1.57 2.30E-14 1.40 1.79E-08 1.22 0.0011 
Ubiquitin specific peptidase 6 (Tre-2 oncogene) (USP6) 182 0.72 0.2233 0.61 0.0298 0.66 0.0766 0.66 0.0716 
 
 
Supplementary Table 2a. Network co-expression analysis of the filtered dataset using Miru and Markov clustering revealed 
five clusters of co-expressed genes.  
 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 
Genes Connections Genes Connections Genes Connections Genes Connections Genes Connections 
MYD88 13 IKZF1 11 STAT1 6 SRGN 6 IL10 3 
REL 13 VIM 11 CD247 5 TLR4 4 IL17A 3 
NFKB1 12 CD53 10 STAT4 5 TNFRSF1B 4 IL21 3 
CHD8 11 SAMSN1 10 IFNG 2 IL1B 3 CXCL13 1 
BCL2 10 RHOH 6 NCR1 2 PTGS2 3 MMP12 1 
TP53 9 TBX21 6 PDGFB 1 SOCS3 3   
CDK13 8 TYMS 6       
NSUN6 8 CD274 4       
PHYH 6 HHEX 3       
CD40 5 TTK 1       
ALOX5 1         
 
 
 
 
 
  
Supplementary Table 2b. Pathway enrichment analysis of genes in each cluster against background, using ConsensusPathDB. 
The first six most enriched pathways (P < 0.05) are shown.  
 
pathway name set size candidates p-value q-value pathway source 
      
Cluster 1      
Neurotrophin signaling pathway  121(3) 3 (100.0%) 0.00217 0.0286 KEGG 
Apoptosis Modulation and Signaling 92(6) 4 (66.7%) 0.00296 0.0286 Wikipathways 
DNA Damage Response (only ATM dependent) 110(4) 3 (75.0%) 0.00798 0.0286 Wikipathways 
IL1 56(4) 3 (75.0%) 0.00798 0.0286 NetPath 
Downstream signaling events of B Cell Receptor (BCR) 147(4) 3 (75.0%) 0.00798 0.0286 Reactome 
Signaling by the B Cell Receptor (BCR) 242(4) 3 (75.0%) 0.00798 0.0286 Reactome 
Viral carcinogenesis  203(4) 3 (75.0%) 0.00798 0.0286 KEGG 
Prostate cancer  89(4) 3 (75.0%) 0.00798 0.0286 KEGG 
      
Cluster 2      
Retinoblastoma (RB) in Cancer 89(3) 2 (66.7%) 0.0418 0.155 Wikipathways 
      
Cluster 3      
Th1 and Th2 cell differentiation  92(7) 4 (57.1%) 0.000344 0.0235 KEGG 
SHP2 signaling 59(4) 3 (75.0%) 0.00102 0.0235 PID 
Downstream signaling in naïve CD8+ T cells 68(4) 3 (75.0%) 0.00102 0.0235 PID 
IL12-mediated signaling events 64(10) 4 (40.0%) 0.00193 0.0333 PID 
Natural killer cell mediated cytotoxicity  135(5) 3 (60.0%) 0.00247 0.0341 KEGG 
IL12 signaling mediated by STAT4 32(6) 3 (50.0%) 0.00479 0.0431 PID 
IFN gamma signaling pathway 6(2) 2 (100.0%) 0.005 0.0431 BioCarta 
IFN gamma signaling 6(2) 2 (100.0%) 0.005 0.0431 INOH 
      
Cluster 4      
TNF signaling pathway  110(14) 4 (28.6%) 0.00837 0.191 KEGG 
Nanomaterial induced inflammasome activation  3(3) 2 (66.7%) 0.0145 0.191 Wikipathways 
TLR ECSIT MEKK1 JNK 27(3) 2 (66.7%) 0.0145 0.191 INOH 
NF-kappa B signaling pathway  95(10) 3 (30.0%) 0.0253 0.191 KEGG 
Glucocorticoid Receptor Pathway 71(4) 2 (50.0%) 0.0279 0.191 Wikipathways 
TLR NFkB 70(4) 2 (50.0%) 0.0279 0.191 INOH 
Nuclear Receptors Meta-Pathway 316(12) 3 (25.0%) 0.0435 0.197 Wikipathways 
Type II interferon signaling (IFNG) 37(5) 2 (40.0%) 0.0448 0.197 Wikipathways 
      
Cluster 5      
Allograft Rejection 80(14) 4 (28.6%) 0.00313 0.0532 Wikipathways 
Cytokine-cytokine receptor interaction  265(25) 4 (16.0%) 0.0343 0.272 KEGG 
 
 
 
  
Supplementary Table 2c. Differential regulation of clusters 1-5 in individuals with C. trachomatis infection and clinical signs. A 
multivariable linear regression was performed using the first principle component as the combined cluster expression value for each 
individual. Using the Benjamini and Hochberg approach for adjusting for multiple comparisons, in order to control the false discovery 
rate <5% only tests with a p-value below 0.018 (highlighted in bold) are considered statistically significant.  
 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 
 P value OR (CI) P value OR (CI) P value OR (CI) P value OR (CI) P value OR (CI) 
TS 0.063 0.63 0.38 - 1.03) 0.334 1.24 (0.80 - 1.93) 0.036 1.47 (1.03 - 2.10) 0.014 1.75 (1.12 - 2.74) 0.010 1.57 (1.12 - 2.22) 
TF 0.174 1.51 (0.84 - 2.72) 0.016 1.91 (1.13 - 3.25) 0.351 1.23 (0.80 - 1.88) 0.370 0.78 (0.46 - 1.33) 0.028 1.59 (1.05 - 2.40) 
TP 0.489 1.23 (0.69 - 2.20) 0.044 1.71 (1.02 - 2.88) 0.361 1.22 (0.80 - 1.86) 3.94E-04 2.60 (1.54 - 4.40) 2.53E-05 2.41 (1.61 - 3.62) 
Infection 0.590 1.19 (0.63 - 2.27) 1.55E-15 11.29 (6.36 - 20.06) 2.00E-16 17.05 (10.71 - 27.14) 0.244 1.41 (0.79 - 2.52) 1.23E-10 4.51 (2.88 - 7.05) 
Age 0.086 0.91 (0.82 - 1.01) 0.111 0.92 (0.84 - 1.02) 2.08E-06 0.82 (0.76 - 0.89) 0.016 0.89 (0.80 - 0.98) 7.53E-08 0.81 (0.75 - 0.87) 
Sex (F) 0.584 1.13 (0.74 - 1.72) 0.081 1.40 (0.96 - 2.06) 0.028 1.41 (1.04 - 1.92) 0.724 0.93 (0.64 - 1.37) 0.078 1.31 (0.97 - 1.76 
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 2 
ABSTRACT 31 
 32 
Background; Trachoma, caused by Chlamydia trachomatis, remains the leading infectious cause of 33 
blindness worldwide. Persistence and progression of the resulting clinical disease appears to be an 34 
immunologically mediated process. Azithromycin, which is distributed at the community level for 35 
trachoma control, has immunomodulatory properties. We investigated the impact of one round of oral 36 
azithromycin on conjunctival immune responses three and six months post treatment.  37 
 38 
Methodology; A cohort of children aged 6 to 10 years were recruited from a trachoma endemic region 39 
of northern Tanzania and were visited five times in a 12-months period. They were examined for 40 
clinical signs of trachoma and conjunctival swabs were collected for laboratory analysis. C. 41 
trachomatis infection was detected and the expression of 46 host genes was quantified using 42 
quantitative PCR. All community members were offered azithromycin treatment immediately after 43 
the six-month timepoint according to international guidelines.  44 
 45 
Findings; The prevalence of C. trachomatis infection and inflammatory disease signs were 46 
significantly reduced three and six months post-mass drug administration (MDA). C. trachomatis 47 
infection was strongly associated with clinical signs at all five time-points.  A profound anti-48 
inflammatory effect on conjunctival gene expression was observed 3 months post-MDA, however, 49 
gene expression had largely returned to pre-treatment levels of variation by 6 months. This effect was 50 
less marked, but still observed, after adjusting for C. trachomatis infection and when the analysis was 51 
restricted to individuals who were free from both infection and clinical disease at all five time-points. 52 
Interestingly, a modest effect was also observed in individuals who did not receive treatment. 53 
 54 
Conclusion; Conjunctival inflammation is the major clinical risk factor for progressive scarring 55 
trachoma, therefore, the reduction in inflammation associated with azithromycin treatment may be 56 
beneficial in limiting the development of potentially blinding disease sequelae. Future work should 57 
seek to determine whether this effect is mediated directly through inhibition of pro-inflammatory 58 
intracellular signalling molecules, through reductions in concurrent, sub-clinical infections, and/or 59 
through reduction of infection exposure. 60 
  61 
  62 
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 3 
INTRODUCTION 63 
 64 
Trachoma remains the leading infectious cause of blindness worldwide, with the greatest burden in 65 
sub-Saharan Africa (WHO, 2016). Trachomatous disease is initiated by repeated conjunctival 66 
infection with Chlamydia trachomatis, which triggers prolonged inflammatory episodes that 67 
contribute to the development of conjunctival scarring (reviewed in Ramadhani et al., 2016a). 68 
Infection and clinical signs of active trachoma (follicular and papillary inflammation) are most 69 
frequently found in younger children (WHO, 2017). Conjunctival scarring gradually accumulates 70 
through childhood, adolescence and into adult life. Eventually this results in the in-turning of the 71 
eyelid (entropion) and eyelashes (trichiasis), abrasion of the eyelashes against the cornea, severe 72 
visual impairment and blindness in later life. According to recent World Health Organisation (WHO) 73 
estimates, around 165.1 million people live in trachoma-endemic areas (of whom 89% are from 74 
WHO’s African region) (WHO, 2018) and 2.8 million have trichiasis (Flueckiger et al., 2018). The 75 
WHO advocates the use of the SAFE Strategy for trachoma control: Surgery to correct trichiasis, 76 
Antibiotics to treat C. trachomatis infection, Facial cleanliness and Environmental improvements to 77 
suppress transmission (WHO, 1998).  78 
 79 
Annual mass drug administration (MDA) with oral azithromycin for a minimum of 3 years is 80 
recommended for communities where the initial prevalence of the clinical sign trachomatous 81 
inflammation-follicular (TF) is ≥10% in children aged 1 to 9 years, with a recommended coverage of 82 
80% of the whole community (WHO, 2004). In low-prevalence settings this usually leads to a 83 
sustained reduction in C. trachomatis infection prevalence over time (Pant et al., 2016, Solomon et 84 
al., 2008, Burton et al., 2010, Burton et al., 2005), however, in highly endemic areas infection can re-85 
emerge shortly after MDA (Melese et al., 2004).  86 
 87 
Inflammatory disease signs are reported to persist longer than infection at both the individual and 88 
population levels, resulting in the observation of clinical signs in the absence of infection (Grassly et 89 
al., 2008, Ramadhani et al., 2016b, Bailey et al., 1999, Faal et al., 2005). The correlation between 90 
clinical signs and C. trachomatis infection in communities prior to MDA is further reduced following 91 
treatment (Ramadhani et al., 2016b). 92 
 93 
Previously we reported on the relationship between clinical signs, C. trachomatis infection and the 94 
expression of 91 immuno-fibrogenic and cell marker genes at the baseline time-point of a long-term 95 
cohort study of Tanzanian children (Ramadhani et al., 2017). We found an increase in transcripts 96 
related to Th1 and NK cell activity in individuals with C. trachomatis infection and an increase in 97 
matrix and fibrogenic factors in individuals with active disease in the absence of infection, supporting 98 
the findings of several earlier studies (Burton et al., 2015, Hu et al., 2012, Burton et al., 2012, Burton 99 
et al., 2004, Burton et al., 2011, Faal et al., 2006, Faal et al., 2005, Bobo et al., 1996). However, the 100 
stability of these transcriptional responses in an untreated population and the changes that might occur 101 
following MDA with azithromycin have not previously been investigated.   102 
 103 
Azithromycin is a macrolide antibiotic which has anti-inflammatory and immunomodulatory 104 
properties via inhibition of the transcription factor Nuclear Factor Kappa-B (Stellari et al., 2014). 105 
Azithromycin has been reported in vitro to suppress T-cell proliferation and activation and to reduce 106 
the expression of mucins and pro-inflammatory cytokines (Ratzinger et al., 2014, Murphy et al., 107 
2008a, Poachanukoon et al., 2014). As a result azithromycin is found to be beneficial in the treatment 108 
of diseases characterised by pathological inflammation (Giamarellos-Bourboulis, 2008). 109 
Azithromycin therefore has the potential to exert broad anti-inflammatory effects on conjunctival 110 
gene expression, independently of the clearance of C. trachomatis.  111 
 112 
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 4 
Here we investigate the stability of clinical signs of active trachoma, C. trachomatis infection and 113 
host immune responses in a cohort of Tanzanian children prior to azithromycin MDA and the changes 114 
induced following treatment.  115 
161
 5 
METHODS 116 
 117 
Ethics Statement 118 
This study was reviewed and approved by the Ethics Committees of the Tanzania National Institute 119 
for Medical Research, Kilimanjaro Christian Medical University College and the London School of 120 
Hygiene & Tropical Medicine. The study adhered to the tenets of the Declaration of Helsinki. A field 121 
worker explained the nature of the study in detail in either Kiswahili or Maasai. Prior to enrolment of 122 
a child into this study, their parent or guardian provided written informed consent, on a consent form 123 
in Kiswahili, which was witnessed by a third person. 124 
 125 
Study Design and Population 126 
This study was conducted in three adjacent trachoma endemic communities in Kilimanjaro and 127 
Arusha regions, Northern Tanzania. In January 2012 we recruited a cohort of children aged 6-10 years 128 
from these communities to study the pathogenesis of trachomatous conjunctival scarring. The cohort 129 
has subsequently been followed-up every three months for four years. All children aged 6-10 years, 130 
who were normally resident in the three villages, were eligible for inclusion. We chose this restricted 131 
age group as we considered that they were more likely to show evidence of incident or progressive 132 
conjunctival scarring during the four years of the study.  133 
 134 
The study population and participant recruitment process are described in more detail in the report of 135 
baseline (time-point 1) findings (Ramadhani et al., 2017). In brief, these villages are relatively remote, 136 
geographically neighbours and have similar patterns of life and traditions. This area is predominately 137 
inhabited by people of the Maasai ethnic group. Pastoral activities are the main occupation. The area 138 
is dry for much of the year, except for the rainy season (February to May). Water supply is therefore 139 
limited, and largely depends on a long-distance water pipe scheme from Mount Kilimanjaro. Family 140 
units are organised in Boma, with living huts arranged in a circle around a central animal enclosure, 141 
which is often characterised by a high density of flies.  142 
 143 
Clinical assessments and sample collection 144 
We visited the cohort of children every three months at their homes or schools. An experienced 145 
ophthalmic nurse examined their left eye for clinical signs of trachoma using x2.5 loupes and a bright 146 
torch. Signs were graded using the 1981 WHO ‘FPC’ detailed grading system (Dawson et al., 1981). 147 
This sub-divides the features into several four-point severity scales: follicles (F), papillary 148 
inflammation (P) and conjunctival scarring (C). This system corresponds to the WHO Simplified 149 
Trachoma Grading System in the following way: Trachomatous inflammation-Follicular (TF) is 150 
equivalent to F2/F3 and Trachomatous inflammation-Intense (TI) is equivalent to P3 (Thylefors et 151 
al., 1987). We followed the widely used definition of “Clinically Active Trachoma”: TF and/or TI. 152 
However, for the purpose of this study, we also consider that both P2 and P3 represent clinically 153 
significant papillary inflammation, and refer to this as “TP” (Burton et al., 2015). High resolution 154 
photographs (Nikon D90 camera with 105mm Macro lens) were taken of the examined eye for 155 
independent grading.  156 
 157 
The conjunctiva was anaesthetised with a drop of preservative-free proxymetacaine hydrochloride 158 
0.5% w/v (Minims®, Chauvin Pharmaceuticals Ltd, Surrey, UK). Two conjunctival swab samples 159 
(Dacron polyester, Puritan Medical Products Company, Maine, USA) were collected for C. 160 
trachomatis detection and gene expression analysis. The swabs were passed across the upper tarsal 161 
conjunctiva four times, with a quarter turn between each pass. The first swab was placed directly into 162 
a tube containing RNAlater solution (Thermo Fisher Scientific, Massachusetts, USA) and the second 163 
into a dry tube. The samples were placed into a cool box. Later the same day the dry swab samples 164 
were stored directly at -80oC and the RNAlater samples kept at 4-8oC overnight and then stored at -165 
80oC.  166 
 167 
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Trachoma control measures 168 
The SAFE Strategy is being implemented in this region of Tanzania. Community members who had 169 
trachomatous trichiasis were offered free surgery in the local health facility. Azithromycin MDA was 170 
distributed to the members of the three villages by our field team under the auspices of the Tanzanian 171 
National NTD Control Programme in the Ministry of Health and with supervision by district eye 172 
coordinators. Azithromycin, donated to the National NTD Control Programme by Pfizer through the 173 
International Trachoma Initiative, was offered to all community members over the age of 6 months. 174 
Single-dose azithromycin MDA (1g for adults and 20mg/kg for children) was distributed annually 175 
for three years. For infants under six months, tetracycline eye ointment was provided to their primary 176 
carer to be applied twice a day to both eyes for six weeks. The project team provided repeated health 177 
education messages around hygiene and sanitation. The first round of MDA was administered to all 178 
individuals in the three cohort villages immediately after time-point 3. No adverse effects were 179 
reported.  180 
 181 
C. trachomatis detection 182 
Two protocols were used for both genomic DNA extraction and C. trachomatis detection. For time-183 
point 1 samples, genomic DNA was extracted from dry swabs using the PowerSoil DNA isolation 184 
Kit (MO Bio Laboratories, California, USA) according to manufacturer’s instructions. For time-185 
points 2 to 5, genomic DNA was extracted from samples stored in RNAlater using the Norgen 186 
DNA/RNA Purification Kit (Norgen Biotek Corp, Canada) following the manufacturer’s instructions. 187 
 188 
C. trachomatis was detected in the time-point 1 samples using a droplet digital PCR assay (ddPCR) 189 
and at time-points 2 to 5 using multiplex quantitative real-time PCR (qPCR) previously evaluated 190 
against ddPCR (Ramadhani et al., 2017, Roberts et al., 2013, Butcher et al., 2017). Both assays detect 191 
chlamydial plasmid open reading frame 2 (pORF2), C. trachomatis outer membrane complex protein 192 
B (omcB) and human endogenous control gene ribonuclease P/MRP Subunit P30 (RPP30) (Butcher 193 
et al., 2017), using the same primer and probe sequences. The ddPCR reaction contained 5µl of DNA 194 
template and primers/probes at a final concentration of 0.3nM using Taqman mastermix. PCR 195 
reaction conditions were as follows: 95OC for 10 minutes, then 40 cycles of 95OC for 10 seconds and 196 
60OC for 30 seconds and finally 98OC for 12 minutes. Droplets were then examined for fluorescence 197 
on a QX200TM Droplet Reader (Bio-Rad, UK), providing a quantitative result. The qPCR assay was 198 
performed on a ViiA7 thermal cycler (Thermo Fisher Scientific, Massachusetts, USA) using TaqMan 199 
Multiplex Master mix in a final volume of 20 µl, containing 4µl of DNA template and primers and 200 
probes each at a final concentration of 0.3nM. Cycling conditions were as follows: 95qC hold for 20 201 
seconds followed by 40 cycles of 95qC for 1 second and 60qC for 20 seconds. Samples were tested 202 
in duplicate and were considered C. trachomatis positive if either replicate amplified omcB and/or 203 
pORF2 with a cycle threshold (CT) value <40. In order to compare agreement between ddPCR and 204 
qPCR assays, Norgen-extracted DNA from  time-point 2 samples (extracted from the first swab stored 205 
in RNAlater) were tested using both methods and the results are shown in Supplementary Table 1a.  206 
 207 
Analysis of human gene expression  208 
Total RNA was extracted from samples stored in RNAlater using the Norgen DNA/RNA Purification 209 
Kit (Norgen Biotek Corp, Canada) and reverse transcribed using the SuperScript® VILO™ cDNA 210 
Synthesis Kit (Life Technologies) following the manufacturer’s instructions. Relative abundance of 211 
host gene targets was quantified by real-time PCR using customized TaqMan® Microfluidic 384-212 
well Array Cards (Thermo Fisher Scientific, Massachusetts, USA ) on a ViiA7 real-time PCR 213 
machine (Thermo Fisher Scientific, Massachusetts, USA), as previously described (Ramadhani et al., 214 
2017). A total of 46 genes of interest were selected based on our previously reported time-point 1 215 
findings, in which we selected genes that were significantly associated with clinical signs and/or C. 216 
trachomatis infection status. HPRT1 was included in each PCR run as an endogenous control gene.   217 
 218 
Statistical analysis   219 
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Data were managed in Microsoft Access. The ∆CT method was used to adjust for the concentration 220 
of input RNA by subtracting the cycle threshold (CT) value of each gene from the CT value of HPRT1 221 
in the same sample (Livak and Schmittgen, 2001). The distribution of ΔCT values were plotted to 222 
assess normality. Host gene expression, C. trachomatis infection and clinical data were analysed in 223 
STATA v14.  224 
 225 
For each time-point the prevalence of clinical signs and C. trachomatis infection was estimated and 226 
the association between infection and each of TF and TP was estimated using logistic regression. The 227 
effect of MDA on infection, TF, TP and AT (Active Trachoma) was estimated using a random effects 228 
logistic regression. Each of infection, TF, TP and AT were used as the outcome variable in four 229 
separate regressions, the observations from the first three time-points were compared with the 230 
observations from time-point 4 (the first observation after the MDA) and participant ID was included 231 
as a random effect to account for the fact that these were repeated observations within individuals. 232 
An identical analysis was repeated comparing the observations from time-point 5 to those from before 233 
MDA to assess whether the estimated effect persisted at six months post treatment.  234 
 235 
The change in mean ΔCT value from time-point 1 was plotted for 46 genes at each of the four 236 
subsequent time-points and inspected to identify any clear differences between time-points. The 237 
change in mean ΔCT following MDA was formally tested by comparing the mean ΔCT in the first 238 
three time-points with that from the fourth time-point using a random effects linear regression, with 239 
the ΔCT value of each gene as the outcome variable, whether an observation was before or after MDA 240 
and whether individuals received treatment as the exposures of interest and participant ID was 241 
included as a random effect to again account for repeated observations of the same individuals. The 242 
relationship between pre-and post- MDA, and between treated and untreated was analysed separately. 243 
Then   an interaction term was included between before/after MDA and treated/untreated variables to 244 
provide evidence of whether gene expression response after MDA was different in treated versus 245 
untreated groups. These analyses were also repeated comparing the fifth time-point with the three 246 
pre-MDA time-points to identify if the effect persisted. Gene expression was then compared at time-247 
point 4 only between treated and untreated individuals. These analyses were initially performed 248 
unadjusted and then adjusted for infection status (clinical signs were not adjusted for as they were 249 
likely to be caused by both infection and gene expression, rather than the other way around so 250 
adjusting for these could bias our estimates).  251 
 252 
Multivariable linear regression was used at each of the five time-points presented in this report, to 253 
test the association of each gene’s expression with clinical signs and infection, adjusting for age and 254 
sex and assuming a false discovery rate (FDR) of 5% in multiple comparisons (Benjamini and 255 
Hochberg, 1995).  256 
 257 
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RESULTS  258 
 259 
Study participants  260 
We registered a total of 666 children aged between 6 and 10 years who were eligible for recruitment 261 
at the beginning of this study from three trachoma-endemic villages. Demography, clinical signs and 262 
infection status of the 506 participants seen at time-point 1 have previously reported in detail 263 
(Ramadhani et al., 2017). In general participants were predominantly from the Maasai ethnic group 264 
(652/666, 97.9%) with a similar number of males (332, [49.9%]) and females (334 [50.1%]) and a 265 
mean age of 7.01 years (SD 2.0) at the time of commencing the study. Following baseline recruitment 266 
new enrolment into the cohort was permitted at the second time-point. There were some few new 267 
enrolments after the second time-point, however these were not included in the analysis. At time-268 
points 2, 3, 4, and 5 we assessed 537 (87.2%), 466 (75.6%), 467 (75.8%) and 477 (77.4m %) children, 269 
respectively. At each time-point some children were not examined due to being absent in the village, 270 
having moved away or declining to participate. MDA was offered immediately after time-point 3 to 271 
all members of the three cohort villages. The reported community-wide coverage was 68.7%. All 272 
study participants examined in time-point 3 (466) were treated except one who refused. At time-point 273 
4, 392/466 (84.1%) of the individuals seen had been treated.  274 
 275 
Clinical signs of trachoma 276 
At time-point 1 the clinical signs previously reported were based on grading of conjunctival 277 
photographs, to enable subsequent comparison with the final time-point for determination of scarring 278 
incidence and progression (Ramadhani et al., 2017). However, for consistency within this analysis of 279 
the first five time-points, the field grading data was used. The agreement between field and 280 
photograph grading for time-point 1 is shown in Supplementary Table 1b. Kappa scores between field 281 
and photographs grading were 0.92 for TF and 0.68 for TP, with TP being slightly under-reported by 282 
field graders.  283 
 284 
The prevalence of TF (F2/F3) in the first three time-points prior to MDA was fairly consistent 285 
(171/506 [33.8%], 163/537 [30.2%] and 104/467 [22.3%]), dropping to 52/467 (11.1%) and 61/479 286 
(12.6%) post-MDA at time-points 4 and 5 (Figure 1). The prevalence of TP (P2/P3) was consistently 287 
lower than TF and also dropped substantially following MDA (Figure 1). There were no statistically 288 
significant differences between males and females in terms of the proportion showing signs of TF 289 
and/or TP at any time-point (Supplementary Table 2), with the exception of time-point 1 where there 290 
was possibly a weak association between TP and female sex. 291 
 292 
C. trachomatis infection  293 
The prevalence of infection was fairly consistent prior to MDA ranging from 11-16%, dropping to 294 
1.3% three months after azithromycin MDA (time-point 4) and increasing slightly to 2.5% at time-295 
point 5 (Figure 1). There was strong evidence for an association between C. trachomatis infection 296 
and clinical signs (TF, TP) at all five time-points (Table 1), with the exception of TP at time-point 5. 297 
There was a significant reduction in TF, TP and C. trachomatis detection in post-MDA time-points 4 298 
and 5 relative to the combined odds at pre-MDA time-points 1-3 (Table 2). The inflammatory disease 299 
(TF and/or TI (active trachoma)) and infection status for each individual at each time-point is shown 300 
in Figure 2; participants were grouped by infection and disease status at baseline. There were no 301 
statistically significant differences between males and females in terms of the proportion testing 302 
positive for C. trachomatis at any time-point (Supplementary Table 2). 303 
 304 
Conjunctival gene expression  305 
Forty-six genes of interest were quantified in all individuals who were sampled at each of the five 306 
time-points. All amplified targets were included in the analyses. For each time-point, multivariate 307 
linear regression models were constructed for expression of each gene to investigate associations with 308 
TF, TP and C. trachomatis infection, adjusting for age and sex (Supplementary Table 3). The 309 
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associations between the expression of specific genes with clinical signs and C. trachomatis infection 310 
was similar at each time-point and was consistent with the baseline (time-point 1) report (Ramadhani 311 
et al., 2017). Briefly, in individuals with C. trachomatis infection, IFNG, IL22, CCL2, IL12B, CD274, 312 
IL21, IL17A and SOCS1 genes were consistently the most upregulated and S100A4, ALOX5, MMP7, 313 
MUC5AC, MUC7, MUC4, MUC1, CDH2 and CDH1 genes were the most downregulated. In 314 
individuals with TF and TP, S100A7, CCL18, MMP12, CXCL13, IL10, IL19, IL21 and IL17A were 315 
the most upregulated while S100A4, SPARCL1, ALOX5 and MUC5AC were the most downregulated. 316 
Thus, suggesting that some of host immune responses are important in the clearance of infection, 317 
whereas others are associated with both clearance of infection and the clinical inflammation 318 
modulation. 319 
 320 
For each target, the difference in mean gene expression (across all individuals) was calculated at each 321 
time-point relative to the mean expression at time-point 1 (Figure 3). There was only modest 322 
variability between these time-points, with the exception of time-point 4, three months after MDA, 323 
which showed marked differences compared to time-point 1 (and the other time-points). The largest 324 
increases in expression at time-point 4 relative to time-point 1 were found in SPARCL1, MUC5AC, 325 
CDH2, CTGF, NCAM1, CDH1, MUC7, S100A4, and IL12B (Figure 3). The largest decreases were 326 
in S1007A, CCL18, CXCL5, DEFB4A, CXCL13, IL19, MMP12, IDO1, IL1B, and IL17A (Figure 3). 327 
By time-point 5, six months after MDA, difference in mean gene expression had mostly returned to 328 
levels that were similar to those prior to treatment (Figure 3).  329 
   330 
The change in mean ΔCT for the expression of each gene from the three time-points before MDA to 331 
the fourth time-point three months after MDA was estimated for all participants, and also separately 332 
for both individuals who received MDA and those who did not, adjusting for changes in C. 333 
trachomatis infection status (Table 3). This showed a significant change in mean ΔCT of most targets 334 
from before MDA compared with three months after MDA. Interestingly, this change was still 335 
observed in the untreated sub-group, albeit at a much reduced scale. The changes in mean ΔCT were 336 
larger when the analysis was not adjusted for C. trachomatis infection (Supplementary table 4).  337 
 338 
To investigate the differences between the treated and untreated groups further, mean ΔCT were 339 
compared between the groups at time-point 4 only (Supplementary Table 5). This revealed only subtle 340 
differences in mean ΔCT between treated and untreated individuals. The anti-inflammatory effect of 341 
MDA on gene expression was observed even in individuals without any detectable episodes of 342 
chlamydial infection or clinical signs at any of these five time-points (Supplementary Table 6).343 
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DISCUSSION  344 
 345 
Infection 346 
The prevalence of C. trachomatis was similar across the three time-points before MDA, suggesting 347 
that the infection prevalence was relatively stable in this antibiotic-naïve community at around 11% 348 
- 16%. There was a substantial reduction in infection prevalence at three months post-MDA, however, 349 
it rose slightly by six months post-MDA, suggesting some limited re-emergence of infection. This 350 
may be due to insufficient MDA coverage within the community, contact with individuals from 351 
surrounding untreated communities, or failure to complete the 6-week daily treatment course of 352 
tetracycline eye ointment for infants under 6 months. Members of these communities travel quite 353 
frequently to search for pastures and water for livestock, to visit markets and for social interactions 354 
with other communities. As a result, it was difficult to achieve high MDA coverage. Previous studies 355 
from Tanzania and The Gambia have also reported on the importance of contact between 356 
communities as a risk factor for reinfection following treatment (West et al., 2015, Burton et al., 2005, 357 
Burton et al., 2010).  358 
 359 
Disease 360 
Clinical signs prevalence was similar prior to treatment (first three time-points) suggesting stability 361 
within the community however, following MDA was strongly reduced. Clinical signs of 362 
inflammation were strongly correlated with C. trachomatis infection at all five time-points. In our 363 
previous systematic review and meta-analysis we found a strong correlation between TF and C. 364 
trachomatis infection and a moderate correlation between intense papillary inflammation (TI) and 365 
infection prior to initiation of MDA, however, after treatment the correlation was weaker for TF and 366 
no correlation was found for TI (Ramadhani et al., 2016b). Most of these earlier studies included 367 
multiple rounds of MDA and reported data several years after initiating treatment, therefore it might 368 
be too early to see this trend in our cohort. There was no consistent difference in the prevalence of 369 
clinical signs of inflammation between males and females, with the exception of the first timepoint 370 
which showed a non-significant trend of more TP in females.  371 
 372 
Gene Expression 373 
Our findings in this study of the associations between host gene expression, C. trachomatis infection 374 
and clinical signs of inflammation were consistent with previous reports from ourselves and others 375 
(Burton et al., 2015, bu El-Asrar et al., 2006, Bobo et al., 1996, Burton et al., 2004, Faal et al., 2005, 376 
Skwor et al., 2008, Burton et al., 2011). Targets that were consistently associated with clinical signs 377 
(TF/TP) at all five time-points included antimicrobial peptides (S100A7), pro-inflammatory cytokines 378 
and chemokines (CCL18, CXCL13, IL10, IL19, IL21, IL17A), matrix modifiers (MMP12 and 379 
SPARCL1), epithelial-mesenchymal transition markers (S100A4), microbiota responses (ALOX5) and 380 
mucins (MUC5AC). Likewise, C. trachomatis infection was consistently associated with pro-381 
inflammatory cytokines and chemokines (IFNG, IL22, CCL2, IL12B, IL21, IL17A), 382 
regulators/signalling pathways (SOCS1, CD274), S100A4, ALOX5, matrix modifiers (MMP7, 383 
SPARCL1) and mucins (MUC7). We discussed the functions of these genes and their potential roles 384 
in the clearance of C. trachomatis infection and immunopathology in detail in our baseline paper 385 
(Ramadhani et al., 2017). The results at each of the subsequent time-points support the data from 386 
baseline, suggesting that strong IFNG/IL12 responses are important in the clearance of infection, 387 
whilst Th17 cell associated cytokines and matrix factors are associated with both infection and the 388 
clinical inflammation which persists after infection has been cleared. 389 
 390 
Large changes in gene expression were detected at time-point 4, three months after MDA with 391 
azithromycin, relative to the three time-points prior to MDA. This variation in gene expression largely 392 
returned to pre-MDA levels by time-point 5, six months post-MDA. Azithromycin appeared to have 393 
an anti-inflammatory effect on gene expression, reversing the direction of gene expression change 394 
usually associated with clinical signs and C. trachomatis infection. Genes normally downregulated 395 
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in individuals with C. trachomatis infection and/or inflammation were upregulated post-MDA 396 
(SPARCL1, MUC5AC, CDH2, CTGF, NCAM1, CDH1, S100A4, MUC7, and FGF2), whilst genes 397 
normally upregulated (S100A7, CCL18, CXCL5, CXCL13, IL19, IDO1, MMP12, IL17A, IL1B and 398 
IL21) were strongly downregulated post-MDA. The effect was greatest when C. trachomatis infection 399 
was not adjusted for, however, the effect was still large after adjustment for infection, suggesting that 400 
azithromycin has an immunomodulatory effect on gene expression that is independent of the 401 
concurrent reduction in infection. This effect was also seen in individuals without any episodes of C. 402 
trachomatis infection and/or clinical signs of inflammation across all 5 time-points, supporting this 403 
hypothesis. However, we cannot exclude the possibility that azithromycin treatment reduced ocular 404 
infections with other sub-clinical or mild inflammation-causing organisms in these individuals. 405 
Interestingly, a change in mean gene expression post-MDA was also observed in individuals who did 406 
not receive treatment. This could be due to a reduction in transmission and therefore exposure to C. 407 
trachomatis and other infectious organisms within the community as a whole.  408 
 409 
Azithromycin has previously been reported to have anti-inflammatory effects in humans, animal and 410 
in vitro models, leading to improved clinical outcomes through a combined approach of clearing 411 
infection and reducing pathological host inflammatory responses (Amsden, 2005). One pre-surgical 412 
dose of azithromycin reduced the level of pro-inflammatory cytokines and chemokines detected in 413 
oral fluid 6 days following dental implant surgery relative to amoxicillin (Escalante et al., 2015). 414 
Relative to other non-macrolide antibiotics, azithromycin reduced levels of IL-6, IL-8, TNF-α and 415 
GM-CSF proteins in individuals with pneumonia and rhinovirus infections (Lorenzo et al., 2015, 416 
Gielen et al., 2010, Murphy et al., 2008b). MMP9 expression was reduced in the airways of lung 417 
transplanted individuals treated with azithromycin between 3 and 6 months (Verleden et al., 2011), 418 
and in an experimental laminectomy model in rats, azithromycin was associated with reduction of 419 
fibrosis and inflammatory cell density six weeks after administration (Emmez et al., 2011). 420 
Immunomodulatory effects of azithromycin are thought to be enhanced by its long half-life in tissue, 421 
lasting for several weeks (Langtry and Balfour, 1998, Leach et al., 1997). In addition to localised 422 
anti-inflammatory effects, one round of azithromycin, administered for trachoma control, was 423 
associated with a large reduction in infectious and all-cause childhood mortality (Keenan et al., 2011); 424 
a finding which was reinforced by a large multi-country placebo-controlled clinical trial (Keenan et 425 
al., 2018). Our findings of an immunomodulatory effect of azithromycin are therefore consistent with 426 
published evidence and suggest that MDA for trachoma control may have an additional protective 427 
effect through a systemic reduction in inflammation.   428 
 429 
This study has several limitations. It was only feasible to sample one eye from study participants, thus 430 
only the left eye was examined and sampled throughout the longitudinal study. The age range of study 431 
participants was limited due to the study design of the overall longitudinal study, which this 432 
investigation was nested within. The method of C. trachomatis detection was changed after the first 433 
time-point, which could introduce inconsistencies between the infection results of the first relative to 434 
later time-points. Agreement between the two methods used was however, deemed acceptable 435 
(Supplementary table 1a). The infection loads of discrepant results were very low and at around the 436 
limit of detection. Given the large sample size and the use of three pre-MDA time-points, this 437 
variation is not expected to significantly alter the results or their interpretation. 438 
 439 
Conclusions  440 
We present evidence that one round of oral azithromycin treatment exerted a strong anti-inflammatory 441 
effect on conjunctival gene expression, detectable three months following treatment but mostly 442 
returning to background levels by six months. This effect was also observed in individuals without 443 
C. trachomatis infection or active trachoma across all five time-points, indicating that the 444 
immunomodulatory effect was at least in part independent of the reduction of C. trachomatis 445 
infection. Interestingly, a reduced effect was also seen in individuals who did not receive treatment, 446 
which could reflect a community reduction in infection transmission and exposure. A limitation of 447 
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this study is that we cannot determine whether this effect is mediated directly through inhibition of 448 
pro-inflammatory intracellular signalling molecules, through reductions in concurrent, sub-clinical 449 
infections, and/or through reduction of infection exposure, and future work should seek to understand 450 
these mechanisms. Conjunctival papillary inflammation is a significant risk factor for scarring 451 
progression (Ramadhani et al., 2016a), therefore the anti-inflammatory effect of azithromycin might 452 
have therapeutic potential in limiting the development of disease sequelae, that goes beyond its effect 453 
on the prevalence of ocular C. trachomatis infection. 454 
 455 
Figure 1. The prevalence of C. trachomatis infection and clinical signs before and after MDA.  456 
 457 
Figure 2. The clinical disease (Active Trachoma, TF and/or TI) and infection status of 458 
individuals at each time-point, ordered by status at baseline. Each row represents an individual 459 
and each column represents a time-point.  460 
 461 
Figure 3. Stability of conjunctival gene expression. The difference in mean ΔCT value (across all 462 
individuals) for each gene at time-points 2, 3, 4 and 5 is shown relative to time-point 1. Values are 463 
adjusted for C. trachomatis infection and clinical phenotypes and are ordered by difference in mean 464 
gene expression at Time-point 4.    465 
 466 
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Table 1. The association between C. trachomatis detection and clinical signs by time-point. 
Clinical signs are based on field grading from all five time-points. 
 
Time-point  Follicular Inflammation (TF) Papillary inflammation (TP) 
No TF (%) TF (%) No TP (%) TP (%) 
1 
(n=506) 
Jan/Feb 
Ct infected (%) 18/335 (5.4) 60/171 (35.1) 38/407 (9.3) 40/99 (40.4) 
OR (95%CI) - 9.52 (5.4-16.8) - 6.58 (3.9-11.1) 
p-value - <0.0001 - <0.0001 
2 
(n=536) 
Apr/May 
Ct infected (%) 29/374 (7.8) 53/162 (32.7) 38/429 (8.9) 44/107 (41.1) 
OR (95%CI) - 5.78 (3.5-9.5) - 7.19 (4.3-12.0) 
p-value - <0.0001 - <0.0001 
3 
(n=466) 
Aug/Sept 
Ct infected (%) 19/362 (5.3) 35/104 (33.7) 30/398 (7.5) 24/68 (35.3) 
OR (95%CI) - 9.16 (4.9-16.9) - 6.69 (3.6-12.5) 
p-value - <0.0001 - <0.0001 
Azithromycin MDA     
4 
(n=467) 
November 
Ct infected (%) 3/415 (0.7) 3/52 (5.8) 4/457 (0.9) 2/10 (20.0) 
OR (95%CI) - 8.41 (1.7-42.8) - 28.31 (4.5-177.5) 
p-value - 0.010 - <0.0001 
5 
(n=477) 
Jan/Feb 
Ct infected (%) 4/417 (1.0) 8/60 (13.1) 10/442 (2.3) 2/35 (5.7) 
OR (95%CI) - 15.88 (4.6-54.5) - 2.62 (0.6-12.4) 
p-value - <0.0001 - 0.226 
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Table 2. Comparison of C. trachomatis infection and disease signs between the pre-treatment 
(odds of Combined time-points 1, 2 and 3) to the post-treatment time-points (4 and 5 analysed 
separately). Clinical signs are based on field grading from all five time-points. 
  
  Infection TF TP Active 
Trachoma  
Odds of combined pre-
MDA time-points vs. 
time-point 4 (3 months 
post-MDA) 
OR  0.01 0.10 0.03 0.08 
(95%CI) (0.004-0.04) (0.06-0.17) (0.01-0.07) (0.05-0.13) 
p-value <0.0001 <0.0001 <0.0001 <0.0001 
Odds of combined pre-
MDA time-points vs. 
time-point 5 (6 months 
post-MDA) 
OR  0.04 0.15 0.18 0.14 
(95%CI) (0.02-0.10) (0.10-0.23) (0.11-0.30) (0.10-0.22) 
p-value <0.0001 <0.0001 <0.0001 <0.0001 
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Table 3. Estimated Fold Changes (FC) with their respective p-values comparing the expression 
of each gene between the combined first three time-points (1, 2 and 3) before MDA and time-
point 4 (three months after MDA), adjusted for C. trachomatis infection. A FC of >1 indicates 
increased expression of the gene at time-point 4. Random effects multivariable linear regression of 
all individuals (first panel), untreated only (second panel) and treated only (third panel). The final 
column (p-value for interaction) provides evidence as to whether the fold change from before to after 
MDA is different in the treated and untreated groups. Results are ordered by FC of ‘’All’’ individuals. 
The Benjamini and Hochberg approach was used to adjust for multiple comparisons, in order to 
control the false discovery rate <5%, only tests with a p-value <0.034 are considered statistically 
significant. 
 
Target All 
Untreated Only 
 Treated Only p-value for interaction FC p-value FC p-value FC p-value 
SPARCL1 11.89 7.76 x10^-186 6.81 9.04 x10^-19 13.13 2.54 x10^-173 0.005 
MUC5AC 4.02 3.95 x10^-145 2.89 1.20 x10^-14 4.26 5.35 x10^-136 0.009 
CDH2 3.42 2.97 x10^-141 2.67 9.16 x10^-16 3.58 3.30 x10^-130 0.026 
NCAM1 2.23 9.10 x10^-89 1.83 1.95 x10^-9 2.31 8.32 x10^-83 0.031 
CTGF 2.20 3.57 x10^-96 2.25 1.27 x10^-17 2.20 4.10 x10^-81 0.818 
MUC7 1.89 7.10 x10^-29 2.17 1.01 x10^-7 1.84 2.24 x10^-23 0.291 
S100A4 1.82 7.83 x10^-79 1.75 1.56 x10^-12 1.83 5.50 x10^-69 0.612 
CDH1 1.72 1.23 x10^-80 1.69 9.80 x10^-14 1.72 2.55 x10^-69 0.808 
FGF2 1.50 2.86 x10^-9 1.48 0.019 1.50 4.19 x10^-8 0.934 
SERPINB4 1.43 1.91 x10^-3 1.65 0.067 1.39 0.009 0.570 
IL12B 1.42 5.47 x10^-15 1.49 4.10 x10^-4 1.41 1.97 x10^-12 0.657 
TGFB1 1.34 2.53 x10^-45 1.43 4.80 x10^-12 1.33 6.55 x10^-36 0.178 
ALOX5 1.29 7.49 x10^-39 1.37 7.71 x10^-11 1.27 1.24 x10^-30 0.133 
MUC1 1.24 8.04 x10^-17 1.35 4.05 x10^-6 1.22 9.95 x10^-13 0.161 
NCR1 1.23 2.51 x10^-10 1.25 0.007 1.23 7.76 x10^-9 0.835 
PDGFB 1.22 7.96 x10^-14 1.35 1.26 x10^-5 1.20 2.59 x10^-10 0.130 
GAPDH 1.20 5.05 x10^-11 1.49 1.68 x10^-8 1.16 1.33 x10^-6 0.001 
SOCS1 1.20 2.64 x10^-8 1.49 5.69 x10^-7 1.15 6.66 x10^-5 0.003 
MUC4 1.16 1.80 x10^-7 1.34 6.1 x10^-5 1.13 6.01 x10^-5 0.034 
VIM 1.15 9.83 x10^-10 1.22 4.08 x10^-4 1.14 2.11 x10^-7 0.242 
CD247 1.01 0.757 1.10 0.196 0.99 0.856  0.205 
MMP9 0.95 0.242 0.98 0883 0.95 .0224 0.731 
IFNG 0.95 0.219 0.93 0.521 0.95 0.293 0.860 
MMP7 0.93 0.033 1.08 0.441 0.90 0.009 0.086 
IL23A 0.88 5.88 x10^-4 1.00 0.989 0.86 1.73 x10^-4 0.127 
IL22 0.83 0.020 1.26 0.232 0.76 0.002 0.016 
IL6 0.83 5.24 x10^-4 0.83 0.150 0.83 0.001 0.959 
CCL20 0.82 3.80 x10^-6 0.92 0.447 0.80 2.29 x10^-6 0.240 
IL8 0.72 1.42 x10^-18 0.72 4.81 x10^-4 0.72 4.02 x10^-16 0.980 
PTGS2 0.70 1.97 x10^-17 0.79 0.02.52 0.69 8.27 x10^-17 0.210 
DUOX2 0.69 7.01 x10^-25 0.87 0.134 0.67 1.81 x10^-26 0.006 
IL10 0.67 7.68 x10^-24 0.80 0.026 0.64 6.84 x10^-24 0.047 
MZB1 0.65 3.20 x10^-17 0.71 0.008 0.64 6.23 x10^-16 0.466 
CD274 0.63 6.37 x10^-37 0.77 0.004 0.61 1.28 x10^-36 0.018 
CCL2 0.60 2.63 x10^-22 0.63 5.52 x10^-4 0.59 5.94 x10^-20 0.617 
SOCS3 0.59 1.13 x10^-38 0.76 0.006 0.57 5.67 x10^-39 0.007 
IL1B 0.52 1.78 x10^-43 0.61 2.81 x10^-5 0.50 1.55 x10^-40 0.140 
IL21 0.51 3.18 x10^-24 0.72 0.044 0.48 1.03 x10^-24 0.022 
IL17A 0.48 6.01 x10^-44 0.64 7.36 x10^-4 0.46 2.57 x10^-43 0.017 
IDO1 0.44 6.25 x10^-90 0.68 1.69 x10^-4 0.41 4.74 x10^-93 9.55 x10^-6 
MMP12 0.43 9.98 x10^-70 0.56 1.87 x10^-6 0.41 6.82 x10^-67 0.018 
IL19 0.40 5.00 x10^-63 0.55 1.42 x10^-5 0.37 4.32 x10^-61 0.012 
CXCL5 0.39 2.79 x10^-65 0.61 3.88 x10^-4 0.36 6.18 x10^-66 7.64 x10^-4 
DEFB4A 0.38 1.32 x10^-64 0.52 1.16 x10^-5 0.36 1.94 x10^-62 0.015 
CXCL13 0.38 1.19 x10^-47 0.50 3.58 x10^-5 0.36 3.28 x10^-45 0.067 
CCL18 0.33 8.10 x10^-49 0.47 5.75 x10^-5 0.31 7.95 x10^-47 0.032 
S100A7 0.28 4.90 x10^-55 0.53 0.002  0.25 3.61 x10^-56 7.03 x10^-4 
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Target description: 
 
Antimicrobial Peptides: DEFB4A, S100A7 
Cytokines/Chemokines: CCL2, CXCL5, CXCL13, CCL18, CCL20, IDO1, IFNG, IL1B, IL6, IL8, IL10, IL12B, IL17A, IL19, IL21,  
IL22, IL23A, PTGS2, 
EMT Markers: CDH1, CDH2, S100A4 and VIM, 
Matrix Modifiers: CTGF-1, FGF2, MMP7, MMP9, MMP12, PDGFB, SPARCL1 and TGFβ1 
Microbiota Response: ALOX5, DUOX2  
Mucins: MUC1, MUC4, MUC5AC, MUC7 
NK Cell Markers: CD247, NCAM1 and NCR1  
Regulators/Signalling Pathways: CD274, MZB1, SERPINB4, SOCS1 and SOCS3
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Supplementary Table 1a. 2 X 2 table showing agreement between qpcr and ddpcr assays for c. 
trachomatis detection in dna extracted from conjunctival swabs at time-point 2.  
 
  ddPCR  
  + - Total 
qPCR + 71 (13.6%) 7 (1.3 %) 78 
- 15 (2.9%) 430 (82.2%) 445 
 Total 86 437 523 
 
Sensitivity = 82.6% (95% CI 72.8 – 89.9), Specificity = 96.7% (95% CI 96.7 -99.4), NPV = 96.6% (95% CI 94.8 
– 97.6%); PPV = 91.0% (95% CI 82.9 – 95.5%); Cohens Kappa = 0.84, Accuracy: overall probability that a 
sample will be correctly classified 95.8% (95% CI 93.7 – 97.4),for these samples at this prevalence (16.4%) 
with ddPCR as the reference standard.  
 
Supplementary Table 1b. Agreement between field and photo grading at baseline (time-
point 1) for follicular and papillary inflammation in the conjunctiva. Kappa scores between 
field and photographs grading were 0.92 for TF and 0.68 for TP.  
 
Field Grading Photo Grading 
  No TF (%) TF (%)    
No TF 317 (94.6%) 18 (5.4%)    
TF 19 (11.1%) 152 (88.9%)    
       
  No TP (%) TP (%)    
No TP 345 (84.8%) 62 (15.2%)    
TP 1 (1.0%) 98 (99.0%)    
       
  F0 (%) F1 (%) F2 (%) F3 (%) 
F0 140 (96.6%) 4 (2.8%) 1 (0.7) 0 (0.0%) 
F1 61 (32.1%) 112 (59.0%) 17 (9.0%) 0 (0.0%) 
F2 0 (0.0%) 16 (21.3%) 49 (65.3%) 10 (13.3%) 
F3 0 (0.0%) 3 (3.1%) 14 (14.6%) 79 (82.3%) 
       
  P0 (%) P1 (%) P2 (%) P3 (%) 
P0 173 (60.5%) 99 (34.6%) 13 (4.6%) 1 (0.4%) 
P1 6 (5.0%) 67 (55.4%) 41 (33.9%) 7 (5.8%) 
P2 1 (1.9%) 0 (0.0%) 38 (70.4%) 15 (27.8%) 
P3 0 (0.0%) 0 (0.0%) 4 (8.9%) 41 (91.1%) 
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S2 Table. The relationship between sex and (i) clinical signs (from field grading) and (ii) c. trachomatis infection of each of the 5 time-points. 
The number of individuals with each clinical phenotype or infection is shown as a proportion of the total number of males and females at each 
time-point. Associations between sex and clinical phenotypes or infection were tested using logistic regression.    
Time-point 1 Time-point 2 Time-point 3 MDA Time-point 4 Time-point 5 
Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p- 
value 
Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p-
value 
Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p- 
value 
 Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p- 
value 
Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p- 
value 
Follicular Trachoma (TF)                  
77/251 
(30.7) 
 
94/255 
(36.9) 
1.32 
(0.9-1.9) 
0.142 72/258 
(27.9) 
90/278 
(32.4) 
1.24 
(0.9-1.8) 
0.261 44/218 
(20.2) 
60/248 
(24.2) 
1.28 
(0.8-2.0) 
0.278  23/216 
(10.7) 
29/251 
(11.6) 
1.10  
(0.6-2.0) 
0.756 27/229 
(11.8) 
34/248 
(13.7) 
1.19 
(0.7-2.0) 
0.531 
Papillary Inflammation (TP)                  
41/251 
(16.3) 
 
58/255 
(26.8) 
1.51 
(1.0-2.4) 
0.070 45/258 
(17.4) 
63/278 
(22.7) 
1.39 
(0.9-2.1) 
0.133 28/218 
(12.8) 
41/248 
(16.5) 
1.34 
(0.8-2.3) 
0.264  6/216 
(2.8) 
4/251 
(1.6) 
0.57 
(0.2-2.0) 
0.384 12/229 
(5.2) 
23/248 
(9.3) 
1.85 
(0.9-3.8) 
0.096 
Chlamydia trachomatis                  
34/252 
(13.5) 
44/255 
(17.3) 
1.34 
(0.8-2.2) 
0.241 32/258 
(12.4) 
48/278 
(17.3) 
1.47 
(0.9-2.4) 
0.116 31/218 
(14.2) 
24/248 
(9.7) 
0.65 
(0.4-1.1) 
0.131  1/216 
(0.5) 
4/251 
(1.60) 
3.48 
(0.4-31) 
0.266 6/229 
(2.6) 
6/248 
(2.4) 
0.92 
(0.3-2.9) 
0.889 
 
Target FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value
Antimicrobial Peptides
Defensin, beta 4B,defensin, beta 4A (DEFB4A ) 1.21 0.314 2.2 0.000 1.67 0.024 1.51 0.005 0.89 0.002 1.28 0.089 2.29 0.000 1.89 0.001 1.37 0.010 0.86 0.000
Psoriasin-1 (S100A7 ) 2.41 0.001 3.68 0.000 2.01 0.024 1.6 0.021 0.86 0.004 2.03 0.000 5.25 0.000 2.12 0.002 1.52 0.009 0.79 0.000
Cytokines/Chemokines
Chemokine ligand 2 (CCL2 ) 1.49 0.019 2.46 0.000 3.52 0.000 1.31 0.045 0.86 0.000 1.5 0.002 2.52 0.000 3.85 0.000 1.17 0.151 0.86 0.000
Chemokine ligand 5 (CXCL5 ) 1.6 0.019 2.18 0.001 0.97 0.889 0.94 0.697 0.9 0.008 1.76 0.000 2.1 0.000 1.53 0.034 1.04 0.791 0.88 0.000
Chemokine ligand 13 (CXCL13 ) 2.13 0.000 2.7 0.000 2.5 0.000 1.4 0.039 0.86 0.000 2.3 0.000 3.33 0.000 2.79 0.000 1.35 0.037 0.83 0.000
Chemokine ligand 18 (CCL18 ) 1.79 0.004 2.95 0.000 2.25 0.001 1.11 0.521 0.86 0.000 2.2 0.000 4.28 0.000 2.26 0.000 1.07 0.660 0.81 0.000
Chemokine ligand 20 (CCL20 ) 1.76 0.000 1.61 0.004 1.47 0.028 1.12 0.338 0.94 0.048 1.66 0.000 1.52 0.001 1.86 0.000 1.11 0.272 0.9 0.000
Indoleamine 2,3-dioxygenase 1 (IDO1 ) 1.5 0.013 1.73 0.003 2.33 0.000 1.54 0.001 0.88 0.000 1.41 0.014 1.53 0.008 2.58 0.000 1.5 0.001 0.83 0.000
Interferon gamma(IFNG ) 1.67 0.000 1.36 0.055 7.95 0.000 1.5 0.000 0.9 0.001 1.77 0.000 1.73 0.000 7.19 0.000 1.28 0.011 0.88 0.000
Interleukin 1 beta(IL1B ) 1.54 0.011 2.09 0.000 1.89 0.002 1.32 0.041 0.9 0.003 1.44 0.005 1.57 0.002 2.46 0.000 1.07 0.531 0.88 0.000
Interleukin 6 (IL6 ) 1.32 0.077 1.82 0.001 1.2 0.000 1.07 0.589 0.93 0.020 1.5 0.001 1.43 0.012 2.46 0.000 1 0.982 0.91 0.000
Interleukin 8 (IL8 ) 1.25 0.085 1.76 0.000 1.55 0.006 1.16 0.154 0.96 0.140 1.38 0.005 1.88 0.000 1.53 0.003 1.04 0.691 0.92 0.001
Interleukin 10 (IL10 ) 1.51 0.003 2.03 0.000 2.12 0.000 1.32 0.012 0.91 0.001 1.72 0.000 2.31 0.000 2.29 0.000 1.15 0.150 0.91 0.000
Interleukin 12 beta (IL12B ) 1.69 0.000 1.43 0.005 3.71 0.000 1.37 0.001 0.97 0.154 1.36 0.000 1.32 0.019 4.99 0.000 1.11 0.214 0.94 0.007
Interleukin 17A (IL17A ) 1.73 0.001 1.82 0.001 2.81 0.000 1.37 0.014 0.87 0.000 2.03 0.000 2.23 0.000 2.95 0.000 1.39 0.005 0.87 0.000
Interleukin 19 (IL19 ) 1.56 0.018 2.73 0.000 2.63 0.000 1.65 0.001 0.85 0.000 1.79 0.000 3.04 0.000 2.82 0.000 1.54 0.001 0.84 0.000
Interleukin 21 (IL21 ) 2.22 0.000 1.97 0.000 3.75 0.000 1.37 0.017 0.89 0.001 2.08 0.000 2.66 0.000 3.51 0.000 1.28 0.063 0.88 0.000
Interleukin 22 (IL22 ) 1.31 0.114 1.83 0.001 7.29 0.000 1.4 0.015 0.92 0.020 1.48 0.021 1.71 0.004 6.99 0.000 1.26 0.099 0.98 0.497
Interleukin 23A (IL23A ) 1.49 0.005 1.98 0.000 2.15 0.000 1.15 0.219 0.92 0.002 1.45 0.000 1.7 0.000 2.47 0.000 1.19 0.040 0.9 0.000
Prostaglandin-endoperoxide synthase 2 (PTGS2 ) 1.4 0.025 1.78 0.001 1.47 0.033 1.06 0.534 0.96 0.137 1.34 0.006 1.62 0.000 1.68 0.000 0.97 0.748 0.94 0.007
EMT Markers
Epithelial cadherin (CDH1 ) 1.22 0.060 1.28 0.034 0.8 0.081 1.05 0.562 0.99 0.762 1.01 0.901 1.12 0.220 1.1 0.364 1.07 0.295 0.98 0.189
Neuronal cadherin (CDH2 ) 0.97 0.787 1.15 0.295 1.29 0.072 1.03 0.271 1.11 0.218 1.01 0.916 1.04 0.756 1.51 0.002 1.13 0.168 1.03 0.279
S100 calcium binding protein A4 (S100A4 ) 1.08 0.523 1.05 0.755 0.49 0.000 0.98 0.846 1.05 0.061 0.82 0.020 0.81 0.036 0.74 0.007 1.04 0.595 1.02 0.371
Vimentin (VIM ) 1.52 0.002 1.42 0.019 1.65 0.002 1.02 0.845 1.01 0.836 1.31 0.001 1.43 0.000 2.05 0.000 1.12 0.095 0.93 0.000
Matrix Modifiers
Connective tissue growth factor (CTGF-1 ) 1.05 0.701 1.2 0.190 1.47 0.009 0.87 0.142 1.01 0.712 0.97 0.735 1.25 0.023 1.24 0.047 0.91 0.171 1 0.992
Fibroblast growth factor 2 (basic) (FGF2 ) 0.9 0.447 1.83 0.000 1.77 0.001 1.03 0.818 0.99 0.658 1.03 0.823 1.69 0.001 1.71 0.001 0.95 0.696 0.97 0.320
Matrix metallopeptidase 7 (MMP7 ) 1.46 0.009 1.43 0.029 0.46 0.000 1.02 0.849 0.94 0.042 1.17 0.225 1.36 0.032 0.61 0.002 1.06 0.576 0.93 0.006
Matrix metallopeptidase 9 (MMP9 ) 1.91 0.000 2.01 0.000 2.06 0.000 1.14 0.251 0.95 0.064 1.67 0.000 1.54 0.001 2.72 0.000 1.13 0.192 0.92 0.001
Matrix metallopeptidase 12 (MMP12 ) 1.78 0.000 2.16 0.000 2.27 0.000 1.28 0.052 0.92 0.013 1.92 0.000 2.59 0.000 2.67 0.000 1.17 0.165 0.88 0.000
Platelet-derived growth factor beta polypeptide (PDGFB ) 1.3 0.012 1.5 0.001 1.7 0.000 1.2 0.011 0.9 0.010 1.29 0.002 1.56 0.000 1.93 0.000 1.15 0.029 0.93 0.000
SPARC-like 1 (hevin) (SPARCL1 ) 0.57 0.004 0.54 0.006 0.52 0.006 0.77 0.095 1.18 0.000 0.51 0.000 0.43 0.000 0.47 0.001 0.88 0.384 1.18 0.000
Transforming growth factor, beta 1 (TGFβ1 ) 1.3 0.012 1.25 0.067 1.51 0.001 1.14 0.109 0.98 0.274 1.21 0.013 1.19 0.048 1.76 0.000 1.06 0.371 0.94 0.000
Microbiota Response
Arachidonate 5-lipoxygenase (ALOX5 ) 1.17 0.157 1.21 0.125 0.85 0.217 1.08 0.351 0.1 0.893 1.04 0.628 1.1 0.301 1.02 0.848 1.04 0.551 0.95 0.004
Dual oxidase 2 (DUOX2 ) 1.2 0.206 1.71 0.001 1.58 0.010 1.36 0.007 0.91 0.001 1.28 0.028 1.56 0.001 1.58 0.001 1.39 0.000 0.88 0.000
Mucins
Mucin 1, cell surface associated (MUC1 ) 1.15 0.227 1.28 0.056 1.08 0.602 1.11 0.220 0.97 0.264 1.12 0.154 1.27 0.012 1.14 0.211 1.12 0.087 0.95 0.003
Mucin 4, cell surface associated  (MUC4 ) 1.22 0.089 1.55 0.001 0.83 0.182 1 0.988 0.96 0.056 1.05 0.615 1.32 0.008 1.02 0.856 1.16 0.046 0.91 0.000
Mucin 5AC, oligomeric mucus/gel-forming (MUC5AC ) 0.86 0.266 0.94 0.679 0.71 0.038 1.09 0.437 1.04 0.111 0.87 0.207 0.85 0.214 0.73 0.026 1.04 0.634 1.06 0.009
Mucin 7, secreted (MUC7 ) 0.98 0.902 0.9 0.555 0.52 0.000 0.66 0.001 1.08 0.014 0.79 0.065 0.76 0.053 0.64 0.005 0.77 0.012 1.06 0.021
NK Cell Markers
CD247  molecule (CD247) 1.41 0.003 1.32 0.031 2.15 0.000 1.2 0.049 1 0.212 1.32 0.001 1.51 0.000 2.14 0.000 1.12 0.106 0.93 0.000
Neural cell adhesion molecule 1 (NCAM1 ) 0.9 0.413 1.12 0.435 2.13 0.000 1.14 0.210 1.01 0.702 1.02 0.832 1.04 0.683 2.01 0.000 1.08 0.268 0.98 0.240
Natural cytotoxicity triggering receptor 1 (NCR1 ) 1.4 0.003 1.33 0.023 2.86 0.000 1.28 0.005 0.94 0.007 1.43 0.000 1.41 0.001 2.86 0.000 1.22 0.009 0.94 0.001
Regulators/Signalling Pathways
CD274 molecule (CD274 ) 1.37 0.029 1.64 0.003 3.36 0.000 1.31 0.020 0.9 0.019 1.46 0.000 1.81 0.000 3.42 0.000 1.18 0.053 0.89 0.000
Marginal zone B and B1 cell-specific protein (MZB1 ) 1.76 0.001 1.33 0.117 2.61 0.000 1.29 0.048 0.96 0.201 1.51 0.008 2.84 0.000 2.92 0.000 1.34 0.020 0.89 0.000
Serpin peptidase inhibitor clade B member 4, (SERPINB4 ) 1.08 0.739 3.72 0.000 5.1 0.000 1.05 0.811 0.97 0.564 1.03 0.878 2.94 0.000 5.77 0.000 1.12 0.514 0.9 0.018
Suppressor of cytokine signalling 1  (SOCS1 ) 1.55 0.000 1.48 0.001 2.26 0.000 1.18 0.057 0.94 0.004 1.36 0.000 1.5 0.000 2.76 0.000 1.1 0.191 0.92 0.000
Suppressor of cytokine signalling 3 (SOCS3 ) 1.56 0.002 1.89 0.000 1.35 0.079 1.17 0.169 0.93 0.015 1.39 0.003 1.6 0.000 1.85 0.000 1.08 0.422 0.88 0.000
Supplementary Table 3: Multivariable linear regression models for conjunctival gene expression associated with clinical signs, C. trachomatis , female sex and age. FC = fold change. Using the Benjamini and Hochberg approach to adjust for multiple 
comparisons,  in order to control the false discovery rate <5% only tests with a p-value below 0.027 are considered statistically significant.
TF TP C. trachomatis Sex AgeTF TP C. trachomatis Sex Age
Time-point 1 Time-point 2
 
Target FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value
Antimicrobial Peptides
Defensin, beta 4B,defensin, beta 4A (DEFB4A ) 1.12 0.567 1.84 0.005 2.23 0.001 1.38 0.018 0.87 0.000 3.01 0.000 1.64 0.400 3.04 0.135 1.23 0.224 0.91 0.026
Psoriasin-1 (S100A7 ) 1.58 0.080 4.18 0.000 3.34 0.000 1.38 0.080 0.78 0.000 3.01 0.000 2.08 0.154 10.81 0.000 1.13 0.391 0.87 0.000
Cytokines/Chemokines
Chemokine ligand 2 (CCL2 ) 1.42 0.039 2.28 0.000 4.1 0.000 1.2 0.124 0.84 0.000 2.43 0.000 1.17 0.646 5.45 0.000 0.94 0.525 0.91 0.000
Chemokine ligand 5 (CXCL5 ) 1.19 0.387 1.72 0.019 2.03 0.004 1.04 0.771 0.82 0.000 4.38 0.000 1.5 0.462 2.51 0.185 1.06 0.731 0.88 0.001
Chemokine ligand 13 (CXCL13 ) 1.68 0.024 2.69 0.000 2.94 0.000 1.43 0.027 0.78 0.000 3.59 0.000 1.41 0.477 10.61 0.000 1.15 0.297 0.84 0.000
Chemokine ligand 18 (CCL18 ) 1.63 0.033 2.92 0.000 3.61 0.000 1.18 0.292 0.83 0.000 2.41 0.000 1.22 0.659 11.77 0.000 0.94 0.635 0.94 0.033
Chemokine ligand 20 (CCL20 ) 1.36 0.059 1.34 0.108 2.05 0.000 1.11 0.367 0.88 0.000 3.12 0.000 1.09 0.844 2.79 0.058 1.13 0.323 0.89 0.000
Indoleamine 2,3-dioxygenase 1 (IDO1 ) 1.39 0.063 1.86 0.002 3.53 0.000 1.61 0.000 0.83 0.000 4.84 0.000 1.49 0.443 6.8 0.004 1.46 0.011 0.88 0.000
Interferon gamma(IFNG ) 1.43 0.019 1.95 0.000 9.71 0.000 1.26 0.032 0.88 0.000 2.79 0.000 1.08 0.836 13.43 0.000 1.28 0.022 0.88 0.000
Interleukin 1 beta(IL1B ) 1.27 0.173 1.71 0.006 2.53 0.000 1.15 0.240 0.89 0.000 2.86 0.000 1.78 0.183 3.29 0.030 1.09 0.502 0.94 0.048
Interleukin 6 (IL6 ) 1.03 0.875 1.4 0.087 2.71 0.000 1.05 0.684 0.93 0.018 2.04 0.001 0.72 0.476 3.73 0.022 1.22 0.124 0.91 0.003
Interleukin 8 (IL8 ) 0.93 0.649 1.72 0.003 2.18 0.000 1.12 0.312 0.92 0.006 2.2 0.000 1.63 0.273 1.71 0.335 1.1 0.462 0.98 0.598
Interleukin 10 (IL10 ) 1.25 0.154 2.25 0.000 2.38 0.000 1.17 0.145 0.89 0.000 2.11 0.000 1.38 0.273 4.81 0.000 1.02 0.769 0.91 0.000
Interleukin 12 beta (IL12B ) 1.44 0.007 1.43 0.018 5.47 0.000 1.16 0.121 0.92 0.000 1.88 0.000 1.06 0.844 10.34 0.000 1.11 0.265 0.92 0.000
Interleukin 17A (IL17A ) 1.65 0.008 2.18 0.000 3.25 0.000 1.43 0.007 0.83 0.000 4.15 0.000 1.57 0.309 10.54 0.000 1.27 0.055 0.88 0.000
Interleukin 19 (IL19 ) 1.24 0.283 2.73 0.000 3.83 0.000 1.57 0.002 0.83 0.000 3 0.000 2.09 0.110 6.86 0.001 1.23 0.119 0.91 0.004
Interleukin 21 (IL21 ) 1.66 0.015 2.62 0.000 4.41 0.000 1.37 0.029 0.83 0.000 3.49 0.000 1.67 0.236 13.11 0.000 1.2 0.164 0.87 0.000
Interleukin 22 (IL22 ) 1.7 0.014 1.54 0.066 8.75 0.000 1.19 0.252 0.96 0.282 1.41 0.148 1.63 0.332 13.13 0.000 1.17 0.321 0.99 0.736
Interleukin 23A (IL23A ) 1.11 0.440 1.8 0.000 2.65 0.000 1.11 0.291 0.89 0.000 1.93 0.000 1.02 0.957 5.04 0.000 0.97 0.778 0.91 0.000
Prostaglandin-endoperoxide synthase 2 1.02 0.515 1.42 0.041 1.84 0.001 1.16 0.172 0.9 0.000 2.4 0.000 1.85 0.109 1.83 0.211 0.97 0.778 0.94 0.022
EMT Markers
Epithelial cadherin (CDH1 ) 1.02 0.797 1.14 0.212 1.22 0.079 1.06 0.359 0.94 0.000 1.55 0.020 0.88 0.763 1.49 0.441 1.05 0.663 1 0.873
Neuronal cadherin (CDH2 ) 1.03 0.808 0.99 0.947 1.24 0.181 1.13 0.189 1.03 0.317 1.02 0.892 0.59 0.158 1.55 0.344 1.05 0.645 0.99 0.644
S100 calcium binding protein A4 (S100A4 ) 0.96 0.738 0.9 0.447 0.72 0.028 1 0.987 1 0.912 1.52 0.060 0.86 0.746 0.84 0.777 0.87 0.318 1.02 0.483
Vimentin (VIM ) 1.18 0.102 1.3 0.024 2.17 0.000 1.07 0.360 0.92 0.000 2.17 0.000 1.01 0.978 3.4 0.017 1.03 0.794 0.97 0.216
Matrix Modifiers
Connective tissue growth factor (CTGF-1 ) 0.99 0.915 0.98 0.872 1.4 0.012 0.9 0.173 0.97 0.089 1.44 0.045 0.59 0.174 2.22 0.105 0.91 0.397 1.02 0.492
Fibroblast growth factor 2 (basic) (FGF2 ) 1.2 0.182 1.34 0.044 1.85 0.000 0.97 0.725 0.95 0.041 1.46 0.035 1.04 0.922 1.96 0.179 0.96 0.756 0.97 0.263
Matrix metallopeptidase 7 (MMP7 ) 1.36 0.052 1.17 0.366 0.68 0.040 0.97 0.754 0.89 0.000 2.3 0.000 1.14 0.760 1.06 0.917 0.97 0.777 0.94 0.056
Matrix metallopeptidase 9 (MMP9 ) 1.78 0.000 1.18 0.332 2.51 0.000 1.06 0.580 0.9 0.000 2.75 0.000 1.55 0.268 3.44 0.014 1.16 0.187 0.9 0.000
Matrix metallopeptidase 12 (MMP12 ) 1.37 0.097 2.16 0.000 2.89 0.000 1.36 0.020 0.83 0.000 3.5 0.000 1.65 0.332 6.38 0.005 1.18 0.256 0.89 0.002
Platelet-derived growth factor beta polypeptide 1.12 0.247 1.48 0.001 2.08 0.000 1.14 0.066 0.92 0.000 1.8 0.000 1.15 0.690 2.98 0.014 1.1 0.319 0.97 0.270
SPARC-like 1 (hevin) (SPARCL1 ) 0.7 0.142 0.58 0.042 0.42 0.003 0.73 0.066 1.12 0.010 0.36 0.000 0.32 0.025 0.32 0.077 0.85 0.252 1.05 0.178
Transforming growth factor, beta 1 (TGFβ1 ) 1.1 0.338 1.15 0.179 1.81 0.000 1.02 0.741 0.93 0.000 2 0.001 0.94 0.878 3.55 0.020 1.04 0.728 0.99 0.621
Microbiota Response
Arachidonate 5-lipoxygenase (ALOX5 ) 0.95 0.633 1.17 0.193 1.1 0.430 1.01 0.845 0.94 0.002 1.75 0.008 1.17 0.726 1.28 0.663 1.03 0.837 0.99 0.729
Dual oxidase 2 (DUOX2 ) 1.16 0.315 1.55 0.008 2.13 0.000 1.5 0.000 0.84 0.000 2.74 0.000 1.95 0.186 4.26 0.023 1.36 0.031 0.91 0.010
Mucins
Mucin 1, cell surface associated (MUC1 ) 1.08 0.496 1.26 0.054 1.35 0.021 1.14 0.074 0.9 0.000 2.04 0.001 1.09 0.857 1.69 0.366 1.1 0.453 0.98 0.497
Mucin 4, cell surface associated  (MUC4 ) 0.96 0.766 1.19 0.243 1.47 0.016 1.04 0.686 0.89 0.000 1.46 0.056 1.64 0.254 1.65 0.362 1.15 0.257 0.95 0.075
Mucin 5AC, oligomeric mucus/gel-forming 0.84 0.185 0.84 0.229 0.77 0.083 1.09 0.315 1.05 0.036 0.79 0.317 0.6 0.314 0.3 0.059 1.2 0.200 1.08 0.032
Mucin 7, secreted (MUC7 ) 1.02 0.913 0.71 0.064 0.78 0.199 0.7 0.002 0.99 0.819 1.52 0.055 0.66 0.375 0.76 0.653 0.76 0.039 0.95 0.111
NK Cell Markers
CD247  molecule (CD247) 1.24 0.061 1.43 0.006 2.8 0.000 1.12 0.178 0.92 0.000 2.07 0.000 0.92 0.812 5.16 0.000 1.07 0.469 0.95 0.019
Neural cell adhesion molecule 1 (NCAM1 ) 0.96 0.719 1.09 0.468 1.83 0.000 0.92 0.271 0.96 0.050 1.57 0.007 0.59 0.150 2.2 0.085 0.9 0.312 0.98 0.539
Natural cytotoxicity triggering receptor 1 1.35 0.011 1.41 0.008 3.01 0.000 1.09 0.291 0.92 0.000 2.46 0.000 1.14 0.704 5.33 0.000 1.17 0.097 0.9 0.000
Regulators/Signalling Pathways
CD274 molecule (CD274 ) 1.27 0.090 1.88 0.000 3.56 0.000 1.22 0.047 0.87 0.000 2.64 0.000 1.16 0.683 9.87 0.000 1.14 0.223 0.9 0.000
Marginal zone B and B1 cell-specific protein 1.58 0.015 1.68 0.013 2.3 0.000 1.03 0.811 0.86 0.000 2.7 0.000 1.09 0.867 10.7 0.000 1.16 0.307 0.88 0.000
Serpin peptidase inhibitor clade B member 4, 1.36 0.205 2.46 0.001 3.69 0.000 0.93 0.672 0.87 0.003 0.88 0.736 1.11 0.892 7.78 0.021 0.75 0.220 0.93 0.211
Suppressor of cytokine signalling 1  (SOCS1 ) 1.26 0.032 1.43 0.003 2.97 0.000 1.13 0.105 0.89 0.000 2.06 0.000 1.32 0.379 4.65 0.000 1.02 0.793 0.96 0.040
Suppressor of cytokine signalling 3 (SOCS3 ) 1.21 0.180 1.6 0.003 2.08 0.000 1.15 0.170 0.87 0.000 2.68 0.000 1.54 0.244 3.27 0.012 1.04 0.678 0.94 0.012
C. trachomatis Sex Age
Time-point 3 Time-point 4
TF TP C. trachomatis Sex Age TF TP
 
Target p-value FC p-value FC p-value FC p-value FC p-value FC p-value
Antimicrobial Peptides
Defensin, beta 4B,defensin, beta 4A (DEFB4A ) 0.026 1.98 0.009 3.44 0.000 4.51 0.018 1.52 0.009 0.82 0.000
Psoriasin-1 (S100A7 ) 0.000 3.31 0.000 4.39 0.000 7.39 0.000 2.06 0.000 0.78 0.000
Cytokines/Chemokines
Chemokine ligand 2 (CCL2 ) 0.000 1.69 0.008 1.71 0.022 8.74 0.000 1.29 0.035 0.92 0.006
Chemokine ligand 5 (CXCL5 ) 0.001 2.5 0.001 2.99 0.001 2 0.215 1.47 0.024 0.82 0.000
Chemokine ligand 13 (CXCL13 ) 0.000 3.26 0.000 2.41 0.003 4.07 0.005 1.59 0.002 0.79 0.000
Chemokine ligand 18 (CCL18 ) 0.033 2.88 0.000 4.07 0.000 7.05 0.000 1.13 0.388 0.84 0.000
Chemokine ligand 20 (CCL20 ) 0.000 2.23 0.000 1.45 0.133 2.61 0.023 1.41 0.007 0.92 0.007
Indoleamine 2,3-dioxygenase 1 (IDO1 ) 0.000 2.49 0.000 3.16 0.000 3.77 0.008 1.46 0.013 0.85 0.000
Interferon gamma(IFNG ) 0.000 1.44 0.032 1.68 0.011 16.98 0.000 1.41 0.001 0.94 0.013
Interleukin 1 beta(IL1B ) 0.048 2.1 0.000 2.09 0.003 3.24 0.006 1.19 0.180 0.87 0.000
Interleukin 6 (IL6 ) 0.003 1.44 0.073 0.96 0.866 4.67 0.000 1.16 0.242 0.94 0.048
Interleukin 8 (IL8 ) 0.598 1.61 0.016 1.58 0.051 3.27 0.003 1.08 0.512 0.94 0.035
Interleukin 10 (IL10 ) 0.000 1.96 0.000 1.66 0.007 3.9 0.000 1.2 0.057 0.88 0.000
Interleukin 12 beta (IL12B ) 0.000 1.36 0.044 0.98 0.909 6.43 0.000 1.2 0.044 1 0.876
Interleukin 17A (IL17A ) 0.000 2.31 0.000 2.4 0.000 5.98 0.000 1.59 0.000 0.86 0.000
Interleukin 19 (IL19 ) 0.004 2.53 0.000 3.49 0.000 7.06 0.000 1.6 0.001 0.83 0.000
Interleukin 21 (IL21 ) 0.000 2.39 0.000 2.1 0.001 7.25 0.000 1.66 0.000 0.88 0.000
Interleukin 22 (IL22 ) 0.736 1.37 0.109 1.85 0.010 13.77 0.000 1.17 0.209 0.98 0.461
Interleukin 23A (IL23A ) 0.000 1.77 0.001 1.71 0.011 3.67 0.000 1.12 0.285 0.91 0.000
Prostaglandin-endoperoxide synthase 2 (PTGS2 ) 0.022 1.7 0.003 1.66 0.018 2.22 0.029 1.25 0.049 0.87 0.000
EMT Markers
Epithelial cadherin (CDH1 ) 0.873 1.19 0.207 1.2 0.272 1.24 0.444 1.12 0.188 0.95 0.032
Neuronal cadherin (CDH2 ) 0.644 0.89 0.461 0.8 0.236 1.63 0.126 1.23 0.038 1.06 0.030
S100 calcium binding protein A4 (S100A4 ) 0.483 0.88 0.499 0.87 0.523 0.84 0.641 1.03 0.780 1.02 0.587
Vimentin (VIM ) 0.216 1.49 0.002 1.38 0.034 2.58 0.000 1.08 0.330 0.95 0.008
Matrix Modifiers
Connective tissue growth factor (CTGF-1 ) 0.492 1.08 0.661 0.93 0.720 1.93 0.056 1 0.985 0.99 0.690
Fibroblast growth factor 2 (basic) (FGF2 ) 0.263 1.37 0.065 1.04 0.836 2.32 0.010 1.09 0.448 1.02 0.417
Matrix metallopeptidase 7 (MMP7 ) 0.056 1.49 0.043 1.34 0.211 0.91 0.810 1.01 0.923 0.89 0.000
Matrix metallopeptidase 9 (MMP9 ) 0.000 1.87 0.001 1.56 0.036 3.42 0.001 1.11 0.330 0.91 0.001
Matrix metallopeptidase 12 (MMP12 ) 0.002 1.89 0.004 1.63 0.065 5.91 0.000 1.23 0.125 0.87 0.000
Platelet-derived growth factor beta polypeptide (PDGFB ) 0.270 1.37 0.017 1.55 0.005 2.77 0.000 1.28 0.002 0.95 0.007
SPARC-like 1 (hevin) (SPARCL1 ) 0.178 0.37 0.000 0.21 0.000 0.27 0.017 0.95 0.736 1.25 0.000
Transforming growth factor, beta 1 (TGFβ1 ) 0.621 1.31 0.054 1.31 0.100 1.89 0.025 1.13 0.166 0.96 0.040
Microbiota Response
Arachidonate 5-lipoxygenase (ALOX5 ) 0.729 1.06 0.719 1.03 0.881 1.43 0.263 1.06 0.576 0.94 0.018
Dual oxidase 2 (DUOX2 ) 0.010 1.96 0.002 2.42 0.001 2.79 0.022 1.32 0.039 0.86 0.000
Mucins
Mucin 1, cell surface associated (MUC1 ) 0.497 1.12 0.504 1.09 0.673 1.91 0.064 1.08 0.449 0.94 0.013
Mucin 4, cell surface associated  (MUC4 ) 0.075 1.26 0.183 1.17 0.442 1.61 0.174 1.17 0.142 0.93 0.010
Mucin 5AC, oligomeric mucus/gel-forming (MUC5AC ) 0.032 0.83 0.293 0.99 0.960 0.76 0.442 1.23 0.062 1.11 0.000
Mucin 7, secreted (MUC7 ) 0.111 0.88 0.533 1.15 0.555 0.7 0.380 0.85 0.174 0.94 0.063
NK Cell Markers
CD247  molecule (CD247) 0.019 1.32 0.097 1.53 0.033 3.21 0.001 1.22 0.056 0.92 0.002
Neural cell adhesion molecule 1 (NCAM1 ) 0.539 0.89 0.427 1.15 0.418 1.72 0.071 1 0.996 1.02 0.363
Natural cytotoxicity triggering receptor 1 (NCR1 ) 0.000 1.43 0.022 1.53 0.021 2.97 0.001 1.28 0.011 0.91 0.000
Regulators/Signalling Pathways
CD274 molecule (CD274 ) 0.000 1.74 0.002 2.02 0.001 5.56 0.000 1.29 0.024 0.87 0.000
Marginal zone B and B1 cell-specific protein (MZB1 ) 0.000 1.83 0.005 1.53 0.102 4.2 0.001 1.46 0.005 0.87 0.000
Serpin peptidase inhibitor clade B member 4, (SERPINB4 ) 0.211 1.18 0.600 2.15 0.044 21.14 0.000 0.98 0.940 1 0.965
Suppressor of cytokine signalling 1  (SOCS1 ) 0.040 1.67 0.001 1.52 0.021 2.89 0.001 1.1 0.311 0.9 0.000
Suppressor of cytokine signalling 3 (SOCS3 ) 0.012 1.76 0.003 1.86 0.006 2.47 0.020 1.12 0.345 0.85 0.000
Time-point 5
TF TP C. trachomatis Sex Age
Supplementary Table 4. Estimated Fold Changes (FC) with their respective p-values comparing the 
expression of each gene between the combined first three time-points (time-points 1, 2 and 3) before MDA 
and time-point 4 (three months after MDA), not adjusted for C. trachomatis infection. A FC of >1 indicates 
increased expression of the gene at time-point 4. Random effects multivariable linear regression of all individuals 
(first panel), untreated only (second panel) and treated only (third panel). The final column (p-value for interaction) 
provides evidence as to whether the fold change from before to after MDA is different in the treated and untreated 
groups. Results are ordered by FC of ‘’All’’ individuals. Benjamini and Hochberg approach was used to adjust for 
multiple comparisons, in order to control the false discovery rate <5%, only tests with a p-value <0.035 are 
considered statistically significant.  
 
Target All Untreated Only Treated Only p-value for interaction FC p-value FC p-value FC p-value 
SPARCL1 18.65 2.75x10^-250 8.21 3.65x10^-23 21.77 1.32x10^-235 2.69X10^-5 
MUC5AC 5.33 7.6x10^-215 3.14 3.06x10^-18 5.88 7.21x10^-206 1.19X10^-5 
CDH2 3.92 2.22x10^-169 2.72 3.72x10^-17 4.24 1.9x10^-158 6.84X10^-4 
MUC7 2.71 2.52x10^-72 2.45 9.19x10^-11 2.74 5.15x10^-62 0.458 
CTGF 2.40 2.04x10^-118 2.29 1.12x10^-19 2.43 1.68x10^-101 0.553 
NCAM1 2.34 5.3x10^-90 1.79 8.89x10^-9 2.49 8.21x10^-86 0.003 
S100A4 2.30 1.87x10^-143 1.95 5.02x10^-17 2.37 4.66x10^-129 0.026 
CDH1 1.94 1.28x10^-122 1.78 1.38x10^-17 1.97 3.13x10^-107 0.173 
ALOX5 1.42 1.61x10^-65 1.45 1.37x10^-13 1.41 2.70x10^-53 0.606 
MUC1 1.39 7.87x10^-39 1.40 4.01x10^-8 1.40 2.12x10^-33 0.975 
FGF2 1.39 6.72X10^-6 1.41 0.046 1.42 1.77x10^-5 0.994 
TGFB1 1.34 9.68x10^-46 1.41 5.79x10^-12 1.32 2.41x10^-35 0.272 
MUC4 1.30 5.69x10^-19 1.40 2.54x10^-6 1.29 4.82x10^-15 0.273 
GAPDH 1.29 6.09x10^-18 1.50 1.65x10^-8 1.25 1.06x10^-11 0.020 
IL12B 1.24 7.69x10^-6 1.28 0.035 1.24 5.35x10^-5 0.794 
PDGFB 1.22 1.49x10^-12 1.29 1.54x10^-4 1.20 1.01x10^-9 0.351 
NCR1 1.21 2.44x10^-8 1.15 0.086 1.22 6.90x10^-8 0.530 
VIM 1.13 7.56x10^-8 1.17 0.005 1.13 3.59x10^-6 0.515 
SOCS1 1.13 2.42x10^-4 1.36 1.35x10^-4 1.09 0.021 0.012 
SX10RPINB4 1.13 0.341 1.34 0.320 1.09 0.565 0.520 
MMP7 1.11 0.006 1.17 0.086 1.09 0.028 0.487 
CD247 0.96 0.122 1.02 0.770 0.94 0.059 0.297 
MMP9 0.84 9.28x10^-5 0.91 0.371 0.83 1.37x10^-4 0.457 
IL23A 0.83 2.24x10^-6 0.92 0.369 0.81 2.43x10^-6 0.250 
IL6 0.80 2.75x10^-5 0.77 0.050 0.81 3.65x10^-4 0.758 
CCL20 0.78 5.98x10^-8 0.88 0.263 0.76 8.80x10^-8 0.232 
IFNG 0.76 7.28x10^-8 0.76 0.030 0.77 1.07x10^-6 0.985 
DUOX2 0.71 1.51x10^-22 0.87 0.116 0.69 1.05x10^-22 0.011 
PTGS2 0.68 1.96x10^-19 0.77 0.011 0.67 3.94x10^-18 0.203 
IL8 0.68 1.75x10^-24 0.69 7.73x10^-5 0.68 2.06x10^-20 0.822 
IL22 0.65 1.91x10^-6 0.95 0.801 0.60 2.79x10^-7 0.042 
IL10 0.60 7.40x10^-35 0.74 0.002 0.58 2.33x10^-33 0.029 
SOCS3 0.58 8.67x10^-40 0.73 0.001 0.56 3.03x10^-38 0.015 
MZB1 0.56 6.51x10^-26 0.65 0.001 0.55 7.23x10^-24 0.260 
CD274 0.54 1.82x10^-57 0.68 3.92x10^-5 0.51 4.37x10^-55 0.008 
CCL2 0.48 3.48x10^-37 0.55 1.23x10^-5 0.47 1.01x10^-32 0.341 
IL1B 0.46 5.42x10^-59 0.56 7.91x10^-07 0.44 4.31x10^-54 0.054 
IDO1 0.41 7.77x10^-102 0.65 2.11x10^-5 0.38 3.28x10^-104 1.56X10^-6 
IL17A 0.40 4.45x10^-62 0.57 2.46x10^-5 0.38 2.21x10^-59 0.005 
IL21 0.40 1.52x10^-39 0.61 0.003 0.37 6.53x10^-39 0.007 
MMP12 0.37 1.06x10^-87 0.51 4.56x10^-8 0.35 3.18x10^-82 0.005 
CXCL5 0.36 3.84x10^-72 0.59 2.11x10^-4 0.32 1.17x10^-72 1.04X10^-4 
DX10FB4A 0.35 1.46x10^-64 0.50 4.51x10^-6 0.33 5.23x10^-61 0.013 
IL19 0.33 1.01x10^-79 0.48 2.57x10^-7 0.31 1.71x10^-75 0.005 
CXCL13 0.30 4.71x10^-66 0.44 9.38x10^-7 0.28 3.44x10^-62 0.015 
S100A7 0.24 2.33x10^-60 0.47 3.39x10^-4 0.21 3.46x10^-61 4.20X10^-4 
CCL18 0.23 1.32x10^-77 0.41 1.17x10^-6 0.21 9.46x10^-76 8.98X10^-4 
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Supplementary Table 5. Estimated Fold Change (FC) with their respective p-values for the 
expression of each gene at time-point 4 only (three months post MDA), comparing MDA 
treated (after time-point 3) to untreated individuals. Multivariable linear regression of all 
individuals adjusted (first panel) and not adjusted (second panel) for C. trachomatis infection. 
Results are ordered by FC of adjusted data with infection. Benjamini and Hochberg approach was 
used to adjust for multiple comparisons, in order to control false discovery rate <5%, only tests 
with a p-value <0.009 are considered statistically significant. 
 
Target Adjusted for infection  Not adjusted for infection  FC p-value FC p-value 
SPARCL1 2.06 3.10x10^-04 2.34 2.55 x10^-5 
MUC5AC 1.44 0.011 1.62 9.45 x10^-4 
MUC7 1.28 0.081 1.35 0.030 
CDH2 1.27 0.062 1.30 0.037 
NCAM1 1.19 0.055 1.19 0.048 
IFNG 1.16 0.225 1.03 0.802 
S100A4 1.08 0.238 1.14 0.052 
MZB1 1.07 0.660 0.97 0.820 
NCR1 1.05 0.568 0.99 0.904 
CDH1 1.03 0.701 1.05 0.464 
CD247 1.02 0.748 0.97 0.668 
IL12B 1.01 0.890 0.92 0.468 
VIM 1.00 0.950 0.97 0.599 
TGFB1 0.98 0.738 0.96 0.429 
SERPINB4 0.97 0.913 0.89 0.700 
ALOX5 0.95 0.389 0.98 0.725 
CCL2 0.95 0.602 0.89 0.247 
PDGFB 0.95 0.440 0.93 0.300 
IL6 0.94 0.627 0.91 0.479 
MMP9 0.94 0.552 0.90 0.331 
CTGF 0.93 0.462 0.94 0.529 
IL23A 0.93 0.340 0.88 0.110 
GAPDH 0.92 0.330 0.91 0.275 
MMP7 0.91 0.370 0.93 0.520 
SOCS1 0.90 0.183 0.86 0.057 
MUC1 0.88 0.046 0.89 0.071 
IL8 0.88 0.208 0.88 0.203 
CD274 0.87 0.088 0.80 0.006 
CCL20 0.86 0.199 0.84 0.123 
PTGS2 0.85 0.100 0.84 0.083 
IL10 0.85 0.028 0.80 0.004 
IL1B 0.84 0.083 0.81 0.034 
CXCL13 0.82 0.199 0.74 0.051 
MUC4 0.82 0.015 0.84 0.024 
FGF2 0.78 0.134 0.79 0.132 
SOCS3 0.78 0.008 0.76 0.003 
DUOX2 0.76 0.017 0.73 0.005 
IL19 0.74 0.018 0.69 0.003 
IL21 0.74 0.041 0.64 0.004 
CCL18 0.73 0.042 0.67 0.008 
IL17A 0.73 0.013 0.66 0.001 
IL22 0.72 0.110 0.64 0.030 
MMP12 0.71 0.009 0.66 0.001 
DEFB4A 0.71 0.068 0.69 0.042 
S100A7 0.70 0.030 0.63 0.005 
IDO1 0.64 8.99 x10^-4 0.59 1.03 x10^-4 
CXCL5 0.57 4.02E-04 0.56 1.98E-04 
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Supplementary Table 6. Estimated fold changes (FC) with their respective p-values comparing the expression of each 
gene between the combined first three time-points (1, 2 and 3) before MDA and separately time-points 4 and 5 (three and 
six months following MDA treatment), in individuals who were free from infection and/or disease at all 5 time-points. 
Results are ordered by Fold Change (FC) in pre-MDA time-points vs. time-point 4. Benjamini and Hochberg approach was used 
to adjust for multiple comparisons, in order to control the false discovery rate <5%, only tests with a p-value <0.035 are 
considered statistically significant.  
 
 
 
 
 
Target 
Pre-MDA vs time-point 4 Pre-MDA vs time-point 5 
 
 FC p-value FC p-value 
SPARCL1 8.97 1.10 x10^-55 1.57 2.15x10^-3 
MUC5AC 3.89 2.69 x10^-50 1.59 3.37 x10^-7 
CDH2 3.36 2.64 x10^-46 1.62 3.16 x10^-9 
CTGF 2.10 3.97 x10^-28 0.98 0.756 
NCAM1 2.01 2.57 x10^-17 1.29 0.002 
CDH1 1.77 2.56 x10^-40 1.16 9.50 x10^-4 
S100A4 1.72 1.29 x10^-28 1.10 0.063 
MUC7 1.53 3.95 x10^-7 1.32 7.86 x10^-4 
SERPINB4 1.51 0.059 1.26 0.210 
TGFB1 1.36 1.26 x10^-16 1.10 0.007 
IL12B 1.35 1.14 x10^-4 1.06 0.467 
PDGFB 1.29 4.08 x10^-9 0.97 0.427 
MUC1 1.27 3.36 x10^-9 1.03 0.418 
SOCS1 1.27 1.08 x10^-5 1.29 6.99 x10^-6 
ALOX5 1.25 3.352 x10^-13 1.02 0.471 
FGF2 1.24 0.0718 0.87 0.240 
GAPDH 1.19 5.74 x10^-4 0.91 0.166 
MUC4 1.18 4.17 x10^-4 1.07 0.214 
NCR1 1.16 0.0122 0.96 0.500 
VIM 1.14 6.14 x10^-4 0.97 0.430 
CD247 1.06 0.224 0.86 9.20 x10^-4 
IL22 1.03 0.854 0.99 0.942 
IL23A 0.97 0.583 1.11 0.080 
MMP9 0.96 0.609 1.07 0.382 
MMP7 0.95 0.357 0.81 1.10 x10^-4 
IFNG 0.94 0.433 0.83 0.009 
CCL20 0.76 3.23 x10^-4 0.79 0.004 
IL6 0.74 9.71 x10^-4 0.81 0.016 
IL10 0.74 2.19 x10^-6 0.84 0.006 
CCL2 0.73 2.76 x10^-4 1.02 0.778 
IL8 0.72 1.036 x10^-7 0.87 0.019 
PTGS2 0.70 6.47 x10^-7 0.87 0.047 
DUOX2 0.70 2.64 x10^-9 0.75 2.37 x10^-5 
CD274 0.65 5.91 x10^-12 0.86 0.017 
MZB1 0.64 6.88 x10^-8 0.83 0.023 
SOCS3 0.63 3.10 x10^-10 0.93 0.359 
IL1B 0.56 1.57 x10^-12 0.89 0.169 
IL21 0.55 2.97 x10^-7 0.78 0.025 
IL17A 0.50 1.66 x10^-14 0.89 0.221 
IL19 0.49 3.98 x10^-15 0.90 0.254 
CCL18 0.47 3.62 x10^-10 0.93 0.505 
MMP12 0.44 1.15 x10^-25 0.64 8.38 x10^-8 
CXCL13 0.44 3.50 x10^-14 0.87 0.211 
DEFB4A 0.42 2.15 x10^-19 0.81 0.035 
S100A7 0.41 7.82 x10^-15 0.76 0.018 
IDO1 0.41 8.19 x10^-38 0.68 5.38 x10^-8 
CXCL5 0.40 1.12 x10^-22 0.90 0.271 
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Abstract  
 
Background 
Trachoma is a progressive blinding disease initiated by infection of the conjunctiva with C. 
trachomatis. Repeated infections are thought to cause chronic inflammation which drives 
scarring, leading to in-turning of the eyelids. The relationship between C. trachomatis, clinical 
inflammation and scarring development in children is not fully understood due to a paucity of 
longitudinal studies with infection data at frequent follow-up.  
 
Methods and Findings 
This longitudinal cohort study took place in northern Tanzania. Children aged 6-10 at baseline 
were eligible for inclusion. Participants were visited every three months for four years. Clinical 
signs and conjunctival swabs for C. trachomatis detection by qPCR were collected at each time-
point. Conjunctival photographs from baseline and final timepoints were graded and compared 
side-by-side to determine scarring incidence and progression.  
 
Of the 666 children enrolled in the study, outcome data was obtained for 448. Scarring 
progression was detected in 103/448 (23%) children; 48 (11%) of which had incident scarring 
and 55 (12%) had progression of existing scarring. Scarring was strongly associated with 
increasing episodes of papillary inflammation. Weaker associations between episodes of 
infection and TF with scarring progression in univariate models were absent in multivariate 
analysis after adjusting for TP (multivariate results: C. trachomatis p=0.44, TF p=0.25, TP 
p=<0.0001, age p=0.13, female sex p=0.05). Individuals with TP at 30% or more of the time-
points they were seen had an odds ratio of 7.5 (95%CI=2.7-20.8) for scarring progression relative 
to individuals without any TP detected during the study period.  
 
Conclusions 
These data suggest that the effect of infection on scarring progression is mediated through TP, 
and that other factors contributing to the development of TP in addition to C. trachomatis 
infection are important in driving conjunctival scarring progression in children.  
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Introduction 
 
Sight loss from trachoma, the leading infectious cause of blindness, is the end result of an 
inflammatory-scarring process. Starting from early childhood, people growing-up in a trachoma 
endemic community may be repeatedly exposed to ocular challenge with Chlamydia 
trachomatis, the causative organism. This is thought to trigger inflammatory responses that lead 
to conjunctival scarring in some individuals.233 Scarring complications usually develop during 
adulthood. The eyelids and eyelashes turn in, scratching the ocular surface (trichiasis), resulting 
in corneal opacification.233 
 
Trachoma control rests on the SAFE Strategy: Surgery for trichiasis, Antibiotic treatment to treat 
C. trachomatis infection, Facial cleanliness and Environmental improvements to reduce 
transmission. Endemic countries and the international community have set the ambitious target 
of 2020 for the elimination of trachoma as a public health problem.268 There is no specific 
treatment to halt the progression of scarring, beyond controlling the infection.  
 
Around 3.2 million people are estimated to have trichiasis and 1.9 million are blind or have 
severe visual impairment.15 Currently WHO estimates that 158 million people live in districts 
that require A, F and E interventions.13 Nearly 90% live in Sub-Saharan Africa.  
 
Longitudinal data sets documenting the incidence or progression of conjunctival scarring are 
limited.233 Such studies are complex and can take many years to complete. In this paper we 
report the clinical signs and infection results of a four-year longitudinal study with 3-monthly 
follow up. The aim of the study was to determine the contributions of C. trachomatis infection, 
clinical signs, age and sex to scarring incidence and progression in Tanzanian children. 
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Methods 
 
Ethical statement 
This study was reviewed and approved by Ethics Committees of the Tanzania National Institute 
for Medical Research, Kilimanjaro Christian Medical University College and the London School 
of Hygiene & Tropical Medicine. It adhered to the tenets of the Declaration of Helsinki. The study 
was explained in detail in Kiswahili or Maasai; written informed consent from a parent or legal 
guardian was necessary for enrolment. 
 
Study Design and Population 
We recruited a cohort of children from three neighbouring villages in northern Tanzania. They 
were assessed every three months for four years, totalling 17 time-points. The communities and 
recruitment have been described in detail.23 These communities are predominantly comprised 
of Maasai people. Children aged between 6 and 10 years at baseline (February 2012), who were 
normally resident in the villages, were eligible for inclusion. This restricted age group was chosen 
as we anticipated that younger children may not have manifest incident / progressive 
conjunctival scarring during the four years of follow-up. A census was conducted and eligible 
children enrolled.  
 
Clinical assessment and sample collection 
At each time-point all available children were examined by an experienced ophthalmic nurse. 
The eye was first anaesthetized with preservative-free proxymetacaine hydrochloride 0.5% 
eyedrops. The left upper eyelid was everted and tarsal conjunctiva examined (using x2.5 loupes 
and torch) for signs of trachoma and graded using the 1981 WHO ‘FPC’ detailed grading 
system.26 This grading system corresponds to the Simplified WHO system: F2/F3 equates to 
Trachomatous Inflammation-Follicular (TF), and P3 to Trachomatous Inflammation-Follicular 
(TI).20 “Clinically Active Trachoma” was defined as presence of TF and/or TI. We also consider 
that both P2 and P3 represent clinically significant papillary inflammation, and refer to this as 
“TP”.260 High resolution photographs (Nikon D90 camera with 105mm Macro lens) were taken 
of the conjunctiva for independent grading. 
 
Two conjunctival swab samples were collected (Dacron polyester, Puritan Medical Products 
Company, Maine) at each time-point. The first was placed in RNAlater (Thermo Fisher, UK) and 
the second was stored dry. Clinical swabs and air control swabs were collected and stored as 
described previously.23 Samples were stored at -800C until processed.   
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Trachoma Control 
Following approval from the Ministry of Health and in collaboration with district eye 
coordinators the SAFE strategy was implemented in study villages by the study field team. 
Education was provided regarding facial cleanliness and environmental improvements, free 
trichiasis surgery was offered and MDA was administered according to WHO guidelines in 
August 2012, August 2013 and August 2014.  
 
Chlamydia trachomatis detection 
At the first time-point, DNA was extracted using the PowerSoil DNA Isolation Kit (Mo Bio 
Laboratories, USA) from swab samples stored in dry tubes and C. trachomatis was detected by 
droplet digital PCR, as previously described.23, 263 In all subsequent time-points, DNA was 
extracted from samples stored in RNAlater using the Norgen RNA/DNA purification kit (Norgen 
Biotek) and C. trachomatis was detected by triplex quantitative PCR (qPCR) for chlamydial 
chromosomal (omcB) and plasmid (pORF2) genes and a human endogenous control gene 
(RPP30), as described previously.258 Time-point 2 Norgen-extracted samples were tested by both 
detection methods and the kappa score for agreement was 0.84. Samples were tested in 
duplicate and were defined as C. trachomatis positive if RPP30 and pORF2 and/or omcB 
amplified in <40 cycles in one or both replicates.  
 
Analysis 
We used photographic grading to determine whether there was either development of incident 
scarring in previously un-scarred conjunctiva or increase in pre-existing scarring. Conjunctival 
photographs from baseline (time-point 1) were compared to the final time-point (time-point 
17). For individuals not seen at time-point 1, the image from time-point 2 was used for baseline. 
Similarly, if an individual was not seen at time-point 17, the image from time-point 16 was used 
as the final time-point. The images were assessed by an ophthalmologist experienced in using a 
detailed scarring grading system.245 Baseline and final photographs were compared side-by-side 
to produce a binary outcome variable “scarring progression”, defined as evidence of incident 
scarring or worsening of pre-existing scarring. We subdivided individuals with “no scarring 
progression” into (1) no scarring at either baseline or final; (2) scarring unchanged between 
baseline and final. We subdivided individuals with “scarring progression” into (3) incident 
scarring (no scarring at baseline and new scarring at final); (4) increasing scarring (some scarring 
at baseline and more at final). 
 
All field data were handled in Access (Microsoft). Data were merged and analyzed in STATA v14. 
The total number of time-points at which participants were seen varied due to absence or 
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refusal. We excluded from the analysis individuals who were seen on fewer than four occasions 
or did not have outcome data (time-point 16 or 17 assessments). A proportion variable was 
generated for each of TF, TP and C. trachomatis infection: number of time-points with each 
factor as a proportion of the total number of time-points that individual was seen. Proportions 
were subsequently categorized.  
 
Separate mixed effects logistic regression models were used to determine the association 
between (1) TP, (2) TF, and (3) C. trachomatis infection with sex and baseline age, using data 
from all time-points in the longitudinal dataset. Mixed effects regression was also performed to 
assess the relationship between (1) TF and C. trachomatis infection, and (2) TP and C. 
trachomatis, again using data from all time-points in the longitudinal dataset (adjusting for age 
at baseline and sex). These analyses were limited to the 448 individuals with outcome data.  
 
To identify risk factors for scarring progression, analysis was initially performed using logistic 
regression to assess the association between categorized proportions of TF, TP or C. trachomatis 
infection with overall scarring progression. Each of these were initially included as exposures 
separately in a logistic regression using scarring progression as the outcome variable and 
adjusting for age at baseline and sex. Following this, all three were included in a final 
multivariable model (adjusting for baseline age and sex), and likelihood ratio tests were 
performed between models including versus excluding each exposure to determine its overall P 
value. The analyses were subsequently repeated to identify risk factors for incident scarring and 
progression of pre-existing scarring separately. In the first set of univariate and multivariate 
analyses (using the same exposures as above) the analysis was restricted to individuals without 
scarring at baseline (incident scarring versus no scarring). In the second set, analysis was 
restricted to individuals with scarring at baseline (progression of existing scarring versus no 
progression of existing scarring).  
 
Chlamydial load was calculated by extrapolating from a standard curve. OmcB in copies/Pl was 
log10 transformed to normalize the distribution. In the longitudinal dataset random effects 
linear regressions were performed to look for associations between a) chlamydial load and 
scarring progression (adjusting for MDA-period, age at baseline and sex), and b) chlamydial load 
and age at time-point (in years) in C. trachomatis positive individuals (adjusting for sex and MDA-
period. Age at time-point was split into four groups; <7.5 years, t7.5 - <10 years, t10 - <12.5 
years, and >12.5 years. A random effects linear regression was then performed to assess for 
association between chlamydial load, age group and progression, including an interaction term 
between age group and progression in order to determine whether the association between 
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chlamydial load and progression was modified by age. MDA-period (pre-MDA, post first MDA, 
post second MDA, post third MDA) was adjusted for to avoid confounding.  
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Results 
 
Study participants 
The participant flow is shown in Figure 1. There were 666 eligible and 616 enrolled. Enrolment 
into the cohort was permitted at only the first or second time-point. We had this restriction as 
we wanted to ensure that children were followed up for sufficient time, with a consistent 
approach to be able to observe scarring progression at the end of study in the fourth year. There 
were a few entries after the second time-point which were not included in the analysis. There 
was naturally variation of number of children available at each time-point and who these were, 
with some missing due to various reasons (highlighted in figure 1).Fifty either refused or were 
absent. We excluded 57 who were examined on less than four occasions, and 111 without 
scarring progression outcome data (no time-point 16 or 17 assessment). This left 448 in the 
analysis, who were seen at a median of 15 time-points (1st – 3rd quartiles = 13-16, Supplementary 
Figure 1).  
 
Figure 1. Participant flow chart showing the number of individuals enrolled, excluded and 
included in the analysis of scarring progression. 
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Supplementary Figure 1. Histogram showing the number of time-points participants were 
seen (448 participants with outcome data).  
 
 
 
The demographic characteristics of the entire cohort were described in the baseline report.23 Of 
the 448 children included in these analyses, 242 (54.0%) were female, mean age at baseline was 
6.8 years, and 438 (97.8%) were Maasai. Of the 218 children not included, 92 (42.2%) were 
female (OR=1.61, 95%CI=1.16-2.23, p=0.004), mean age was 7.4 years (OR=0.86,95% CI=0.79-
0.93, p<0.0002) and 214 (98.2%) were Maasai. Younger children and females were therefore 
more likely to be included in this study analysis. 
 
Antibiotic coverage of the 448 children included in scarring progression analysis was 355 (79.2%) 
in 2012, 374 (83.5%) in 2013 and 344 (76.8%) in 2014. The estimated community-wide MDA 
coverage in 2012, 2013 and 2014 were 68.7%, 42.9% and 72.9%, respectively. 
 
Clinical Disease 
Of the 448 participants, 240 (53.6%) had TF (F2/F3), 185 (41.3%) had TP (P2/P3)), and 248 
(55.4%) had clinically active trachoma (F2/3 and/or P3) at one or more time-point. The 
prevalence of TF and TP is shown for each time-point in Figure 2. There was a significant 
reduction in inflammatory disease following MDA, although TP prevalence was particularly high 
at time-point 6.  
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Figure 2. The prevalence of C. trachomatis infection and clinical signs at each time-point in the 
448 individuals with outcome data. Red vertical lines indicate MDA treatment. 
 
 
 
Examination of inflammation and infection prevalence by village revealed that this peak in TP 
was found in only two of the three villages (“A” and “C”), and did not appear to correlate with 
infection (Supplementary Figure 2 & Figure 3).  
 
The number of individuals with categorized proportions of time-points with TF, TP and C. 
trachomatis infection is shown in Table 1. At baseline, 93 (20.8%) had some degree of 
conjunctival scarring. 
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Table 1: The number of individuals with C. trachomatis infection, TF and TP, categorized by 
the proportion of time-points at which C. trachomatis infection, TF and TP were detected as a 
percentage of the total number of time-points that individual was seen. 
 
Proportion of time-points 
C. trachomatis TF TP 
n (%) n (%) n (%) 
None 229 (51.1) 208 (46.4) 263 (58.7) 
<10% 78 (17.5) 52 (11.6) 71 (15.8) 
10-19% 79 (17.6) 71 (15.9) 48 (10.7) 
20-29% 43 (9.6) 56 (12.5) 41 (9.2) 
30% + 19 (4.2) 61 (13.6) 25 (5.6) 
 
The odds of TF were estimated to be higher in females (OR=1.49, 95%CI=1.05-2.11, P=0.025) 
and lower with each additional year of age (OR=0.65, 95%CI=0.59-0.71, p<0.0001) in the 
longitudinal dataset. The odds of TP were also estimated to reduce with age (OR=0.79, 
95%CI=0.71-0.88, p<0.0001) but the evidence of an association with sex was much weaker 
(OR=1.39, 95%CI=0.92-2.09, p=0.119. There was no difference between children included and 
those excluded in the analysis in terms of sex, baseline TF (OR=1.32, 5%CI=0.86-2.04, P=0.203), 
baseline TP (OR=1.46, 5%CI=0.85-2.50, P=0.165) and baseline infection (OR=1.41, 5%CI=0.78-
2.54, P=0.257), although those excluded tended to be slightly older on average than those 
included (mean age 7.4 vs 6.8, p<0.001). 
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Supplementary Figure 2. The prevalence of C. trachomatis infection and clinical signs at each 
time-point in all 17 time-points in the 448 individuals with outcome data, split by village. Red 
vertical lines indicate MDA treatment. 
 
 
 
C. trachomatis infection  
C. trachomatis was detected in 219/448 (48.9%) at one or more time-points. The prevalence of 
infection is shown for each time-point in Figure 2. The proportion of time-points that each 
individual had infection is shown in Table 1. The median proportion of time-points infected 
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among the 219 individuals who had C. trachomatis detected on at least one occasion was 12.5%, 
which was equivalent to ~2 time-points if someone had been seen on all 17 visits.  
 
Infection prevalence declined following each round of MDA, however, at time point 10 (9 
months after second MDA) it had increased and at time-point 14 (9 months after third MDA) 
infection prevalence had returned to pre-MDA levels (10-15%). Infection prevalence dropped 
again by time-points 16 and 17. Further examination of infection and clinical sign prevalence in 
each of the three villages showed that the majority of infection and TF at later time-points was 
found in only village “C” (Supplementary Figure 2). This village is located in a different 
administrative district, which received government-administered MDA treatment in 2015, 
possibly explaining the drop in infection prevalence at time-points 16 and 17 (Supplementary 
Figure 2).  
 
In a mixed effects logistic regression of infection at any time-point, female sex (OR=1.7, 
95%CI=1.25-2.34, p=0.001) and younger baseline age (OR=0.82, 95%CI=0.75-0.99, p<0.0001) 
were significantly associated with C. trachomatis infection. 
 
Clinical disease and infection  
Overall, there was a strong association between C. trachomatis infection and TF (OR=11.6, 
95%CI=8.9-15.0, P<0.0001) and TP (OR=9.6, 95%CI=7.1-12.8, P<0.0001) in the longitudinal 
dataset (adjusted for baseline age and sex). The odds ratios for TP and TF as predictors of C. 
trachomatis infection (adjusted for TP/TF, age at baseline and sex) at each time-point were 
generally similar to or slightly higher after the initiation of MDA, however, confidence intervals 
were much wider (Supplementary Figure 3).  
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Supplementary Figure 3. The association between C. trachomatis infection and TF (blue 
points) and TP (red points) at each timepoint. Odds ratios with 95% confidence intervals are 
plotted. Vertical red lines indicate MDA. The OR for TP at time-point 5 is missing as there was 
insufficient data to generate a result.  
 
 
  
 
Scarring progression 
Overall, scarring progression was observed in 103/448 (23.0%) participants (Table 2). There 
were 307 (68.5%) who had no scarring; 38 (8.5%) with unchanged scarring; 48 (10.7%) with 
incident scarring; and 55 (12.3%) with increasing scarring. 
 
Table 2: Scarring progression category by presence of C. trachomatis infection and clinical 
features, detected at one or more time-points. 
  Overall scarring  Scarring subgroups 
Clinical phenotype Total Progression No progression  No scarring 
Unchanged 
scarring 
Incident 
scarring 
Increasing 
scarring 
Total 448 103 (23%) 345 (77%)  291 (65%) 54 (12%) 48 (10.7%) 55 (12.3%) 
No infection/TP/TF 122 17 (13.9%) 105 (86.1%)  95 (77.9%) 10 (8.2%) 11 (9%) 6 (4.9%) 
Any TF 240 67 (27.9%) 173 (72.1%)  136 (56.7%) 37 (15.4%) 31 (12.9%) 36 (15%) 
Any TP 185 67 (36.2%) 118 (63.8%)  89 (48.1%) 29 (15.7%) 28 (15.1%) 39 (21.1%) 
Any C. trachomatis  219 55 (25.1%) 164 (74.9%)  137 (62.6%) 27 (12.3%) 29 (13.2%) 26 (11.9%) 
 
The relationships between scarring progression and proportion of time-points when C. 
trachomatis was detected or signs of inflammation (TF and TP) seen, adjusting only for age and 
sex, are shown in Table 3. In these models strong evidence was found of an association between 
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progression and both TP and TF, but the association between infection and progression was 
weaker. There was also evidence of a greater odds of progression in females compared to males.  
 
Table 3: Univariate associations between overall scarring progression and categorized 
proportions of time-points with C. trachomatis infection, TF and TP, adjusted for age and sex. 
The overall P value for each model is shown in line with the variable name. 
 
 n/N (%) OR 95% CI P value 
C. trachomatis      0.041 
None 48/229 (20.9)  
 
 
<10% 12/78 (15.4) 0.64 0.3 - 1.3  
10-19% 21/79 (26.6) 1.29 0.7 - 2.4 
 
20-29% 15/43 (34.9) 1.91 0.9 - 3.9 
 
30% + 7/19 (36.8) 2.20 0.8 - 6.0 
 
TF     0.0004 
None 36/208 (17.3)  
 
 
<10% 8/52 (15.4) 0.93 0.4 - 2.2 
 
10-19% 18/71 (25.4) 1.96 1.0 - 3.9 
 
20-29% 15/56 (26.8) 1.92 0.9 - 4.0 
 
30% + 26/61 (42.6) 4.41 2.2 - 8.8 
 
TP     <0.0001 
None 36/263 (13.7)    
<10% 17/71 (23.9) 2.14 1.1 - 4.2  
10-19% 15/48 (31.3) 3.08 1.5 - 6.4  
20-29% 21/41 (51.2) 7.26 3.5 - 15.0  
30% + 14/25 (56.0) 8.41 3.5 - 20.2  
Age at baseline   1.01 0.9 -1.1 0.853 
Sex 
Male  
Female 
 
38/206 
65/242 
 
(18.5) 
(26.9) 
 
 
1.62 
 
 
1.0 -2.6 
 
 
0.036 
 
In a multivariable model (Table 4) for scarring progression (retaining infection, TF, TP, age and 
sex), the strong relationship between increasing proportion of time-points with TP and scarring 
progression remained. Female sex was marginally associated. There was no association with 
either TF or infection, suggesting that the univariate associations between TF and infection with 
scarring were mediated through TP. 
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Table 4: Multivariable logistic regression model for overall scarring progression, retaining 
categorized proportions of time-points with C. trachomatis infection, TF and TP, adjusted for 
age and sex. The overall P value for each variable is shown in line with the variable name, derived 
from a likelihood ratio test of the model including versus excluding that variable. 
 
 OR 95% CI P value 
C. trachomatis   0.4396 
None    
<10% 0.49 0.2 - 1.1  
10-19% 0.90 0.5 - 1.8  
20-29% 0.80 0.3 - 1.9  
30% + 0.72 0.2 - 2.5  
TF   0.2535 
None  
 
 
<10% 0.85 0.3 - 2.1  
10-19% 1.07 0.5 -2.3  
20-29% 0.84 0.3 - 2.0  
30% + 2.09 0.9 - 5.0  
TP   <0.0001 
None    
<10% 2.19 1.1 - 4.4  
10-19% 2.94 1.3 - 6.7  
20-29% 6.67 3.0 - 14.9  
30% + 7.48 2.7 - 20.8  
Age at baseline 1.11 1.0 -1.3 0.128 
Sex (Female) 1.65 1.0 -2.7 0.051 
 
The analysis was repeated, restricted to individuals with (a) no scarring at baseline, and (b) some 
scarring at baseline, in order to differentiate between factors associated with incident scarring 
and progression of pre-existing scarring, respectively. In univariate models there was evidence 
for associations between episodes of C. trachomatis infection, TF and TP with incident scarring 
(Supplementary Table 1). In the multivariate model however, only TP was significantly 
associated with incident scarring, again suggesting that the effect of infection and TF was 
mediated through TP (Supplementary Table 2). Neither infection, TF nor TP were significantly 
associated with progression of pre-existing scarring in either univariate models or multivariate 
models. There was a trend for increasing risk of progressive scarring with increasing episodes of 
TP however, this effect was not statistically significant, possibly due to the relatively small 
sample size in this group with pre-existing scarring at baseline. These data from children with 
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pre-existing scarring did not demonstrate that additional episodes of C. trachomatis infection 
were associated with further progression of scarring. Female sex was associated with an 
increase in pre-existing scarring but not with incident scarring. There were no associations with 
age. 
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Supplementary Table 1: Univariate logistic regression models for a) incident scarring and b) 
increase in pre-existing scarring, in individuals with (a) no scarring at baseline or (b) some 
scarring at baseline. Univariate associations between scarring and infection, TF and TP were 
adjusted for age at baseline and sex.   
 
A) INCIDENT SCARRING n/N % OR 95% CI P value  
48/339 14.16 
   
C. trachomatis         0.0307 
None  19/173 10.98 
   
<10%  5/67 7.46 0.68 0.24 - 1.91 
 
10-19%  10/53 18.87 1.98 0.84 - 4.64 
 
20-29%  9/32 28.13 3.40 1.33 - 8.68 
 
30% +  5/14 35.71 4.75 1.42 - 15.90 
 
TF         0.0013 
None  17/172 9.88 
   
<10%  2/37 5.41 0.62 0.13 - 2.86 
 
10-19%  6/47 12.77 1.63 0.58 - 4.58 
 
20-29%  8/43 18.60 2.54 0.96 - 6.71 
 
30% +  15/40 37.50 7.35 2.91 - 18.54 
 
TP         <0.0000 
None  20/222 9.01 
   
<10%  4/49 8.16 0.99 0.32 - 3.09 
 
10-19%  5/29 17.24 2.40 0.80 - 7.19 
 
20-29%  15/28 53.57 13.42 5.34 - 33.73 
 
30% +  4/11 36.36 6.03 1.61 - 22.63 
 
Age at baseline     0.99 0.84 - 1.15 0.859 
Sex            
Male 24/168 14.29 
   
Female 24/171 14.04 0.98 0.53 - 1.80 0.947       
 
B) PROGRESSIVE SCARRING n/N % OR 95% CI P value 
  55/109 50.46       
C. trachomatis         0.3973 
None  29/56 51.79 
   
<10%  7/11 63.64 0.93 0.21 - 4.18 
 
10-19%  11/26 42.31 0.51 0.18 - 1.46 
 
20-29%  6/11 54.55 0.80 0.20 - 3.18 
 
30% +  2/5 40.00 0.62 0.09 - 4.36 
 
TF         0.5382 
None 19/36 52.78 
   
<10%  6/15 40.00 0.68 0.19 - 2.40 
 
10-19%  12/24 50.00 1.01 0.33 - 3.09 
 
20-29%  7/13 53.85 1.19 0.31 - 4.60 
 
30% +  11/21 52.38 0.87 0.26 - 2.91 
 
TP         0.1783 
None  16/41 39.02 
   
<10%  13/22 59.09 2.17 0.73 - 6.46 
 
10-19%  10/19 52.63 1.79 0.57 - 5.63 
 
20-29%  6/13 46.15 1.44 0.40 - 5.23 
 
30% +  10/14 71.43 3.63 0.94 - 14.04 
 
Age at baseline     1.02 0.84 - 1.24 0.839 
Sex            
Male 14/38 36.84 
   
Female 41/71 57.75 2.34 1.04 - 5.27 0.039 
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Supplementary Table 2: Multivariable logistic regression models for a) incident scarring and 
b) increase in pre-existing scarring, in individuals with (a) no scarring at baseline or (b) some 
scarring at baseline. 
 
A) INCIDENT SCARRING OR 95% CI P value 
C. trachomatis 
  
0.3477 
None 
   
<10% 0.46 0.14 - 1.48 
 
10-19% 1.52 0.57 - 4.04 
 
20-29% 1.19 0.36 - 3.93 
 
30% + 1.90 0.38 - 9.46   
TF 
  
0.1472 
None 
   
<10% 0.70 0.14 - 3.41 
 
10-19% 0.71 0.20 - 2.49 
 
20-29% 0.75 0.20 - 2.75 
 
30% + 2.77 0.79 - 9.65   
TP 
  
0.0003 
None 
   
<10% 1.04 0.30 - 3.56 
 
10-19% 2.00 0.57 - 7.08 
 
20-29% 11.97 3.74 - 38.31 
 
30% + 3.81 0.76 - 19.22   
Age at baseline 1.16 0.95 - 1.42 0.149 
Sex (female) 0.95 0.46 - 1.94 0.885 
    
B) PROGRESSIVE SCARRING       
C. trachomatis 
  
0.5287 
None 
   
<10% 0.89 0.16 - 4.87 
 
10-19% 0.42 0.13 - 1.38 
 
20-29% 0.41 0.07 - 2.35 
 
30% + 0.31 0.03 - 3.26   
TF 
  
0.9483 
None 
   
<10% 0.76 0.19 - 3.07 
 
10-19% 1.01 0.28 - 3.62 
 
20-29% 0.84 0.16 - 4.46 
 
30% + 0.59 0.13 - 2.63   
TP 
  
0.1777 
None 
   
<10% 2.26 0.73 - 6.98 
 
10-19% 2.95 0.76 - 11.48 
 
20-29% 1.51 0.40 - 5.79 
 
30% + 6.30 1.23 - 32.26   
Age at baseline 0.95 0.74 - 1.22 0.678 
Sex (female) 2.54 0.91 - 7.03 0.074 
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C. trachomatis infection load  
Bacterial load in C. trachomatis positive individuals was equivalent between people with and 
without scarring progression, using data from all time-points (adjusting for age at baseline, sex 
and pre/post-MDA period) (OR=1.1, 95% CI=0.86-1.42, p=0.45). There was evidence of an 
association between age at time-point (in years) and infection load among C. trachomatis 
positive individuals, with lower loads in older individuals (OR=0.91, 95%CI=0.86-0.97, p=0.004) 
(adjusting for sex and MDA period). Bacterial load in C. trachomatis positive progressors and 
non-progressors was plotted across different age groups (derived from age in years at time-
point) to determine whether the association between scarring progression and load varied by 
age. In the oldest age group, progressors had a slightly higher infection load relative to non-
progressors, Figure 4, which was supported by evidence for an interaction between age group 
and progression in their association with bacterial load (p=0.012). The model including the 
interaction explained the data better than the model without the interaction (p=0.016).    
 
Figure 4. Distribution of omcB load in scarring progressors and non-progressors, split by age 
group at time-point. 
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Discussion  
 
The development of trachomatous scarring is probably the result of a complex interaction 
between C. trachomatis infection, variation in the host immune response and possibly other 
pro-inflammatory stimuli. However, long-term data exploring the relative contributions of these 
factors to the development of scarring in children are limited.  
 
In this cohort of Tanzanian children aged 6-10 years old at baseline we found that 23% had 
trachomatous scarring progression over the course of four years. Roughly half of this was new 
scarring whilst the other half involved progression of pre-existing scarring. Scarring progression 
was strongly associated with increasing frequency of conjunctival papillary inflammation (TP).  
 
We found only weak evidence of an association between C. trachomatis infection and scarring 
progression. Increasing proportions of infection episodes were associated with incident scarring, 
however, multivariable analysis showed that this effect was mediated through TP. These data 
suggest that other factors, in addition to C. trachomatis infection, are important determinants 
of the development of TP and progression of scarring. The data also indicate that the clinical 
sign of TF has no association with scarring progression after adjusting for TP, suggesting that TF 
is not a direct cause of, nor the best prognostic marker for scarring progression. For this purpose, 
TP prevalence might be a more informative clinical marker, and control programs could consider 
using TF in combination with TP prevalence to predict future risk of scarring.  
 
Our finding that increasing frequency of papillary inflammation is strongly associated with 
scarring progression has consistently been reported by other studies,233 however, the 
relationship between chlamydial infection and scarring progression is less definitive.  
 
The first longitudinal study to try to investigate scarring progression was conducted by Dawson 
et al in Tunisia, starting in the late 1960’s. They examined a group of children and younger adults 
(n=213) on two occasions about 14 years apart; no tests for C. trachomatis infection were 
performed. TI (P3) was the strongest risk factor for developing severe scarring (RR=18), whilst 
TF had a weaker association (RR=2.8).269 Interestingly, there also appeared to be increased 
scarring risk associated with P2. 
 
West et al investigated the relationship between “constant severe trachoma” (TI diagnosed on 
more than half examinations) in a group of children (n=190) examined on four occasions during 
the baseline year and again at 7 years.270 Constant severe trachoma (TI) was associated with 
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increased risk of developing scarring by 7 years. TF alone was not associated with development 
of scarring.  
 
Only one study, by Wolle et al, has previously examined the relationship between C. trachomatis 
infection and the subsequent development of scarring in children.271 They reported a five-year 
cohort of Tanzanian children (n=189) that were examined on five occasions during the first 18 
months and again at 5 years. They found that incident scarring over the five years was associated 
with constant inflammation and/or constant C. trachomatis infection during the first 18 months 
(OR 5.74, 95%CI 2.39-13.8). However, the effects of infection and inflammation were not 
modelled independently of each other, possibly due to sample size limitations, therefore, the 
contribution from infection remained unclear. 
 
Burton et al found a strong association between progression of pre-existing scarring in adults 
and increasing episodes of papillary inflammation (P2/P3) in Ethiopia (n=585; OR 5.93, 95%CI 
3.31–10.6, p<0.0001) and Tanzania (n=577; OR 5.76, 95%CI 2.60–12.7, p<0.0001).260 The study 
examined and sampled participants on a 6-monthly basis for two years. Episodes of C. 
trachomatis infection were very infrequent, and they were not associated with disease 
progression. 
 
Our finding that C. trachomatis infection was marginally associated with incident scarring 
(before adjustment) but not progressive scarring suggests that chlamydial infection may be 
important in initiating the scarring disease process. However, once scarring is established, other 
factors driving TP are perhaps increasingly important in scarring progression. However, the 
analysis of progression of pre-existing scarring was limited by a smaller sample size.  
 
Conjunctival inflammation may be associated with other bacterial or viral infections, or with 
allergic conjunctivitis.68, 70. Several cross-sectional studies have found associations between non-
chlamydial ocular bacterial infections and active trachoma (TF/TP), conjunctival scarring, 
trichiasis/recurrent trichiasis and corneal scarring.3, 69, 245, 246, 272-274 A recent longitudinal study in 
452 Tanzanian adults found that ocular commensal and pathogenic non-chlamydial bacterial 
infections were more common in scarring progressors relative to non-progressors and that, after 
adjusting for other factors, ocular infections were marginally associated with 2-year scarring 
progression.248  
 
C. trachomatis infection might damage the barrier function or homeostasis of the conjunctival 
epithelium, such that external stimuli cause inflammation where they would not have done 
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otherwise. The expression of mucins has consistently been found to be dysregulated in active 
and scarring trachoma, supporting this hypothesis.23, 166 Long-term exposure to cooking smoke 
has also been linked to conjunctival inflammation,275 particularly affecting women, however, a 
Tanzanian longitudinal study did not find any association between exposure to cooking fires and 
incident scarring.276 Use of traditional medicines might also have a role, as could differences in 
diet or coinfections that lead to variation in host immune responses.  
 
Genetic or epigenetic factors might also contribute to differences in host inflammatory 
responses. Several studies have reported associations between genetic differences and risk of 
trachoma, including one genome-wide association study.101, 102, 277-281 Further detailed 
investigations of ocular microbial infections and host genetics are required to establish their 
roles in this disease.  
 
There was a marginal association between female sex and overall scarring progression. Further 
analysis revealed that female sex was associated with progression of pre-existing scarring but 
not with incident scarring. Female sex was also associated with C. trachomatis infection, TF and 
very marginally with TP. These findings are difficult to reconcile; there were associations 
between infection and incident (but not progressive) scarring, and between infection and 
female sex, whereas there was no association between infection and progressive scarring and 
only a marginal link between TP and female sex, yet female sex was associated with scarring 
progression but not incidence. Our findings also contrast those of previous longitudinal studies 
(reviewed in where female sex was associated with scarring incidence but not progression.233 
The numbers in our analysis of pre-existing scarring were relatively small, therefore a larger 
sample size might explain these findings. Nevertheless, overall females were at greater risk of 
scarring after adjustment for C. trachomatis infection and TP, suggesting that this effect was 
mediated by another mechanism.  
 
We found no association between age and scarring progression, which may be due to the limited 
age range of our study participants. Age was strongly associated with C. trachomatis infection, 
TF and TP, all of which were more common in younger participants, perhaps suggesting that 
some level of protective immunity develops. There was some evidence that in the oldest age 
group, scarring progressors had a higher chlamydial load relative to non-progressors, perhaps 
suggesting that their immunity was impaired, although this evidence was very weak.    
 
A strong association was seen between infection and TF or TP. In contrast to previous reports 
the association did not diminish after MDA,282 however, C. trachomatis infection was still 
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relatively common and the effect estimates had very wide confidence intervals. Infection 
prevalence recovered after MDA to near pre-MDA levels, whereas TP and TF prevalence 
remained low post-MDA. A study from central Tanzania has shown a significant reduction of 
both C. trachomatis infection and TF after each of Four annual rounds of MDA in children aged 
1 year and above, where MDA coverage was >80%.283 The overall TF prevalence was reduced 
from 27.3% at baseline to 9.4% in fourth year (one year after final MDA) and infection 
prevalence was reduced from >20% in 1-9-year olds to <10% in the fourth year. The recovery of 
infection prevalence in our study may be due to inadequate MDA coverage and interaction with 
untreated neighboring communities. Community members are mainly pastoralists and often 
away from their homes during the day. These results highlight the need for high MDA coverage 
to effectively bring C. trachomatis prevalence under control. However, the sustained reduction 
in TP prevalence may be promising in terms of reducing scarring risk. 
 
Conclusion 
 
Progressive scarring trachoma was strongly associated with papillary inflammation in this 
longitudinal study. C. trachomatis infection was no longer associated with scarring progression 
after adjustment for TP, suggesting that the effect of infection is mediated through TP, and   that 
other factors contributing to TP in addition to C. trachomatis infection are important 
determinants of disease progression. Further research is required to understand what these 
factors are; they might include other ocular or non-ocular infections, genetic variation in host 
immune responses or environmental factors. Females were at greater risk of C. trachomatis 
infection, clinical inflammation and scarring progression. The addition of TP to trachoma control 
programs might provide a more accurate indication of the need for future trichiasis 
interventions, which are likely to be needed for many years to come in this community.  
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9. Discussion 
 
 
This chapter discusses all the findings in this thesis, implications for 
trachoma control, study limitations and proposed areas for future work 
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9.1. Implications for Trachoma Control 
 
Rate of Scarring Progression 
Evidence of scarring progression was found even at this very early stage of life in children in this 
trachoma endemic setting. A total of 103 (23.0%) out of 448 children had scarring progression. 
Of those who progressed, 48 (10.7%) had incident scarring and 55 (12.3%) had progression of 
pre-existing scarring into more severe scarring. Incident and progressive scarring rates per year 
were 2.7% and 3.1%, respectively. These were broadly similar to the rates reported in earlier 
studies discussed below.260, 269-271, 284 The rate of progression in this community was lower than 
expected (23% versus 30%); that was probably because of our previous prediction which was 
relied on microscopic scarring detectable by IVCM which is not clinically apparent.   
 
One hundred and eleven children were not seen during the last two time-points. Of these, 63 
children were seen during time-points 13 to 15. We compared the baseline image to the latest 
(timepoint 13, 14 or 15) to determine whether they had progressed. We found a similar rate of 
scarring progression among these 63 individuals, compared to the overall scarring progression 
in children who had outcome data in the last two time-points. Fourteen (22.2%) out of 63 had 
scarring progression, in which 2 (3.2%) were new cases while 12 (19.0%) had progression of pre-
existing scarring. 
 
There are several studies that have reported incidence and progression of scarring from 
different geographical locations and ages. A 14 year study from Tunisia, which included children 
and younger adults (<30 years), found 17.1% (14/82) had incident severe scarring (developed 
from normal to scarring) with an incident scarring rate of 1.2% per year.269 Individuals reported 
to progress from pre-existing scarring into more severe scarring were 53.8% (70/130), with a 
progression rate of 3.8% per year. In the Tunisian study there were no observations made 
between the baseline and 14-year follow-up. No tests for infection were performed at any stage. 
 
Three longitudinal studies have been conducted in central Tanzania. The first, a 7 year study of 
children aged 1-7 years, found incident scarring developed in 29.2% (28/96) of those who were 
documented to have constant severe trachoma and in 9.6% (9/94) of children who did not have 
constant severe trachoma. Constant TI was diagnosed if children were found to have at least 3 
out of 4 examinations with TI. This gives incidence rates of 4.2%/year and 1.4%/year, 
respectively.270 In the second study of a cohort of children followed for five years, 17.4% 
(32/183) showed incident scarring with rate of 3.5%/year.271  
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Neither of these two studies from central Tanzania reported on progression of previous pre-
existing scarring. A third, separate 5 year study of all ages from central Tanzania examined both 
incident and progression of pre-existing scarring: 20.4% (75/367) had incident scarring, (rate of 
4.1%/year) and 47.1% (40/85) had progression of pre-existing scarring (rate of 9.4%/year).284  
 
Two similar studies each conducted for two years in adults from Ethiopia and Tanzania found 
respectively 23.1% (135/585) and 30.0% (173/577) of individuals progressed from pre-existing 
into more severe scarring, with yearly progression rates of 11.6% and 15.0%.260  
 
Collectively all the studies referred to above, including the data presented in this thesis, show 
an ongoing process of scarring progression in trachoma endemic community settings. The rates 
are consistently higher for the progression of pre-existing scarring, compared to the 
development of incident scarring. This suggests that, scarred/compromised tissues are easier to 
progress into severe than unscarred one.   
 
Scarring progression and active trachoma (TF/TP) and C. trachomatis infection 
In this cohort study we found only relatively weak evidence directly linking detection of C. 
trachomatis infection to scarring progression. In contrast, we found evidence of a strong 
association between increasing numbers of TP inflammatory episodes and the development of 
scarring.  
 
Previous cohort studies have had fewer, less frequent observations and fewer or no laboratory 
testing for C. trachomatis. However, a consistent pattern has emerged from these, that similarly 
links the development and progression of scarring to diffuse, papillary conjunctival inflammation 
characterised by P2 or P3 (TI / TP).  
 
In the Tunisian study TI was reported as the main predictor of scarring progression.269 
Interestingly the authors emphasised the importance of the P2 sign in addition to P3 as a 
precursor to development of scarring. TF and household density were also reported to associate 
with scarring progression, but their association was far weaker than TI. The study did not report 
association of sex or infection. 
 
As outlined above, the rate of scarring progression in the first study from central Tanzania was 
found to be strongly associated with constant TI, in which incident scarring was more than three 
times higher in the constant TI group than in the controls.270 Children were matched for age, sex 
and neighbourhood. In the two later studies from central Tanzania, incident scarring was 
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strongly associated with TI and moderately with age, female sex and TF in children.270, 271 None 
of these studies reported a clear association with scarring progression and C. trachomatis 
infection. The studies in Ethiopia and Tanzania in adults found strong association between 
scarring progression and P2/P3, but not chlamydial infection.260  
 
These studies all seem to point to TP / TI being the clinical correlate of the disease process that 
leads to scarring, rather than TF. One interpretation of this observation might be that in an 
environment in which many people are repeatedly exposed to C. trachomatis, whether or not 
they progress to develop scarring depends much more on how they react to the infection. If 
they react with a very severe inflammatory phenotype (TP/TI) they are at substantially increased 
risk of scarring, and it could be that this is determined by the immunogenetic background of the 
individual. Alternatively, other environmental (such as diet, allergy, dust) or non-chlamydial 
infectious factors causing TP/TI might contribute to driving the scarring process after initiation 
by C. trachomatis.  
 
We found a stronger association between TF and C. trachomatis infection than TP and infection.  
This difference might be because TF was mainly caused by C. trachomatis infection while TP can 
have other causes. At time-points 5 and 6 we observed a peak in the prevalence of TP in two of 
the three study villages which did not correlate with C. trachomatis infection. This TP may have 
been caused by another infection and further study is required to find out the cause, and 
subsequently, whether this can also contribute to driving scarring.    
 
Presence of scarring progression even at a young age, as observed, implies that many years later 
development of scarring complications will persist in this community or others even when 
infection was formerly brought under control. There is evidence from The Gambia in which C. 
trachomatis infection and active trachoma were reported to have been at very low levels for 
some years but there was ongoing incidence of trichiasis.285, 286 
 
Interestingly, progression of scarring was observed in some children who were never diagnosed 
as having either infection or any clinical signs of active trachoma throughout the four years of 
study. Previous studies which categorized children by age (0-4, 5-14 and ≥15 years) reported 
clinical signs of disease and infection in children 5 years and above that were resolved within 
three months.27-29 The age range of the present cohort study was between 6 and 10 years at 
baseline. This finding of progression of scarring in the absence of a single documented episode 
of infection or clinical sign throughout the study time is perhaps most likely due to the 
observation intervals. For cost and logistical reasons, the study reassessed the cohort at intervals 
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of three months. This gap between examinations may well be long enough for someone to be 
infected or develop clinical signs and then for these to fully resolve.  
 
An alternative explanation might be that scarring progression in individuals without 
documented infection or disease might be due to the background of high infection endemicity, 
during the years of their earlier childhood. Children who had been repeatedly exposed to 
infection before joining the cohort may already have initiated an ongoing immunological process 
that led to scarring progression.  
 
 
What is driving TP leading to scarring?  
Several studies have reported other ocular bacteria, rather than chlamydia, to be associated 
with trachomatous inflammation. The most commonly reported pathogenic and nonpathogenic 
bacteria found to be associated with active trachoma are Haemophilus influenzae, Haemophilus 
aegyptius, Streptococcus pneumoniae, Moraxella spp, Neisseria spp, Staphylococcus aureus, 
Streptococcus viridians, Corynebacterium xerosis, Staphylococcus pyogenes, Escherichia coli and 
diphtheroids.22, 239-241, 246 Recently Hu and colleagues have reported an association between 
trachomatous scarring progression and non-chlamydial ocular bacterial infection in adults.248 
Progression of scarring was assessed by comparing photographs of baseline and two years and 
microbial results were obtained through culture. An association was seen between progression 
of scarring and the presence of pathogens with or without commensal organisms, however, the 
association was no longer statistically significant when the analysis included only commensal 
microorganisms. This association between progression of scarring and other ocular bacteria 
increases confidence that other factors may contribute to TP, however, the relationship 
between conjunctival inflammatory signs and ocular bacteria was not evaluated in Hu et al’s 
study. However inversely, cross sectional study in central Tanzania in women aged between 18 
and 47 years found no association between scarring and non-chlamydial bacterial carriage.249    
 
The interaction between host and other bacterial communities (microbial dysbiosis), loss of 
epithelial homeostasis/integrity, host immunogenetics and epigenetics might also cause 
persistence of TP previously triggered by C. trachomatis. These factors are discussed in detail 
below in the ‘future work’ subsection. Furthermore, TP can be triggered by many other things 
such as allergy, viruses, smoke, dust and probably type of diet. 
 
Immune responses, clinical signs and C. trachomatis infection 
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Several animal model and human studies from other groups investigated associations between 
trachoma and host immune responses which support our main findings. Studies from chlamydial 
genital tract infection in mice found IL-22, IL-23 and IFNγ were associated with reduction of the 
infection pathogenesis and suggested pathogenic potential of IL-17;287, 288 these cytokines where 
also highly expressed in infected individuals in our study. In human studies IL-1β, TNFα and 
TGFβ1 were significantly associated with both C. trachomatis infection and  trachomatous 
disease;289, 290 these proinflammatory cytokines were similarly expressed in our participants. 
Generally our main findings are consistent with that published elsewhere.169, 287, 288, 290-296 The 
differential expression of cytokines associated with Th1 cell and NK cell pathways including IFN-
J, indoleamine-2,3-dioxgenase-1 (IDO1) and IL-12 were diminished after the clearance of 
infection, suggesting that their activity is tightly regulated in relation to infection. In contrast, 
Th17 associated cytokine genes were upregulated across all clinical signs and in response to 
infection. IFN-J induces IDO1, an enzyme which catabolizes tryptophan.297 Tryptophan is an 
amino acid required for ocular chlamydial replication, therefore this mechanism likely inhibits 
chlamydial growth.  
 
Studies in animal models found that both Th1 and Th17 cells were involved in clearance of C. 
trachomatis infections; however, they were also associated with pathogenic inflammatory 
disease.298 The role of Th17 associated mediators in the pathogenesis of ocular C. trachomatis 
infections is not fully understood, however, the same dual protective and pathogenic roles might 
also be active in humans, perhaps with different contributions during early and late stages of 
disease. Many studies in animal models reported protective behaviour of Th17 cytokines mostly 
in extracellular infections, but they are thought to have a pathological effect during 
Mycobacterium tuberculosis infection (discussed in the introduction).  However, when IL-17 is 
deficient in humans, such as in hyper-IgE syndrome with STAT3 gene mutations they are highly 
susceptible to a number of infections such as S. aureus, Streptococcus pneumoniae and C. 
albicans .299 Th17 cells are important in recruiting neutrophils to the site of infection, which clear 
infection but also cause significant tissue damage. Inflammation (TF/TP) was strongly associated 
with upregulation of antimicrobial peptides, chemokines, cytokines some EMT markers and 
matrix modifiers (with the exception of SPARCL1 which was strongly downregulated). 
Inflammation was also associated with downregulation of genes associated with cell survival 
and apoptosis (TNFRSF1A, TNFRSF1B, CD40, ALOX5 and DUOX2), and mucins (MUC5AC and 
MUC7). A previous study conducted in a neighboring area to this study site found that TF and TP 
in children were significantly associated with increased expression of S100A7, IL1-7A, CCL18, 
CXCL5, and CTGF.259  Another study from Gambia found higher expression of TNF-α, IL-1, IL-10 
and MMP-9 in children with active trachoma.164 Studies in adults from Ethiopia and Tanzania 
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found strong association between inflammation and increased expression of S100A7, IL-1B, IL-
17A, CXCL5, CTGF, CEACAM5, MMP-7, CD83 and reduced SPARCL1.260 Increased expression of 
TNF, IL-1β and MMP-9 was also associated with inflammation in adults following trichiasis 
surgery.300 These findings and those of this study show consistent upregulation of IL-17 even 
after clearance of infection. It is possible that Th17 cells and associated cytokines in the absence 
of C. trachomatis infection might be associated more with pathogenesis than protection.  
 
Increased expression of some EMT markers and reduced expression of MUC5AC and MUC7 may 
be associated with loss of epithelial homeostasis and barrier function, possibly due to the influx 
of immune cells.  The presence of macrophages and neutrophils likely contributes to the 
increased expression of MMPs. Initiation of the wound healing process possibly results in the 
reduced expression of SPARCL1, contributing to matrix remodeling, collagen deposition and 
subsequent conjunctival scarring. This gene expression data implies that inflammation (TP) is 
associated with an ongoing epithelial-derived innate inflammatory response, perhaps with some 
interaction with Th17 cells. A loss of epithelial homeostasis due to inflammatory damage and 
exposure to foreign antigens or microbes could promote a positive inflammatory feedback loop, 
sustaining chronic TP and leading to accumulating scar tissue. A similar profile of genes were 
expressed in both TP and TF, however, expression tended to be higher in TP probably because 
of increased immune cell recruitment to the conjunctiva, which was seen in our previous 
studies.259 However, IL-12β, IFN-J and TNF were consistently more expressed in TF than TP, 
cytokines which stimulate Th1 cell differentiation and proliferation from naïve CD4 T cells.  
 
Most frequently reported interleukins influencing allergic inflammatory reactions are IL-4 and 
IL-13 (cause a switch to IgE production by differentiating B cells and mast cell growth factors), 
IFN-J (inhibits switching and prevention of specific IgE production), IL-10 (inhibits the activity of 
IFN-J and allowing the original IL-4 to proceed in the IgE cascade) and Th2 differentiation 
factors.301 However, from this finding (excluding IFN-J) there was no direct evidence of host 
immune responses (gene expression) related with allergy associated with ocular inflammation. 
Studies in animal models found strong association between Th2 associated factors with 
conjunctival allergy.302-305 Contribution of allergy in trachoma complication is not clearly known.  
 
Impact of Azithromycin on Chlamydia infection, inflammation (TF and/or TP) and gene 
expression  
Prior to MDA treatment the prevalence of infection and clinical signs and host immune 
responses appeared to be relatively stable, suggesting there was a consistent rate of 
infection/re-infection in this community. Following MDA, TF, TP and C. trachomatis infection 
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prevalence were strongly reduced, which was reflected by a reduction in the expression of pro-
inflammatory cytokines and other genes associated with chlamydial disease three months later. 
Infection and clinical signs remained at a lower prevalence for most of the remaining study 
period, with some fluctuation. There was evident variation by village, with one village, 
Tingatinga, harbouring the majority of infection at later time-points.   
 
Azithromycin treatment reduces infection prevalence if coverage guidance is properly 
implemented. MDA coverage in this study was not particularly high: First MDA: 72.7% 
community-wide, increasing to 79.2% (355/448) when considering study participants with 
sufficient outcome data (retained in the analysis); Second MDA: 42.9% community-wide 
increasing to 83.5% (374) of study participants; Third MDA, 72.9% community-wide increasing 
to 76.8% (344) of study participants. Between baseline and the final time-point (18 months post 
third and last MDA) TF was reduced from 33.8% to 3.5%, TP from 19.6% to 6% and infection 
prevalence from 15.4% to 4.9%. Low MDA coverage village-wide and being surrounded by 
untreated communities with similar patterns of life might have significantly contributed to the 
observed disease and infection prevalences.  
 
Azithromycin was delivered by the field team under the supervision of the district eye 
coordinator. This was probably more effective because it was directly witnessed that the drug 
had been taken by the community members. However, this was not the case for tetracycline 
eye ointment which was given to the community members to be given to infants and pregnant 
women twice a day for six weeks by themselves. It was not practical for tetracycline eye 
ointment to be administered by our field team, therefore we are uncertain how good the 
adherence was, and might represent a source of reinfection in that community if was not 
properly applied. 
 
A study from central Tanzania showed a significant reduction of both C. trachomatis infection 
and TF after each of three annual rounds of MDA in children aged 1 year and above, where MDA 
coverage was >80%.283 The overall TF prevalence was reduced from 27.3% at baseline to 9.4% 
at the fourth year (one year after finishing MDA). Infection prevalence was reduced from >20% 
in 1-9-year old to <10% at the fourth year. Another study from the same area in Tanzania 
reported reductions in infection prevalence from 20.1% and 23.8% at baseline to 4% and 5% at 
36 months respectively, one year after the third round of MDA, in two separate cohorts. 
Likewise TF prevalence was reduced from 30.4% and 30.9% at baseline to 6.1% and 9% at 36 
months.306 No differences in prevalence were found between the cohorts, despite one achieving 
>90% coverage whereas the other received the standard 80%.  
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In The Gambia, at a time when trachoma was meso-endemic, Burton and co-authors showed a 
significant reduction of infection prevalence from 7% to 2% and active trachoma from 8% to 4%, 
17 months after finishing three years of MDA with a coverage of 83%.307 Studies from The 
Gambia and Tanzania found that communities with extensive contact with untreated 
populations and immigrants were strongly associated with re-emergence of infection.308, 309 
These studies illustrate that a sustained reduction in TF and infection prevalence can be 
achieved if a high MDA coverage is maintained with a wider geographical coverage.  
 
The MDA coverage achieved in this study was relatively low (WHO guidance requires no less 
than 80% MDA coverage of the total population), however, the reduction of infection, TF and 
TP prevalence was comparable to the other studies reported over a similar timescale, despite 
those studies reporting >80% coverage. Government-administered MDA was provided to 
Tingatinga in 2015, which likely contributed to the overall reduction in disease. We were unable 
to achieve high coverage due to several reasons including individuals being absent in the village 
during the day (due to taking care of their livestock away from home) and some refused due to 
cultural beliefs or bad personal history of MDA. Due to budgetary reason and study design, only 
the three study villages were offered MDA as the rest of the district was not, therefore there 
was high risk of re-infection due to contact with neighbouring communities. 
 
Other findings have reported variation of azithromycin treatment effectiveness in different 
disease endemicities. A study in children under 10 years C. trachomatis was found to cluster by 
household after first and second rounds of MDA but was not seen after the third round.   
Infection was brought under  control, however, active trachoma did not cluster at any round of 
MDA.310 Hyperendemic areas with an active trachoma prevalence >50% have been reported to 
require over 7 annual rounds of MDA to bring the prevalence down to 5%,311 similarly, a study 
from the same (hyperendemic) area, 2 rounds of annual MDA was administered with an average 
coverage of >80%, however, an impact survey three years after the last MDA  found  trachoma 
was not eliminated.312 In low trachoma endemic setting both one and three annual rounds of 
azithromycin MDA with a coverage of >80% at baseline, 1st and 2nd years were enough to bring 
down both TF and C. trachomatis infection prevalence in children below 10 years from 6.5% and 
0.8% respectively at the baseline to 2.8% and 0.5% after 36 months.313 Low trachoma prevalence 
communities require only a few rounds of MDA, whereas high prevalence communities need 
several more rounds of MDA to bring the disease under control. In this cohort study, three 
annual MDAs were sufficient to bring TF from >30% to <5%. 
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MDA resulted in a reduction of pro-inflammatory gene expression responses that was evident 
three months post treatment, however, this effect was mostly lost at six months post MDA. The 
effect was observed in individuals without infection or inflammatory disease, and even in 
individuals that did not receive treatment, though the effect size was less. These results suggest 
that azithromycin may act to reduce pro-inflammatory gene expression through some or all of 
the following mechanisms; through killing C. trachomatis and possibly other species, through 
directly modulating pro-inflammatory signalling pathways, and/or by reducing transmission and 
exposure to C. trachomatis and other species.  
 
Azithromycin has a long half-life in the tissues, though previous findings from several diseases 
have reported uncertainty of azithromycin’s effects on immunomodulation after six months.314, 
315 Direct immunomodulatory effects of azithromycin have previously been reported in the 
absence of disease. In 12 healthy human volunteers who received azithromycin (500mg/day) for 
3 days, blood samples were taken 1 hour (h) before treatment and then 2.5h, 24h and 28 days 
after treatment.316 Neutrophil activity was strongly reduced shown by a decrease in azurophilic 
granule enzyme activities in cells as azithromycin concentration increased in serum and 
neutrophils. This was associated with a reduction in IL-6 concentration in the serum, delayed 
oxidative burst and an increase in apoptosis of neutrophils. 
 
Azithromycin immunomodulation occurs through interaction with structural cells such as 
epithelial or endothelial cells, smooth muscle cells or fibroblasts, and leukocytes.317 In these 
immune and non-immune cells azithromycin interacts with phospholipids and Erk1/2, which 
modulate transcription factors AP-1 and NFκB, resulting in reduced production of pro-
inflammatory cytokines in the acute phase, promoting the resolution of chronic inflammation in 
the late phase, and reduction of mucin (MUC5AC) production in epithelial cells.317-320 
Azithromycin has also been reported to reduce all-cause childhood mortality in <5 year olds, 
though the mechanism is unclear.134, 321 
 
Many studies reported an anti-inflammatory effect of MDA on gene expression (discussed in 
chapter 7). This might be beneficial in reducing the TP that drives scarring progression, 
independently of its role in reducing C. trachomatis infection. Wolle and colleagues offered 
azithromycin MDA twice, annually to the community, however, there was no difference in 
progression of scarring between those who received MDA once and those who received it 
twice.284 Currently there is no therapy to halt conjunctival scarring progression and the potential 
benefits of azithromycin warrant further investigation.   
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Sex and Age 
Trachoma is strongly associated with female sex and increasing age. According to a recent WHO 
report, females requiring trichiasis surgery outnumber males by four times.12 In this study, 
despite the early age group we found a significant increase in scarring progression in females 
relative to males. This might be caused by more frequent exposure of females to C. trachomatis, 
as they spend more time at home looking after younger siblings (who are most likely to be 
infected), while males are more likely to spend time taking care of their livestock away from 
home.  
 
The natural history of trachoma is strongly associated with age. Infection and active trachoma 
(TF/TP) are commonly diagnosed during childhood, with very few cases of scarring and almost 
no trichiasis cases. Some degree of natural immunity is thought to develop, leading to little 
infection/TF detected in adults. The most common features during adulthood are TP, scarring, 
trichiasis and corneal scarring. This highlights the difference again between TF and TP, with TF 
mostly associated with C. trachomatis infection. The factors causing TP in adults are not known.  
 
Summarizing Implications of this work for trachoma control 
In this trachoma endemic community progression of scarring was apparent at a very early age. 
Progression of scarring complications will therefore persist for many years in this community as 
this cohort and their peers age. Even after C. trachomatis is controlled in this community, 
trichiasis surveillance and interventions will be required for many years beyond GET2020. 
 
A strong association was found between TF and C. trachomatous infection; this was somewhat 
stronger than the association between TP and infection. Azithromycin MDA was followed by a 
reduction in both TF and TP. However, infection started to increase again, probably due to low 
MDA coverage (discussed in chapter 7). In agreement with reported literature (Chapter 4), the 
reduction in TF prevalence lagged behind the reduction in C. trachomatis infection prevalence 
after the first round of MDA. Therefore, as a proxy marker for C. trachomatis infection 
prevalence in the community, TF is a better clinical sign to use than TP, although the relationship 
is weakened after MDA with TF overestimating infection prevalence. A cost-effective and simple 
test for C. trachomatis infection in communities for use in trachoma control programs remains 
desirable.  
 
The strong association between TP and scarring progression and the weak associations between 
TF and C. trachomatis infection with scarring progression raise important questions for 
trachoma surveillance and predicting future disease burden. The district prevalence of TF alone 
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is unlikely to provide reliable estimates of future need for trichiasis intervention, whereas TP 
alone is poorly specific for trachoma. The use of combined TF and TP prevalence in trachoma 
control programs might be more suitable for predicting future need for trichiasis interventions.  
 
In addition to C. trachomatis clearance azithromycin MDA reduces inflammation through its 
immunomodulatory activities and is used to treat other chronic inflammatory diseases. Given 
the strong association between TP and scarring progression, azithromycin treatment may be 
beneficial in reducing risk of scarring progression.  
 
Among the challenges encountered in this community during our visits was the implementation 
of ‘FE’ from SAFE strategy. Some of community members responded negatively following our 
campaign on face washing and improving environmental hygiene. In the future another 
approach should be implemented, such as conducting a short training of more educated 
individuals among the community members about the nature of trachoma, mode of 
transmission and its control, and to ask them to share with their neighbours. Furthermore, to 
conduct several education meetings with community leaders discussing trachoma so they can 
discuss with their community members during their formal village meetings. This could be easy 
to convey the message to the community through their leaders as they are already built trust in 
them. Printing big coloured pictures showing different stages of clinical trachoma may help to 
in the explanation. 
 
Limitations of this work  
This work has several limitations. The age group of 6-10 years was chosen as it was expected to 
be the age group in which we were most likely to detect incident and progressive scarring during 
the four years of study. However, selection of only this age group might have led us to miss some 
important information as we did not know the participant’s clinical and infection histories prior 
to commencing the study.  
 
Progression of trachoma occurs throughout an individual’s life-time, thus, the four year duration 
of this study is relatively limited and might have led to missing some important features of 
scarring progression and its relation to clinical signs and infection. To further investigate incident 
scarring and the role of C. trachomatis infection in initiating trachoma it might be necessary to 
study a younger age group.  
 
Previous findings have reported the clearance of infection and resolution of active trachoma 
clinical signs within three months, especially for the children aged 5 years and above, hence the 
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three-month interval used in this study might have also led us to miss some intermediate 
infection and clinical signs.  
 
We did not record environmental and behavioural variables in this study. These risk factors 
might have important roles in the development of TP and scarring and might further explain the 
differences between males and females.   
 
A few genes did not amplify in some samples during qPCR and were therefore not included in 
the analysis. This might be due to several reasons such as poor choice of primer/probe sets for 
this population, perhaps due to genetic variation within the population, or low expression of the 
target genes. We did not examine whether they were associated with infection or clinical signs 
in a binary (on/off) capacity.  
 
The delta delta CT (2-ΔΔCT) method has been extensively used for relative quantification of qPCR 
data analysis.  However, this method does not consider the different amplification efficiency of 
various primer pairs, different uses of probes, presence of PCR inhibitors or enhancers and 
enzymes as it assumes that the amplification efficiency is 100%. 2-ΔΔCT subtracts an unknown 
background automatically. This may result in generating inaccurate data (and probably 
misleading interpretation) hence may not be the most suitable calculation method. An 
alternative approach was reported by Rao et al, Pfaffi et al, and others, in which improved 
relative quantification of nucleic acid (Individual Efficiency Corrected Calculation)  method 
overcomes all the mentioned weakness of 2-ΔΔCT322-324. In this method, PCR efficiency for each 
individual sample is considered through serial dilution of estimated initial nucleic acid.  Note 
that, qPCR data reported here are MIQE compliant (The protocols used in our analyses are 
accessible on protocols.io website using the accession number 
https://dx.doi.org/10.17504/protocols.io.zyhf7t6). 
 
 
9.2. Future Work 
 
This study has reported on the association between gene expression profiles and presence of 
clinical signs of trachoma in children at the baseline time-point of this cohort study. It would be 
desirable to investigate whether any of these genes are also associated with progression of 
scarring in the longitudinal dataset. This would help to improve our understanding of the 
molecular immunopathogenic processes that lead to scarring. qPCR data for the expression 
profile of 46 genes has already been generated for the first five time-points and time-points 7, 
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9, 11, 13, 15 and 17. It was not within the scope of this thesis to present or analyse these data.  
Identifying genes associated with resistance and susceptibility to TP/scarring disease would 
increase our understanding of the immunopathogenesis of trachoma and might inform C. 
trachomatis vaccine design.  
 
It was not feasible to present further data on the immunomodulatory effect of MDA in this 
cohort after the second and third annual rounds. It would also be of interest to examine whether 
study participants who received MDA were less likely to develop TP and scarring than their 
counterparts who did not receive treatment; it was not possible to analyse these data and to be 
included in this thesis.  
 
Genetic variation in host immune responses might explain why some individuals appear to be 
resistant to disease while others are highly susceptible (for example some individuals respond 
with more TP while others do not). There is some evidence that variation in host single 
nucleotide polymorphisms (SNP) have been found between scarring cases and controls. Several 
previous studies, mostly from The Gambia, used candidate gene approaches and suggested that 
scarring and/or trichiasis were associated with a number of HLA alleles, cytokine genes, 
transcription factors and receptors.102, 277-281, 325-328 A recent genome wide association study from 
The Gambia found 27 SNPs which were strongly associated with scarring in adults; however, 
these did not reach genome wide significance.101 These studies were case-control and in all age 
groups, and none assessed the association between these SNPs and longitudinal progression of 
scarring. It was not possible to investigate the association between genetic variation and 
development of disease sequalae in this thesis, however, the samples might be valuable for 
future studies to investigate this question.  
 
During infection, C. trachomatis might cause changes to host gene expression that are heritable 
through cell division (known as epigenetics), resulting in the triggering of chronic inflammation 
which persists even once infection has been cleared.102 C. trachomatis has a protein nuclear 
effector that is a histone methylase which  might cause chromatin changes to host cells.329 C. 
trachomatis was reported to induce EMT in cell lines, which was associated with a reduction in 
E-cadherin through changing DNA methylation status of the E-cadherin promoter and a 
concurrent increase in the expression of fibronectin and α-SMA, resulting in changes from 
epithelial to mesenchymal phenotype.330 The authors suggested that this process might be an 
early event in the initiation of the scarring process, however, this study was based on laboratory 
cell lines. Further investigation is required to understand the role of epigenetics in chronic 
trachomatous inflammation and scarring.    
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In this study we only tested the expression of selected genes. Whether differences in gene 
expression persisted into differences in protein levels is not known and would require further 
examination, as post-transcriptional regulation by miRNA or other mechanisms might have 
downstream effects as previously reported.331-333  
 
It was outside the scope of this project to investigate the role of non-chlamydial infections in 
driving inflammation. Several studies have reported differences in non-chlamydial infections in 
trachoma cases and controls. It is unclear however, if these microbes cause disease 
pathogenesis or whether they are just bystanders, expanding to fill an altered (diseased) 
mucosal environment. Further questions include whether only pathogenic species promote TP, 
or whether commensal organisms can become pathogenic in certain circumstances, and 
whether they initiate the process or they are secondary infections. Only one longitudinal study 
has investigated the association between non-chlamydial infections and progression of 
trachomatous scarring in adults.248 This sample set will have great value for investigating the 
role of non-chlamydial infections in the incidence and progression of scarring in children.  
 
An imbalance of normal conjunctival microbial communities (dysbiosis) might be initiated by 
infection with C. trachomatis infection. Large-scale studies have been conducted in the intestine 
and have presented associations between changes of microbial composition and pathogenesis 
of bowel disease.334 There has been some recent research in healthy and diseased eyes on 
polymicrobial communities colonizing the conjunctival epithelia, which have suggested that 
certain species have a protective immunological role in preventing colonization with pathogenic 
species.235, 236 272 Thus far there is just a single conjunctival microbiome study using culture 
independent 16S-deep sequencing in adults with trachomatous scarring versus  controls. This 
study found a dysbiosis in the  conjunctival microbiome that occurred in trachomatous scarring  
increasing with trachomatous trichiasis.272 There were no changes in richness and diversity in 
children with TF compared endemic healthy controls. Changes following C. trachomatis infection 
or disturbed ocular homeostasis resulting from inflammation might lead to microbial dysbiosis 
and outgrowth of pathogens. Recently a case-control study of conjunctival surface infection in 
children and adults with trachoma in Sudan found presence association between chlamydia-like 
organisms and old age but not with clinical signs.335 Longitudinal investigation of microbial 
communities in these samples would enhance our understanding of the pathogenesis of 
trachoma.  
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The immunological determinants of protective immunity and immunopathology in 
trachoma 
KCMC / LSHTM Trachoma Research Programme 
London School of Hygiene & Tropical Medicine 
 
What is this study about? 
Trachoma is one of the main causes of blindness in Tanzania. It starts in childhood when children 
get redness and soreness under their eyelids, caused by infection with a bacteria called 
chlamydia. As people get older they may develop eyelid scarring causing the eyelashes to turn 
inwards and rub on the eyeball. This is called trichiasis. This can cause the clear part of the eye 
to become white leading to blindness and the trichiasis is often painful. Currently, this disease 
process is only poorly understood and the treatments for it are only partially effective. We 
believe that the reason some people develop a problem from trachoma is because of the nature 
of the way their bodies defence systems respond to this infection. In the long term it is hoped 
that it will be possible to develop a vaccine for this disease. However, before that can happen 
we need to find out much more about the way the body fights the infection. We would like to 
follow a group of 650 children aged 6 to 10 years. They would be assessed every three months 
for  
 
Whose help do we need? 
We need the help of some about 650 children of families living in the community.  
 
What will we ask you to do? 
We would conduct a census of the village. We will come to visit you at your home. If you agree 
to participate we will ask you several questions about yourself, such as your age and where you 
live. The children aged 6-10 years would be recruited into a four year study in which we would 
come back to see you every three months. We will examine the children’s eyes and collect one 
swab sample by gently rubbing it on the surface of the eye. We would take a photograph of the 
eyes on each occasion. At the beginning and again at two and four years we would use a special 
microscope (“camera”) to take a photograph of the very fine detail of the surface of the eye. 
 
Every year, in partnership with the regional trachoma control programme the whole community 
would be offered antibiotic treatment to control the infection, according to the Tanzanian 
National guidelines. 
 
What benefits are there to taking part in the study? 
It is only poorly understood how this disease causes blindness. You will be helping us to answer 
this question. 
We will check the general health of your eyes and refer you to receive appropriate eye care 
through the Eye Clinic in Moshi or an alternative clinic if it is more convenient.  
 
Are there any risks caused by taking part in the study? 
There is no known risk from taking swabs samples, and has been done in many studies 
conducted in Tanzania and elsewhere. Azithromycin is a very safe medicine which is widely used 
in Tanzania and elsewhere for trachoma control, as part of the National Trachoma Control 
Programme’s work to stop blindness from this disease. 
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What tests will we do on the sample? 
The eye swab samples will be tested in various ways to try to help improve the understanding 
of trachoma. Samples will be tested in laboratories in Moshi and London. This will involve tests 
for chlamydial infection. We will also study the human body’s response to the infection to try to 
understand better how it fights the infection and how the scarring problems develop.  
 
 
What will happen to the records and photos we keep about your eye? 
All the information we collect will be kept confidential. It will be kept securely and only the 
people organising the study will have access to it.  
 
Do I have to take part in this study? 
You do not have to take part in this study, it is entirely voluntary. 
 
Who is doing this study? 
This project is a collaboration between the KCMC / LSHTM Trachoma Research Project,  
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK and 
Kilimanjaro Centre for Community Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, 
Tanzania. The study will be coordinated in Moshi by Dr Matthew Burton. The examinations will 
be conducted by a small team of eye nurses or an eye doctor.  
If you have any questions please ask us: 
 
Athumani Mchana Ramadhani 
Patrick Massae 
KCMC / LSHTM Trachoma Research Project,  
KCMC Hospital, Moshi, Tanzania. 
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Participant Consent Form 
 
The immunological determinants of protective immunity and immunopathology in 
trachoma 
KCMC / LSHTM Trachoma Research Programme 
London School of Hygiene & Tropical Medicine 
 
Name of Child: ……………………………………………………………………. 
Study Reference Number:      
 
 
I …………………………………………………… (Name of Parent / Guardian) have read / had explained to 
me the information about the research study. I understand what will be involved in taking part 
in the study.  
 
 
.………….…………………………….(field worker)  has answered all my questions about the study. 
I agree to the above named child to be enrolled in this study. 
 
 
Signed……………………………………..       Date…………………….. 
 
Name:……………………………….     Relationship:………………………………. 
 
 
I have explained the purpose of the study to the above subject and I am satisfied that he/she 
willingly agrees to participate 
 
 
Signed……………………………………..       Date…………………….. 
 
Name:………………………………. 
 
In the event that the patient can not read the above information, an additional witness is 
required: 
I have witnessed the explanation and informed consent to this study of above named patient 
 
 
Signed……………………………………..       Date…………………….. 
 
Name:………………………………. 
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Appendix 2: Clinical Assessment and Photography Protocol 
 
Clinical assessment will be performed at baseline and at every three months after that. This will 
involve the following: 
1. Examination of conjunctiva and eyelids and grading signs as below 
2. Photograph 
3. Swabs 
 
Initially on arriving in a Boma, ask for all the children on the enumeration list.  
Identify the individual child from the enumeration list. Fill in the card with name and number on 
it.  
Enter the number and date of examination into the database on the field laptop computer. 
 
4.1. Examination: 
Patrick Massae and Aiweda Malisa performed all the examinations and grade using the WHO 
“FPC” system.   
 
Only the left eye to be examined, photographed and swabbed.  
Use 2.5x loupe and bright torch, under the Land Rover canopy.  
Wear a fresh pair of non-sterile latex examination gloves. These will be changed between each 
examination, to minimise the risk of cross contamination.    
 
Instill one or two drops of proxymetacaine anaesthetic into the eye conjunctiva. If the dropper 
touches skin / conjunctiva then discard it. 
 
Step 1: Grading Trichiasis/Entropion and the Cornea:   
Inspect the left eye (without touching the eyelids) for trichiasis. Then examine the cornea for 
signs of scarring. Grade T and C according to the following system. Enter the data into the access 
database. 
 
a. Trichiasis and/or entropion (T): 
T/E 0 No trichiasis and/or entropion. 
T/E 1 Lashes deviated towards the eye, but not touching the globe. 
T/E 2 Lashes touching the globe but not rubbing the cornea. 
T/E 3 Lashes constantly rubbing the cornea. 
 
b. Corneal scarring (C): 
C 0 Absent 
C 1 Minimal scarring or opacity but not involving the visual axis, and with clear 
central cornea. 
C 2 Moderate scarring or opacity involving the visual axis, with the papillary margin 
visible through the opacity. 
C 3 Severe central scarring or opacity with the papillary margin not visible through 
the opacity. 
 
 
Step 2: Lid Eversion and Tarsal Plate grading: 
The left upper lid will be everted and the conjunctival surface examined and graded as follows. 
Record the data in the database. 
 
b. Upper Tarsal Follicles (F): 
F 0 No follicles. 
F 1 Follicles present, but no more than 5 in zones 2 and 3 together.   (1-4) 
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F 2 More than 5 follicles in zones 2 and 3 together, but less than 5 in zone 3.   (5-9) 
F 3 Five or more follicles in each of the three zones.   (10+) 
 
c. Upper tarsal papillary hypertrophy and diffuse inflammation (P): 
P 0 Absent: normal appearance 
P 1 Minimal: individual vascular tufts (papillae) prominent, but deep 
subconjunctival vessels on the tarsus not obscured.  
P 2 Moderate: more prominent papillae, and normal vessels appear hazy, even 
when seen by the naked eye. 
P 3 Pronounced: conjunctiva thickened and opaque, normal vessels on the tarsus 
are hidden over more than half of the surface. 
d. Conjunctival scarring (S): 
S 0 No scarring on the conjunctiva 
S 1 Mild: fine scattered scars on the upper tarsal conjunctiva, or scars on other parts 
of the conjunctiva. 
S 2 Moderate: more severe scarring but without shortening or distortion of the 
upper tarsus. 
S 3 Severe: scarring with distortion of the upper tarsus. 
 
 
Step 3 – Photography of the tarsal conjunctival:  
The tarsal conjunctiva on the left upper lid will be photographed. 
 
Check camera settings: 
1. Put the battery and memory card in. 
2. Turn camera on. 
3. Press “Info” button. On the display: 
1) Check the battery is fully charged. 
2) Check the memory card has enough photos left. You should have space for at least 500 
photos. 
4. Check that the lens is properly and securely attached to the camera. 
5. Set the camera to manual focus: (M) on the lens 
6. Set camera to “full” on the lens 
7. Set the lens to 1:1 (0.314) 
8. Set the camera to aperture (A) on the dial 
9. Press “Info” button. Using the display, set the F-stop to F57 by turning the “wind on” dial. 
-  Sometimes, it won’t let you go to F57. One reason for this may be because the lens is not 
at 1:1. 
10. Press “menu” button. Using arrows, move up and down and through the menu options. 
- By pressing the left arrow, you can move up and down through the different menus. 
- Once in the menu you want (e.g. set-up menu), press the right arrow to go to setting 
you want (e.g. ISO sensitivity, image quality, or image size). 
a.) ISO sensitivity: Turn camera on → Press “menu” → Arrow left → Go to set-up 
menu → Go down to ISO sensitivity → arrow to right → arrow down to choose 
400 → OK 
b.) Image quality: In set-up menu, go down to image quality → arrow to right → 
arrow down to choose JPEG normal → OK 
c.) Resolution: In set-up menu, go down to image size → arrow to right → arrow 
down to choose large → OK 
 
When taking the photo: 
Materials: camera, batteries, photo logbook, labels. 
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This is a combined effort between the photographer and examiner. The photographer can ask 
the grader to help improve the photo, and vice versa. 
a) Focus in on the child’s eye  
b) Try and aim for the following for the photo: 
a.) Make sure the eye is centred 
b.) Try and avoid getting glare on the photo 
c.) Try and avoid gloved finger – if the grader’s finger is covering the lid, ask them to pull it 
back 
d.) Make sure the grader hasn’t everted the lid too aggressively to not get blanching. Tell 
the grader to release some pressure if this is the case. 
e.) Make sure the cornea is not showing. Ask the grader to re-evert to correct this. 
f.) Ask the grader to avoid “folding” the lid. 
c) Take one photo of the left eye.  
d) Check the quality of the photo. Check that the lid appears  
a) well everted  
b) not “blanched”  
c) in focus 
d) well centred in the frame 
e) filling the frame 
e) If you think the photo isn’t good, take another. 
f) Record the DSC photo number in the Database. 
 
Step 4 – Conjunctival Swabs: 
Assistant to open will open the swab packet carefully so not to touch the end of the stick, and 
will hold it so that Patrick can take one of the swabs from the packet. 
 
Patrick will then swab (sterile Dacron Polyester tipped swabs) the left upper tarsal conjunctiva 
with two swabs, one after the other. 
1. RNA swab – CR♯-♯♯♯ 
2. DNA swab – CD♯-♯♯♯ 
 
RNA swab – CR♯-♯♯♯ 
a. Sweep swab horizontally four times with a quarter turn of swab after each pass. 
b. Place swab into RNAlater tube, break end off the swab and seal tube. The end will be 
broken off without touching any part of the swab that is in the tube 
c. Label tube 
d. Check labelling is correct 
e. Record swab number in the database. 
f. Place tube in cool box 
g. On return to Moshi place tube into fridge over night. 
h. Place in -80qC freezer the following morning. 
 
DNA swab – CD♯-♯♯♯ 
a. Sweep swab horizontally four times with a quarter turn of swab after each pass. 
b. Place swab into RNAlater tube, break end off the swab and seal tube. The end will be 
broken off without touching any part of the swab that is in the tube 
c. Label tube 
d. Check labelling is correct 
e. Record swab number in the database. 
f. Place tube in cool box 
g. On return to Moshi place tube immediately into -80qC freezer. 
 
Step 5 - Control Swabs 
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After every 50 subjects collect a pair of air control swabs. 
To do this: 
a. Collect air swabs under the examination canopy (same place as all examinations) 
b. put on fresh gloves. 
c. open swab packet. 
d. hold swabs in the air in front of you for 15 seconds. 
e. Place one swab in a tube containing RNA later and the second in a dry tube. 
f. Label tubes with a sequential number indicating control swab 1, 2, 3, etc. 
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Appendix 3: DNA/RNA Extraction Protocol 
 
RNA/DNA Purification Kit (Norgen)-Aimed to extract both genomic DNA and total RNA 
Kit storage 
Store proteinase K at -200C 
Other reagents have to be stored at room temperature 
Note; unopened reagents are stable for a year 
 
Precautions 
Please wear gloves, Lab coat and goggle during work or visit at www.norgenbiotek.com for 
further details 
 
Reagents and equipment 
Microcentrifuge 
Pipettes 
96 - 100 % ethanol 
Molecular biology grade water (Milli-Q® water) 
 
Preparation of working reagents 
Note; label on the bottle indicating that ethanol has added 
RNA washing solution; 
Add 50 mL of 96 – 100% ethanol for a final volume of 72 mL 
 
gDNA washing solution I; 
Add 20 mL of 95 – 100% ethanol for a final volume of 30 mL 
 
gDNA washing solution II; 
Add 15 mL of 95 – 100% ethanol for a final volume of 30 mL  
 
A. Cells lysis 
a. Transfer the swab samples with RNA later solution into nuclease free 2ml tubes 
b. Add 300 µl of the LYSIS solution into 2ml tube 
c. Vortex for 15-20 seconds and ensure the entire swabs part is in fluid  
d. Squeeze the swabs against the wall of tube to express as much of the fluid out of the 
swab back into the tube 
e. Discard the swabs 
 
B. Genomic DNA purification 
1. Binding DNA to gDNA purification column 
a) Add up to about 300µl of the lysate in the column 
b) Centrifuge at 14,000 x g (~14,000 RPM) for 1 minute 
c) Retain the flowthrough for RNA purification  
d) Reassemble DNA Purification spin Column to collection tubes 
e) Store the DNA purification spin column on ice for DNA extraction 
 
C. Total RNA Purification 
Note; It is important to work quickly when purifying RNA. 
 
2. Binding RNA to column 
a) Add 180µl of 96-100 % Ethanol in the RNA flowthrough from Step 1c,  
b) Mix by pipetting  
c) Assemble an RNA Purification Column with collection tubes. 
d) Add up to about 480µl of lysate with ethanol onto the column 
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e) Centrifuge at 14,000 x g (~14,000 RPM) for 1 minute. 
f) Discard the flowthrough  
g) Reassemble an RNA Purification Column to collection tubes 
 
3.  RNA Wash 
a) Add 400µl of RNA wash solution to the column 
b) Centrifuge at 14,000 x g (~14,000 RPM) for 1 minute 
c) Discard the flowthrough 
d) Reassemble RNA Purification Column to collection tubes 
e) Repeat the procedures above (a-d) 
f) Again repeat the procedures above (a-d) 
g) Spin the column at 14,000 x g (~14,000 RPM) for 2 minutes to thoroughly dry the resin 
h) Discard the collection tube 
 
4. RNA Elution 
a) Place the column into a fresh 1.7 ml Elution tube provided with the kit. 
b) Add 50µl of RNA Elution Solution to the column. 
c) Centrifuge for 2 minutes at 200 x g,  
d) Then centrifuge for 1 minute at 14,000 x g (~14,000 RPM). 
 
5. Store purified RNA samples at -200C for few days or at -700C for long term storage 
 
6. Genomic DNA Wash from DNA purification spin column (from 1e above) 
a) Add 500µl of gDNA Wash Solution I to the column  
b) Centrifuge at 14,000 x g (~14,000 RPM) for 1 minute.  
c) Discard the flowthrough. 
d) Add 500µl of gDNA Wash Solution II to the column 
e) Centrifuge at 14,000 x g (~14,000 RPM) for 1 minute.  
f) Discard the flowthrough. 
g) Spin the column at 14,000 x g (~14,000 RPM) for 2 minutes to thoroughly dry the 
resin.  
h) Discard the collection tube. 
 
7. Genomic DNA Elution 
a) Place the column into a fresh 1.7 ml Elution tube provided with the kit. 
b) Add 50 µl of gDNA Elution Buffer to the column. 
c) Centrifuge for 2 minutes at 200 x g (~2,000 RPM),  
d) Then centrifuge for 1 minute at 14,000 x g (~14,000 RPM). 
 
8. Store purified DNA at 40C for short time or at -200C for long term storage 
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Appendix 4: Chlamydia trachomatis Detection Protocol 
 
(A) Droplet Digital PCR 
 
Chlamydia Research programme 
 Summary 
This protocol describes a method for droplet digital PCR of using the Biorad dx100 
instrument PCR products should be 22 PL, from which a 20 PL reaction will be used for 
droplet generation. The assay detects either the chlamydial plasmid or the chlamydial 
OMCB gene. Both implementations use the 30 kDa subunit of H.s. RNAseP gene as the 
endogenous control 
 
Molecular targets 
Endogenous control  
 gi|13937783|gb|BC006991.1|     Homo sapiens ribonuclease P/MRP 30kDa subunit, 
*Forward (HURNASE-P-F)   5’AGA TTT GGA CCT GCG AGC G 3’ 
*Reverse (HURNASE-P-R)   5’GAG CGG CTG TCT CCA CAA GT 3’ 
^Probe (HURNASE_HEX_BHQ1)  5’FAM-TTC TGA CCT GAA GGC TCT GCG CG-BHQ1-3’ 
 AMPLICON and priming sites 
 
agatttggacctgcgagcgggttctgacctgaaggctctgcgcggacttgtggagacagccgctc 
 
TARGET ONE : Chlamydia Trachomatis cryptic plasmid pLGV440  (X06707; SV 3; circular; genomic 
DNA; STD; PRO; 7500 BP.) 
*Forward (Ct-Plasmid-F)  5’cagcttgtagtcctgcttgagaga3’ 
*Reverse (Ct-Plasmid-R)  5’caagagtacatcggtcaacgaaga3’ 
^Probe (Ct-plasmid-FAM-BHQ1)  5’HEX-ccccaccatttttccggagcga-BHQ1-3’ 
AMPLICON and priming sites 
 
cagcttgtagtcctgcttgagagaacgtgcgggcgatttgccttaaccccaccatttttccggagcgagttacgaagacaaaacctctt 
cgttgaccgatgtactcttg 
 
TARGET TWO : Chlamydia Trachomatis (Serovar A) OMCB gene. 
*Forward (Ct-OMCB-F)  5’gacaccaaagcgaaagacaacac3’ 
*Reverse (Ct-OMCB-R)  5’actcatgaaccggagcaacct3’ 
^Probe (Ct-OMCB-HEX-BHQ1) 5’FAM-aagcaaaaaagcaagaaaaaaccacagcaaagag-BHQ1-3’ 
AMPLICON and priming sites 
 
gacaccaaagcgaaagacaacacttctcataaaagcaaaaaagcaagaaaaaaccacagcaaagagactcccgtagaccgtaaag
aggttgctccggttcatgagt 
 
Preparation of primers and probes 
 
ALL STOCK SOLUTIONS should be at 100 μM 
Primer/probe supermix A (CtPLASMID/HURNASEp) 
2 μM Human RNAse P gene primers and probes 
2 μM Chlamydia plasmid primers and probes 
 
NOTE: This can be scaled for smaller volumes 
  
 To prepare 1100 μL (enough for 500 reactions plus 10%) 
      volume 
 100 μM HURNASE-P-F   22 μL  
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 100 μM HURNASE-P-R   22 μL 
 100 μM HURNASE_HEX_BHQ1               22 μL 
 100 μM Ct-Plasmid-F   22 μL 
 100 μM Ct-Plasmid-R   22 μL 
 100 μM Ct-Plasmid-FAM-BHQ1  22 μL 
 1X TE buffer (sterile/nuclease free) 968 μL 
                 ______ 
 Total     1100 μL 
 
Primer/probe supermix B (Ct_OMCB/HURNASEp) 
 
NOTE: This can be scaled for smaller volumes 
2 μM Human RNAse P gene primers and probes 
2 μM Chlamydia OMCB primers and probes 
  To prepare 1100 μL (enough for 500 reactions plus 10%) 
      volume 
 100 μM HURNASE-P-F    22 μL  
 100 μM HURNASE-P-R    22 μL 
 100 μM HURNASE_HEX_BHQ1    22 μL 
 100 μM Ct-OMCB-F    22 μL 
 100 μM Ct-OMCB-R    22 μL 
 100 μM Ct-OMCB-FAM-BHQ1   22 μL 
 1X TE buffer (sterile/nuclease free)  968 μL 
                  ______ 
 Total      1100 μL 
 
PCR set up 
Work In a PCR Clean & DNA Free Environment 
Each assay uses EITHER primer/probe supermix A OR primer/probe supermix B.  
CRITICAL STEP : MIX AND INVERT THE SUPERMIX AND PCR MIXES EXTREMELY WELL, THEY ARE 
VISCOUS AND THE TESTS WILL FAIL IF YOU DON”T DO THIS PROPERLY. 
 Composition per reaction 
        1X    
2X ddPCR supermix       11 PL    
Primer/probe supermix (2 μM each of six oligos)  2.2 μL 
Nuclease free H2O      3.85 μL     
SAMPLE DNA       4.95 μL     
                                    ________ 
Total                             22 μL 
  
1. To prepare sufficient ddPCR MASTERMIX to run one 96 well plate (100 reactions) 
In A 2 mL, conical based microtube, add the following 
        100X    
2X ddPCR supermix      1100 PL (2 X 550 PL)  
  
Primer/probe supermix (2 μM each of six oligos)  220 μL 
Nuclease free H2O      385 μL     
               ________ 
 Total                1705 μL 
 
Move to DNA loading/PCR clean area 
2. To each well of a 96 well SKIRTED EPPENDORF twin-tec plate (in retainer), aliquot  17.05 PL 
ddPCR MASTERMIX 
3. Aliquot 4.95 PL of DNA from samples to each well of the plate.  
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4.| Seal with microamp cover film (ensure close seal) and vortex gently (1000 rpm) to mix 
reagents for 30 seconds 
5. Centrifugate at 1000 rcf for 1 minute to pool PCR mix at bottom of plate. 
6. Proceed to droplet generation 
 
Droplet generation 
Turn on the heat sealer 
7. Place a new, clean and EPPENDORF TWIN-TEC SEMI-SKIRTED 96 well plate in a retainer 
8. Carefully remove the microamp film, without disturbing the PCR mixes 
9. Place a new droplet generation (DG8) cartridge in the droplet cassette, the notch should face 
left (SEE FIGURE). Close the cassette by applying gentle pressure to the short edges. 
 
 
 
 
 
 
 
 
 
10. Transfer 20 PL of each PCR mixture from row 1 in to each sample well of the cartridge (green 
on figure, marked “sample” on the cassette).  
Take care to avoid introducing air by putting pipette tips to the lowest point where the wall of 
the vessel meets the base. Hold pipette at around 20 degree angle to wall, actuate slowly and 
raise tips from the base as the wells continue to fill 
11. Transfer 70 PL droplet generation oil to each oil well of the cartridge (red on figure, marked 
“oil” on the cassette”) 
12. Attach a rubber gasket to the notched teeth on the cassette. Take care not to move the 
rubber across the wells as this could lead to cross-contamination. Ensure that the four teeth are 
properly engaged with the gasket as failure to do this will prevent a good seal forming. 
13. Transfer the cassette to the droplet generation machine. Holding the cassette gently at the 
top and bottom, place on the magnetised platform. A green light will indicate proper 
engagement. 
14. Activate droplet generation by pressing the button. 
15. Proceed to prepare the next cassette 
16. When the first droplets are complete, exchange the first cassette for the second in the 
droplet generator. Reactivate the device 
17. Carefully transfer 45 PL of droplets from the droplet wells (blue on figure) to row 1 of the 
SEMI-SKIRTED plate. Ensure that aspiration is performed slowly (around 10 s) when drawing and 
expelling droplets as failure to do this will lead to droplet instability 
18. Use a short length of orange lab-tape to temporarily seal the wells of row 1 
19. Prepare the droplet cassette for row 3, then transfer the droplets from row 2 
20. Continue this process until the plate is completed. 
21. Remove all orange lab-tape and replace with an easy-pierce, heat seal, ensuring that it is the 
right way up 
22. Place tray in the heat sealer, pull down the heat-block and press down again, hard for 5 
seconds. Release, turn the plate through 180 degrees, then repeat sealing for another 5 seconds. 
23. Put plate in Bio-Rad thermal cycler and run the program “DDPCR” 
Thermal cycler parameters are 
The PCR reaction is performed on a thermo cycler (stage 1, 95OC for 10 minutes, stage 2, 95OC 
for 10 seconds and 60OC for 30 seconds for 40 cycles and stage 3, 98OC for 12 minutes)024 | 
When the cycle is complete, droplets can be stored for up to 48 hours, or counted immediately. 
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Droplet reading 
 
If this is the first read of the day, start by performing a prime/flush/prime operation 
25. Transfer the plate to the special retainer and place this device in the droplet reader. A green 
light will indicate correct engagement with the platform. Close the door by pressing the button. 
26. Open the droplet reader software and load the appropriate template “plasmid” or “omcb” 
27. Select all wells on the plate and double click on the plate diagram to edit the details.  
28. For sample names, all wells should be labelled with the plate identifier number (1-16) 
29. Start the droplet count by pressing the run button 
 
Analysis 
 
 
(B) Detection of Chlamydia trachomatis from human eyes collected by swabs 
 
Preparation of Primer-Probe Mix 
Note; All this work should be done in the pre-PCR room inside the UV hood. 
 
1. Primer Rehydration to 100µM stock: 
a) Primers come dehydrated in the tube 
b) Rehydrate the primer to a concentration of 100µM, using sterile water (sigma) 
c) The volume of water to use is found on the quality assurance document. 
d) Write the abbreviated name of the primer and whether it is forward or reverse, on lid. 
e) This stock can be frozen at -200C 
 
2. Probe Rehydration to 100µM stock: 
a) Probes come dehydrated in the tube. 
b) Rehydrate the probe to a concentration of 100µM, using sterile water (sigma) 
c) The volume of water to use is found on the quality assurance document. 
d) Write the abbreviated name of the probe on the lid. 
e) This stock can be frozen at -200C 
 
3. Preparation of 500µl of 10x Primer-Probe Mix for each individual target SEPARATELY: 
Equipment: 
a) Pipette 1000μl + tips 
b) Pipette 20μl + tips 
c) Sterile 1.5ml tube 
Procedures: 
a) Add 470µl of sterile water 
b) Add 10µl of Forward Primer from 100µM stock 
c) Add 10µl of Reverse Primer from 100µM stock 
d) Add 10µl of Probe from 100µM stock 
e) Gentle / Brief vortex – make sure it is mixed 
f) Keep in fridge and use in short term. 
Note; probes must be protected from light as this will degrade them or will bleach dye 
 
4. Preparing master mix for multiplex PCR 
Note; All this work should be done in the pre-PCR room inside the UV hood. 
 Equipments 
a) Pipette 1000μl + tips 
b) Pipette 200μl + tips 
c) Tube 5ml 
Reagents 
a) Multiplex PCR Master Mix 
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b) Water (from kit) 
c) Primer and Probe mixes for all THREE targets of the set being tested 
 
Procedures 
Add the following to the 5 ml tube, as tabulated below (aiming 400 reactions) 
a) Master Mix 2000μl  
b) Water 1516μl 
c) Primer/Probe mix 84μl 
 
Components Quantity per single sample (µl) Quantity per X samples (µl) 
PCR master mix 5 5× X 
Primers and Probes 0.21 0.21 × X 
H2O 3.79 3.79 × X 
Samples 1  
Total 10 (10-1 (samples)) × X 
 
d) Gentle vortex      
 
Take the master mix to the DNA/RNA extraction room/PCR preparation room 
 
5. Preparing PCR reaction 
Equipments and materials 
a) Prepared master mix 
b) Pipette 10μl + tips 
c) Pipette 2μl + tips (option) 
d) DNA samples (defrosted and spun) 
e) Water (negative control) 
f) Ct positive control 
Procedures 
Add the following to the 384 wells plate 
a) Dispense 9µl of master mix in 384 wells 
b) Add 1µl of DNA samples in 380 wells 
c) Add 1µl of water in 2 wells 
d) Add 1µl of positive control in 2 wells 
e) Seal the plate with the sealer plate 
 
6. Loading in ViiA7 
a) Open SDS 2.4 program 
b) Escape password 
c) Open new document (from file) 
d) Assay (standard curve) 
i. Container 384 well clear plate 
ii. Template-blank template 
iii. Barcode-type from the plate 
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e) Select the field  
 
 
f) Set up-Add detector 
g) List of detector such as; 
i. ATTO550 (detect Ct plasmid)-------------NED 
ii. RPP30 (detect human genome)----------VIC 
iii. OMC B (detect Ct genome)-----------------FAM 
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h) Select each one and then click “copy to plate document” 
i) Done 
j) To select (cross) the boxes 
k) Instrument 
l) Sorting thermo cycler (stage 1,2,3) 
m) Adjust volume (accordingly), usually 10µl 
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n) Real time-connect to instrument 
o) Open the plate (from open/close button) 
p) Close  
q) Start the run 
r) Save  
 
 
7. Preliminary analysis 
a) Click “click analyse”  (top tool bar) 
b) Result tab 
c) Select the field  
d) Detect (at the bottom)-to see the channels 
e) Select plot (Rn vs cycle) etc, 
f) Analyse settings (to tool bar)-select detector with ATTO550 etc 
i. Auto baseline (NO) 
ii. Manual baseline (YES) 
iii. Click apply 
1) Change in Rn vs cycle 
2) Repeat the procedures from 2 for FAM and VIC 
iv. Add sample name 
v. Save 
vi. Export- Tab delimited text 
vii. Analysis 
 
8. Analysis   
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Appendix 5: cDNA Synthesis Protocol  
 
SuperScript® VILO™ cDNA Synthesis Kit  
 
Aim: Reverse transcription of Total RNA.  
 
Storage: Reagents are stored at -200C 
 
Preparation of samples and reagents 
✓ Thaw extracted RNA on ice in the molecular lab 
✓ Thaw reagents in RNA/DNA free room 
✓ Prepare RT master mix on ice in UV hood in RNA/DNA free room 
 
Procedures 
Add the following to the 5 ml tube on ice, as tabulated below (e.g aiming 100 reactions) 
 
Components Quantity per single sample (µl) Quantity per 96 samples (µl) 
5X VILO™ Reaction 8 μl 800 μl 
10X SuperScriptR Enzyme 4 μl 400 μl 
RNA  Add 28 μl in molecular lab  
Total 40 μl 
 
a) Gently mix the tube  contents  
 
b) incubate at 250C for 10 minutes    
c) Then incubate tubes at 420C for 1 hour  
d) Terminate the reaction at 850C at 5 minutes 
e) Store cDNA at -200C until use or at -800C for long storage 
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Appendix 6: Host Gene Expression Protocol 
 
Host gene expression detection protocol (Taqman Array Card-TAC) 
 
Aim    
To identify different host genes expressed in different individual children with different stages 
of trachoma progression in endemic area. 
 
Materials 
✓ Vortex 
✓ Microcentrifuge 
✓ Pipettes (20µl, 200µl/100µl and 1000µl) 
✓ Life technologies real time system (ViiA7 with TAC block) 
✓ Compatible Heraeus Centrifuge 
✓ Nuclease free water 
✓ 1.5ml microcentrifuge tubes 
✓ Array card 
✓ cDNA from RNA samples extracted from eye’s swabs 
 
PCR Reagents preparation  
✓ Keep all the reagents on ice during assay set up 
✓ Prepare master mix as follows; 
 
Components A single sample 9 samples 
RT-PCR buffer (Taqman universal master mix II with 
UNG 
50µl 450µl 
Nuclease free water     30µl 270µl 
cDNA Samples 20µl-in molecular 
lab 
 
Total 100µl      
 
a) Label all 8 microcentrifuge tubes 
b) Aliquot 80µl of master mix into each of 8 1.5ml microcentrifuge tubes 
c) Add 20µl of cDNA to each tube  
d) Vortex gently 
e) Centrifuge the tubes to eliminate any air bubbles from the mixtures 
 
Loading samples into TAC  
a) Thaw the TAC to room temperature 
b) Carefully remove TAC from its packaging 
c) Place the TAC on a lab bench, with the foil side down 
d) Transfer 100µl of each PCR reaction mix into the fill port-the large hole, hold pipette in 
an angle and slowly dispense the mix into sweeps in and around to fill reservoir toward 
the vent port without introducing air bubbles. 
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Important; Put new strip to the plate with remaining cDNA samples 
 
Centrifugation of the TAC 
a) Insert TAC into the array holder, please make sure, 
i. The fill reservoirs project upwards out of the array holder 
ii. The reaction wells face the same direction as the ‘’this side out’’ label 
iii. Use blank balance arrays or used arrays to fill any remaining positions in the 
array holder 
Note; sample loading will be impaired if inserting procedures will not be accomplished.   
    
b) Place the filled array holder in the bucket, labelled ‘’This Side Out’’ facing away from the 
centre of centrifuge  
   
 
c) Centrifuge at 1200 RPM for one minute, (buckets and contents must be balanced) 
d) Remove the buckets from the centrifuge, and then remove array holders 
e) Gently remove the TAC by their carrier sides 
f) The filling reservoirs should be uniform and consistent with the amount of reaction mix 
g) If is inconsistence proceeds with next step but avoid results of affected sample 
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Sealing the TAC 
Note; Sealer isolates the wells of TAC after it loaded with reaction mix. Proper operation of sealer 
such as slow, steady and deliberate motion is critical for successful use of TAC.  
a) Place sealer on the table near to centrifuge (used for TAC) 
b) Place the carriage sits in the starting motion which is at your side.  
Note; never insert the TAC into the sealer if carriage is NOT in its starting motion, 
otherwise will cause irreparable damage 
 
 
c) Insert TAC into the sealer 
i. Orient the TAC in the proper direction over the sealer insert plate, foil side up 
and the fill reservoir end should be end closest to the far end of the sealer base. 
ii. Line the card’s rear pin groves to the stylus pins on the sealer 
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iii. Gently place the TAC on top of the insert plate and gently push until is securely 
fitted and foil surface is level with the base sealer. 4 spring clips ensure the card 
is held in proper position 
 
 
iv. Push the carriage in slow motion in the direction of arrow to far end labelled 
with ‘’Push to stake’’  until the carriage reaches mechanical stop 
v. Remove the sealed TAC. Use the thumb slot at the middle of sealer for easy 
access 
vi. Inspect the TAC for proper sealing. If indentations do not match up or if foil is 
anyway damaged do not use the TAC.  
vii. Return the carriage to its staring position on the base of the sealer 
d) Use scissors to trim the fill reservoir from the TAC  
 
 
TAC set up; 
➢ Turn on ViiA7 and its computer 
➢ Make sure Block, Adaptor and heated cover are matching   
➢ Open instrument’s tray and insert TAC with well A1 at the top left corner and notched 
corner at the top right and barcode toward front of the instrument 
Fill reservoir end of the card 
Starting Position 
Thumb slot 
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➢ Click close to close the tray 
 
➢ New Experiment  
➢ Click “Setup” 
➢ Click ‘’Experiment Properties’’ and fill the following;  
✓ Experiment Name___________________ 
✓ Barcode__________________________ 
✓ User Name_______________________ 
✓ Comments (if necessary)____________ 
➢ Tick the following as indicated below 
✓ Array Card Block 
✓ Relative Standard Curve 
✓ TaqMan@ Reagents 
✓ Standard  
 
 
➢ Click ‘’Define’’ 
➢ Import the targets names stored in the computer or CD 
➢ Write samples names 
➢ Flourophore: FAM (ROX as reference) 
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➢ Click ‘’Assign’’ and will appear as below 
 
➢ Click “Run Methods”, set cycling conditions of RT-PCR as below 
➢ Cycling conditions of RT-PCR 
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Step Temperature Time 
✓ Hold stage     
    1 500C 2min 
    2 950C 10min 
✓ PCR Stage (Number of cycles 40)  
   1 950C 15sec 
   2 600C 1min (data detection) 
 
 
 
➢ Click Run -------Start Run 
➢ Save the experiment in a designated folder 
Athumani M. Ramadhani – PhD Thesis 272 
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Appendix 7: DNA Extraction Protocol for Microbiome  
 
PowerSoil®DNA Isolation Kit 
 
Aim 
To extract DNA from Eye swabs 
  
Kit storage 
Both reagents and components are stored at room temperature (15-300C)  
 
Precautions 
Wear gloves all the time and avoid all skin contact with kit reagents (wash thoroughly with water 
in case there is contact or see material safety data sheet at www.mobio.com for details)  
 
Equipment 
Microcentrifuge (10,000 x g) 
Pipettors (50 µl – 500 µl) 
Bead beater  
Vortex Adapter  
 
Reagents preparation 
Add 120ml of absolute ethanol into solution C5-D to make total of 240ml  
 
Procedures 
1. Please wear gloves at all times 
2. Sample/solution 1 preparation 
a) Prepare a maximum of 16 swab samples (equal number with the bead beater available) 
b) Check Solution C1. If it is precipitated, heat solution to 600C until dissolved before use 
c) Add dry swab samples to the PowerBead Tubes. 
3. Cells lysis 
a) Add 60 µl of Solution C1  
b) Beat on bead beater for 1 minute  
c) Repeat beating for another 1 minute 
d) Centrifuge tubes at 10,000 x g for 30 seconds at room temperature (RT).  
e) Transfer the supernatant to a clean 2 ml Collection Tube (provided). 
       Note: Expect between 400 to 500 µl of supernatant.  
4.  Inhibitor removal      
a) Add 250 µl of Solution C2 and vortex for 5 seconds.  
b) Incubate at 40C for 5 minutes. 
c) Centrifuge the tubes at RT for 1 minute at 10,000 x g. 
d) Avoiding the pellet, transfer up to, but no more than, 600µl of supernatant to a clean 2 
ml  
               Collection Tube (provided). 
e) Add 200µl of Solution C3 and vortex briefly.  
f) Incubate at 40C for 5 minutes. 
g) Centrifuge the tubes at RT for 1 minute at 10,000 x g. 
h) Avoiding the pellet, transfer up to, but no more than, 750 µl of supernatant into a 
clean 2 ml   
Collection Tube (provided). 
5.  DNA binding 
a) Shake to mix Solution C4 before use.  
b) Add 1200 µl of Solution C4 to the supernatant and vortex for 5 seconds. 
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c) Load approximately 600 µl of supernatant onto a Spin Filter  
d) Centrifuge at 10,000 x g for 1minute at RT.  
e) Discard the flow through 
f) Repeat as in 5 (c-e) above 
g) Again repeat as in 5(c-e) above    
6.  Washing 
a) Add 500µl of Solution C5  
b) Centrifuge at RT for 30 seconds at 10,000 x g. 
c) Discard the flow through.  
d) Centrifuge again at RT for 1 minute at 10,000 x g. 
e) Carefully place spin filter in a clean 2 ml Collection Tube (provided). Avoid splashing 
any   
Solution C5 onto the Spin Filter. 
7.  Elution 
a) Add 100µl of Solution C6 to the centre of the white filter membrane. Or 100µl of 
sterile   
         DNA-Free PCR Grade Water  
b) Centrifuge for 2 minutes at 200 x g,  
c) Centrifuge for 30 seconds at 10,000 x g. 
d) Discard the Spin Filter.  
8.  Place extracted DNA samples in -800C freezer (for long storage) or -200C for short term 
storage 
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Appendix 8: Ocular Immune Responses, Chlamydia trachomatis infection and 
Clinical Signs of Trachoma Before and After Azithromycin Mass Drug 
Administration in a Treatment Naïve Trachoma-Endemic Tanzanian Community 
(Equivalent to Chapter 7)  
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Abstract
Background
Trachoma, caused by Chlamydia trachomatis, remains the leading infectious cause of blind-
ness worldwide. Persistence and progression of the resulting clinical disease appears to be
an immunologically mediated process. Azithromycin, which is distributed at the community
level for trachoma control, has immunomodulatory properties. We investigated the impact of
one round of oral azithromycin on conjunctival immune responses, C. trachomatis infection
and clinical signs three- and six- months post treatment relative to three pre-treatment time-
points.
Methodology
A cohort of children aged 6 to 10 years were recruited from a trachoma endemic region of
northern Tanzania and were visited five times in a 12-month period. They were examined
for clinical signs of trachoma and conjunctival swabs were collected for laboratory analysis.
C. trachomatis infection was detected and the expression of 46 host genes was quantified
using quantitative PCR. All community members were offered azithromycin treatment
immediately after the six-month timepoint according to international guidelines.
Findings
The prevalence of C. trachomatis infection and inflammatory disease signs were signifi-
cantly reduced three- and six- months post-mass drug administration (MDA). C. trachomatis
infection was strongly associated with clinical signs at all five time-points. A profound anti-
inflammatory effect on conjunctival gene expression was observed 3 months post-MDA,
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however, gene expression had largely returned to pre-treatment levels of variation by 6
months. This effect was less marked, but still observed, after adjusting for C. trachomatis
infection and when the analysis was restricted to individuals who were free from both infec-
tion and clinical disease at all five time-points. Interestingly, a modest effect was also
observed in individuals who did not receive treatment.
Conclusion
Conjunctival inflammation is the major clinical risk factor for progressive scarring trachoma,
therefore, the reduction in inflammation associated with azithromycin treatment may be ben-
eficial in limiting the development of potentially blinding disease sequelae. Future work
should seek to determine whether this effect is mediated directly through inhibition of pro-
inflammatory intracellular signalling molecules, through reductions in concurrent, sub-clini-
cal infections, and/or through reduction of infection exposure.
Author summary
Trachoma, caused by conjunctival infection with Chlamydia trachomatis, remains the
leading infectious cause of blindness. Repeated infection during childhood can trigger
prolonged inflammation, which is the main risk factor for conjunctival scarring. Azithro-
mycin is distributed globally for trachoma control, however it is also widely reported to
have immunomodulatory properties. This report investigated the impact of one round of
oral azithromycin for trachoma control on conjunctival immune responses, clinical signs
and C. trachomatis infection in Tanzanian children. A large anti-inflammatory effect of
azithromycin on conjunctival gene expression was observed 3 months post-treatment,
however, gene expression patterns had mostly resumed to pre-treatment levels by 6
months. The effect was evident after adjusting for C. trachomatis infection and when anal-
ysis was restricted to uninfected individuals, however it was also observed to a lesser
extent in individuals that did not receive treatment. These findings suggest that azithro-
mycin may have a direct immunomodulatory effect on conjunctival gene expression but
that it may also reduce inflammation by reducing exposure to C. trachomatis and other
infections. This anti-inflammatory effect could have therapeutic potential in limiting the
development of disease sequelae, that goes beyond its effect on the clearance of ocular C.
trachomatis infection.
Introduction
Trachoma remains the leading infectious cause of blindness worldwide, with the greatest
burden in sub-Saharan Africa [1]. Trachomatous disease is initiated by repeated conjuncti-
val infection with Chlamydia trachomatis, which triggers prolonged inflammatory episodes
that contribute to the development of conjunctival scarring [2]. Infection and clinical signs
of active trachoma (follicular and papillary inflammation) are most frequently found in
younger children [3]. Conjunctival scarring gradually accumulates through childhood, ado-
lescence and into adult life. Eventually this results in the in-turning of the eyelid (entropion)
and eyelashes (trichiasis), abrasion of the eyelashes against the cornea, severe visual
impairment and blindness in later life. According to recent World Health Organisation
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(WHO) estimates, around 165.1 million people live in trachoma-endemic areas (of whom
89% are fromWHO’s African region) [4] and 2.8 million have trichiasis [5]. The WHO
advocates the use of the SAFE Strategy for trachoma control: Surgery to correct trichiasis,
Antibiotics to treat C. trachomatis infection, Facial cleanliness and Environmental improve-
ments to suppress transmission [6].
Annual mass drug administration (MDA) with oral azithromycin for a minimum of 3 years
is recommended for communities where the initial prevalence of the clinical sign trachoma-
tous inflammation-follicular (TF) is 10% in children aged 1 to 9 years, with a recommended
coverage of 80% of the whole community [7]. In low-prevalence settings this usually leads to a
sustained reduction in C. trachomatis infection prevalence over time [8–11], however in highly
endemic areas infection can re-emerge shortly after MDA [12].
Inflammatory disease signs are reported to persist longer than infection at both the individ-
ual and population levels, resulting in the observation of clinical signs in the absence of infec-
tion [13–16]. The correlation between clinical signs and C. trachomatis infection in
communities prior to MDA is further reduced following treatment [14].
Previously we reported on the relationship between clinical signs, C. trachomatis infection
and the expression of 91 immuno-fibrogenic and cell marker genes at the baseline time-point
of a long-term cohort study of Tanzanian children [17]. We found an increase in transcripts
related to Th1 and NK cell activity in individuals with C. trachomatis infection and an increase
in matrix and fibrogenic factors in individuals with active disease in the absence of infection,
supporting the findings of several earlier studies [16, 18–24]. However, the changes of these
transcriptional responses in an untreated population and the changes that might occur follow-
ing MDA with azithromycin have not previously been investigated.
Azithromycin is a macrolide antibiotic which has anti-inflammatory and immunomodula-
tory properties via inhibition of the transcription factor Nuclear Factor Kappa-B [25]. Azithro-
mycin has been reported in vitro to suppress T-cell proliferation and activation and to reduce
the expression of mucins and pro-inflammatory cytokines [26–28]. As a result azithromycin is
found to be beneficial in the treatment of diseases characterised by pathological inflammation
[29]. Azithromycin therefore has the potential to exert broad anti-inflammatory effects on
conjunctival gene expression, independently of the clearance of C. trachomatis.
Here we investigate the changes in clinical signs of trachoma, C. trachomatis infection and
host immune responses in a cohort of Tanzanian children three- and six-months post azithro-
mycin MDA relative to three pre-treatment time-points. We also investigate the associations
between clinical signs, infection and immune responses before and after MDA. This investiga-
tion uses data from the first five time-points of a four-year longitudinal study, the baseline
findings of which have previously been reported [17].
Methods
Ethics statement
This study was reviewed and approved by the Ethics Committees of the Tanzania National
Institute for Medical Research, Kilimanjaro Christian Medical University College and the Lon-
don School of Hygiene & Tropical Medicine. The study adhered to the tenets of the Declara-
tion of Helsinki. A field worker explained the nature of the study in detail in either Kiswahili
or Maasai. Prior to enrolment of a child into this study, their parent or guardian provided writ-
ten informed consent, on a consent form in Kiswahili, which was witnessed by a third person.
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Study design and population
This study was conducted in three adjacent trachoma endemic communities in Kilimanjaro
and Arusha regions, Northern Tanzania. In January 2012 we recruited a cohort of children
aged 6–10 years from these communities to study the pathogenesis of trachomatous conjuncti-
val scarring. The cohort has subsequently been followed-up every three months for four years.
All children aged 6–10 years, who were normally resident in the three villages, were eligible for
inclusion. We chose this restricted age group as we considered that they were more likely to
show evidence of incident or progressive conjunctival scarring during the four years of the
study. The investigation presented in this paper is nested within this overall longitudinal study
and uses data from the first five time-points only. The objectives of this nested investigation
were to examine changes in C. trachomatis infection, clinical signs of trachoma and host
immune responses, and the associations between them, three- and six-months post treatment
relative to three pre-treatment time-points.
The study population and participant recruitment process are described in more detail in
the report of baseline (time-point 1) findings [17]. In brief, these villages are relatively remote,
geographically neighbours and have similar patterns of life and traditions. This area is predom-
inately inhabited by people of the Maasai ethnic group. Pastoral activities are the main occupa-
tion. The area is dry for much of the year, except for the rainy season (February to May).
Water supply is therefore limited, and largely depends on a long-distance water pipe scheme
fromMount Kilimanjaro. Family units are organised in Boma, with living huts arranged in a
circle around a central animal enclosure, which is often characterised by a high density of flies.
Clinical assessments and sample collection
We visited the cohort of children every three months at their homes or schools. An experi-
enced ophthalmic nurse examined their left eye for clinical signs of trachoma using x2.5 loupes
and a bright torch. Signs were graded using the 1981WHO ‘FPC’ detailed grading system
[30]. This sub-divides the features into several four-point severity scales: follicles (F), papillary
inflammation (P) and conjunctival scarring (C). This system corresponds to the WHO Simpli-
fied Trachoma Grading System in the following way: Trachomatous inflammation-Follicular
(TF) is equivalent to F2/F3 and Trachomatous inflammation-Intense (TI) is equivalent to P3
[31]. Where we refer to “Active Trachoma”, we follow the widely used definition of TF (F2/3)
and/or TI (P3). However for the purpose of this study, we also consider that both P2 and P3
represent clinically significant papillary inflammation, and refer to this as “TP” [18]. High res-
olution photographs (Nikon D90 camera with 105mmMacro lens) were taken of the exam-
ined eye for independent grading.
The conjunctiva of the left eye was anaesthetised with a drop of preservative-free proxyme-
tacaine hydrochloride 0.5% w/v (Minims, Chauvin Pharmaceuticals Ltd, Surrey, UK). Two
conjunctival swab samples (Dacron polyester, Puritan Medical Products Company, Maine,
USA) were collected for C. trachomatis detection and gene expression analysis. The swabs
were passed across the upper tarsal conjunctiva four times, with a quarter turn between each
pass. The first swab was placed directly into a tube containing RNAlater solution (Thermo
Fisher Scientific, Massachusetts, USA) and the second into a dry tube. The samples were
placed into a cool box. Later the same day the dry swab samples were stored directly at -80˚C
and the RNAlater samples kept at 4–8˚C overnight and then stored at -80˚C.
Trachoma control measures
The SAFE Strategy is being implemented in this region of Tanzania. Community members
who had trachomatous trichiasis were offered free surgery in the local health facility.
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Azithromycin MDA was distributed to the members of the three villages by our field team
under the auspices of the Tanzanian National NTD Control Programme in the Ministry of
Health and with supervision by district eye coordinators. Azithromycin, donated to the
National NTD Control Programme by Pfizer through the International Trachoma Initiative,
was offered to all community members over the age of 6 months. Single-dose azithromycin
MDA (1g for adults and 20mg/kg for children) was distributed annually for three years. For
infants under six months, tetracycline eye ointment was provided to their primary carer to be
applied twice a day to both eyes for six weeks. The project team provided repeated health edu-
cation messages around hygiene and sanitation. The first round of MDA was administered to
all individuals in the three cohort villages immediately after time-point 3. No adverse effects
were reported.
C. trachomatis detection
Two protocols were used for both genomic DNA extraction and C. trachomatis detection. For
time-point 1 samples, genomic DNA was extracted from dry swabs using the PowerSoil DNA
isolation Kit (MO Bio Laboratories, California, USA) according to manufacturer’s instruc-
tions. For time-points 2 to 5, genomic DNA was extracted from samples stored in RNAlater
using the Norgen DNA/RNA Purification Kit (Norgen Biotek Corp, Canada) following the
manufacturer’s instructions.
C. trachomatis was detected in the time-point 1 samples using a droplet digital PCR assay
(ddPCR) and at time-points 2 to 5 using multiplex quantitative real-time PCR (qPCR) previ-
ously evaluated against ddPCR [17, 32, 33]. Both assays detect chlamydial plasmid open read-
ing frame 2 (pORF2), C. trachomatis outer membrane complex protein B (omcB) and human
endogenous control gene ribonuclease P/MRP Subunit P30 (RPP30) [33], using the same
primer and probe sequences. The ddPCR reaction contained 5μl of DNA template and prim-
ers/probes at a final concentration of 0.3nM using Taqman mastermix. PCR reaction condi-
tions were as follows: 95˚C for 10 minutes, then 40 cycles of 95˚C for 10 seconds and 60˚C for
30 seconds and finally 98˚C for 12 minutes. Droplets were then examined for fluorescence on
a QX200TM Droplet Reader (Bio-Rad, UK), providing a quantitative result. The qPCR assay
was performed on a ViiA7 thermal cycler (Thermo Fisher Scientific, Massachusetts, USA)
using TaqMan Multiplex Master mix in a final volume of 20 μl, containing 4μl of DNA tem-
plate and primers and probes each at a final concentration of 0.3nM. Cycling conditions were
as follows: 95˚C hold for 20 seconds followed by 40 cycles of 95˚C for 1 second and 60˚C for
20 seconds. Samples were tested in duplicate and were considered C. trachomatis positive if
either replicate amplified omcB and/or pORF2 with a cycle threshold (CT) value<40. In order
to compare agreement between ddPCR and qPCR assays, Norgen-extracted DNA from time-
point 2 samples (extracted from the first swab stored in RNAlater) were tested using both
methods and the results are shown in S1A Table.
Analysis of human gene expression
Total RNA was extracted from samples stored in RNAlater using the Norgen DNA/RNA Puri-
fication Kit (Norgen Biotek Corp, Canada) and reverse transcribed using the SuperScript
VILO cDNA Synthesis Kit (Life Technologies) following the manufacturer’s instructions. Rela-
tive abundance of host gene targets was quantified by real-time PCR using customized Taq-
ManMicrofluidic 384-well Array Cards (Thermo Fisher Scientific, Massachusetts, USA) on a
ViiA7 real-time PCR machine (Thermo Fisher Scientific, Massachusetts, USA), as previously
described [17]. A total of 46 genes of interest were selected based on our previously reported
time-point 1 findings, in which we selected genes that were significantly associated with
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clinical signs and/or C. trachomatis infection status.HPRT1 was included to each PCR run as
an endogenous control gene.
Statistical analysis
Data were managed in Microsoft Access. The ïCTmethod was used to adjust for the concen-
tration of input RNA by subtracting the cycle threshold (CT) value of each gene from the CT
value ofHPRT1 in the same sample [34]. The distribution of ïCT values were plotted to assess
normality. Host gene expression, C. trachomatis infection and clinical data were analysed in
STATA v14.
For each time-point the prevalence of clinical signs and C. trachomatis infection was esti-
mated and the association between infection and each of TF and TP was estimated using logis-
tic regression. The effect of MDA on infection, TF, TP and AT (Active Trachoma) was
estimated using a random effects logistic regression. Each of infection, TF, TP and AT were
used as the outcome variable in four separate regressions, the observations from the first three
time-points were compared with the observations from time-point 4 (the first observation
after the MDA) and participant ID was included as a random effect to account for the fact that
these were repeated observations within individuals. An identical analysis was repeated com-
paring the observations from time-point 5 to those from before MDA to assess whether the
estimated effect persisted at six months post treatment.
The change in mean ïCT value from time-point 1 was plotted for 46 genes at each of the
four subsequent time-points and inspected to identify any clear differences between time-
points. The change in mean ïCT following MDA was formally tested by comparing the mean
ïCT in the first three time-points with that from the fourth time-point using a random effects
linear regression, with the ïCT value of each gene as the outcome variable, whether an obser-
vation was before or after MDA as the exposure. Participant ID was included as a random
effect to again account for repeated observations of the same individuals. An interaction term
was included between before/after MDA and whether an individual was actually treated or not
to assess the evidence of whether gene expression response after MDA was different in the
treated and the untreated groups. These analyses were also repeated comparing the fifth time-
point with the three pre-MDA time-points to identify if the effect persisted. Gene expression
was then compared at time-point 4 only between treated and untreated individuals. These
analyses were initially performed unadjusted and then adjusted for infection status (clinical
signs were not adjusted for as they were likely to be caused by both infection and gene expres-
sion, rather than the other way around so adjusting for these could bias our estimates). The
Benjamini and Hochberg method was used to control for the false discovery rate of 5% [35].
Multivariable linear regression was used at each of the five time-points presented in this
report, to test the association of each gene’s expression with clinical signs and infection, adjust-
ing for age and sex and assuming a false discovery rate (FDR) of 5% in multiple comparisons
[35].
A Preferred Reporting Item (STROBE_checklist_cohort 2-12-18) is included in the sup-
porting information. Accession numbers for each gene included in this analysis are included
at the end of this manuscript. The protocols used in our analyses are accessible on protocols.io
website using the accession number https://dx.doi.org/10.17504/protocols.io.zyhf7t6
List of accession numbers for genes
HPRT1-Hs02800695, ALOX5-Hs01095330, CCL18-Hs00268113, CCL2-Hs00234140,
CCL20-Hs01011368, CD247-Hs00609515, NCAM1-Hs00941830, CDH1-Hs01023894,
CDH2-Hs00983056, CXCL13-Hs00757930, CXCL5-Hs01099660, DEFB4B;
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DEFB4A-Hs00175474, DUOX2-Hs00204187, FGF2-Hs00266645, IFNG-Hs00989291,
IL10-Hs00961622, IL12B-Hs01011518, IL17A-Hs00174383, IL19-Hs00604657,
IL1B-Hs01555410, IL21-Hs00222327, IL22-Hs01574154, IL23A-Hs00900828,
IL6-Hs00985639, IL8-Hs00174103, MMP12-Hs00899662, MMP7-Hs01042796,
MMP9-Hs00234579, MUC1-Hs00159357, MUC4-Hs00366414, MUC5AC-Hs00873651,
MUC7-Hs03047182, MZB1-Hs00414907, NCR1-Hs00183118, PDGFB-Hs00966522,
CD274-Hs01125301, S100A4-Hs00243202, S100A7-Hs01923188, SERPINB4;SER-
PINB3-Hs00741313, SOCS1-Hs00705164, SOCS3-Hs02330328, SPARCL1-Hs00949881,
TGFB1-Hs00998133, VIM-Hs00185584, CTGF-Hs00170014, PTGS2-Hs00153133,
Results
Study participants
At census we registered a total of 666 children aged between 6 and 10 years who were eligible
for recruitment at the beginning of this study from three trachoma-endemic villages. At time-
point one 506 participants were assessed; their demography, clinical signs and infection status
have previously reported in detail [17]. In general participants were predominantly from the
Maasai ethnic group (652/666, 97.9%) with a similar number of males (332, [49.9%]) and
females (334 [50.1%]) and a mean age of 7.01 years (SD 2.0) at the time of commencing the
study. At time-points 2, 3, 4, and 5 we assessed 537, 466, 467 and 477 children, respectively. At
each time-point some children were not examined due to being absent in the village, having
moved away or declining to participate. After time-point 1, the recruitment of new partici-
pants into the longitudinal study was permitted at the second time-point only. MDA was
offered immediately after time-point 3 to all members of the three cohort villages. The
reported community-wide coverage was 68.7%. All study participants examined in time-point
3 (466) were treated except one who refused. At time-point 4, 392/466 (84.1%) of the individu-
als seen had been treated.
Clinical signs of trachoma
At time-point 1 the clinical signs previously reported were based on grading of conjunctival
photographs, to enable subsequent comparison with the final time-point for determination of
scarring incidence and progression [17]. However, for consistency within this analysis of the
first five time-points, the field grading data was used. The agreement between field and photo-
graph grading for time-point 1 is shown in S1B Table. Kappa scores between field and photo-
graphs grading were 0.92 for TF and 0.68 for TP, with TP being slightly under-reported by
field graders.
The prevalence of TF in the first three time-points prior to MDA was fairly consistent (171/
506 [33.8%], 163/537 [30.2%] and 104/467 [22.3%]), dropping to 52/467 (11.1%) and 61/479
(12.6%) post-MDA at time-points 4 and 5 (Fig 1). The prevalence of TP was consistently lower
than TF and also dropped substantially following MDA (Fig 1). There were no statistically sig-
nificant differences between males and females in terms of the proportion showing signs of TF
and/or TP at any time-point (S2 Table), with the exception of time-point 1 where there was
possibly a weak association between TP and female sex.
C. trachomatis infection
The prevalence of infection was fairly consistent prior to MDA, dropping very slightly from
15.4% and 15.3% at time-points 1 and 2 to 11.6% at time-point 3. Three months after azithro-
mycin MDA (time-point 4) infection prevalence dropped to 1.3% and then increased slightly
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to 2.5% at time-point 5 (Fig 1). There was strong evidence for an association between C. tra-
chomatis infection and clinical signs (TF, TP) at all five time-points (Table 1), with the excep-
tion of TP at time-point 5. There was a significant reduction in TF, TP and C. trachomatis
detection in post-MDA time-points 4 and 5 relative to the combined odds at pre-MDA time-
points 1–3 (Table 2). The inflammatory disease (TF and/or TI (active trachoma)) and infection
status for each individual at each time-point is shown in Fig 2; participants were grouped by
infection and disease status at baseline. There were no statistically significant differences
between males and females in terms of the proportion testing positive for C. trachomatis at any
time-point (S2 Table).
Fig 1. The prevalence of C. trachomatis infection and clinical signs before and after MDA. At time-points 1, 2, 3, 4,
and 5 data are shown for 506, 537, 466, 467 and 477 children respectively.
https://doi.org/10.1371/journal.pntd.0007559.g001
Table 1. The association between C. trachomatis detection and clinical signs by time-point. Clinical signs are based on field grading from all five time-points.
Time-point Follicular Inflammation (TF) Papillary inflammation (TP)
No TF (%) TF (%) No TP (%) TP (%)
1
(n = 506)
Ct infected (%) 18/335 (5.4) 60/171 (35.1) 38/407 (9.3) 40/99 (40.4)
OR (95%CI) - 9.52 (5.4–16.8) - 6.58 (3.9–11.1)
p-value - <0.0001 - <0.0001
2
(n = 536)
Ct infected (%) 29/374 (7.8) 53/162 (32.7) 38/429 (8.9) 44/107 (41.1)
OR (95%CI) - 5.78 (3.5–9.5) - 7.19 (4.3–12.0)
p-value - <0.0001 - <0.0001
3
(n = 466)
Ct infected (%) 19/362 (5.3) 35/104 (33.7) 30/398 (7.5) 24/68 (35.3)
OR (95%CI) - 9.16 (4.9–16.9) - 6.69 (3.6–12.5)
p-value - <0.0001 - <0.0001
Azithromycin MDA
4
(n = 467)
Ct infected (%) 3/415 (0.7) 3/52 (5.8) 4/457 (0.9) 2/10 (20.0)
OR (95%CI) - 8.41 (1.7–42.8) - 28.31 (4.5–177.5)
p-value - 0.010 - <0.0001
5
(n = 477)
Ct infected (%) 4/417 (1.0) 8/60 (13.1) 10/442 (2.3) 2/35 (5.7)
OR (95%CI) - 15.88 (4.6–54.5) - 2.62 (0.6–12.4)
p-value - <0.0001 - 0.226
https://doi.org/10.1371/journal.pntd.0007559.t001
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Conjunctival gene expression
Forty-six genes of interest were quantified in all individuals who were sampled at each of the
five time-points. All amplified targets were included in the analyses. For each time-point, mul-
tivariate linear regression models were constructed for expression of each gene to investigate
associations with TF, TP and C. trachomatis infection, adjusting for age and sex (S3 Table).
The associations between the expression of specific genes with clinical signs and C. trachomatis
infection was similar at each time-point and was consistent with the baseline (time-point 1)
report [17]. Briefly, in individuals with C. trachomatis infection, IFNG, IL22, CCL2, IL12B,
CD274, IL21, IL17A and SOCS1 genes were consistently the most upregulated and S100A4,
ALOX5,MMP7,MUC5AC,MUC7,MUC4,MUC1, CDH2 and CDH1 genes were the most
downregulated. In individuals with TF and TP, S100A7, CCL18,MMP12, CXCL13, IL10, IL19,
IL21 and IL17A were the most upregulated while S100A4, SPARCL1, ALOX5 andMUC5AC
were the most downregulated.
For each target, the difference in mean gene expression (across all individuals) was calculated
at each time-point relative to the mean expression at time-point 1 (Fig 3). There was only mod-
est variability between these time-points, with the exception of time-point 4, three months after
MDA, which showed marked differences compared to time-point 1 (and the other time-points).
The largest increases in expression at time-point 4 relative to time-point 1 were found in
Table 2. Comparison of C. trachomatis infection and disease signs between the pre-treatment (odds of time-points 1, 2 and 3) to the post-treatment time-points (4
and 5 analysed separately). Clinical signs are based on field grading from all five time-points.
Infection TF TP Active Trachoma
Combined odds of pre-MDA time-points vs. time-point 4 (3 months post-MDA) OR 0.01 0.10 0.03 0.08
(95%CI) (0.004–0.04) (0.06–0.17) (0.01–0.07) (0.05–0.13)
p-value <0.0001 <0.0001 <0.0001 <0.0001
Combined odds of pre-MDA time-points vs. time-point 5 (6 months post-MDA) OR 0.04 0.15 0.18 0.14
(95%CI) (0.02–0.10) (0.10–0.23) (0.11–0.30) (0.10–0.22)
p-value <0.0001 <0.0001 <0.0001 <0.0001
https://doi.org/10.1371/journal.pntd.0007559.t002
Fig 2. The clinical disease (Active Trachoma) and infection status of individuals at each time-point, ordered by
status at baseline. Each row represents an individual and each column represents a time-point.
https://doi.org/10.1371/journal.pntd.0007559.g002
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SPARCL1,MUC5AC, CDH2, CTGF,NCAM1, CDH1,MUC7, S100A4, and IL12B (Fig 3). The
largest decreases were in S1007A, CCL18, CXCL5,DEFB4A, CXCL13, IL19,MMP12, IDO1,
IL1B, and IL17A (Fig 3). By time-point 5, six months after MDA, difference in mean gene
expression had mostly returned to levels that were similar to those prior to treatment (Fig 3).
The change in mean ïCT for the expression of each gene from the three time-points before
MDA to the fourth time-point three months after MDA was estimated for all participants, and
also separately for both individuals who received MDA and those who did not, adjusting for
changes in C. trachomatis infection status (Table 3). This showed a significant change in mean
ïCT of most targets from before MDA compared with three months after MDA. Interestingly,
this change was still observed in the untreated sub-group, albeit at a much reduced scale. The
changes in mean ïCT were larger when the analysis was not adjusted for C. trachomatis infec-
tion (S4 Table).
To investigate the differences between the treated and untreated groups further, mean ïCT
were compared between the groups at time-point 4 only (S5 Table). This revealed only subtle
differences in mean ïCT between treated and untreated individuals. The anti-inflammatory
effect of MDA on gene expression was observed even in individuals without any detectable
episodes of chlamydial infection or clinical disease (F0, P0) at any of these five time-points (S6
Table).
Discussion
Infection
The prevalence of C. trachomatis was similar across the three time-points before MDA, sug-
gesting that the infection prevalence was relatively stable in this antibiotic-naïve community at
around 11% - 16%. The drop in the prevalence of infection and clinical signs at time-point 3
may have been due to medium term natural variation in the prevalence, as strains of Chla-
mydia trachomatis come and go, due to the introduction of public health education to the
communities by the field team or possibly due to the change in seasons. There was a
Fig 3. Variation in conjunctival gene expression. The difference in mean ïCT value (across all individuals) for each
gene at time-points 2, 3, 4 and 5 is shown relative to time-point 1. Values are adjusted for C. trachomatis infection and
active trachoma and are ordered by difference in mean gene expression at Time-point 4.
https://doi.org/10.1371/journal.pntd.0007559.g003
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Table 3. Estimated Fold Changes (FC) with their respective p-values comparing the expression of each gene pre-MDA (time-points 1,2 and 3) and post-MDA
(time-point 4). A FC of>1 indicates increased expression of the gene after MDA. Column 1 includes all participants, columns 2 and 3 show the results stratified by
whether an individual actually received the treatment or not. The final column (p-value for interaction) assesses the evidence as to whether the fold change from before to
after MDA is different in the treated and untreated groups. Results are ordered by FC of ‘‘All” individuals (column 1).
Target All Untreated Only Treated Only p-value for interaction
FC p-value FC p-value FC p-value
SPARCL1 11.89 7.76 x10^-186 6.81 9.04 x10^-19 13.13 2.54 x10^-173 0.005
MUC5AC 4.02 3.95 x10^-145 2.89 1.20 x10^-14 4.26 5.35 x10^-136 0.009
CDH2 3.42 2.97 x10^-141 2.67 9.16 x10^-16 3.58 3.30 x10^-130 0.026
NCAM1 2.23 9.10 x10^-89 1.83 1.95 x10^-9 2.31 8.32 x10^-83 0.031
CTGF 2.20 3.57 x10^-96 2.25 1.27 x10^-17 2.20 4.10 x10^-81 0.818
MUC7 1.89 7.10 x10^-29 2.17 1.01 x10^-7 1.84 2.24 x10^-23 0.291
S100A4 1.82 7.83 x10^-79 1.75 1.56 x10^-12 1.83 5.50 x10^-69 0.612
CDH1 1.72 1.23 x10^-80 1.69 9.80 x10^-14 1.72 2.55 x10^-69 0.808
FGF2 1.50 2.86 x10^-9 1.48 0.019 1.50 4.19 x10^-8 0.934
SERPINB4 1.43 1.91 x10^-3 1.65 0.067 1.39 0.009 0.570
IL12B 1.42 5.47 x10^-15 1.49 4.10 x10^-4 1.41 1.97 x10^-12 0.657
TGFB1 1.34 2.53 x10^-45 1.43 4.80 x10^-12 1.33 6.55 x10^-36 0.178
ALOX5 1.29 7.49 x10^-39 1.37 7.71 x10^-11 1.27 1.24 x10^-30 0.133
MUC1 1.24 8.04 x10^-17 1.35 4.05 x10^-6 1.22 9.95 x10^-13 0.161
NCR1 1.23 2.51 x10^-10 1.25 0.007 1.23 7.76 x10^-9 0.835
PDGFB 1.22 7.96 x10^-14 1.35 1.26 x10^-5 1.20 2.59 x10^-10 0.130
GAPDH 1.20 5.05 x10^-11 1.49 1.68 x10^-8 1.16 1.33 x10^-6 0.001
SOCS1 1.20 2.64 x10^-8 1.49 5.69 x10^-7 1.15 6.66 x10^-5 0.003
MUC4 1.16 1.80 x10^-7 1.34 6.1 x10^-5 1.13 6.01 x10^-5 0.034
VIM 1.15 9.83 x10^-10 1.22 4.08 x10^-4 1.14 2.11 x10^-7 0.242
CD247 1.01 0.757 1.10 0.196 0.99 0.856 0.205
MMP9 0.95 0.242 0.98 0883 0.95 .0224 0.731
IFNG 0.95 0.219 0.93 0.521 0.95 0.293 0.860
MMP7 0.93 0.033 1.08 0.441 0.90 0.009 0.086
IL23A 0.88 5.88 x10^-4 1.00 0.989 0.86 1.73 x10^-4 0.127
IL22 0.83 0.020 1.26 0.232 0.76 0.002 0.016
IL6 0.83 5.24 x10^-4 0.83 0.150 0.83 0.001 0.959
CCL20 0.82 3.80 x10^-6 0.92 0.447 0.80 2.29 x10^-6 0.240
IL8 0.72 1.42 x10^-18 0.72 4.81 x10^-4 0.72 4.02 x10^-16 0.980
PTGS2 0.70 1.97 x10^-17 0.79 0.02.52 0.69 8.27 x10^-17 0.210
DUOX2 0.69 7.01 x10^-25 0.87 0.134 0.67 1.81 x10^-26 0.006
IL10 0.67 7.68 x10^-24 0.80 0.026 0.64 6.84 x10^-24 0.047
MZB1 0.65 3.20 x10^-17 0.71 0.008 0.64 6.23 x10^-16 0.466
CD274 0.63 6.37 x10^-37 0.77 0.004 0.61 1.28 x10^-36 0.018
CCL2 0.60 2.63 x10^-22 0.63 5.52 x10^-4 0.59 5.94 x10^-20 0.617
SOCS3 0.59 1.13 x10^-38 0.76 0.006 0.57 5.67 x10^-39 0.007
IL1B 0.52 1.78 x10^-43 0.61 2.81 x10^-5 0.50 1.55 x10^-40 0.140
IL21 0.51 3.18 x10^-24 0.72 0.044 0.48 1.03 x10^-24 0.022
IL17A 0.48 6.01 x10^-44 0.64 7.36 x10^-4 0.46 2.57 x10^-43 0.017
IDO1 0.44 6.25 x10^-90 0.68 1.69 x10^-4 0.41 4.74 x10^-93 9.55 x10^-6
MMP12 0.43 9.98 x10^-70 0.56 1.87 x10^-6 0.41 6.82 x10^-67 0.018
IL19 0.40 5.00 x10^-63 0.55 1.42 x10^-5 0.37 4.32 x10^-61 0.012
CXCL5 0.39 2.79 x10^-65 0.61 3.88 x10^-4 0.36 6.18 x10^-66 7.64 x10^-4
DEFB4A 0.38 1.32 x10^-64 0.52 1.16 x10^-5 0.36 1.94 x10^-62 0.015
(Continued)
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substantial reduction in infection prevalence at three months post-MDA, however, it rose
slightly by six months post-MDA, suggesting some limited re-emergence of infection. This
may be due to insufficient MDA coverage within the community, contact with individuals
from surrounding untreated communities, or failure to complete the 6-week daily treatment
course of tetracycline eye ointment for infants under 6 months. Members of these communi-
ties travel quite frequently to search for pastures and water for livestock, to visit markets and
for social interactions with other communities. As a result, it was difficult to achieve high
MDA coverage. Previous studies from Tanzania and The Gambia have also reported on the
importance of contact between communities as a risk factor for reinfection following treat-
ment [10, 11, 36].
Disease
Clinical signs of inflammation were strongly correlated with C. trachomatis infection at all five
time-points. In our previous systematic review and meta-analysis we found a strong correlation
between TF and C. trachomatis infection and a moderate correlation between intense papillary
inflammation (TI) and infection prior to initiation of MDA, however after treatment the corre-
lation was weaker for TF and no correlation was found for TI [14]. Most of these earlier studies
included multiple rounds of MDA and reported data several years after initiating treatment,
therefore it might be too early to see this trend in our cohort. There was no consistent difference
in the prevalence of clinical signs of inflammation between males and females, with the excep-
tion of the first timepoint which showed a non-significant trend of more TP in females.
Gene expression
Our findings in this study of the associations between host gene expression, C. trachomatis
infection and clinical signs of inflammation were consistent with previous reports from our-
selves and others [16, 18, 21, 22, 24, 37, 38]. Targets that were consistently associated with clini-
cal signs (TF/TP) at all five time-points included antimicrobial peptides (S100A7), pro-
inflammatory cytokines and chemokines (CCL18, CXCL13, IL10, IL19, IL21, IL17A), matrix
modifiers (MMP12 and SPARCL1), epithelial-mesenchymal transition markers (S100A4),
microbiota responses (ALOX5) and mucins (MUC5AC). Likewise, C. trachomatis infection was
consistently associated with pro-inflammatory cytokines and chemokines (IFNG, IL22, CCL2,
IL12B, IL21, IL17A), regulators/signalling pathways (SOCS1, CD274), S100A4, ALOX5, matrix
modifiers (MMP7, SPARCL1) and mucins (MUC7). We discussed the functions of these genes
and their potential roles in the clearance of C. trachomatis infection and immunopathology in
detail in our baseline paper [17]. The results at each of the subsequent time-points support the
data from baseline, suggesting that strong IFNG/IL12 responses are important in the clearance
of infection, whilst Th17 cell associated cytokines and matrix factors are associated with both
infection and the clinical inflammation which persists after infection has been cleared.
Large changes in gene expression were detected at time-point 4, three months after MDA
with azithromycin, relative to the three time-points prior to MDA. This variation in gene
Table 3. (Continued)
Target All Untreated Only Treated Only p-value for interaction
FC p-value FC p-value FC p-value
CXCL13 0.38 1.19 x10^-47 0.50 3.58 x10^-5 0.36 3.28 x10^-45 0.067
CCL18 0.33 8.10 x10^-49 0.47 5.75 x10^-5 0.31 7.95 x10^-47 0.032
S100A7 0.28 4.90 x10^-55 0.53 0.002 0.25 3.61 x10^-56 7.03 x10^-4
https://doi.org/10.1371/journal.pntd.0007559.t003
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expression largely returned to pre-MDA levels by time-point 5, six months post-MDA. Azithro-
mycin appeared to have an anti-inflammatory effect on gene expression, reversing the direction
of gene expression change usually associated with clinical signs and C. trachomatis infection.
Genes normally downregulated in individuals with C. trachomatis infection and/or inflamma-
tion were upregulated post-MDA (SPARCL1,MUC5AC, CDH2, CTGF,NCAM1, CDH1,
S100A4,MUC7, and FGF2), whilst genes normally upregulated (S100A7, CCL18, CXCL5,
CXCL13, IL19, IDO1,MMP12, IL17A, IL1B and IL21) were strongly downregulated post-MDA.
The effect was greatest when C. trachomatis infection was not adjusted for, however the effect
was still large after adjustment for infection, suggesting that azithromycin has an immunomod-
ulatory effect on gene expression that is independent of the concurrent reduction in infection.
This effect was also seen in individuals without any episodes of C. trachomatis infection and
clinical signs of inflammation across all 5 time-points, supporting this hypothesis. However, we
cannot exclude the possibility that azithromycin treatment reduced ocular infections with other
sub-clinical or mild inflammation-causing organisms in these individuals. Interestingly, a
change in mean gene expression post-MDA was also observed in individuals who did not
receive treatment. This could be due to a reduction in transmission and therefore exposure to
C. trachomatis and/or other infectious organisms within the community as a whole.
Azithromycin has previously been reported to have anti-inflammatory effects in humans,
animal and in vitromodels, leading to improved clinical outcomes through a combined
approach of clearing infection and reducing pathological host inflammatory responses [39].
One pre-surgical dose of azithromycin reduced the level of pro-inflammatory cytokines and
chemokines detected in oral fluid 6 days following dental implant surgery relative to amoxicil-
lin [40]. Relative to other non-macrolide antibiotics, azithromycin reduced levels of IL-6, IL-8,
TNF-ċ and GM-CSF proteins in individuals with pneumonia and rhinovirus infections [41–
43]. MMP9 expression was reduced in the airways of lung transplanted individuals treated
with azithromycin between 3 and 6 months [44], and in an experimental laminectomy model
in rats, azithromycin was associated with reduction of fibrosis and inflammatory cell density
six weeks after administration [45]. Immunomodulatory effects of azithromycin are thought
to be enhanced by its long half-life in tissue, lasting for several weeks [46, 47]. In addition to
localised anti-inflammatory effects, one round of azithromycin, administered for trachoma
control, was associated with a large reduction in infectious and all-cause childhood mortality
[48]; a finding which was reinforced by a large multi-country placebo-controlled clinical trial
[49]. Our findings of an immunomodulatory effect of azithromycin are therefore consistent
with published evidence and suggest that MDA for trachoma control may have an additional
protective effect through a systemic reduction in inflammation.
This study has several limitations. It was only feasible to sample one eye from study partici-
pants, thus only the left eye was examined and sampled throughout the longitudinal study. The
age range of study participants was limited due to the study design of the overall longitudinal
study, which this investigation was nested within. The method of C. trachomatis detection was
changed after the first time-point, which could introduce inconsistencies between the infection
results of the first relative to later time-points. Agreement between the two methods used was
however deemed acceptable (S1A table). The infection loads of discrepant results were very low
and at around the limit of detection. Given the large sample size and the use of three pre-MDA
time-points, this variation is not expected to significantly alter the results or their interpretation.
Conclusions
We present evidence that one round of oral azithromycin treatment exerted a strong anti-
inflammatory effect on conjunctival gene expression, detectable three months following
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treatment but mostly returning to pre-MDA levels by six months. This effect was also observed
in individuals without C. trachomatis infection and clinical signs of inflammation across all
five time-points, indicating that the immunomodulatory effect was at least in part independent
of the reduction of C. trachomatis infection. Interestingly, a reduced effect was also seen in
individuals who did not receive treatment, which could reflect a community reduction in
infection transmission and exposure. A limitation of this study is that we cannot determine
whether this effect is mediated directly through inhibition of pro-inflammatory intracellular
signalling molecules, through reductions in concurrent, sub-clinical infections, and/or
through reduction of infection exposure, and future work should seek to understand these
mechanisms. Conjunctival papillary inflammation is a significant risk factor for scarring pro-
gression [2], therefore the anti-inflammatory effect of azithromycin might have therapeutic
potential in limiting the development of disease sequelae, that goes beyond its effect on the
prevalence of ocular C. trachomatis infection.
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Supplementary Table 1a. 2 x 2 table showing agreement between qPCR and ddPCR assays for C. 
trachomatis detection in DNA extracted from conjunctival swabs at time-point 2.  
 
  ddPCR  
  + - Total 
qPCR + 71 (13.6%) 7 (1.3 %) 78 
- 15 (2.9%) 430 (82.2%) 445 
 Total 86 437 523 
 
Sensitivity = 82.6% (95% CI 72.8 – 89.9), Specificity = 96.7% (95% CI 96.7 -99.4), NPV = 96.6% (95% CI 94.8 
– 97.6%); PPV = 91.0% (95% CI 82.9 – 95.5%); Cohens Kappa = 0.84, Accuracy: overall probability that a 
sample will be correctly classified 95.8% (95% CI 93.7 – 97.4),for these samples at this prevalence (16.4%) 
with ddPCR as the reference standard.  
 
Supplementary Table 1b. Agreement between field and photo grading at baseline (time-point 1) for 
follicular and papillary inflammation in the conjunctiva. Kappa scores between field and photographs 
grading were 0.92 for TF and 0.68 for TP.  
 
Field Grading Photo Grading 
  No TF (%) TF (%)    
No TF 317 (94.63%) 18 (5.37%)    
TF 19 (11.11%) 152 (88.89%)    
       
  No TP (%) TP (%)    
No TP 345 (84.77%) 62 (15.23%)    
TP 1 (1.01%) 98 (98.99%)    
       
  F0 (%) F1 (%) F2 (%) F3 (%) 
F0 140 (96.55%) 4 (2.76%) 1 (0.69) 0 (0.00%) 
F1 61 (32.11%) 112 (58.95%) 17 (8.95%) 0 (0.00%) 
F2 0 (0.00%) 16 (21.33%) 49 (65.33%) 10 (13.33%) 
F3 0 (0.00%) 3 (3.13%) 14 (14.58%) 79 (82.29%) 
       
  P0 (%) P1 (%) P2 (%) P3 (%) 
P0 173 (60.49%) 99 (34.62%) 13 (4.55%) 1 (0.35%) 
P1 6 (4.96%) 67 (55.37%) 41 (33.88%) 7 (5.79%) 
P2 1 (1.85%) 0 (0.00%) 38 (70.37%) 15 (27.78%) 
P3 0 (0.00%) 0 (0.00%) 4 (8.89%) 41 (91.11%) 
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Supplementary Table 2. The relationship between sex and (i) clinical signs (from field grading) and (ii) C. trachomatis infection of each of the 5 time-
points. The number of individuals with each clinical phenotype or infection is shown as a proportion of the total number of males and females at each 
time-point. Associations between sex and clinical phenotypes or infection were tested using logistic regression.    
 
Time-point 1 Time-point 2 Time-point 3 MDA Time-point 4 Time-point 5 
Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p- 
value 
Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p-
value 
Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p- 
value 
 Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p- 
value 
Male 
(%) 
Female 
(%) 
OR 
(95%CI) 
p- 
value 
Follicular Trachoma (TF)                  
77/251 
(30.7) 
 
94/255 
(36.9) 
1.32 
(0.9-1.9) 
0.142 72/258 
(27.9) 
90/278 
(32.4) 
1.24 
(0.9-1.8) 
0.261 44/218 
(20.2) 
60/248 
(24.2) 
1.28 
(0.8-2.0) 
0.278  23/216 
(10.7) 
29/251 
(11.6) 
1.10  
(0.6-2.0) 
0.756 27/229 
(11.8) 
34/248 
(13.7) 
1.19 
(0.7-2.0) 
0.531 
Papillary Inflammation (TP)                  
41/251 
(16.3) 
 
58/255 
(26.8) 
1.51 
(1.0-2.4) 
0.070 45/258 
(17.4) 
63/278 
(22.7) 
1.39 
(0.9-2.1) 
0.133 28/218 
(12.8) 
41/248 
(16.5) 
1.34 
(0.8-2.3) 
0.264  6/216 
(2.8) 
4/251 
(1.6) 
0.57 
(0.2-2.0) 
0.384 12/229 
(5.2) 
23/248 
(9.3) 
1.85 
(0.9-3.8) 
0.096 
Chlamydia trachomatis                  
34/252 
(13.5) 
44/255 
(17.3) 
1.34 
(0.8-2.2) 
0.241 32/258 
(12.4) 
48/278 
(17.3) 
1.47 
(0.9-2.4) 
0.116 31/218 
(14.2) 
24/248 
(9.7) 
0.65 
(0.4-1.1) 
0.131  1/216 
(0.5) 
4/251 
(1.60) 
3.48 
(0.4-31) 
0.266 6/229 
(2.6) 
6/248 
(2.4) 
0.92 
(0.3-2.9) 
0.889 
 
Target FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value
Antimicrobial Peptides
Defensin, beta 4B,defensin, beta 4A (DEFB4A ) 1.21 0.314 2.2 0.000 1.67 0.024 1.51 0.005 0.89 0.002 1.28 0.089 2.29 0.000 1.89 0.001 1.37 0.010 0.86 0.000
Psoriasin-1 (S100A7 ) 2.41 0.001 3.68 0.000 2.01 0.024 1.6 0.021 0.86 0.004 2.03 0.000 5.25 0.000 2.12 0.002 1.52 0.009 0.79 0.000
Cytokines/Chemokines
Chemokine ligand 2 (CCL2 ) 1.49 0.019 2.46 0.000 3.52 0.000 1.31 0.045 0.86 0.000 1.5 0.002 2.52 0.000 3.85 0.000 1.17 0.151 0.86 0.000
Chemokine ligand 5 (CXCL5 ) 1.6 0.019 2.18 0.001 0.97 0.889 0.94 0.697 0.9 0.008 1.76 0.000 2.1 0.000 1.53 0.034 1.04 0.791 0.88 0.000
Chemokine ligand 13 (CXCL13 ) 2.13 0.000 2.7 0.000 2.5 0.000 1.4 0.039 0.86 0.000 2.3 0.000 3.33 0.000 2.79 0.000 1.35 0.037 0.83 0.000
Chemokine ligand 18 (CCL18 ) 1.79 0.004 2.95 0.000 2.25 0.001 1.11 0.521 0.86 0.000 2.2 0.000 4.28 0.000 2.26 0.000 1.07 0.660 0.81 0.000
Chemokine ligand 20 (CCL20 ) 1.76 0.000 1.61 0.004 1.47 0.028 1.12 0.338 0.94 0.048 1.66 0.000 1.52 0.001 1.86 0.000 1.11 0.272 0.9 0.000
Indoleamine 2,3-dioxygenase 1 (IDO1 ) 1.5 0.013 1.73 0.003 2.33 0.000 1.54 0.001 0.88 0.000 1.41 0.014 1.53 0.008 2.58 0.000 1.5 0.001 0.83 0.000
Interferon gamma(IFNG ) 1.67 0.000 1.36 0.055 7.95 0.000 1.5 0.000 0.9 0.001 1.77 0.000 1.73 0.000 7.19 0.000 1.28 0.011 0.88 0.000
Interleukin 1 beta(IL1B ) 1.54 0.011 2.09 0.000 1.89 0.002 1.32 0.041 0.9 0.003 1.44 0.005 1.57 0.002 2.46 0.000 1.07 0.531 0.88 0.000
Interleukin 6 (IL6 ) 1.32 0.077 1.82 0.001 1.2 0.000 1.07 0.589 0.93 0.020 1.5 0.001 1.43 0.012 2.46 0.000 1 0.982 0.91 0.000
Interleukin 8 (IL8 ) 1.25 0.085 1.76 0.000 1.55 0.006 1.16 0.154 0.96 0.140 1.38 0.005 1.88 0.000 1.53 0.003 1.04 0.691 0.92 0.001
Interleukin 10 (IL10 ) 1.51 0.003 2.03 0.000 2.12 0.000 1.32 0.012 0.91 0.001 1.72 0.000 2.31 0.000 2.29 0.000 1.15 0.150 0.91 0.000
Interleukin 12 beta (IL12B ) 1.69 0.000 1.43 0.005 3.71 0.000 1.37 0.001 0.97 0.154 1.36 0.000 1.32 0.019 4.99 0.000 1.11 0.214 0.94 0.007
Interleukin 17A (IL17A ) 1.73 0.001 1.82 0.001 2.81 0.000 1.37 0.014 0.87 0.000 2.03 0.000 2.23 0.000 2.95 0.000 1.39 0.005 0.87 0.000
Interleukin 19 (IL19 ) 1.56 0.018 2.73 0.000 2.63 0.000 1.65 0.001 0.85 0.000 1.79 0.000 3.04 0.000 2.82 0.000 1.54 0.001 0.84 0.000
Interleukin 21 (IL21 ) 2.22 0.000 1.97 0.000 3.75 0.000 1.37 0.017 0.89 0.001 2.08 0.000 2.66 0.000 3.51 0.000 1.28 0.063 0.88 0.000
Interleukin 22 (IL22 ) 1.31 0.114 1.83 0.001 7.29 0.000 1.4 0.015 0.92 0.020 1.48 0.021 1.71 0.004 6.99 0.000 1.26 0.099 0.98 0.497
Interleukin 23A (IL23A ) 1.49 0.005 1.98 0.000 2.15 0.000 1.15 0.219 0.92 0.002 1.45 0.000 1.7 0.000 2.47 0.000 1.19 0.040 0.9 0.000
Prostaglandin-endoperoxide synthase 2 (PTGS2 ) 1.4 0.025 1.78 0.001 1.47 0.033 1.06 0.534 0.96 0.137 1.34 0.006 1.62 0.000 1.68 0.000 0.97 0.748 0.94 0.007
EMT Markers
Epithelial cadherin (CDH1 ) 1.22 0.060 1.28 0.034 0.8 0.081 1.05 0.562 0.99 0.762 1.01 0.901 1.12 0.220 1.1 0.364 1.07 0.295 0.98 0.189
Neuronal cadherin (CDH2 ) 0.97 0.787 1.15 0.295 1.29 0.072 1.03 0.271 1.11 0.218 1.01 0.916 1.04 0.756 1.51 0.002 1.13 0.168 1.03 0.279
S100 calcium binding protein A4 (S100A4 ) 1.08 0.523 1.05 0.755 0.49 0.000 0.98 0.846 1.05 0.061 0.82 0.020 0.81 0.036 0.74 0.007 1.04 0.595 1.02 0.371
Vimentin (VIM ) 1.52 0.002 1.42 0.019 1.65 0.002 1.02 0.845 1.01 0.836 1.31 0.001 1.43 0.000 2.05 0.000 1.12 0.095 0.93 0.000
Matrix Modifiers
Connective tissue growth factor (CTGF-1 ) 1.05 0.701 1.2 0.190 1.47 0.009 0.87 0.142 1.01 0.712 0.97 0.735 1.25 0.023 1.24 0.047 0.91 0.171 1 0.992
Fibroblast growth factor 2 (basic) (FGF2 ) 0.9 0.447 1.83 0.000 1.77 0.001 1.03 0.818 0.99 0.658 1.03 0.823 1.69 0.001 1.71 0.001 0.95 0.696 0.97 0.320
Matrix metallopeptidase 7 (MMP7 ) 1.46 0.009 1.43 0.029 0.46 0.000 1.02 0.849 0.94 0.042 1.17 0.225 1.36 0.032 0.61 0.002 1.06 0.576 0.93 0.006
Matrix metallopeptidase 9 (MMP9 ) 1.91 0.000 2.01 0.000 2.06 0.000 1.14 0.251 0.95 0.064 1.67 0.000 1.54 0.001 2.72 0.000 1.13 0.192 0.92 0.001
Matrix metallopeptidase 12 (MMP12 ) 1.78 0.000 2.16 0.000 2.27 0.000 1.28 0.052 0.92 0.013 1.92 0.000 2.59 0.000 2.67 0.000 1.17 0.165 0.88 0.000
Platelet-derived growth factor beta polypeptide (PDGFB ) 1.3 0.012 1.5 0.001 1.7 0.000 1.2 0.011 0.9 0.010 1.29 0.002 1.56 0.000 1.93 0.000 1.15 0.029 0.93 0.000
SPARC-like 1 (hevin) (SPARCL1 ) 0.57 0.004 0.54 0.006 0.52 0.006 0.77 0.095 1.18 0.000 0.51 0.000 0.43 0.000 0.47 0.001 0.88 0.384 1.18 0.000
Transforming growth factor, beta 1 (TGFβ1 ) 1.3 0.012 1.25 0.067 1.51 0.001 1.14 0.109 0.98 0.274 1.21 0.013 1.19 0.048 1.76 0.000 1.06 0.371 0.94 0.000
Microbiota Response
Arachidonate 5-lipoxygenase (ALOX5 ) 1.17 0.157 1.21 0.125 0.85 0.217 1.08 0.351 0.1 0.893 1.04 0.628 1.1 0.301 1.02 0.848 1.04 0.551 0.95 0.004
Dual oxidase 2 (DUOX2 ) 1.2 0.206 1.71 0.001 1.58 0.010 1.36 0.007 0.91 0.001 1.28 0.028 1.56 0.001 1.58 0.001 1.39 0.000 0.88 0.000
Mucins
Mucin 1, cell surface associated (MUC1 ) 1.15 0.227 1.28 0.056 1.08 0.602 1.11 0.220 0.97 0.264 1.12 0.154 1.27 0.012 1.14 0.211 1.12 0.087 0.95 0.003
Mucin 4, cell surface associated  (MUC4 ) 1.22 0.089 1.55 0.001 0.83 0.182 1 0.988 0.96 0.056 1.05 0.615 1.32 0.008 1.02 0.856 1.16 0.046 0.91 0.000
Mucin 5AC, oligomeric mucus/gel-forming (MUC5AC ) 0.86 0.266 0.94 0.679 0.71 0.038 1.09 0.437 1.04 0.111 0.87 0.207 0.85 0.214 0.73 0.026 1.04 0.634 1.06 0.009
Mucin 7, secreted (MUC7 ) 0.98 0.902 0.9 0.555 0.52 0.000 0.66 0.001 1.08 0.014 0.79 0.065 0.76 0.053 0.64 0.005 0.77 0.012 1.06 0.021
NK Cell Markers
CD247  molecule (CD247) 1.41 0.003 1.32 0.031 2.15 0.000 1.2 0.049 1 0.212 1.32 0.001 1.51 0.000 2.14 0.000 1.12 0.106 0.93 0.000
Neural cell adhesion molecule 1 (NCAM1 ) 0.9 0.413 1.12 0.435 2.13 0.000 1.14 0.210 1.01 0.702 1.02 0.832 1.04 0.683 2.01 0.000 1.08 0.268 0.98 0.240
Natural cytotoxicity triggering receptor 1 (NCR1 ) 1.4 0.003 1.33 0.023 2.86 0.000 1.28 0.005 0.94 0.007 1.43 0.000 1.41 0.001 2.86 0.000 1.22 0.009 0.94 0.001
Regulators/Signalling Pathways
CD274 molecule (CD274 ) 1.37 0.029 1.64 0.003 3.36 0.000 1.31 0.020 0.9 0.019 1.46 0.000 1.81 0.000 3.42 0.000 1.18 0.053 0.89 0.000
Marginal zone B and B1 cell-specific protein (MZB1 ) 1.76 0.001 1.33 0.117 2.61 0.000 1.29 0.048 0.96 0.201 1.51 0.008 2.84 0.000 2.92 0.000 1.34 0.020 0.89 0.000
Serpin peptidase inhibitor clade B member 4, (SERPINB4 ) 1.08 0.739 3.72 0.000 5.1 0.000 1.05 0.811 0.97 0.564 1.03 0.878 2.94 0.000 5.77 0.000 1.12 0.514 0.9 0.018
Suppressor of cytokine signalling 1  (SOCS1 ) 1.55 0.000 1.48 0.001 2.26 0.000 1.18 0.057 0.94 0.004 1.36 0.000 1.5 0.000 2.76 0.000 1.1 0.191 0.92 0.000
Suppressor of cytokine signalling 3 (SOCS3 ) 1.56 0.002 1.89 0.000 1.35 0.079 1.17 0.169 0.93 0.015 1.39 0.003 1.6 0.000 1.85 0.000 1.08 0.422 0.88 0.000
Supplementary Table 3: Multivariable linear regression models for conjunctival gene expression associated with clinical signs, C. trachomatis , female sex and age. FC = fold change. Using the Benjamini and Hochberg approach to adjust for multiple 
comparisons,  in order to control the false discovery rate <5% only tests with a p-value below 0.027 are considered statistically significant.
TF TP C. trachomatis Sex AgeTF TP C. trachomatis Sex Age
Time-point 1 Time-point 2
 
Target FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value FC p-value
Antimicrobial Peptides
Defensin, beta 4B,defensin, beta 4A (DEFB4A ) 1.12 0.567 1.84 0.005 2.23 0.001 1.38 0.018 0.87 0.000 3.01 0.000 1.64 0.400 3.04 0.135 1.23 0.224 0.91 0.026
Psoriasin-1 (S100A7 ) 1.58 0.080 4.18 0.000 3.34 0.000 1.38 0.080 0.78 0.000 3.01 0.000 2.08 0.154 10.81 0.000 1.13 0.391 0.87 0.000
Cytokines/Chemokines
Chemokine ligand 2 (CCL2 ) 1.42 0.039 2.28 0.000 4.1 0.000 1.2 0.124 0.84 0.000 2.43 0.000 1.17 0.646 5.45 0.000 0.94 0.525 0.91 0.000
Chemokine ligand 5 (CXCL5 ) 1.19 0.387 1.72 0.019 2.03 0.004 1.04 0.771 0.82 0.000 4.38 0.000 1.5 0.462 2.51 0.185 1.06 0.731 0.88 0.001
Chemokine ligand 13 (CXCL13 ) 1.68 0.024 2.69 0.000 2.94 0.000 1.43 0.027 0.78 0.000 3.59 0.000 1.41 0.477 10.61 0.000 1.15 0.297 0.84 0.000
Chemokine ligand 18 (CCL18 ) 1.63 0.033 2.92 0.000 3.61 0.000 1.18 0.292 0.83 0.000 2.41 0.000 1.22 0.659 11.77 0.000 0.94 0.635 0.94 0.033
Chemokine ligand 20 (CCL20 ) 1.36 0.059 1.34 0.108 2.05 0.000 1.11 0.367 0.88 0.000 3.12 0.000 1.09 0.844 2.79 0.058 1.13 0.323 0.89 0.000
Indoleamine 2,3-dioxygenase 1 (IDO1 ) 1.39 0.063 1.86 0.002 3.53 0.000 1.61 0.000 0.83 0.000 4.84 0.000 1.49 0.443 6.8 0.004 1.46 0.011 0.88 0.000
Interferon gamma(IFNG ) 1.43 0.019 1.95 0.000 9.71 0.000 1.26 0.032 0.88 0.000 2.79 0.000 1.08 0.836 13.43 0.000 1.28 0.022 0.88 0.000
Interleukin 1 beta(IL1B ) 1.27 0.173 1.71 0.006 2.53 0.000 1.15 0.240 0.89 0.000 2.86 0.000 1.78 0.183 3.29 0.030 1.09 0.502 0.94 0.048
Interleukin 6 (IL6 ) 1.03 0.875 1.4 0.087 2.71 0.000 1.05 0.684 0.93 0.018 2.04 0.001 0.72 0.476 3.73 0.022 1.22 0.124 0.91 0.003
Interleukin 8 (IL8 ) 0.93 0.649 1.72 0.003 2.18 0.000 1.12 0.312 0.92 0.006 2.2 0.000 1.63 0.273 1.71 0.335 1.1 0.462 0.98 0.598
Interleukin 10 (IL10 ) 1.25 0.154 2.25 0.000 2.38 0.000 1.17 0.145 0.89 0.000 2.11 0.000 1.38 0.273 4.81 0.000 1.02 0.769 0.91 0.000
Interleukin 12 beta (IL12B ) 1.44 0.007 1.43 0.018 5.47 0.000 1.16 0.121 0.92 0.000 1.88 0.000 1.06 0.844 10.34 0.000 1.11 0.265 0.92 0.000
Interleukin 17A (IL17A ) 1.65 0.008 2.18 0.000 3.25 0.000 1.43 0.007 0.83 0.000 4.15 0.000 1.57 0.309 10.54 0.000 1.27 0.055 0.88 0.000
Interleukin 19 (IL19 ) 1.24 0.283 2.73 0.000 3.83 0.000 1.57 0.002 0.83 0.000 3 0.000 2.09 0.110 6.86 0.001 1.23 0.119 0.91 0.004
Interleukin 21 (IL21 ) 1.66 0.015 2.62 0.000 4.41 0.000 1.37 0.029 0.83 0.000 3.49 0.000 1.67 0.236 13.11 0.000 1.2 0.164 0.87 0.000
Interleukin 22 (IL22 ) 1.7 0.014 1.54 0.066 8.75 0.000 1.19 0.252 0.96 0.282 1.41 0.148 1.63 0.332 13.13 0.000 1.17 0.321 0.99 0.736
Interleukin 23A (IL23A ) 1.11 0.440 1.8 0.000 2.65 0.000 1.11 0.291 0.89 0.000 1.93 0.000 1.02 0.957 5.04 0.000 0.97 0.778 0.91 0.000
Prostaglandin-endoperoxide synthase 2 1.02 0.515 1.42 0.041 1.84 0.001 1.16 0.172 0.9 0.000 2.4 0.000 1.85 0.109 1.83 0.211 0.97 0.778 0.94 0.022
EMT Markers
Epithelial cadherin (CDH1 ) 1.02 0.797 1.14 0.212 1.22 0.079 1.06 0.359 0.94 0.000 1.55 0.020 0.88 0.763 1.49 0.441 1.05 0.663 1 0.873
Neuronal cadherin (CDH2 ) 1.03 0.808 0.99 0.947 1.24 0.181 1.13 0.189 1.03 0.317 1.02 0.892 0.59 0.158 1.55 0.344 1.05 0.645 0.99 0.644
S100 calcium binding protein A4 (S100A4 ) 0.96 0.738 0.9 0.447 0.72 0.028 1 0.987 1 0.912 1.52 0.060 0.86 0.746 0.84 0.777 0.87 0.318 1.02 0.483
Vimentin (VIM ) 1.18 0.102 1.3 0.024 2.17 0.000 1.07 0.360 0.92 0.000 2.17 0.000 1.01 0.978 3.4 0.017 1.03 0.794 0.97 0.216
Matrix Modifiers
Connective tissue growth factor (CTGF-1 ) 0.99 0.915 0.98 0.872 1.4 0.012 0.9 0.173 0.97 0.089 1.44 0.045 0.59 0.174 2.22 0.105 0.91 0.397 1.02 0.492
Fibroblast growth factor 2 (basic) (FGF2 ) 1.2 0.182 1.34 0.044 1.85 0.000 0.97 0.725 0.95 0.041 1.46 0.035 1.04 0.922 1.96 0.179 0.96 0.756 0.97 0.263
Matrix metallopeptidase 7 (MMP7 ) 1.36 0.052 1.17 0.366 0.68 0.040 0.97 0.754 0.89 0.000 2.3 0.000 1.14 0.760 1.06 0.917 0.97 0.777 0.94 0.056
Matrix metallopeptidase 9 (MMP9 ) 1.78 0.000 1.18 0.332 2.51 0.000 1.06 0.580 0.9 0.000 2.75 0.000 1.55 0.268 3.44 0.014 1.16 0.187 0.9 0.000
Matrix metallopeptidase 12 (MMP12 ) 1.37 0.097 2.16 0.000 2.89 0.000 1.36 0.020 0.83 0.000 3.5 0.000 1.65 0.332 6.38 0.005 1.18 0.256 0.89 0.002
Platelet-derived growth factor beta polypeptide 1.12 0.247 1.48 0.001 2.08 0.000 1.14 0.066 0.92 0.000 1.8 0.000 1.15 0.690 2.98 0.014 1.1 0.319 0.97 0.270
SPARC-like 1 (hevin) (SPARCL1 ) 0.7 0.142 0.58 0.042 0.42 0.003 0.73 0.066 1.12 0.010 0.36 0.000 0.32 0.025 0.32 0.077 0.85 0.252 1.05 0.178
Transforming growth factor, beta 1 (TGFβ1 ) 1.1 0.338 1.15 0.179 1.81 0.000 1.02 0.741 0.93 0.000 2 0.001 0.94 0.878 3.55 0.020 1.04 0.728 0.99 0.621
Microbiota Response
Arachidonate 5-lipoxygenase (ALOX5 ) 0.95 0.633 1.17 0.193 1.1 0.430 1.01 0.845 0.94 0.002 1.75 0.008 1.17 0.726 1.28 0.663 1.03 0.837 0.99 0.729
Dual oxidase 2 (DUOX2 ) 1.16 0.315 1.55 0.008 2.13 0.000 1.5 0.000 0.84 0.000 2.74 0.000 1.95 0.186 4.26 0.023 1.36 0.031 0.91 0.010
Mucins
Mucin 1, cell surface associated (MUC1 ) 1.08 0.496 1.26 0.054 1.35 0.021 1.14 0.074 0.9 0.000 2.04 0.001 1.09 0.857 1.69 0.366 1.1 0.453 0.98 0.497
Mucin 4, cell surface associated  (MUC4 ) 0.96 0.766 1.19 0.243 1.47 0.016 1.04 0.686 0.89 0.000 1.46 0.056 1.64 0.254 1.65 0.362 1.15 0.257 0.95 0.075
Mucin 5AC, oligomeric mucus/gel-forming 0.84 0.185 0.84 0.229 0.77 0.083 1.09 0.315 1.05 0.036 0.79 0.317 0.6 0.314 0.3 0.059 1.2 0.200 1.08 0.032
Mucin 7, secreted (MUC7 ) 1.02 0.913 0.71 0.064 0.78 0.199 0.7 0.002 0.99 0.819 1.52 0.055 0.66 0.375 0.76 0.653 0.76 0.039 0.95 0.111
NK Cell Markers
CD247  molecule (CD247) 1.24 0.061 1.43 0.006 2.8 0.000 1.12 0.178 0.92 0.000 2.07 0.000 0.92 0.812 5.16 0.000 1.07 0.469 0.95 0.019
Neural cell adhesion molecule 1 (NCAM1 ) 0.96 0.719 1.09 0.468 1.83 0.000 0.92 0.271 0.96 0.050 1.57 0.007 0.59 0.150 2.2 0.085 0.9 0.312 0.98 0.539
Natural cytotoxicity triggering receptor 1 1.35 0.011 1.41 0.008 3.01 0.000 1.09 0.291 0.92 0.000 2.46 0.000 1.14 0.704 5.33 0.000 1.17 0.097 0.9 0.000
Regulators/Signalling Pathways
CD274 molecule (CD274 ) 1.27 0.090 1.88 0.000 3.56 0.000 1.22 0.047 0.87 0.000 2.64 0.000 1.16 0.683 9.87 0.000 1.14 0.223 0.9 0.000
Marginal zone B and B1 cell-specific protein 1.58 0.015 1.68 0.013 2.3 0.000 1.03 0.811 0.86 0.000 2.7 0.000 1.09 0.867 10.7 0.000 1.16 0.307 0.88 0.000
Serpin peptidase inhibitor clade B member 4, 1.36 0.205 2.46 0.001 3.69 0.000 0.93 0.672 0.87 0.003 0.88 0.736 1.11 0.892 7.78 0.021 0.75 0.220 0.93 0.211
Suppressor of cytokine signalling 1  (SOCS1 ) 1.26 0.032 1.43 0.003 2.97 0.000 1.13 0.105 0.89 0.000 2.06 0.000 1.32 0.379 4.65 0.000 1.02 0.793 0.96 0.040
Suppressor of cytokine signalling 3 (SOCS3 ) 1.21 0.180 1.6 0.003 2.08 0.000 1.15 0.170 0.87 0.000 2.68 0.000 1.54 0.244 3.27 0.012 1.04 0.678 0.94 0.012
C. trachomatis Sex Age
Time-point 3 Time-point 4
TF TP C. trachomatis Sex Age TF TP
 
Target p-value FC p-value FC p-value FC p-value FC p-value FC p-value
Antimicrobial Peptides
Defensin, beta 4B,defensin, beta 4A (DEFB4A ) 0.026 1.98 0.009 3.44 0.000 4.51 0.018 1.52 0.009 0.82 0.000
Psoriasin-1 (S100A7 ) 0.000 3.31 0.000 4.39 0.000 7.39 0.000 2.06 0.000 0.78 0.000
Cytokines/Chemokines
Chemokine ligand 2 (CCL2 ) 0.000 1.69 0.008 1.71 0.022 8.74 0.000 1.29 0.035 0.92 0.006
Chemokine ligand 5 (CXCL5 ) 0.001 2.5 0.001 2.99 0.001 2 0.215 1.47 0.024 0.82 0.000
Chemokine ligand 13 (CXCL13 ) 0.000 3.26 0.000 2.41 0.003 4.07 0.005 1.59 0.002 0.79 0.000
Chemokine ligand 18 (CCL18 ) 0.033 2.88 0.000 4.07 0.000 7.05 0.000 1.13 0.388 0.84 0.000
Chemokine ligand 20 (CCL20 ) 0.000 2.23 0.000 1.45 0.133 2.61 0.023 1.41 0.007 0.92 0.007
Indoleamine 2,3-dioxygenase 1 (IDO1 ) 0.000 2.49 0.000 3.16 0.000 3.77 0.008 1.46 0.013 0.85 0.000
Interferon gamma(IFNG ) 0.000 1.44 0.032 1.68 0.011 16.98 0.000 1.41 0.001 0.94 0.013
Interleukin 1 beta(IL1B ) 0.048 2.1 0.000 2.09 0.003 3.24 0.006 1.19 0.180 0.87 0.000
Interleukin 6 (IL6 ) 0.003 1.44 0.073 0.96 0.866 4.67 0.000 1.16 0.242 0.94 0.048
Interleukin 8 (IL8 ) 0.598 1.61 0.016 1.58 0.051 3.27 0.003 1.08 0.512 0.94 0.035
Interleukin 10 (IL10 ) 0.000 1.96 0.000 1.66 0.007 3.9 0.000 1.2 0.057 0.88 0.000
Interleukin 12 beta (IL12B ) 0.000 1.36 0.044 0.98 0.909 6.43 0.000 1.2 0.044 1 0.876
Interleukin 17A (IL17A ) 0.000 2.31 0.000 2.4 0.000 5.98 0.000 1.59 0.000 0.86 0.000
Interleukin 19 (IL19 ) 0.004 2.53 0.000 3.49 0.000 7.06 0.000 1.6 0.001 0.83 0.000
Interleukin 21 (IL21 ) 0.000 2.39 0.000 2.1 0.001 7.25 0.000 1.66 0.000 0.88 0.000
Interleukin 22 (IL22 ) 0.736 1.37 0.109 1.85 0.010 13.77 0.000 1.17 0.209 0.98 0.461
Interleukin 23A (IL23A ) 0.000 1.77 0.001 1.71 0.011 3.67 0.000 1.12 0.285 0.91 0.000
Prostaglandin-endoperoxide synthase 2 (PTGS2 ) 0.022 1.7 0.003 1.66 0.018 2.22 0.029 1.25 0.049 0.87 0.000
EMT Markers
Epithelial cadherin (CDH1 ) 0.873 1.19 0.207 1.2 0.272 1.24 0.444 1.12 0.188 0.95 0.032
Neuronal cadherin (CDH2 ) 0.644 0.89 0.461 0.8 0.236 1.63 0.126 1.23 0.038 1.06 0.030
S100 calcium binding protein A4 (S100A4 ) 0.483 0.88 0.499 0.87 0.523 0.84 0.641 1.03 0.780 1.02 0.587
Vimentin (VIM ) 0.216 1.49 0.002 1.38 0.034 2.58 0.000 1.08 0.330 0.95 0.008
Matrix Modifiers
Connective tissue growth factor (CTGF-1 ) 0.492 1.08 0.661 0.93 0.720 1.93 0.056 1 0.985 0.99 0.690
Fibroblast growth factor 2 (basic) (FGF2 ) 0.263 1.37 0.065 1.04 0.836 2.32 0.010 1.09 0.448 1.02 0.417
Matrix metallopeptidase 7 (MMP7 ) 0.056 1.49 0.043 1.34 0.211 0.91 0.810 1.01 0.923 0.89 0.000
Matrix metallopeptidase 9 (MMP9 ) 0.000 1.87 0.001 1.56 0.036 3.42 0.001 1.11 0.330 0.91 0.001
Matrix metallopeptidase 12 (MMP12 ) 0.002 1.89 0.004 1.63 0.065 5.91 0.000 1.23 0.125 0.87 0.000
Platelet-derived growth factor beta polypeptide (PDGFB ) 0.270 1.37 0.017 1.55 0.005 2.77 0.000 1.28 0.002 0.95 0.007
SPARC-like 1 (hevin) (SPARCL1 ) 0.178 0.37 0.000 0.21 0.000 0.27 0.017 0.95 0.736 1.25 0.000
Transforming growth factor, beta 1 (TGFβ1 ) 0.621 1.31 0.054 1.31 0.100 1.89 0.025 1.13 0.166 0.96 0.040
Microbiota Response
Arachidonate 5-lipoxygenase (ALOX5 ) 0.729 1.06 0.719 1.03 0.881 1.43 0.263 1.06 0.576 0.94 0.018
Dual oxidase 2 (DUOX2 ) 0.010 1.96 0.002 2.42 0.001 2.79 0.022 1.32 0.039 0.86 0.000
Mucins
Mucin 1, cell surface associated (MUC1 ) 0.497 1.12 0.504 1.09 0.673 1.91 0.064 1.08 0.449 0.94 0.013
Mucin 4, cell surface associated  (MUC4 ) 0.075 1.26 0.183 1.17 0.442 1.61 0.174 1.17 0.142 0.93 0.010
Mucin 5AC, oligomeric mucus/gel-forming (MUC5AC ) 0.032 0.83 0.293 0.99 0.960 0.76 0.442 1.23 0.062 1.11 0.000
Mucin 7, secreted (MUC7 ) 0.111 0.88 0.533 1.15 0.555 0.7 0.380 0.85 0.174 0.94 0.063
NK Cell Markers
CD247  molecule (CD247) 0.019 1.32 0.097 1.53 0.033 3.21 0.001 1.22 0.056 0.92 0.002
Neural cell adhesion molecule 1 (NCAM1 ) 0.539 0.89 0.427 1.15 0.418 1.72 0.071 1 0.996 1.02 0.363
Natural cytotoxicity triggering receptor 1 (NCR1 ) 0.000 1.43 0.022 1.53 0.021 2.97 0.001 1.28 0.011 0.91 0.000
Regulators/Signalling Pathways
CD274 molecule (CD274 ) 0.000 1.74 0.002 2.02 0.001 5.56 0.000 1.29 0.024 0.87 0.000
Marginal zone B and B1 cell-specific protein (MZB1 ) 0.000 1.83 0.005 1.53 0.102 4.2 0.001 1.46 0.005 0.87 0.000
Serpin peptidase inhibitor clade B member 4, (SERPINB4 ) 0.211 1.18 0.600 2.15 0.044 21.14 0.000 0.98 0.940 1 0.965
Suppressor of cytokine signalling 1  (SOCS1 ) 0.040 1.67 0.001 1.52 0.021 2.89 0.001 1.1 0.311 0.9 0.000
Suppressor of cytokine signalling 3 (SOCS3 ) 0.012 1.76 0.003 1.86 0.006 2.47 0.020 1.12 0.345 0.85 0.000
Time-point 5
TF TP C. trachomatis Sex Age
Supplementary Table 4. Estimated Fold Changes (FC) with their respective p-values comparing the expression 
of each gene between the combined first three time-points (time-points 1, 2 and 3) before MDA and time-
point 4 (three months after MDA), not adjusted for C. trachomatis infection. A FC of >1 indicates increased 
expression of the gene at time-point 4. Random effects multivariable linear regression of all individuals (first 
panel), untreated only (second panel) and treated only (third panel). The final column (p-value for interaction) 
provides evidence as to whether the fold change from before to after MDA is different in the treated and 
untreated groups. Results are ordered by FC of ‘’All’’ individuals. Benjamini and Hochberg approach was used to 
adjust for multiple comparisons, in order to control the false discovery rate <5%, only tests with a p-value <0.035 
are considered statistically significant.  
 
Target All Untreated Only Treated Only p-value for interaction FC p-value FC p-value FC p-value 
SPARCL1 18.65 2.75x10^-250 8.21 3.65x10^-23 21.77 1.32x10^-235 2.69X10^-5 
MUC5AC 5.33 7.6x10^-215 3.14 3.06x10^-18 5.88 7.21x10^-206 1.19X10^-5 
CDH2 3.92 2.22x10^-169 2.72 3.72x10^-17 4.24 1.9x10^-158 6.84X10^-4 
MUC7 2.71 2.52x10^-72 2.45 9.19x10^-11 2.74 5.15x10^-62 0.458 
CTGF 2.40 2.04x10^-118 2.29 1.12x10^-19 2.43 1.68x10^-101 0.553 
NCAM1 2.34 5.3x10^-90 1.79 8.89x10^-9 2.49 8.21x10^-86 0.003 
S100A4 2.30 1.87x10^-143 1.95 5.02x10^-17 2.37 4.66x10^-129 0.026 
CDH1 1.94 1.28x10^-122 1.78 1.38x10^-17 1.97 3.13x10^-107 0.173 
ALOX5 1.42 1.61x10^-65 1.45 1.37x10^-13 1.41 2.70x10^-53 0.606 
MUC1 1.39 7.87x10^-39 1.40 4.01x10^-8 1.40 2.12x10^-33 0.975 
FGF2 1.39 6.72X10^-6 1.41 0.046 1.42 1.77x10^-5 0.994 
TGFB1 1.34 9.68x10^-46 1.41 5.79x10^-12 1.32 2.41x10^-35 0.272 
MUC4 1.30 5.69x10^-19 1.40 2.54x10^-6 1.29 4.82x10^-15 0.273 
GAPDH 1.29 6.09x10^-18 1.50 1.65x10^-8 1.25 1.06x10^-11 0.020 
IL12B 1.24 7.69x10^-6 1.28 0.035 1.24 5.35x10^-5 0.794 
PDGFB 1.22 1.49x10^-12 1.29 1.54x10^-4 1.20 1.01x10^-9 0.351 
NCR1 1.21 2.44x10^-8 1.15 0.086 1.22 6.90x10^-8 0.530 
VIM 1.13 7.56x10^-8 1.17 0.005 1.13 3.59x10^-6 0.515 
SOCS1 1.13 2.42x10^-4 1.36 1.35x10^-4 1.09 0.021 0.012 
SX10RPINB4 1.13 0.341 1.34 0.320 1.09 0.565 0.520 
MMP7 1.11 0.006 1.17 0.086 1.09 0.028 0.487 
CD247 0.96 0.122 1.02 0.770 0.94 0.059 0.297 
MMP9 0.84 9.28x10^-5 0.91 0.371 0.83 1.37x10^-4 0.457 
IL23A 0.83 2.24x10^-6 0.92 0.369 0.81 2.43x10^-6 0.250 
IL6 0.80 2.75x10^-5 0.77 0.050 0.81 3.65x10^-4 0.758 
CCL20 0.78 5.98x10^-8 0.88 0.263 0.76 8.80x10^-8 0.232 
IFNG 0.76 7.28x10^-8 0.76 0.030 0.77 1.07x10^-6 0.985 
DUOX2 0.71 1.51x10^-22 0.87 0.116 0.69 1.05x10^-22 0.011 
PTGS2 0.68 1.96x10^-19 0.77 0.011 0.67 3.94x10^-18 0.203 
IL8 0.68 1.75x10^-24 0.69 7.73x10^-5 0.68 2.06x10^-20 0.822 
IL22 0.65 1.91x10^-6 0.95 0.801 0.60 2.79x10^-7 0.042 
IL10 0.60 7.40x10^-35 0.74 0.002 0.58 2.33x10^-33 0.029 
SOCS3 0.58 8.67x10^-40 0.73 0.001 0.56 3.03x10^-38 0.015 
MZB1 0.56 6.51x10^-26 0.65 0.001 0.55 7.23x10^-24 0.260 
CD274 0.54 1.82x10^-57 0.68 3.92x10^-5 0.51 4.37x10^-55 0.008 
CCL2 0.48 3.48x10^-37 0.55 1.23x10^-5 0.47 1.01x10^-32 0.341 
IL1B 0.46 5.42x10^-59 0.56 7.91x10^-07 0.44 4.31x10^-54 0.054 
IDO1 0.41 7.77x10^-102 0.65 2.11x10^-5 0.38 3.28x10^-104 1.56X10^-6 
IL17A 0.40 4.45x10^-62 0.57 2.46x10^-5 0.38 2.21x10^-59 0.005 
IL21 0.40 1.52x10^-39 0.61 0.003 0.37 6.53x10^-39 0.007 
MMP12 0.37 1.06x10^-87 0.51 4.56x10^-8 0.35 3.18x10^-82 0.005 
CXCL5 0.36 3.84x10^-72 0.59 2.11x10^-4 0.32 1.17x10^-72 1.04X10^-4 
DX10FB4A 0.35 1.46x10^-64 0.50 4.51x10^-6 0.33 5.23x10^-61 0.013 
IL19 0.33 1.01x10^-79 0.48 2.57x10^-7 0.31 1.71x10^-75 0.005 
CXCL13 0.30 4.71x10^-66 0.44 9.38x10^-7 0.28 3.44x10^-62 0.015 
S100A7 0.24 2.33x10^-60 0.47 3.39x10^-4 0.21 3.46x10^-61 4.20X10^-4 
CCL18 0.23 1.32x10^-77 0.41 1.17x10^-6 0.21 9.46x10^-76 8.98X10^-4 
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Supplementary Table 5. Estimated Fold Change (FC) with their respective p-values for the expression of 
each gene at time-point 4 only (three months post MDA), comparing MDA treated (after time-point 3) 
to untreated individuals. Multivariable linear regression of all individuals adjusted (first panel) and not 
adjusted (second panel) for C. trachomatis infection. Results are ordered by FC of adjusted data with 
infection. Benjamini and Hochberg approach was used to adjust for multiple comparisons, in order to 
control false discovery rate <5%, only tests with a p-value <0.009 are considered statistically significant. 
 
Target 
Adjusted for infection 
 
Not adjusted for infection 
 
FC p-value FC p-value 
SPARCL1 2.06 3.10x10^-04 2.34 2.55 x10^-5 
MUC5AC 1.44 0.011 1.62 9.45 x10^-4 
MUC7 1.28 0.081 1.35 0.030 
CDH2 1.27 0.062 1.30 0.037 
NCAM1 1.19 0.055 1.19 0.048 
IFNG 1.16 0.225 1.03 0.802 
S100A4 1.08 0.238 1.14 0.052 
MZB1 1.07 0.660 0.97 0.820 
NCR1 1.05 0.568 0.99 0.904 
CDH1 1.03 0.701 1.05 0.464 
CD247 1.02 0.748 0.97 0.668 
IL12B 1.01 0.890 0.92 0.468 
VIM 1.00 0.950 0.97 0.599 
TGFB1 0.98 0.738 0.96 0.429 
SERPINB4 0.97 0.913 0.89 0.700 
ALOX5 0.95 0.389 0.98 0.725 
CCL2 0.95 0.602 0.89 0.247 
PDGFB 0.95 0.440 0.93 0.300 
IL6 0.94 0.627 0.91 0.479 
MMP9 0.94 0.552 0.90 0.331 
CTGF 0.93 0.462 0.94 0.529 
IL23A 0.93 0.340 0.88 0.110 
GAPDH 0.92 0.330 0.91 0.275 
MMP7 0.91 0.370 0.93 0.520 
SOCS1 0.90 0.183 0.86 0.057 
MUC1 0.88 0.046 0.89 0.071 
IL8 0.88 0.208 0.88 0.203 
CD274 0.87 0.088 0.80 0.006 
CCL20 0.86 0.199 0.84 0.123 
PTGS2 0.85 0.100 0.84 0.083 
IL10 0.85 0.028 0.80 0.004 
IL1B 0.84 0.083 0.81 0.034 
CXCL13 0.82 0.199 0.74 0.051 
MUC4 0.82 0.015 0.84 0.024 
FGF2 0.78 0.134 0.79 0.132 
SOCS3 0.78 0.008 0.76 0.003 
DUOX2 0.76 0.017 0.73 0.005 
IL19 0.74 0.018 0.69 0.003 
IL21 0.74 0.041 0.64 0.004 
CCL18 0.73 0.042 0.67 0.008 
IL17A 0.73 0.013 0.66 0.001 
IL22 0.72 0.110 0.64 0.030 
MMP12 0.71 0.009 0.66 0.001 
DEFB4A 0.71 0.068 0.69 0.042 
S100A7 0.70 0.030 0.63 0.005 
IDO1 0.64 8.99 x10^-4 0.59 1.03 x10^-4 
CXCL5 0.57 4.02E-04 0.56 1.98E-04 
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Supplementary Table 6. Estimated fold changes (FC) with their respective p-values comparing the expression of 
each gene between the combined first three time-points (1, 2 and 3) before MDA and separately time-points 4 
and 5 (three and six months following MDA treatment), in 122 individuals who were free from infection and 
disease (F0, P0) at all 5 time-points. Results are ordered by Fold Change (FC) in pre-MDA time-points vs. time-point 4. 
Benjamini and Hochberg approach was used to adjust for multiple comparisons, in order to control the false discovery rate 
<5%, only tests with a p-value <0.035 are considered statistically significant.  
 
  Pre-MDA vs time-point 4 Pre-MDA vs time-point 5 
Target FC p-value FC p-value 
SPARCL1 7.84 8.25x10-23 1.44 0.130 
CDH2 3.34 7.15x10-21 1.61 1.78x10-04 
MUC5AC 3.07 1.75x10-16 1.38 0.033 
CTGF 1.99 2.71x10-10 0.96 0.684 
NCAM1 1.93 4.07x10-15 1.42 4.88x10-05 
CDH1 1.88 3.74x10-19 1.17 0.019 
S100A4 1.74 3.57x10-14 0.97 0.724 
MUC7 1.40 9.60x10-03 1.03 0.846 
IL12B 1.36 0.0147 1.01 0.927 
TGFB1 1.35 4.53x10-07 1.10 0.111 
MUC1 1.29 8.18x10-05 0.99 0.872 
ALOX5 1.29 8.31x10-09 1.00 0.998 
PDGFB 1.27 8.69x10-04 0.94 0.346 
GAPDH 1.25 2.23x10-04 0.94 0.351 
SOCS1 1.23 0.0193 1.07 0.544 
IL23A 1.16 0.13 1.04 0.694 
MUC4 1.12 0.139 0.91 0.359 
NCR1 1.09 0.355 0.92 0.416 
FGF2 1.08 0.683 0.97 0.890 
VIM 1.07 0.26 0.90 0.102 
CD247 1.07 0.387 0.91 0.254 
MMP7 1.04 0.698 0.73 4.32x10-04 
IFNG 0.93 0.534 0.82 0.125 
IL22 0.89 0.636 0.94 0.769 
CCL2 0.87 0.253 0.76 0.058 
SERPINB4 0.86 0.661 1.72 0.166 
MMP9 0.83 0.146 0.90 0.453 
DUOX2 0.83 0.049 0.61 5.06x10-04 
IL8 0.78 0.015 0.86 0.118 
CCL20 0.78 0.073 0.89 0.442 
PTGS2 0.75 0.022 0.82 0.123 
IL10 0.74 3.28x10-03 0.83 0.061 
IL6 0.72 0.0384 0.77 0.079 
CD274 0.70 7.10x10-04 0.83 0.092 
IL21 0.65 0.0166 0.71 0.064 
SOCS3 0.64 6.95x10-04 0.76 0.057 
MZB1 0.61 3.29x10-04 0.82 0.142 
IL17A 0.60 8.87x10-04 0.82 0.234 
IL1B 0.58 5.77x10-05 0.79 0.101 
IL19 0.56 4.06x10-05 0.78 0.120 
IDO1 0.55 1.23x10-08 0.69 2.28x10-03 
CCL18 0.53 3.07x10-04 0.74 0.103 
CXCL13 0.48 1.64x10-05 0.70 0.049 
CXCL5 0.46 4.97x10-07 0.83 0.242 
MMP12 0.44 5.06x10-10 0.54 7.17x10-05 
DEFB4A 0.42 4.16x10-08 0.64 0.012 
S100A7 0.41 6.23x10-08 0.68 0.029 
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Appendix 9: Progression of Scarring Trachoma in Tanzanian Children: a Four-year 
Cohort Study (Equivalent to Chapter 8)
RESEARCH ARTICLE
Progression of scarring trachoma in
Tanzanian children: A four-year cohort study
Athumani M. RamadhaniID1,2, Tamsyn Derrick1,2, David MacleodID1, Patrick Massae2,
Elias Mafuru2, Aiweda Malisa2, Kelvin Mbuya2, Chrissy h. RobertsID1, William Makupa2,
Tara Mtuy1,2, Robin L. Bailey1, David C. W. Mabey1, Martin J. HollandID1, Matthew
J. BurtonID1
1 London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 Kilimanjaro Christian
Medical Centre, Moshi, Tanzania
* Athumani.Ramadhani@lshtm.ac.uk
Abstract
Background
Trachoma is a progressive blinding disease initiated by infection of the conjunctiva with
Chlamydia trachomatis. Repeated infections are thought to cause chronic inflammation,
which drives scarring, leading to in-turning of the eyelids. The relationship between C. tra-
chomatis, clinical inflammation and scarring development in children is not fully understood
due to a paucity of longitudinal studies with infection data at frequent follow-up.
Methods and findings
This longitudinal cohort study took place in northern Tanzania. Children aged 6–10 years at
baseline were eligible for inclusion. Participants were visited every three months for four
years. Clinical signs and conjunctival swabs for C. trachomatis detection by qPCR were col-
lected at each time-point. Conjunctival photographs from baseline and final time-points
were graded and compared side-by-side to determine scarring incidence and progression.
Of the 666 children enrolled in the study, outcome data were obtained for 448. Scarring
progression was detected in 103/448 (23%) children; 48 (11%) of which had incident scar-
ring and 55 (12%) had progression of existing scarring. Scarring was strongly associated
with increasing episodes of trachomatous papillary inflammation (TP). Weaker associations
were found between episodes of C. trachomatis infection and follicular trachoma (TF) with
scarring progression in unadjusted models, which were absent in multivariable analysis
after adjusting for inflammation (multivariable results: C. trachomatis p = 0.44, TF p = 0.25,
TP p = 0.0001, age p = 0.13, female sex p = 0.05). Individuals having TP at 30% or more of
the time-points they were seen had an odds ratio of 7.5 (95%CI = 2.7–20.8) for scarring pro-
gression relative to individuals without any TP detected during the study period.
Conclusions
These data suggest that the effect of infection on scarring progression is mediated through
papillary inflammation, and that other factors contributing to the development of
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inflammation, in addition to C. trachomatis infection, may be important in driving conjunctival
scarring progression in children. The addition of TP as a measure in trachoma control pro-
grams would provide an indication of the future risk of developing scarring sequelae.
Author summary
Trachoma is the leading cause of preventable blindness worldwide and is targeted for
elimination as a public health problem by 2020. The natural history of trachoma is not
completely understood however. We conducted a four-year longitudinal study in a tra-
choma-endemic area of northern Tanzania with detailed follow up every three months. In
the four-year study period, nearly one quarter of children developed progression of con-
junctival scarring, despite three rounds of annual mass drug administration (MDA) for
trachoma control. Disease progression was strongly associated with increasing proportion
of episodes with conjunctival papillary inflammation (TP), and only weakly associated
with Chlamydia trachomatis infection and trachomatous inflammation–follicular (TF).
Analysis revealed that associations between infection and TF with scarring progression
were mediated through TP, and that other factors causing individual differences in TP
were also contributing to scarring progression. These data have significant implications
for trachoma control. We hypothesise that in individuals who have previously experienced
ocular C. trachomatis infection, TP is the primary driver of scarring progression. The
addition of TP to trachoma surveillance programs would provide an indicator for active
disease progression in the community and a more accurate guide to the need for future
trichiasis interventions.
Introduction
Sight loss from trachoma, the leading infectious cause of blindness, is the end result of an
inflammatory-scarring process. Starting from early childhood, people growing-up in a tra-
choma endemic community may be repeatedly exposed to ocular challenge with Chlamydia tra-
chomatis, the causative organism. This is thought to trigger inflammatory responses that lead to
conjunctival scarring in some individuals[1]. As a result of conjunctival scarring the eyelids
(entropion) and eyelashes (trichiasis) turn in, scratching the ocular surface and resulting in cor-
neal opacification[1]. These complications of scarring usually develop during adulthood.
Trachoma control rests on the SAFE Strategy: Surgery for trichiasis, Antibiotic treatment
to treat C. trachomatis infection, Facial cleanliness and Environmental improvements to
reduce transmission. Endemic countries and the international community have set the ambi-
tious target of 2020 for the elimination of trachoma as a public health problem[2]. There is no
specific treatment to halt the progression of scarring, beyond controlling the infection.
Around 3.2 million people are estimated to have trichiasis and 1.9 million of these are blind
or have severe visual impairment[3]. Currently WHO estimates that 158 million people live in
districts that require A, F and E interventions[4]. Nearly 90% of these people live in Sub-Saha-
ran Africa.
Longitudinal data sets documenting the incidence or progression of conjunctival scarring
trachoma are limited[1]. Such studies are complex and can take many years to complete. In this
paper we report the clinical signs and infection results of children who were followed up every
three months for four years. The aim of the study was to investigate the risk factors associated
Progressive scarring trachoma in children
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with scarring incidence and progression in Tanzanian children. We investigated the association
between scarring progression and clinical signs of inflammation, C. trachomatis infection, age
and sex, in order to strengthen the evidence base that supports trachoma control programs.
Methods
Ethical statement
This study was reviewed and approved by Ethics Committees of the Tanzania National Insti-
tute for Medical Research, Kilimanjaro Christian Medical University College and the London
School of Hygiene & Tropical Medicine. It adhered to the tenets of the Declaration of Helsinki.
The study was explained in detail in Kiswahili or Maasai; written informed consent from a par-
ent or legal guardian was necessary for enrollment.
Study design and population
We recruited a cohort of children from three neighboring villages in northern Tanzania. Two
villages were in Siha district located in Kilimanjaro region and one was in Longido district
located in Arusha region. They were assessed every three months for four years, totaling 17
time-points. The communities and recruitment have been previously described in detail[5].
These communities are predominantly comprised of Maasai people. Children aged between 6
and 10 years at baseline (February 2012), who were normally resident in the villages, were eli-
gible for inclusion. This restricted age group was chosen as we anticipated that younger chil-
dren may not have manifest incident / progressive conjunctival scarring during the four years
of follow-up. A census was conducted and eligible children enrolled.
Clinical assessment and sample collection
At each time-point all available children were examined by an experienced ophthalmic nurse.
The eye was first anaesthetized with preservative-free proxymetacaine hydrochloride 0.5% eye-
drops. The left upper eyelid was everted and tarsal conjunctiva examined (using x2.5 loupes
and torch) for signs of trachoma and graded using the 1981 WHO ‘FPC’ detailed grading sys-
tem[6]. This grading system corresponds to the WHO Simplified Trachoma Grading System:
F2/F3 equates to Trachomatous Inflammation-Follicular (TF), and P3 to Trachomatous Inflam-
mation-Intense (TI)[7]. “Clinically Active Trachoma” was defined as presence of TF and/or TI.
We also consider that both P2 and P3 represent clinically significant papillary inflammation,
and refer to this as “TP”[8]. High resolution photographs (Nikon D90 camera with 105mm
Macro lens) were taken of the conjunctiva for independent grading.
Two conjunctival swab samples were collected (Dacron polyester, Puritan Medical Products
Company, Maine) at each time-point. The first was placed in RNAlater (Thermo Fisher, UK)
and the second was stored dry. Clinical swabs and air control swabs were collected and stored
as described previously[5]. Samples were stored on ice in the field and were transferred to a
-80˚C freezer upon return to the laboratory later the same day.
Trachoma control
Following approval from the Ministry of Health (MoH) and in collaboration with the district
eye coordinators the SAFE strategy was implemented in study villages by the study field team.
Education was provided regarding facial cleanliness and environmental improvements and
free trichiasis surgery was offered. Azithromycin mass drug administration (MDA) was
administered by the study team, according to WHO guidelines, in August 2012, August 2013
and August 2014. In mid-2015, one of the three villages from Longido district, which had a
Progressive scarring trachoma in children
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persistently elevated TF prevalence, received a further round of MDA. This was delivered by
the local MoH team as part of the district-wide distribution. The other two villages, which are
in the neighboring district (Siha), were not re-treated as the district-wide prevalence was
below the treatment indication threshold, and these two villages had shown a good response to
the three rounds of MDA.
Chlamydia trachomatis detection
At the first time-point, DNA was extracted using the PowerSoil DNA Isolation Kit (Mo Bio
Laboratories, USA) from swab samples stored in dry tubes and C. trachomatis was detected by
droplet digital PCR, as previously described[5, 9]. At all subsequent time-points, DNA was
extracted from samples stored in RNAlater using the Norgen RNA/DNA purification kit (Nor-
gen Biotek) and C. trachomatis was detected by triplex quantitative PCR (qPCR) for chlamyd-
ial chromosomal (omcB) and plasmid (pORF2) genes and a human endogenous control gene
(RPP30), as described previously[10]. Time-point 2 Norgen-extracted samples were tested by
both detection methods and the kappa score for agreement was 0.84. Samples were tested in
duplicate and were defined as C. trachomatis positive if RPP30 and pORF2 and/or omcB ampli-
fied in<40 cycles in one or both replicates.
Analysis
We used photographic grading to determine whether there was either development of incident
scarring in previously un-scarred conjunctiva, or increase in pre-existing scarring. Conjunctival
photographs from baseline (time-point 1) were compared to the final time-point (time-point
17). For individuals not seen at time-point 1, the image from time-point 2 was used for their
baseline. Similarly, if an individual was not seen at time-point 17, the image from time-point 16
was used as their final time-point. The images were assessed by an ophthalmologist experienced
in using a detailed scarring grading system[11]. Baseline and final photographs were compared
side-by-side to produce the main binary outcome variable of overall “scarring progression”,
defined as evidence of either incident scarring or worsening of pre-existing scarring. For further
sub-analyses, we subdivided individuals with “no scarring progression” into (1) no scarring at
either baseline and final; (2) scarring unchanged between baseline and final. We subdivided
individuals with “scarring progression” into (3) incident scarring (no scarring at baseline and
new scarring at final); (4) increasing scarring (some scarring at baseline and more at final).
All field data were managed in Access (Microsoft). Data were merged and analyzed in
STATA v14. The total number of time-points at which participants were seen varied due to
absence or refusal. We excluded from the analysis individuals who were seen on fewer than
four occasions or did not have outcome data (time-point 16 or 17 assessments). A proportion
variable was generated for each of TF, TP and C. trachomatis infection: number of time-points
with each factor as a proportion of the total number of time-points that individual was seen.
Proportions were subsequently categorized.
Separate mixed effects logistic regression models were used to determine the association
between (1) TP, (2) TF, and (3) C. trachomatis infection with sex and baseline age, using data
from all time-points in the longitudinal dataset. Mixed effects regression was also performed
to assess the relationship between (1) TF and C. trachomatis infection, and (2) TP and C. tra-
chomatis, again using data from all time-points in the longitudinal dataset (adjusting for age at
baseline and sex). These analyses were limited to the 448 individuals with outcome data.
To identify risk factors for scarring progression, analysis was initially performed using
logistic regression to assess the association between categorized proportions of TF, TP or C.
trachomatis infection and overall scarring progression (either incident scarring in those
Progressive scarring trachoma in children
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without scarring at baseline or progression of pre-existing scarring). Each of these were ini-
tially included as exposures separately in a logistic regression using scarring progression as the
outcome variable and adjusting for age at baseline and sex. Following this, all three were
included in a final multivariable model (adjusting for baseline age and sex), and likelihood
ratio tests were performed between models including versus excluding each exposure to deter-
mine its overall P value. The analyses were subsequently repeated to identify risk factors for
incident scarring and progression of pre-existing scarring separately. In the first set of univari-
able and multivariable analyses (using the same exposures as above) the analysis was restricted
to individuals without scarring at baseline (incident scarring versus no scarring). In the second
set, analysis was restricted to individuals with scarring at baseline (progression of existing scar-
ring versus no progression of existing scarring).
Chlamydial load was calculated by extrapolating from a standard curve. OmcB in copies/μl
was log10 transformed to normalize the distribution. In the longitudinal dataset random
effects linear regressions were performed to look for associations between a) chlamydial load
and scarring progression (adjusting for MDA-period, age at baseline and sex), and b) chla-
mydial load and age at time-point (in years) in C. trachomatis positive individuals (adjusting
for sex and MDA-period). Age at time-point was split into four groups;<7.5 years, 7.5 -<10
years, 10 -<12.5 years, and 12.5 years. A random effects linear regression was then per-
formed to assess for association between chlamydial load, age group and progression, includ-
ing an interaction term between age group and progression in order to determine whether the
association between chlamydial load and progression was modified by age. MDA-period (pre-
MDA, post first MDA, post second MDA, post third MDA) was included in the model to
adjust for confounding.
Results
Study participants
The participant flow is shown in Fig 1. There were 666 potentially eligible children and 616
enrolled. Fifty either refused or were absent. We excluded 57 who were examined on less than
four occasions, and 111 without scarring progression outcome data (no time-point 16 or 17
assessment). This left 448 in this analysis, who were seen at a median of 15 time-points (1st–
3rd quartiles = 13–16, S1 Fig).
The demographic characteristics of the entire cohort were described in the baseline report
[5]. Of the 448 children included in this analysis, 242 (54.0%) were female, mean age at base-
line was 6.8 years, and 438 (97.8%) were Maasai. Of the 218 children not included, 92 (42.2%)
were female (OR = 1.61, 95%CI = 1.16–2.23, p = 0.004), mean age at baseline was 7.4 years
(OR = 0.86, 95% CI = 0.79–0.93, p<0.0002) and 214 (98.2%) were Maasai. Younger children
and females were therefore more likely to be included in this study analysis.
Antibiotic coverage of the 448 children included in scarring progression analysis was 355
(79.2%) in 2012, 374 (83.5%) in 2013 and 338 (75.4%) in 2014. The estimated community-
wide MDA coverage in 2012, 2013 and 2014 were 68.7%, 42.9% and 72.9%, respectively.
Clinical disease
Of the 448 participants, 240 (53.6%) had TF (F2/F3), 185 (41.3%) had TP (P2/P3)), and 248
(55.4%) had clinically active trachoma (F2/3 and/or P3) at one or more time-point. The preva-
lence of TF and TP is shown for each time-point in Fig 2.
There was a significant reduction in inflammatory disease following MDA, although TP
prevalence was particularly high at time-point 6. Examination of inflammation and infection
prevalence by village revealed that this peak in TP was found in only two of the three villages
Progressive scarring trachoma in children
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Fig 1. Flow chart for eligible study participants. The chart shows the number of individuals enrolled, excluded and
included in the analysis of scarring progression.
https://doi.org/10.1371/journal.pntd.0007638.g001
Fig 2. The prevalence of C. trachomatis infection and clinical signs at each time-point.Data are shown for the 448 individuals with outcome data.
There were three-month intervals between time-points. Red vertical lines indicate annual MDA treatment given to all three study villages. The red
dashed vertical line indicates treatment given to one village with residual disease.
https://doi.org/10.1371/journal.pntd.0007638.g002
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(“A” and “C”), and did not appear to correlate with infection (S2 Fig), indicating that it may
have been driven by non-chlamydial infection.
The number of individuals with categorized proportions of time-points (none,<10%, 10–
19%, 20–29%, 30%+) that they were found to have (1) TF, (2) TP and (3) C. trachomatis infec-
tion is shown in Table 1. At baseline, 93 (20.8%) had some degree of conjunctival scarring.
The odds of TF were estimated to be higher in females (OR = 1.49, 95%CI = 1.05–2.11,
P = 0.025) and lower with each additional year of age (OR = 0.65, 95%CI = 0.59–0.71,
p<0.0001) in the longitudinal dataset. The odds of TP were also estimated to reduce with age
(OR = 0.79, 95%CI = 0.71–0.88, p<0.0001) but the evidence of an association with sex was
much weaker (OR = 1.39, 95%CI = 0.92–2.09, p = 0.119). There was little difference between
children included and those excluded in the analysis in terms of sex and baseline TF/TP/infec-
tion although those excluded tended to be slightly older on average than those included (mean
baseline age 7.4 vs 6.8, p<0.001).
C. trachomatis infection
C. trachomatis was detected in 219/448 (48.9%) at one or more time-points. The prevalence of
infection is shown for each time-point in Fig 2. The proportion of time-points that each indi-
vidual had infection is shown in Table 1. The median proportion of time-points infected
among the 219 individuals who had C. trachomatis detected on at least one occasion was
12.5%, which was equivalent to ~2 time-points if someone had been seen on all 17 visits.
Infection prevalence declined following each round of MDA, however at time point 10 (9
months after second MDA) it had increased and at time-point 14 (9 months after third MDA)
infection prevalence had returned to pre-MDA levels (10–15%). Infection prevalence dropped
again by time-points 16 and 17. Further examination of infection and clinical sign prevalence
in each of the three villages showed that the majority of infection and TF at later time-points
were found in only village “C” (S2 Fig). Village “C” is located in a different administrative dis-
trict, which (unlike the other two villages) was eligible for and received MoH administered
MDA treatment in July-2015. This was subsequently followed by a further drop in infection,
TF and TP prevalence in village “C” at time-points 16 and 17 (S2 Fig).
In a mixed effects logistic regression of infection at any time-point, female sex (OR = 1.7,
95%CI = 1.25–2.34, p = 0.001) and younger baseline age (OR = 0.82, 95%CI = 0.75–0.99,
p<0.0001) were significantly associated with C. trachomatis infection.
Clinical disease and infection
Overall, there was a strong association between C. trachomatis infection and TF (OR = 11.6,
95%CI = 8.9–15.0, P<0.0001) and TP (OR = 9.6, 95%CI = 7.1–12.8, P<0.0001) in the longitu-
dinal dataset (adjusted for baseline age and sex). The odds ratios for TP and TF as predictors
Table 1. Number of individuals with C. trachomatis infection, TF and TP, categorized by proportion of time-points. C. trachomatis infection, TF and TP were
detected as a percentage of the total number of time-points that individual was seen.
Proportion of time-points C. trachomatis TF TP
n (%) n (%) n (%)
None 229 (51.1%) 208 (46.4%) 263 (58.7%)
<10% 78 (17.5%) 52 (11.6%) 71 (15.8%)
10–19% 79 (17.6%) 71 (15.9%) 48 (10.7%)
20–29% 43 (9.6%) 56 (12.5%) 41 (9.2%)
30% + 19 (4.2%) 61 (13.6%) 25 (5.6%)
https://doi.org/10.1371/journal.pntd.0007638.t001
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of C. trachomatis infection (adjusted for TP/TF, age at baseline and sex) at each time-point
were generally similar to or slightly higher after the initiation of MDA, however confidence
intervals were much wider (S3 Fig).
Scarring progression
Overall, scarring progression was observed in 103/448 (23.0%) participants (Table 2). There
were 307 (68.5%) who had no scarring; 38 (8.5%) with unchanged scarring; 48 (10.7%) with
incident scarring; and 55 (12.3%) with increasing scarring.
The relationships between scarring progression and proportion of time-points when C. tra-
chomatis was detected or signs of inflammation (TF or TP) were seen, adjusting only for age at
baseline and sex, are shown in Table 3. In these models strong evidence was found of an associ-
ation between progression and both TP and TF, but the association between infection and pro-
gression was weaker. There was also evidence of a greater risk of progression in females
compared to males.
In a multivariable model (Table 4) for scarring progression (retaining infection, TF, TP, age
at baseline and sex), the strong relationship between increasing proportion of time-points with
TP and scarring progression remained. Female sex was marginally associated. There was no
association with either TF or infection, suggesting that the associations between TF and infec-
tion with scarring were mediated through TP.
The analysis was repeated, restricted to individuals with (a) no scarring at baseline, and (b)
some scarring at baseline, in order to differentiate between factors associated with incident
scarring and progression of pre-existing scarring, respectively. In the unadjusted models there
was evidence for associations between episodes of C. trachomatis infection, TF and TP and
incident scarring (S1 Table). In the multivariable model however, only TP was significantly
associated with incident scarring, again suggesting that the effect of infection and TF was
mediated through TP (S2 Table). Neither infection, TF nor TP were significantly associated
with progression of pre-existing scarring in either the unadjusted or adjusted models. There
seemed to be a trend for increasing risk of progressive scarring with increasing episodes of TP,
however the evidence for this effect was weak, it should be noted that the sample size for these
sub-analyses was small. These data from children with pre-existing scarring did not demon-
strate that additional episodes of C. trachomatis infection were associated with further progres-
sion of scarring. Female sex was associated with an increase in pre-existing scarring but not
with incident scarring. There were no associations with age.
C. trachomatis infection load
Bacterial load in C. trachomatis positive individuals was equivalent between people with and
without scarring progression, using data from all time-points (adjusting for age at baseline, sex
Table 2. Scarring progression category by presence of C. trachomatis infection and clinical features. Both infection and clinical features were detected at one or more
time-points.
Overall scarring Scarring subgroups
Clinical phenotype Total Progression No progression No scarring Unchanged scarring Incident scarring Increasing scarring
Total 448 103 (23%) 345 (77%) 291 (65%) 54 (12%) 48 (10.7%) 55 (12.3%)
No infection/TP/TF 122 17 (13.9%) 105 (86.1%) 95 (77.9%) 10 (8.2%) 11 (9%) 6 (4.9%)
Any TF 240 67 (27.9%) 173 (72.1%) 136 (56.7%) 37 (15.4%) 31 (12.9%) 36 (15%)
Any TP 185 67 (36.2%) 118 (63.8%) 89 (48.1%) 29 (15.7%) 28 (15.1%) 39 (21.1%)
Any C. trachomatis 219 55 (25.1%) 164 (74.9%) 137 (62.6%) 27 (12.3%) 29 (13.2%) 26 (11.9%)
https://doi.org/10.1371/journal.pntd.0007638.t002
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and pre/post-MDA period) (OR = 1.1, 95% CI = 0.86–1.42, p = 0.45). There was evidence of
an association between age at time-point (in years) and infection load among C. trachomatis
positive individuals, with lower loads in older individuals (OR = 0.91, 95%CI = 0.86–0.97,
p = 0.004), adjusting for sex and MDA period. Bacterial load in C. trachomatis positive pro-
gressors and non-progressors was plotted across different age groups (derived from age in
years at that time-point) to determine whether the association between scarring progression
and load varied by age. In the oldest age group, progressors had a slightly higher infection load
relative to non-progressors, Fig 3, which was supported by evidence for an interaction between
age group and progression in their association with bacterial load (p = 0.012). The model
including the interaction explained the data better than the model without the interaction
(p = 0.016).
Discussion
The development of trachomatous scarring is probably the result of a complex interaction
between C. trachomatis infection, variation in the host immune response and possibly other
pro-inflammatory stimuli. However, long-term data exploring the relative contributions of
these factors to the development of scarring in children are limited.
In this cohort of Tanzanian children aged 6–10 years old at baseline we found that 23% had
trachomatous scarring progression over the course of four years. Roughly half of this was new
scarring whilst the other half involved progression of pre-existing scarring. Scarring progres-
sion was strongly associated with increasing frequency of conjunctival papillary inflammation
(TP). This suggests that controlling TP could potentially limit progressive scarring trachoma.
Table 3. Univariable logistic regressionmodels of the associations between overall scarring progression and C. trachomatis infection and clinical features. C. tracho-
matis infection, TF and TP were categorized by proportions of time-points present, and were adjusted only for age at baseline and sex. The overall P value for each model
is shown in line with the variable name.
n/N (%) OR 95% CI P value
C. trachomatis 0.041
None 48/229 (20.9%)
<10% 12/78 (15.4%) 0.64 0.3–1.3
10–19% 21/79 (26.6%) 1.29 0.7–2.4
20–29% 15/43 (34.9%) 1.91 0.9–3.9
30% + 7/19 (36.8%) 2.20 0.8–6.0
TF 0.0004
None 36/208 (17.3%)
<10% 8/52 (15.4%) 0.93 0.4–2.2
10–19% 18/71 (25.4%) 1.96 1.0–3.9
20–29% 15/56 (26.8%) 1.92 0.9–4.0
30% + 26/61 (42.6%) 4.41 2.2–8.8
TP <0.0001
None 36/263 (13.7%)
<10% 17/71 (23.9%) 2.14 1.1–4.2
10–19% 15/48 (31.3%) 3.08 1.5–6.4
20–29% 21/41 (51.2%) 7.26 3.5–15.0
30% + 14/25 (56.0%) 8.41 3.5–20.2
Age at baseline 1.01 0.9–1.1 0.853
Sex
Male
Female
38/206
65/242
(18.5%)
(26.9%)
1.62 1.0–2.6 0.036
https://doi.org/10.1371/journal.pntd.0007638.t003
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We found only weak evidence of an association between C. trachomatis infection and scar-
ring progression. Increasing proportions of infection episodes were associated with incident
scarring, however, multivariable analysis showed that this effect was mediated through TP.
These data suggest that other factors, in addition to C. trachomatis infection, are important
determinants of the development of TP and progression of scarring. The data also indicate
that the clinical sign of TF has no association with scarring progression after adjusting for TP,
suggesting that TF is not a direct cause of, nor the best prognostic marker for scarring progres-
sion. For this purpose, TP prevalence might be a more informative clinical marker, and control
programs could consider using TF in combination with TP prevalence to predict future risk of
scarring.
Our finding that increasing frequency of papillary inflammation is strongly associated with
scarring progression has consistently been reported by other studies[1], however the relation-
ship between chlamydial infection and scarring progression is less definitive.
The first longitudinal study to try to investigate scarring progression was conducted by
Dawson et al in Tunisia, starting in the late 1960’s. They examined a group of children and
younger adults (n = 213) on two occasions about 14 years apart; no tests for C. trachomatis
infection were performed. TI (P3) was the strongest risk factor for developing severe scarring
(RR = 18), whilst TF had a weaker association (RR = 2.8)[12]. Interestingly, there also appeared
to be increased scarring risk associated with moderate papillary inflammation (P2).
West et al investigated the relationship between “constant severe inflammatory trachoma”
(TI diagnosed at more than half of the examinations) in a group of children (n = 190) exam-
ined on four occasions during the baseline year and once again at 7 years[13]. TI was
Table 4. Multivariable logistic regression model for the association between overall scarring progression and C.
trachomatis infection and clinical features. Categorized proportions of time-points with C. trachomatis infection, TF
and TP were included, adjusting for age at baseline and sex. The overall P value for each variable is shown in line with
the variable name, derived from a likelihood ratio test of the model including versus excluding that variable.
OR 95% CI P value
C. trachomatis 0.4396
None
<10% 0.49 0.2–1.1
10–19% 0.90 0.5–1.8
20–29% 0.80 0.3–1.9
30% + 0.72 0.2–2.5
TF 0.2535
None
<10% 0.85 0.3–2.1
10–19% 1.07 0.5–2.3
20–29% 0.84 0.3–2.0
30% + 2.09 0.9–5.0
TP <0.0001
None
<10% 2.19 1.1–4.4
10–19% 2.94 1.3–6.7
20–29% 6.67 3.0–14.9
30% + 7.48 2.7–20.8
Age at baseline 1.11 1.0–1.3 0.128
Sex (Female) 1.65 1.0–2.7 0.051
https://doi.org/10.1371/journal.pntd.0007638.t004
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associated with increased risk of developing scarring by 7 years. TF alone was not associated
with development of scarring.
Only one study, by Wolle et al, has previously examined the relationship between C. tracho-
matis infection and the subsequent development of scarring in children[14]. They reported a
five-year cohort of Tanzanian children (n = 189) that were examined on five occasions during
the first 18 months and once again at 5 years. They found that incident scarring over the five
years was associated with constant inflammation and/or constant C. trachomatis infection dur-
ing the first 18 months (OR 5.74, 95%CI 2.39–13.8). However, the effects of infection and
inflammation were not modelled independently of each other, possibly due to sample size lim-
itations, therefore, the independent contribution from infection remained unclear.
Burton et al found a strong association between progression of pre-existing scarring in
adults and increasing episodes of papillary inflammation (P2/P3) in Ethiopia (n = 585; OR
5.93, 95%CI 3.31–10.6, p<0.0001) and Tanzania (n = 577; OR 5.76, 95%CI 2.60–12.7,
p<0.0001)[8]. The study examined and sampled participants on a 6-monthly basis for two
years. Episodes of C. trachomatis infection were very infrequent, and they were not associated
with disease progression.
Our finding that C. trachomatis infection was marginally associated with incident scarring
(before adjustment) but not with progressive scarring is consistent with chlamydial infection
being important for initiating the scarring disease process. However, once scarring is estab-
lished, other factors driving TP are perhaps increasingly important for scarring progression.
However, an alternative but perhaps less likely explanation for this finding might be that peo-
ple who are more innately predisposed to developing scarring clear infection episodes rapidly
Fig 3. Distribution of omcB load in scarring progressors and non-progressors, split by age group at time-point.
https://doi.org/10.1371/journal.pntd.0007638.g003
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(which are therefore not readily detected), but also experience more severe and prolonged
inflammation (TP) in the aftermath[15, 16]. Our analysis of progression of pre-existing scar-
ring was also limited by a smaller sample size.
Conjunctival inflammation may be associated with other bacterial or viral infections, or
with allergic conjunctivitis[17, 18]. Several cross-sectional studies have found associations
between non-chlamydial ocular bacterial infections and active trachoma (TF/TP), conjunctival
scarring, trichiasis/recurrent trichiasis and corneal scarring[11, 19–24]. A recent longitudinal
study in 452 Tanzanian adults found that ocular commensal and pathogenic non-chlamydial
bacterial infections were more common in scarring progressors relative to non-progressors
and that, after adjusting for other factors, ocular infections were marginally associated with
scarring progression at two years[25].
C. trachomatis infection might damage the barrier function or homeostasis of the conjunc-
tival epithelium, such that external stimuli cause inflammation where they would not have
done otherwise. The expression of mucins has consistently been found to be dysregulated in
active and scarring trachoma, supporting this hypothesis[5, 26]. Long-term exposure to cook-
ing smoke has also been linked to conjunctival inflammation[27], particularly affecting
women, however a Tanzanian longitudinal study did not find any association between expo-
sure to cooking fires and incident scarring[28]. Use of traditional medicines might also have a
role, as could differences in diet or coinfections that lead to variation in host immune
responses.
Genetic or epigenetic factors might also contribute to differences in host inflammatory
responses. Several studies have reported associations between genetic differences and risk of
trachoma, including one genome-wide association study[29–35]. Further detailed investiga-
tions of ocular microbial infections and host genetics are required to establish their roles in
this disease.
There was a marginal association between female sex and overall scarring progression. Fur-
ther analysis revealed that female sex was associated with progression of pre-existing scarring
but not with incident scarring (S1 Table). Female sex was also associated with C. trachomatis
infection, TF and only very marginally with TP. These findings are difficult to reconcile, as
there were associations between infection and incident scarring, and between infection and
female sex. Whereas, there was no association between infection and progressive scarring and
only a marginal association between TP and female sex. Our findings also contrast those of
previous longitudinal studies in which female sex was associated with scarring incidence but
not progression[1]. The numbers in our analysis of pre-existing scarring were relatively small,
therefore sample size limitations might explain these findings. Nevertheless, overall females
were at greater risk of overall scarring progression, after adjustment for C. trachomatis infec-
tion and TP, suggesting that this effect was mediated by another mechanism.
We found no association between age and scarring progression, which may be due to the
limited four year age range of our study participants. Age was strongly associated with C. tra-
chomatis infection, TF and TP, all of which were more common in younger participants, per-
haps suggesting that some level of acquired protective immunity develops. There was some
evidence that in the oldest age group, scarring progressors had a higher chlamydial load rela-
tive to non-progressors, perhaps suggesting that their immunological control of the infection
was less effective, although this evidence was very weak.
A strong association was seen between infection and TF or TP. In contrast to previous
reports the association did not diminish after MDA[36], however C. trachomatis infection was
still relatively common and the effect estimates had very wide confidence intervals. Infection
prevalence recovered after MDA to near pre-MDA levels, whereas TP and TF prevalence
remained low post-MDA. Most of the residual disease and infection was concentrated in
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village “C”, which lies within a district with historically higher levels of endemic trachoma. A
study from central Tanzania has shown a significant reduction of both C. trachomatis infection
and TF after each of three annual rounds of MDA in children aged 1 year and above, where
MDA coverage was>80%[37]. The overall TF prevalence was reduced from 27.3% at baseline
to 9.4% one year after the third MDA round, and infection prevalence was reduced from
>20% in 1-9-year olds to<10% in the fourth year. The resurgence of infection prevalence dur-
ing our study may have been due to a combination of insufficient MDA coverage and interac-
tion with untreated neighboring communities. Community members are mainly pastoralists
and often away from their homes during the day. These results highlight the need for high
MDA coverage to effectively bring C. trachomatis prevalence under control. However, the sus-
tained reduction in TP prevalence following MDAmay be promising in terms of reducing
scarring risk.
This study has several limitations. Only the left eye was examined and sampled throughout
the longitudinal study as it was not feasible to process samples from both eyes at all time-
points. There were changes in the detection method for C. trachomatis between baseline and
all other time-points, which could have introduced some variability, however the agreement
between methods was good and due to the large sample size and high number of time-points
the interpretation of the results is not expected to be affected. As with any longitudinal study
there was some loss to follow-up. In this study we found that the children for whom we were
unable to collect outcome data were slightly older and more likely to be male. Although this
moderate difference between those seen and not seen could potentially introduce some bias,
the cohort size remained substantial to the end, and despite the loss to follow-up we were able
draw clear conclusions. It is possible that MDA treatment could have had a beneficial effect
against scarring progression through the known anti-inflammatory properties of azithromy-
cin, however further investigation of this was outside the scope of the current study. The three-
monthly spacing of observations are too far apart to be able to estimate the duration of disease
and infection episodes. The study was designed to investigate individual level risk of progres-
sion in scarring and was of sufficient size to demonstrate this. However, it was not designed to
provide community level estimates of the risk of progression, which would require a much
larger number of communities and many more to children.
Conclusion
Progressive scarring trachoma was strongly associated with papillary inflammation in this lon-
gitudinal study. C. trachomatis infection was no longer associated with scarring progression
after adjustment for TP, suggesting that the effect of infection is mediated through TP, and
that other factors contributing to TP in addition to C. trachomatis infection are important
determinants of disease progression. Further research is required to understand what these
factors are; they might include other ocular or non-ocular infections, genetic variation in host
immune responses or environmental factors. Females were at greater risk of C. trachomatis
infection, clinical inflammation and scarring progression. The addition of TP as an indicator
for trachoma control programs might provide a more accurate marker for the risk of disease
progression and of the need for future trichiasis interventions, which are likely to be needed
for many years to come in this community.
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S1 Fig. Histogram showing the number of time-points at which participants were seen.
Data are shown for the 448 participants with outcome data.
(TIF)
S2 Fig. The prevalence of C. trachomatis infection and clinical signs at each time-point.
Data are shown for the 448 individuals with outcome data, split by village. Red vertical lines
indicate MDA treatment. The red dashed vertical line in village C indicates treatment given
with residual disease
(TIF)
S3 Fig. The association between C. trachomatis infection and clinical signs at each
time-point. TF is shown in blue and TP in red. Odds ratios with 95% confidence intervals
are plotted. The grey vertical lines indicate MDA treatment given to all three study vil-
lages. The grey dashed vertical line indicates treatment given to one village with residual
disease. The OR for TP at time-point 5 is missing as there was insufficient data to generate
a result.
(TIF)
S1 Table. Univariable logistic regression models for scarring progression. These include; a)
incident scarring and b) increase in pre-existing scarring, in individuals with (a) no scarring at
baseline or (b) some scarring at baseline. Univariate associations between scarring and infec-
tion, TF and TP were adjusted for age at baseline and sex.
(DOCX)
S2 Table. Multivariable logistic regression models for scarring progression. These include;
a) incident scarring and b) increase in pre-existing scarring, in individuals with (a) no scarring
at baseline or (b) some scarring at baseline.
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S1 Table. Univariate logistic regression models for scarring progression. That includes; a) incident 
scarring and b) increase in pre-existing scarring, in individuals with (a) no scarring at baseline or (b) some 
scarring at baseline. Univariate associations between scarring and infection, TF and TP were adjusted for 
age at baseline and sex 
 
A) INCIDENT SCARRING n/N % OR 95% CI P value 
 48/339 14.16    
C. trachomatis         0.0307 
None  19/173 (11.0%)    
<10%  5/67 (7.5%) 0.68 0.24 - 1.91  
10-19%  10/53 (18.9%) 1.98 0.84 - 4.64  
20-29%  9/32 (28.1%) 3.40 1.33 - 8.68  
30% +  5/14 (35.7%) 4.75 1.42 - 15.90  
TF         0.0013 
None  17/172 (9.9%)    
<10%  2/37 (5.4%) 0.62 0.13 - 2.86  
10-19%  6/47 (12.8%) 1.63 0.58 - 4.58  
20-29%  8/43 (18.6%) 2.54 0.96 - 6.71  
30% +  15/40 (37.5%) 7.35 2.91 - 18.54  
TP         <0.0000 
None  20/222 (9.0%)    
<10%  4/49 (8.2%) 0.99 0.32 - 3.09  
10-19%  5/29 (17.2%) 2.40 0.80 - 7.19  
20-29%  15/28 (53.6%) 13.42 5.34 - 33.73  
30% +  4/11 (36.4%) 6.03 1.61 - 22.63  
Age at baseline     0.99 0.84 - 1.15 0.859 
Sex            
Male 24/168 (14.3%)    
Female 24/171 (14.0%) 0.98 0.53 - 1.80 0.947 
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B) PROGRESSIVE SCARRING n/N % OR 95% CI P value 
  55/109 (50.5%)       
C. trachomatis         0.3973 
None  29/56 (51.8%)    
<10%  7/11 (63.6%) 0.93 0.21 - 4.18  
10-19%  11/26 (42.3%) 0.51 0.18 - 1.46  
20-29%  6/11 (54.6%) 0.80 0.20 - 3.18  
30% +  2/5 (40.0%) 0.62 0.09 - 4.36  
TF         0.5382 
None 19/36 (52. 
8%) 
   
<10%  6/15 (40.0%) 0.68 0.19 - 2.40  
10-19%  12/24 (50.0%) 1.01 0.33 - 3.09  
20-29%  7/13 (53.9%) 1.19 0.31 - 4.60  
30% +  11/21 (52.4%) 0.87 0.26 - 2.91  
TP         0.1783 
None  16/41 (39.0%)    
<10%  13/22 (59.1%) 2.17 0.73 - 6.46  
10-19%  10/19 (52.6%) 1.79 0.57 - 5.63  
20-29%  6/13 (46.2%) 1.44 0.40 - 5.23  
30% +  10/14 (71.4%) 3.63 0.94 - 14.04  
Age at baseline     1.02 0.84 - 1.24 0.839 
Sex            
Male 14/38 (36.8%)    
Female 41/71 (57.8%) 2.34 1.04 - 5.27 0.039 
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S2 Table. Multivariable logistic regression models for scarring progression. That includes; a) incident 
scarring and b) increase in pre-existing scarring, in individuals with (a) no scarring at baseline or (b) some 
scarring at baseline.  Multivariable associations between scarring and infection, TF and TP were adjusted 
for age at baseline and sex. 
 
 
A) INCIDENT SCARRING OR 95% CI P value 
C. trachomatis 
 
 0.3477 
None 
 
  
<10% 0.46 0.14 - 1.48 
 
10-19% 1.52 0.57 - 4.04 
 
20-29% 1.19 0.36 - 3.93 
 
30% + 1.90 0.38 - 9.46   
TF 
 
 0.1472 
None 
 
  
<10% 0.70 0.14 - 3.41 
 
10-19% 0.71 0.20 - 2.49 
 
20-29% 0.75 0.20 - 2.75 
 
30% + 2.77 0.79 - 9.65   
TP 
 
 0.0003 
None 
 
  
<10% 1.04 0.30 - 3.56 
 
10-19% 2.00 0.57 - 7.08 
 
20-29% 11.97 3.74 - 38.31 
 
30% + 3.81 0.76 - 19.22   
Age at baseline 1.16 0.95 - 1.42 0.149 
Sex (female) 0.95 0.46 - 1.94 0.885 
B) PROGRESSIVE SCARRING       
C. trachomatis 
 
 0.5287 
None 
 
  
<10% 0.89 0.16 - 4.87 
 
10-19% 0.42 0.13 - 1.38 
 
20-29% 0.41 0.07 - 2.35 
 
30% + 0.31 0.03 - 3.26   
TF 
 
 0.9483 
None 
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<10% 0.76 0.19 - 3.07 
 
10-19% 1.01 0.28 - 3.62 
 
20-29% 0.84 0.16 - 4.46 
 
30% + 0.59 0.13 - 2.63   
TP 
 
 0.1777 
None 
 
  
<10% 2.26 0.73 - 6.98 
 
10-19% 2.95 0.76 - 11.48 
 
20-29% 1.51 0.40 - 5.79 
 
30% + 6.30 1.23 - 32.26   
Age at baseline 0.95 0.74 - 1.22 0.678 
Sex (female) 2.54 0.91 - 7.03 0.074 
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